
<html lang="en"     class="pb-page"  data-request-id="2f1abd83-fb1a-45db-bc02-6dcb9d6781dc"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;article:article:10.1021/acs.jmedchem.5b00991;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2015.58.issue-16;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells" /></meta><meta name="dc.Creator" content="Amélie  Fouqué" /></meta><meta name="dc.Creator" content="Olivier  Delalande" /></meta><meta name="dc.Creator" content="Mickael  Jean" /></meta><meta name="dc.Creator" content="Rémy  Castellano" /></meta><meta name="dc.Creator" content="Emmanuelle  Josselin" /></meta><meta name="dc.Creator" content="Marine  Malleter" /></meta><meta name="dc.Creator" content="Kenji&#xA;F.  Shoji" /></meta><meta name="dc.Creator" content="Mac Dinh  Hung" /></meta><meta name="dc.Creator" content="Hariniaina  Rampanarivo" /></meta><meta name="dc.Creator" content="Yves  Collette" /></meta><meta name="dc.Creator" content="Pierre  van de Weghe" /></meta><meta name="dc.Creator" content="Patrick  Legembre" /></meta><meta name="dc.Description" content="Constitutive activation of the PI3K/mTOR signaling pathway contributes to carcinogenesis and metastasis in most, if not all, breast cancers. From a chromene backbone reported to inhibit class I PI3..." /></meta><meta name="Description" content="Constitutive activation of the PI3K/mTOR signaling pathway contributes to carcinogenesis and metastasis in most, if not all, breast cancers. From a chromene backbone reported to inhibit class I PI3..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="August 3, 2015" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.5b00991" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2015 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b00991" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.5b00991" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b00991" /></link>
        
    
    

<title>A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.5b00991" /></meta><meta property="og:title" content="A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0016.jpeg" /></meta><meta property="og:description" content="Constitutive activation of the PI3K/mTOR signaling pathway contributes to carcinogenesis and metastasis in most, if not all, breast cancers. From a chromene backbone reported to inhibit class I PI3K catalytic subunits, several rounds of chemical syntheses led to the generation of a new collection of chromologues that showed enhanced ability to kill PI3K-addicted cancer cells and to inhibit Akt phosphorylation at serine 473, a hallmark of PI3K/mTOR activation. This initial screen uncovered a chromene designated DHM25 that exerted potent antitumor activity against breast tumor cell lines. Strikingly, DHM25 was shown to be a selective and covalent inhibitor of mTOR using biochemical and cellular analyses, modeling, and a large panel of kinase activity assays spanning the human kinome (243 kinases). Finally, in vivo, this novel drug was an efficient inhibitor of growth and metastasis of triple-negative breast cancer cells, paving the way for its clinical application in oncology." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.5b00991"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b00991">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.5b00991&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.5b00991&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.5b00991&amp;href=/doi/10.1021/acs.jmedchem.5b00991" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2015</span><span class="cit-fg-volume">, 58</span><span class="cit-fg-issue">, 16</span><span class="cit-fg-pageRange">, 6559-6573</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/58/16" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.5b00659" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.5b00706" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="article_relation"><span class="article_relation-correction"><i class="icon-asterisk"></i><span class="relation-text"><a href="/doi/10.1021/acs.jmedchem.9b01578"><span class="relation-type">ADDITION / CORRECTION</span><span class="relation-desc">This article has been corrected. View the notice.</span></a></span></span></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Amélie Fouqué</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Amélie Fouqué</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Université de Rennes-1, 2 avenue du Prof. Leon Bernard, 35043 Rennes, France</div><div class="loa-info-affiliations-info">CLCC Eugène Marquis, INSERM ER440 Oncogenesis, Stress & Signaling, rue bataille Flandres Dunkerque, 35042 Rennes, France</div><div class="loa-info-affiliations-info">Equipe Labellisée Ligue Contre le Cancer, rue bataille Flandres Dunkerque, Rennes, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Am%C3%A9lie++Fouqu%C3%A9">Amélie Fouqué</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Olivier Delalande</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Olivier Delalande</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Université de Rennes-1, 2 avenue du Prof. Leon Bernard, 35043 Rennes, France</div><div class="loa-info-affiliations-info">IGDR, CNRS UMR 6290, UFR des Sciences Biologiques et Pharmaceutiques, 2 Av. du Professeur Léon Bernard, 35043 Rennes, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Olivier++Delalande">Olivier Delalande</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mickael Jean</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mickael Jean</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Université de Rennes-1, 2 avenue du Prof. Leon Bernard, 35043 Rennes, France</div><div class="loa-info-affiliations-info">UMR6226, CNRS, Institut des Sciences Chimiques de Rennes, Equipe Produits Naturels, Synthèses, Chimie Médicinale, UFR des Sciences Biologiques et Pharmaceutiques, 2 Av. du Professeur Léon Bernard, 35043 Rennes, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mickael++Jean">Mickael Jean</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rémy Castellano</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rémy Castellano</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">CRCM, INSERM, U1068; Institut Paoli-Calmettes; Aix-Marseille Université; CNRS, UMR 7258, Marseille, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=R%C3%A9my++Castellano">Rémy Castellano</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Emmanuelle Josselin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Emmanuelle Josselin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">CRCM, INSERM, U1068; Institut Paoli-Calmettes; Aix-Marseille Université; CNRS, UMR 7258, Marseille, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Emmanuelle++Josselin">Emmanuelle Josselin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Marine Malleter</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Marine Malleter</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Université de Rennes-1, 2 avenue du Prof. Leon Bernard, 35043 Rennes, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Marine++Malleter">Marine Malleter</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kenji F. Shoji</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kenji F. Shoji</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Université de Rennes-1, 2 avenue du Prof. Leon Bernard, 35043 Rennes, France</div><div class="loa-info-affiliations-info">INSERM, U1085, 2 avenue du Prof. Leon Bernard, 35043 Rennes, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kenji%0AF.++Shoji">Kenji F. Shoji</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mac Dinh Hung</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mac Dinh Hung</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Faculty of Chemistry, National Vietnam University, 19 Le Thanh Tong, Hanoi, Vietnam</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mac+Dinh++Hung">Mac Dinh Hung</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hariniaina Rampanarivo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hariniaina Rampanarivo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Université de Rennes-1, 2 avenue du Prof. Leon Bernard, 35043 Rennes, France</div><div class="loa-info-affiliations-info">CLCC Eugène Marquis, INSERM ER440 Oncogenesis, Stress & Signaling, rue bataille Flandres Dunkerque, 35042 Rennes, France</div><div class="loa-info-affiliations-info">Equipe Labellisée Ligue Contre le Cancer, rue bataille Flandres Dunkerque, Rennes, France</div><div class="loa-info-affiliations-info">IGDR, CNRS UMR 6290, UFR des Sciences Biologiques et Pharmaceutiques, 2 Av. du Professeur Léon Bernard, 35043 Rennes, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hariniaina++Rampanarivo">Hariniaina Rampanarivo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yves Collette</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yves Collette</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">CRCM, INSERM, U1068; Institut Paoli-Calmettes; Aix-Marseille Université; CNRS, UMR 7258, Marseille, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yves++Collette">Yves Collette</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Pierre van de Weghe</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Pierre van de Weghe</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Université de Rennes-1, 2 avenue du Prof. Leon Bernard, 35043 Rennes, France</div><div class="loa-info-affiliations-info">UMR6226, CNRS, Institut des Sciences Chimiques de Rennes, Equipe Produits Naturels, Synthèses, Chimie Médicinale, UFR des Sciences Biologiques et Pharmaceutiques, 2 Av. du Professeur Léon Bernard, 35043 Rennes, France</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: (+33)-2-2323-3803. Fax: (+33)-2-2323-4425. E-mail: <a href="/cdn-cgi/l/email-protection#2b5b424e59594e055d4a45064f4e065c4e4c434e6b5e45425d06594e45454e581a054d59"><span class="__cf_email__" data-cfemail="a9d9c0ccdbdbcc87dfc8c784cdcc84decccec1cce9dcc7c0df84dbccc7c7ccda9887cfdb">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Pierre++van+de+Weghe">Pierre van de Weghe</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Patrick Legembre</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Patrick Legembre</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Université de Rennes-1, 2 avenue du Prof. Leon Bernard, 35043 Rennes, France</div><div class="loa-info-affiliations-info">CLCC Eugène Marquis, INSERM ER440 Oncogenesis, Stress & Signaling, rue bataille Flandres Dunkerque, 35042 Rennes, France</div><div class="loa-info-affiliations-info">Equipe Labellisée Ligue Contre le Cancer, rue bataille Flandres Dunkerque, Rennes, France</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: (+33)-2-2323-7241. Fax: (+33)-2-9925-3164. E-mail: <a href="/cdn-cgi/l/email-protection#c4b4a5b0b6ada7afeaa8a1a3a1a9a6b6a184adaab7a1b6a9eaa2b6"><span class="__cf_email__" data-cfemail="cfbfaebbbda6aca4e1a3aaa8aaa2adbdaa8fa6a1bcaabda2e1a9bd">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Patrick++Legembre">Patrick Legembre</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b00991&amp;href=/doi/10.1021%2Facs.jmedchem.5b00991" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2015</span></span><span class="cit-volume">, 58</span><span class="cit-issue">, 16</span><span class="cit-pageRange">, 6559–6573</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 3, 2015</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>5 May 2015</li><li><span class="item_label"><b>Published</b> online</span>3 August 2015</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 27 August 2015</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.5b00991" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00991</a></div><div class="article_header-article-copyright"><strong>Copyright © 2015 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6559%26pageCount%3D15%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DAm%25C3%25A9lie%2BFouqu%25C3%25A9%252C%2BOlivier%2BDelalande%252C%2BMickael%2BJean%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D58%26issueNum%3D16%26contentID%3Dacs.jmedchem.5b00991%26title%3DA%2BNovel%2BCovalent%2BmTOR%2BInhibitor%252C%2BDHM25%252C%2BShows%2Bin%2BVivo%2BAntitumor%2BActivity%2Bagainst%2BTriple-Negative%2BBreast%2BCancer%2BCells%26numPages%3D15%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6573%26publicationDate%3DAugust%2B2015">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.5b00991"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3089</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">19</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.5b00991" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Amélie&quot;,&quot;last_name&quot;:&quot;Fouqué&quot;},{&quot;first_name&quot;:&quot;Olivier&quot;,&quot;last_name&quot;:&quot;Delalande&quot;},{&quot;first_name&quot;:&quot;Mickael&quot;,&quot;last_name&quot;:&quot;Jean&quot;},{&quot;first_name&quot;:&quot;Rémy&quot;,&quot;last_name&quot;:&quot;Castellano&quot;},{&quot;first_name&quot;:&quot;Emmanuelle&quot;,&quot;last_name&quot;:&quot;Josselin&quot;},{&quot;first_name&quot;:&quot;Marine&quot;,&quot;last_name&quot;:&quot;Malleter&quot;},{&quot;first_name&quot;:&quot;Kenji\nF.&quot;,&quot;last_name&quot;:&quot;Shoji&quot;},{&quot;first_name&quot;:&quot;Mac&quot;,&quot;last_name&quot;:&quot;Dinh Hung&quot;},{&quot;first_name&quot;:&quot;Hariniaina&quot;,&quot;last_name&quot;:&quot;Rampanarivo&quot;},{&quot;first_name&quot;:&quot;Yves&quot;,&quot;last_name&quot;:&quot;Collette&quot;},{&quot;first_name&quot;:&quot;Pierre&quot;,&quot;last_name&quot;:&quot;van de Weghe&quot;},{&quot;first_name&quot;:&quot;Patrick&quot;,&quot;last_name&quot;:&quot;Legembre&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2015&quot;,&quot;month&quot;:&quot;08&quot;,&quot;day&quot;:&quot;03&quot;,&quot;issue&quot;:&quot;16&quot;,&quot;volume&quot;:&quot;58&quot;,&quot;pages&quot;:&quot;6559-6573&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.5b00991&quot;},&quot;abstract&quot;:&quot;Constitutive activation of the PI3K/mTOR signaling pathway contributes to carcinogenesis and metastasis in most, if not all, breast cancers. From a chromene backbone reported to inhibit class I PI3K catalytic subunits, several rounds of chemical syntheses led to the generation of a new collection of chromologues that showed enhanced ability to kill PI3K-addicted cancer cells and to inhibit Akt phosphorylation at serine 473, a hallmark of PI3K/mTOR activation. This initial screen uncovered a chromene designated DHM25 that exerted potent antitumor activity against breast tumor cell lines. Strikingly, DHM25 was shown to be a selective and covalent inhibitor of mTOR using biochemical and cellular analyses, modeling, and a large panel of kinase activity assays spanning the human kinome (243 kinases). Finally, in vivo, this novel drug was an efficient inhibitor of growth and metastasis of triple-negative breast cancer cells, paving the way for its clinical application in oncology.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b00991&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b00991" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b00991&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b00991" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b00991&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b00991" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b00991&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b00991&amp;href=/doi/10.1021/acs.jmedchem.5b00991" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.5b00991" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.5b00991" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (11 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00991&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.5b00991%26sid%3Dliteratum%253Aachs%26pmid%3D26237138%26genre%3Darticle%26aulast%3DFouqu%25C3%25A9%26date%3D2015%26atitle%3DA%2BNovel%2BCovalent%2BmTOR%2BInhibitor%252C%2BDHM25%252C%2BShows%2Bin%2BVivo%2BAntitumor%2BActivity%2Bagainst%2BTriple-Negative%2BBreast%2BCancer%2BCells%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D58%26issue%3D16%26spage%3D6559%26epage%3D6573%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (4)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290969" title="Cell and molecular biology">Cell and molecular biology</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/58/16" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/jmcmar.2015.58.issue-16/20150827/jmcmar.2015.58.issue-16.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/medium/jm-2015-00991u_0016.gif" alt="" id="_i2" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00991&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Constitutive activation of the PI3K/mTOR signaling pathway contributes to carcinogenesis and metastasis in most, if not all, breast cancers. From a chromene backbone reported to inhibit class I PI3K catalytic subunits, several rounds of chemical syntheses led to the generation of a new collection of chromologues that showed enhanced ability to kill PI3K-addicted cancer cells and to inhibit Akt phosphorylation at serine 473, a hallmark of PI3K/mTOR activation. This initial screen uncovered a chromene designated DHM25 that exerted potent antitumor activity against breast tumor cell lines. Strikingly, DHM25 was shown to be a selective and covalent inhibitor of mTOR using biochemical and cellular analyses, modeling, and a large panel of kinase activity assays spanning the human kinome (243 kinases). Finally, in vivo, this novel drug was an efficient inhibitor of growth and metastasis of triple-negative breast cancer cells, paving the way for its clinical application in oncology.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43613" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43613" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The PI3K/mTOR signaling pathway controls cell survival, growth, proliferation, differentiation, and motility. Therefore, it is not surprising to find this signaling pathway deregulated in human cancers. PI3K phosphorylates the D3 position on phosphoinositide to yield phosphatidylinositol-3,4,5-trisphosphate (PIP3). This phosphorylated lipid can then interact with several proteins containing a pleckstrin homology (PH) domain. Negative regulation of this pathway is mainly conferred by phosphatase and tensin homologue deleted on chromosome 10 (PTEN)<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> and inositol polyphosphate-4-phosphatase (INPP4B),<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> which dephosphorylate PIP3 and PIP2, respectively. The serine/threonine kinase Akt possesses a PH domain, and its recruitment to the plasma membrane induces its activation through phosphorylation at threonine 308 by PDK1<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> and at serine 473 by mammalian target of rapamycin complex 2 (mTORC2).<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Once activated, Akt phosphorylates and thereby inactivates tuberous sclerosis complex-2 (TSC2), a GTPase-activating protein (GAP) that inhibits the GTPase Rheb (RAS homologue expressed in brain).<a onclick="showRef(event, 'ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8">(6−8)</a> The release of the TSC2-driven Rheb blockage leads to the activation of the serine-threonine kinase mTOR.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> mTOR belongs to the PI3K-related kinase family and forms at least two complexes whose exhaustive composition, cellular distribution, and function remain to be defined. While mTOR complex 1 (mTORC1) is instrumental in translation and cell growth regulation via phosphorylation of substrates such as eukaryotic initiation factor eIF4E binding protein (4E-BP1), mTOR complex 2 (mTORC2) regulates a different set of substrates, including Akt.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Of interest, mTORC1 exerts a negative feedback loop on both PI3K and mTORC2<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11,12)</a> and thereby downregulates Akt activity. Rapamycin, a macrolide<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> interacting with FKBP12, selectively inhibits mTORC1.<a onclick="showRef(event, 'ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16">(14−16)</a> Despite promising results in animal models of cancer, rapamycin and rapalogues were generally disappointing in human trials (reviewed in ref <a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a>). One explanation for these disappointing results is that by eliminating the mTORC1-dependent negative feedback program, rapalogues lead to prolonged activation of the mTORC2/Akt signaling pathway,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> which may promote the occurrence of new cancers during chronic treatment. To overcome this limitation, ATP-competitive inhibitors that potently block both mTORC1 and mTORC2 are sought as anticancer agents.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Beyond rapalogues that show limited clinical benefit in cancers, few N-heterocyclic derivatives have been identified as mTOR inhibitors. These small molecules, AZD8055, NVP-BEZ235, OSI-027, INK128, and Torin1, inhibit both mTORC1 and mTORC2 and are currently in clinical trials.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Although these ATP-competitive inhibitors exert an anticancer activity, only NVP-BEZ235 presents some interest to treat breast cancer patients and may be used in combination with other chemotherapeutic drugs to improve clinical outcomes in this pathology (tested in phase I and II clinical trials, see <a href="http://clinicaltrials.gov/" class="extLink">clinicaltrials.gov/</a>). This deficiency of small inhibitors of the mTOR activity for the treatment of breast cancer reveals the urgent need for the development of new and potent compounds.</div><div class="NLM_p">The most common cancers are colorectal cancers (13.6%) and breast cancers (13.1%).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> On the basis of their gene expression profiles, breast cancers are categorized as luminal A/B, HER-2+, and basal-like, with a close relationship between this classification and the clinical outcome of the tumors.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Basal-like breast cancers are closely related to triple-negative breast cancers (TNBCs).<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Representing 10–20% of all breast cancers, TNBC/basal-like tumors account for a disproportionate number of mortalities, in part due to their aggressiveness and the lack of effective therapeutic regimens. Indeed, while the estrogen receptor (ER)-positive cancers closely related to luminal A/B cancers receive hormone therapy<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> and HER2-amplified cancers are a clinical success because of neutralizing antibodies targeting HER2,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> TNBCs can only be treated with chemotherapy.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> A recent large-scale study of 50 luminal breast cancer genomes sequenced at high coverage identified over 1700 genic mutations, but only three of these genes were mutated at frequencies that approached or exceeded 10%.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Among these genes, <i>PIK3CA</i>, which codes for the p110α catalytic subunit of PI3K, harbored mutations in 43% of the analyzed tumors.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Although PIK3CA mutations remain less frequent in TNBCs as compared to non-TNBCs, loss-of-function mutations or reduced expression of PTEN or INPP4B are detected in 67% and 53% of TNBCs, respectively,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> confirming that deregulation of the PI3K/mTOR signaling pathway is a common event in breast carcinogenesis and supporting the need to develop potent and selective inhibitors of the PI3K/mTOR signaling pathway to treat this pathology.</div><div class="NLM_p last">From a chromene derivative showing a weak affinity for PI3K (IC<sub>50</sub> of 10–50 μM for the different p110 catalytic subunits of PI3K),<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> we used cell-based, enzyme, and biochemical assays to generate a potent and irreversible mTOR inhibitor designated DHM25 [6,8-dibromo-2-(4-bromophenyl)-3-nitro-2<i>H</i>-chromene] that efficiently kills breast cancer cells.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54123" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54123" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Synthesis of Chromene Derivatives</h3><div class="NLM_p">To develop new and potent PI3K inhibitors, a chromene backbone designated S14161/pichromene was selected for its ability to kill malignant cell lines by inhibiting all class I PI3K catalytic subunits.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Accordingly, a number of synthetic strategies have been described for the preparation of chromene derivatives. Among them, we sought to use an approach based on the addition of salicylaldehydes to α,β-unsaturated compounds promoted by organic bases. The utilization of small chiral organic molecules as metal-free catalysts, especially in the synthesis of pharmaceuticals, was chosen because of the “green” advantage of not contaminating the final product with traces of heavy metals.<a onclick="showRef(event, 'ref30 ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref30 ref31 ref32">(30−32)</a> The chromene derivatives were synthesized using pipecolic acid or tetramethylguanidine as catalyst to promote the addition of various substituted salicylaldehydes to several α,β-unsaturated derivatives (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). By varying first the west part of the pichromene and second the aryl group of the east part, several structural modifications were progressively undertaken until the generation of the two chromene derivatives, DHM9 and DHM25 (see below).</div><figure id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/medium/jm-2015-00991u_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0012.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthesis of Chromene Derivatives</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00991&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Selection of a Potent PI3K Inhibitor</h3><div class="NLM_p">By modifying first the west part of the scaffold, new compounds were synthesized, and their ability to kill two PI3K-dependent leukemic T cell lines (CEM and Jurkat) was tested (<a class="ref internalNav" href="#notes-2" aria-label="Figure S1A">Figure S1A</a>, Supporting Information).<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33,34)</a> To focus on compounds that were potentially selective for the PI3K signaling pathway, chromologues were selected that exerted more cytotoxic activity on CEM/Jurkat cells than on the leukemic T cell line H9, whose survival relies to a lesser extent on PI3K signaling (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B).<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> This screening test highlighted that although pichromene was more efficient at killing CEM and Jurkat cells than the well-established and potent PI3K inhibitor wortmannin (<a class="ref internalNav" href="#notes-2" aria-label="Figure S1A">Figure S1A</a>), it probably did not exert its cytotoxic effect by inhibiting the PI3K signaling pathway, because CEM/Jurkat and H9 cells were killed to a similar extent (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B,C). Although PWPHT45, PWPHT47, PWPHT88, PWPHT89, and PWPHT90 showed increased cytotoxic activity compared to pichromene (<a class="ref internalNav" href="#notes-2" aria-label="Figure S1A">Figure S1A</a>), only PWPHT45 and PWPHT89 killed more efficiently CEM/Jurkat cells than H9 cells (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B,C), indicating that these two chromene derivatives could exert their cytotoxic effect by selectively inhibiting the PI3K signaling pathway. To confirm this assumption, the ability of these chemicals to inhibit the PI3K signaling pathway in CEM cells (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>D) and in Jurkat cells (<a class="ref internalNav" href="#notes-2" aria-label="Figure S1B">Figure S1B</a>) was next analyzed by assessing their impact on the phosphorylation of Akt, a downstream PI3K effector. Confirming the cell-based assay, incubation of CEM or Jurkat cells for 1 or 2 h with pichromene (10 μM) did not reduce the level of Akt phosphorylation at serine 473 in (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>D and <a class="ref internalNav" href="#notes-2" aria-label="S1B">S1B</a>), indicating that this compound was not a direct inhibitor of PI3K and that its cytotoxic activity on CEM and Jurkat cells likely occurred through a PI3K-independent mechanism. By contrast, chromene derivatives PWPHT33, PWPHT45, PWPHT47, PWPHT54, PWPHT52, PWPHT88, and PWPHT89 showed an inhibitory effect on Akt phosphorylation (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>D). PWPHT45 and PWPHT89 were, therefore, the most interesting backbones from this first set of chromologues and were subsequently used to design a second collection of derivatives (<a class="ref internalNav" href="#notes-2" aria-label="Figure S2">Figure S2</a>, Supporting Information). The aryl substituents were modified in order to study the influence of various compounds with different electronic or lipophilic properties and steric hindrance on the cytotoxic activity of our lead compound. Among this second library, five derivatives displayed better cytotoxic activity toward the leukemic T cell line CEM than PWPHT45 and PWPHT89 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>E). Next, DHM9, DHM10, and DHM25 were selected for their ability to inhibit Akt phosphorylation at serine 473 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>F–I). Of note, DHM9 and DHM25 corresponded to PWPHT89 and PWPHT45 backbones, respectively, in which the fluoride atom was replaced by bromine. Finally, these three compounds exhibited an in cellulo IC<sub>50</sub> of between 0.376 and 2.744 μM, whereas the PI3K inhibitor LY294002, which shares some structural similarities with chromologues, showed an IC<sub>50</sub> close to 100 μM in CEM cells (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>H,I). In summary, from a weak PI3K inhibitor (pichromene) and two cell-based/biochemical assays, two rounds of synthesis led to the identification of two novel chromologues (DHM9 and DHM25) showing dramatically improved PI3K inhibitory activity as compared to S14161/pichromene.</div><figure id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/medium/jm-2015-00991u_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0002.jpeg" id="gr5" class="inline-fig internalNav" /></img><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/medium/jm-2015-00991u_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0003.jpeg" id="GRAPHIC-d7e602-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Selection of new chromologues according to their ability to kill PI3K-addicted tumor cells and inhibit Akt phosphorylation. A. Representation of the first set of chromologues. B. The indicated compounds were incubated for 24 h with leukemic T cell lines, relying (CEM) or not (H9) on the PI3K signaling pathway for survival, and cell death was measured using an MTT viability assay. C. The 50% effective dose (ED<sub>50</sub>) selectivity determined from data depicted in B. D. Upper panel: The PI3K-addicted T cell leukemia cell line CEM was incubated for 1 or 2 h with 10 μM of the indicated chromologues. Cells were lysed, and the indicated immunoblots were performed. β-Actin was used as a loading control. Lower panel: The immunoblots were assessed by densitometric analysis using ImageJ software, and the percentage of Akt phosphorylation was calculated using the following formula: [(phosphorylated Akt band intensity at time point <i>x</i>/intensity of whole protein band at time point <i>x</i>)/(intensity of P-Akt band at time zero/intensity of whole protein band at time point 0)]. E. Upper panel: The leukemic T cell line CEM was incubated with the indicated compounds for 24 h, and cell death was measured by MTT viability assay. Lower panel: ED<sub>50</sub> was assessed for each molecule using the MTT data depicted in the upper panel. F. CEM cells were incubated with the indicated chromologues (10 μM) for 1 or 2 h. The cells were then lysed, and the indicated immunoblots were performed. Akt was used as a loading control. G. The percentage of Akt phosphorylation (P-Akt) was assessed as indicated in D. H. CEM cells were incubated with the indicated concentrations of chromologues for 2 h. Cells were lysed, and the indicated immunoblots were performed. Akt was used as a loading control. I. The percentage of Akt phosphorylation (P-Akt) was assessed as indicated in D, and the half maximal inhibitory concentration (IC<sub>50</sub>) was determined for each chromologue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0002.jpeg jm-2015-00991u_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00991&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> DHM9 and DHM25 Efficiently Kill Breast Tumor Cells</h3><div class="NLM_p">Because carcinogenesis in breast epithelial cells relies on the constitutive activation of the PI3K/mTOR signaling pathway, which occurs through the deregulation of various molecular mechanisms including down-regulation of PTEN activity and/or expression (see <a class="ref internalNav" href="#notes-2" aria-label="Figure S3">Figure S3</a>, Supporting Information), constitutive activation of PI3K (gain-of-function mutations in <i>PIK3CA</i> or <i>PIK3R1</i> indicated in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A), or induction of the Ras signaling pathway, we next evaluated the cytotoxic effect of our leads on nine breast tumor cell lines covering all breast cancer subtypes and exhibiting deregulation of PI3K signaling through various molecular mechanisms (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A). Independently of their histological classification (TNBC, non-TNBC, or HER2<sup>+</sup>), all breast cancer cell lines exposed for 24 h to the selected chromologues underwent a cell death program (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A,B). Among the molecules tested, DHM25 and, to a lesser extent, DHM9 showed the most efficient cytotoxic activity (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A). Because all breast malignant cells were sensitive to DHM25 treatment regardless of mutations in the PI3K signaling pathway, either these mutations did not affect the inhibitory capacity of DHM25, or DHM25 targeted a downstream protein in the PI3K signaling pathway.</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/medium/jm-2015-00991u_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0005.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Cytotoxic activity of different chromologues toward triple-negative, non-triple-negative, or HER2<sup>+</sup> breast cancer cell lines. A. A collection of cancer cell lines covering all types of breast cancers were incubated for 24 h with the indicated chromologues, and cell death was measured by MTT viability assay. B. Table summarizing the ED<sub>50</sub> of DHM25 against the breast cancer cell lines. Data are the means ± SEM of three different experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00991&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> DHM25 is a Selective mTOR Inhibitor</h3><div class="NLM_p">To identify the molecular targets of DHM9 and DHM25, their inhibitory activity against 243 human protein kinases was evaluated using KinaseProfiler assay. Strikingly, despite structural similarities between DHM25 and DHM9 (only one additional bromine in position 8 of DHM25 as compared to DHM9), the KinaseProfiler assay revealed that different sets of kinases were targeted by DHM9 and DHM25 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A). More importantly, no PI3Ks were inhibited by DHM25 or DHM9. Indeed, while 1 μM DHM9 abrogated the activity of tyrosine (c-yes) and serine/threonine kinases (p70S6K, LOK, BrSK1, TSSK1, and NLK), the same concentration of DHM25 inhibited only mTOR activity (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A). It is noteworthy that Akt phosphorylation at serine 473, the biochemical marker that we followed to determine the PI3K inhibitory effect of chromologues, is the direct target of mTORC2.<a onclick="showRef(event, 'ref10 ref35'); return false;" href="javascript:void(0);" class="ref ref10 ref35">(10,35)</a> To confirm that DHM25 was an mTOR inhibitor, its ability to inhibit the phosphorylation of mTORC1 and C2 substrates was evaluated. To this end, the phosphorylation status of 4E-BP1 (a direct substrate of mTORC1) and S6 (a substrate of p70S6K, another target of mTORC1) was monitored (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B,C). DHM25 activity was also compared with that of rapamycin, an mTORC1 kinase inhibitor that exerts its activity by preventing its binding to FK506-binding protein of 12 kDa (FKBP12)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> while sparing mTORC2 activity.<a onclick="showRef(event, 'ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref37 ref38">(37,38)</a> While DHM25 exposure blocked Akt phosphorylation at serine 473 (IC<sub>50</sub> = 1.5 μM), rapamycin treatment did not affect the intensity of phosphorylation of this mTORC2 substrate (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B). By densitometry analysis, DHM25 exhibited a similar capacity to inhibit the phosphorylation of 4E-BP1 (IC<sub>50</sub> = 8.3 μM) and S6 (IC<sub>50</sub> = 1 μM). By contrast, 4E-BP1 phosphorylation was relatively resistant to rapamycin treatment (IC<sub>50</sub> = 9.5 μM) compared to S6 phosphorylation (IC<sub>50</sub> = 0.3 nM). A recent study demonstrated that the difference in rapamycin sensitivity between these two mTORC1 substrates was dependent on their different affinities for the mTORC1 kinase domain.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Indeed, p70S6K activity was more sensitive to rapamycin treatment because of its weaker affinity for mTORC1 as compared to 4E-BP1.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> The differential inhibitory effects of rapamycin on 4E-BP1 and S6 contrasted with those of ATP-competitive inhibitors that blocked the phosphorylation of mTORC1 substrates regardless of their affinity for the kinase.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Accordingly, these results strongly suggested that DHM25 was a competitive mTOR inhibitor (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B,C).</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/medium/jm-2015-00991u_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0006.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. DHM25 is a selective inhibitor of mTOR. A. DHM9 and DHM25 (1 μM) were tested by KinaseProfile assay to measure their inhibitory effect on 243 kinases. B. Using immunoblotting, the inhibitory effect of DHM25 and rapamycin on mTORC1 and mTORC2 activity was assessed by monitoring S6 and 4EB-P1 phosphorylation (for mTORC1) and Akt (Ser473) phosphorylation (for mTORC2). C. Comparison of the effects of DHM25 on mTOR activity. The amount of phosphorylation of the different substrates was quantified by densitometric analysis using ImageJ software and the following formula: [(phosphorylated band intensity at time point <i>x</i>/intensity of whole protein band at time point <i>x</i>)/(intensity of phosphorylated band at time 0/intensity of whole protein band at time point 0)].</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00991&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> The (<i>S</i>)-DHM25 Enantiomer Kills Cancer Cells and Inhibits mTOR More Efficiently Than (<i>R</i>)-DHM25</h3><div class="NLM_p">More than half of drugs are chiral compounds, and 90% of these molecules are marketed as racemic mixtures. Because enantiomers do not show the same spatial arrangement, their biological, pharmacodynamic, and pharmacokinetic properties can differ. In addition, the US Food and Drug Administration (FDA) recommends that the activity of each enantiomer be evaluated for racemic drugs and that chiral drugs be developed as single enantiomers.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> DHM25 is a chiral molecule due to its stereogenic carbon atom, C2 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A). To evaluate the therapeutic activity of both DHM25 stereoisomers, the (<i>R</i>)- and (<i>S</i>)-enantiomers were separated by HPLC, and the absolute configuration of their chiral centers was determined using circular dichroism (<a class="ref internalNav" href="#notes-2" aria-label="Figure S4">Figure S4</a>, Supporting Information). Next, the biological effects of (<i>R</i>)- and (<i>S</i>)-DHM25 were evaluated on Jurkat and CEM leukemic T cells (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B,C). Although the difference was not large, (<i>S</i>)-DHM25 killed leukemic T cells more efficiently than its isomer (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B), and this increased the cytotoxic effect correlated with a greater inhibition of mTOR activity (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C). In summary, (<i>S</i>)-DHM25 showed a slightly better mTOR inhibitory effect than its enantiomer, but this difference was not substantial enough to merit separating the two enantiomers in subsequent experiments.</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/medium/jm-2015-00991u_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0007.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. The (<i>S</i>)-DHM25 enantiomer kills tumor cells and inhibits mTOR more efficiently than (<i>R</i>)-DHM25. A. Representation of the (<i>R</i>)- and (<i>S</i>)-DHM25 enantiomers. B. Leukemic cell lines reliant on PI3K signaling for survival (CEM and Jurkat cells) were incubated with the indicated chemicals for 24 h, and cell death was measured by MTT viability assay. Data represent the means ± SEM of three independent experiments. C. CEM cells were incubated with the Indicated concentrations of (<i>R</i>)- and (<i>S</i>)-DHM25 for 2 h. Cells were lysed, and the indicated immunoblots were performed. Whole Akt and β-actin were used as loading controls. Data are representative of three independent experiments. D. Computer models for (<i>S</i>)-DHM25 and (<i>S</i>)-DHM9 in the catalytic pocket of human mTOR based on experimental structure PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JSN">4JSN</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00991&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Molecular simulations were next undertaken to understand why (<i>S</i>)-DHM25 targeted mTOR while (<i>S</i>)-DHM9 did not (<a class="ref internalNav" href="#notes-2" aria-label="Figure S5A">Figure S5A</a>, Supporting Information). Structural models of DHM9 and DHM25 within the ATP pocket of mTOR provided the first basis for understanding the binding modes and structure–activity relationships (SAR) of these compounds. First, the presence of the additional bromine in DHM25 compared to DHM9 influenced its position inside the ATP pocket of mTOR (<a class="ref internalNav" href="#notes-2" aria-label="Figure S5A,B">Figure S5A,B</a>). While DHM9 seemed to be preferentially positioned in the adenine pocket, DHM25 overlapped both the adenine pocket and the affinity pocket, notably through interactions with hinge residues Ile2237, Trp2239, and Val2240 at one side and with P-loop residues Ile2163, Ser2165, and Gln2167 at the other side, which are all also ATP-contact amino acids (<a class="ref internalNav" href="#notes-2" aria-label="Figure S5C">Figure S5C</a>). Because interactions between chromene derivatives and the mTOR catalytic pocket were mainly driven through hydrophobic contacts, the dynamics of the ligand-free diffusion into the ATP pocket were further investigated. A contact frequency analysis over simulated trajectories confirmed that DHM25 interacted with more key amino acid residues (about 80% of ATP experimental contacts) in comparison to DHM9 (only 60% of ATP contacts, <a class="ref internalNav" href="#notes-2" aria-label="Figure S5C">Figure S5C</a>). Models highlighted that unlike DHM9, DHM25 interacted inside the ATP-binding pocket of mTOR with amino acid residues of the P-loop (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>D). It is noteworthy that despite the fact that these P-loop basic amino acids showed a relatively high level of conservation among the PI3KK family members (<a class="ref internalNav" href="#notes-2" aria-label="Figure S6A">Figure S6A</a>, Supporting Information), this stretch of positively charged amino acids was lost in the sequences of PI3K family members (<a class="ref internalNav" href="#notes-2" aria-label="Figure S6B">Figure S6B</a>), potentially explaining why DHM25 exhibited a selectivity for mTOR.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> DHM25 is an Irreversible mTOR Inhibitor</h3><div class="NLM_p">Computer modeling was next used to design and synthesize two molecular tools in order to confirm that this novel drug interacted with mTOR. On the basis of the most stable position of both the (<i>R</i>)- and (<i>S</i>)-enantiomers of DHM25 inside the catalytic pocket of mTOR, DHM25 was conjugated with a probe (biotin or FITC, <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>) at the C6 position (solvent front position, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A). Strikingly, confocal microscopy revealed that breast cancer cells treated with DHM25-FITC exhibited a dot-like distribution pattern (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B) that colocalized with mTOR labeled with an anti-mTOR mAb (yellow color in the merge panel, Pearson’s coefficient = 0.899, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B). In agreement with modeling analyses, conjugation of biotin to C6 of DHM25 did not alter its inhibitory effect on mTORC2 activity (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C). More importantly, a pull-down assay using streptavidin beads confirmed that DHM25–biotin interacted with mTOR (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>D). In addition, the affinity of DHM25–biotin for mTOR was stronger than that of DHM9–biotin (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>E). Overall, these findings confirmed that DHM25 was an mTOR inhibitor.</div><figure id="sch2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/medium/jm-2015-00991u_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0013.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of DHM9 and DHM25 Conjugated to Different Probes</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00991&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/medium/jm-2015-00991u_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0008.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. In cellulo analyses confirm that DHM25 is an mTOR inhibitor. A. DHM25 was conjugated with a biotin moiety. Models present the most representative structure of 60 ns molecular dynamics trajectories into the mTOR catalytic pocket (based on PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JSN">4JSN</a>) computed for DHM25 and its biotin-conjugated counterpart. B. MDA-MB-231 cells were preincubated with FITC alone or DHM25-FITC (10 μM) for 3 h, fixed, and stained with anti-mTOR mAb. Images were analyzed by confocal microscopy (magnification, 40×). Data are representative of three independent experiments. C. CEM cells were incubated for 2 h with the indicated concentrations of DHM25-biotin. Cells were lysed, and phosphorylation of Akt at serine 473 (mTORC2 substrate) was monitored by immunoblot. D. CEM cells were treated with 10 μM DHM25 alone or DHM25 conjugated to biotin for the indicated times, after which cells were lysed and the biotin moiety was pulled down with streptavidin-coated beads. Immunoprecipitates were subjected to an anti-mTOR immunoblot. E. CEM cells were treated for 2 h with the indicated concentration of DHM25 or DHM9 conjugated to biotin. Cells were lysed, and the biotin moiety was pulled down with streptavidin-coated beads. Immunoprecipitates were subjected to an anti-mTOR immunoblot.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00991&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Modeling analysis also suggested that the electrophilic C4 in DHM25 was close enough to the lysine at position 2187 (K2187; see <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A and <a class="ref internalNav" href="#notes-2" aria-label="S5">S5</a>) in the mTOR catalytic domain to undergo a covalent link through a Michael reaction (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A). In agreement with this observation, the DHM25-biotin/mTOR interaction was not lost after cell lysis under denaturing/reducing/boiling conditions (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>D,E). In addition, whereas extensive washing after 2 h of incubation with the reversible mTOR inhibitor AZD8055 led to a rapid restoration of Akt phosphorylation at serine 473, identical treatment with DHM25 did not, suggesting an irreversible association with the kinase (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B). To confirm this possibility, two types of DHM25 modifications were performed. First, a DHM25 derivative was synthesized in which the C3–C4 double bond was reduced (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a> and <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>C). Conversion of the C3–C4 double bond into a single C–C bond removes the electrophilic property of the carbon at position C4 and its ability to form a covalent bond with the nitrogen atom at K2187. Of note, DHM25-H2 showed a dramatic reduction in cytotoxicity toward leukemic (Jurkat and CEM) and breast cancer cells (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>D) as compared to DHM25 and also lost its ability to inhibit phosphorylation of mTORC1 (4E-BP1) and mTORC2 (Akt-S473) substrates (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>E). Next, NO<sub>2</sub>, a strong electron-withdrawing group (EWG) in DHM25 was replaced by various chemical groups to reduce the capacity of C4 to act as an electron acceptor. To this end, four chromologues were prepared in which the NO<sub>2</sub> group was replaced by aldehyde (LR20), amide (LR28), ester (LR29), or carboxylic acid (LR24) functional groups showing an electrophilic strength gradient (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). Except for LR29, the lower the withdrawing capacity of the substituted group, the weaker the cytotoxic activity of the resulting compound (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>F). In agreement with this observation, the decreased cytotoxic activity of LR20 (replacement of NO<sub>2</sub> by an aldehyde) and LR28 (replacement of NO<sub>2</sub> by an amide functional group) toward CEM and Jurkat cells (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>F) was associated with their inability to inhibit Akt phosphorylation at Ser473 (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>G). These chemical modifications of DHM25 provided some insights into how carbon 4 could serve as a Michael acceptor to covalently bind lysine at position 2187 inside the ATP pocket of mTOR. Overall, these findings revealed that DHM25 could act as a covalent inhibitor of mTOR.</div><figure id="sch3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/medium/jm-2015-00991u_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0014.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Reduction of DHM25</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00991&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/medium/jm-2015-00991u_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0015.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Preparation of DHM25 Analogue (variation of the EWG)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00991&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/medium/jm-2015-00991u_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0009.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. DHM25 is a covalent mTOR inhibitor. A. Models present the most representative structure of 60 ns molecular dynamics trajectories computed for DHM25 compounds into the mTOR catalytic pocket (based on PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JSN">4JSN</a>). The lysine at position 2187 (K2187) is very close to the C4 atom of DHM25, suggesting a nucleophilic attack via a Michael addition leading to a covalent bond within the mTOR ATP pocket. B. CEM cells were incubated for 2 h with 10 μM DHM25 or AZD8055. Then cells were extensively washed and incubated for the indicated times in medium devoid of inhibitor. Cells were lysed, and phosphorylation of Akt at serine 473 (mTORC2 substrate) was monitored by immunoblot. C. DHM25 and its derivatives (DHM25-H2) in which the C3–C4 double bond was reduced. D. The indicated cells were treated for 16 h with DHM25 or DHM25-H2, and cell death was evaluated by MTT assay. E. CEM cells were treated for 2 h with the indicated concentration of DHM25 or DHM25-H2, and cells were lysed and the indicated immunoblots were performed. Data are representative of at least three independent experiments. F. The leukemic T cell lines CEM and Jurkat were incubated for 16 h with the indicated concentration of DHM25 or its derivatives. Cell death was assessed by MTT assay. Data represent the mean ± SD of three independent experiments. Data represent the mean ± SD of three independent experiments. G. CEM cells were treated for 2 h with the indicated concentrations of DHM25 or derivatives, and then the cells were lysed and the indicated immunoblots were performed. Data are representative of at least three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00991&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> DHM25 Inhibits CD95-Mediated Cell Migration and Prevents in Vivo Tumor Progression of TNBC Cells</h3><div class="NLM_p">CD95L (also known as FasL) belongs to the TNF (tumor necrosis factor) family and is the ligand for the “death receptor” CD95 (Fas/APO1). This transmembrane receptor can be cleaved by metalloproteases<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> to produce a soluble ligand. This naturally processed CD95L (cl-CD95L) is increased in patients affected by TNBC and enhances the risk of metastatic dissemination in these patients.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Unlike membrane-bound CD95L, cl-CD95L fails to induce apoptosis and instead promotes the formation of an atypical receptosome that we designated the motility-inducing signaling complex (MISC).<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> MISC formation leads to the induction of the pro-oncogenic PI3K/mTOR signaling pathway.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43,44)</a> The ability of DHM25 to prevent this CD95-mediated cell migration was assessed in TNBC cells. To address this question, the highest dose of DHM25 that did not cause cell death in two TNBC cell lines (BT549 and MDA-MB-231) was determined (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A). In Boyden chamber assays, although 1 μM DHM25 did not exhibit any cytotoxicity (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A), it inhibited the CD95-mediated PI3K/mTOR activation (data not shown) and abrogated CD95-mediated cell migration in TNBC cells (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B).</div><figure id="fig7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/medium/jm-2015-00991u_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Nontoxic amounts of DHM25 inhibit cell migration in TNBC cells. A. TNBC cell lines (MDA-MB-231 and BT549) were incubated for 16 h with the indicated concentration of DHM25. Cell death was assessed by MTT assay. Data represent the mean ± SD of three independent experiments. B. TNBC cell lines were preincubated for 1 h in the presence or absence of DHM25 (1 μM) and then treated with CD95L (100 ng/mL) for 24 h. Cell migration was analyzed by Boyden chamber assay. Migrating Giemsa-stained cells were lysed, and absorbance was measured at a wavelength of 560 nm. Values represent the means ± SEM of three independent experiments. *<i>p</i> < 0.05, as calculated by two-tailed Mann–Whitney test. C. Upper panel: NSG mice injected with DHM25 (10 mg/kg) or with vehicle (control) were sacrificed 50 days after implantation of MDA-MB-231 xenografts. For each mouse, the primary tumor was harvested and weighed. ***<i>p</i> < 0.0001, as calculated by two-tailed Mann–Whitney test. Lower panel: Metastatic dissemination in the lungs of luminescent MDA-MB-231 tumor cells was evaluated in xenografted mice treated (+) or untreated (−) with DHM25 (10 mg/kg). For each mouse, lungs were harvested and the amount of invasive MDA-MB-231 cells was assessed by bioluminescence imaging (BLI). *<i>p</i> < 0.05, as calculated by two-tailed Mann–Whitney test. Inset: Lungs of xenografted mice analyzed by BLI.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00991&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Finally, the in vivo therapeutic activity of DHM25 against TNBCs was assessed. In immunodeficient NOD/SCID/γc (NSG) mice, the maximum intravenous tolerated dose of DHM25 was 10 mg/kg (<a class="ref internalNav" href="#notes-2" aria-label="Figure S7A,B">Figure S7A,B</a>). Human MDA-MB-231 TNBC cells were orthotopically (mammary fat pad) transplanted in NSG mice, and when tumors were palpable, mice received repeated intravenous injections of DHM25 (10 mg/kg) or vehicle. DHM25 treatment significantly and markedly reduced primary tumor growth (primary site, <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>C) and prevented distant metastasis to lungs (classical secondary tumor site) (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>C). In conclusion, we generated an irreversible and competitive mTOR inhibitor that exhibited in vivo antitumor activity against TNBC cells.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Discussion and Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71466" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71466" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Using different tumor cell lines characterized for their high or low reliance on the PI3K/mTOR signaling pathway for survival, classical biochemical analysis (Akt phosphorylation), large-scale kinase profiling, and several rounds of chemical synthesis, we developed a novel irreversible inhibitor of mTOR showing in vitro and in vivo cytotoxic activity against breast cancer cells.</div><div class="NLM_p">Inactivation of the DHM25 electrophilic warhead reduces or abrogates its ability to inhibit mTOR activity, indicating that its mechanism of inhibition occurs mainly through its capacity to covalently interact with a nucleophilic amino acid inside the ATP pocket. In agreement with this, DHM25 analogues with an inactivated warhead (DHM25-H2) or a reduced electrophilic C4, which were generated by replacing the strong EWG NO<sub>2</sub>, indicate that the carbon at position 4 undergoes a nucleophilic attack, probably by K2187 in the mTOR catalytic pocket. Also, washout experiments show that whereas transient incubation with the reversible mTOR inhibitor AZD8055 allows for the rapid recovery of mTOR activity, similar treatment with DHM25 does not. This latter experiment highlights one of the advantages expected in vivo with mTOR covalent inhibitors, namely, prolonged action even when the drug has been systemically eliminated. Indeed, the overall pharmacological effect in vivo will be largely dependent on the de novo protein synthesis rate (the half-life of mTOR is approximately 18 h<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a>). Of note, PI3K lipid kinases and PI3KK members such as mTOR share motifs in their catalytic domain,<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> and K2187 in mTOR is a highly conserved motif among all PI3K members (<a class="ref internalNav" href="#notes-2" aria-label="Figure S6B">Figure S6B</a>), which suggested that DHM25 might also be an inhibitor of PI3Ks. Nonetheless, our study ruled out this possibility. Also, although DHM25 and DHM9 differ only by one bromine, they inhibit a completely different set of kinases (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A), illustrating that although the covalent bond in the ATP pocket of mTOR is instrumental in the ability of DHM25 to inhibit mTOR, the electrophilic warheads of DHM25, DHM9, and S14161 must be properly oriented for a prolonged time within the targeted protein to efficiently undergo the appropriate nucleophilic Michael addition. Our hypothesis is that by interacting with mTOR P-loop residues, DHM25 has better positioning and stronger stability than DHM9 inside the ATP pocket, favoring its nucleophilic attack by K2187.</div><div class="NLM_p">It is noteworthy that some covalent drugs have been evaluated in clinical trials and been approved by the US FDA.<a onclick="showRef(event, 'ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref47 ref48">(47,48)</a> Although the risks of covalent inhibitors are known (compounds with reactive functionality and potentially increased off-target interactions), the sustained duration of inhibition of covalent inhibitors yields a number of potential advantages, including improved inhibitory activity, as competition with endogenous substrates is reduced. Another advantage is the dissociation of pharmacokinetics from pharmacodynamics (PD), as PD relies on protein resynthesis. This means that covalent drugs can be clinically useful even if their half-lives are short, as only a short exposure would be required for the drug to reach its molecular target and inhibit it for a prolonged period of time.</div><div class="NLM_p">There is no approved targeted therapy for TNBC, and TNBC patients are treated with traditional chemotherapy alone. In the first 3 years after diagnosis, TNBC patients account for a disproportionate number of early deaths not only due to its aggressive nature but also because of the lack of targeted therapeutic treatment options.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Therefore, there is a crucial need for targeted therapy for this pathology. We recently demonstrated that after cleavage by metalloprotease, soluble CD95L promotes metastatic dissemination of TNBC cells by activating an atypical PI3K/mTOR signaling pathway.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> The current study demonstrates that DHM25 is not only able to kill TNBC cells in vitro and in vivo, but it can also block cell migration of TNBC cells exposed to soluble CD95L at noncytotoxic (low) concentrations. These data clearly suggest that DHM25, alone or in combination with classical chemotherapy, may be an attractive therapeutic option not only as a primary therapy for TNBC patients but also to reduce/prevent the risk of metastatic occurrence in TNBC patients with high concentrations of serum CD95L.</div><div class="NLM_p last">Among 52 ongoing clinical trials exploring the therapeutic effect of mTOR inhibitors on breast cancer patients, only four are being conducted in metastatic TNBCs using derivatives of the mTORC1 inhibitor rapamycin (e.g., temsirolimus or everolimus) or an imidazoquinoline derivative called BEZ235 (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a>). Nonetheless, preliminary results from these studies confirmed those obtained with temsirolimus and everolimus in individuals with metastatic breast cancer.<a onclick="showRef(event, 'ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref51 ref52">(51,52)</a> Indeed, rapalogues are primarily cytostatic, not cytotoxic, and clinical efficacy largely reflects disease stabilization rather than regression.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> One reason for the compromised clinical benefit of rapalogues is that by only targeting mTORC1, they release the negative feedback circuits of this molecular complex, driving mitogenic signaling by activating the upstream PI3K pathway.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Indeed, mTORC1-driven activation of p70S6K induces insulin receptor substrate degradation, which in turn reduces PI3K activation.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Also, p70S6K phosphorylates Rictor to inhibit mTORC2 activity<a onclick="showRef(event, 'ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref54 ref55">(54,55)</a> and thereby reduces mTORC2-mediated Akt activation. Consequently, everolimus-mediated mTORC1 inhibition leads to Akt activation in tumor biopsies of colon cancers.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Overall, this evidence suggests that competitive inhibitors of mTOR that target both mTORC1 and mTORC2 may represent attractive opportunities to treat PI3K-addicted malignant tumors such as TNBC.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42468" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42468" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Chemistry</h3><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> General Information</h4><div class="NLM_p last">All reagents and solvents were used as purchased from commercial suppliers or were purified/dried according to Armarego and Chai.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a><sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Bruker Avance 300 or 500 instrument using TMS and CDCl<sub>3</sub>, respectively, as internal standard. Chemical shifts (δ values) are given in parts per million (ppm), coupling constants (<i>J</i> values) are given in hertz (Hz), and multiplicity of signals is reported as usual. HRMS analyses were obtained using a Waters Q-TOF 2 or a Bruker MicrO-TOF Q II instrument for ESI. Optical rotations were recorded on a PerkinElmer Model 341 polarimeter. The purity of final tested compounds was typically determined to be ⩾95% by HPLC, conducted on a Shimadzu Prominence system using a Grace Prevail C18 column and diode array detector. Chiral HPLC was performed using a Daicel Chiralpak IA column. Elementary analysis of the injected DHM25 was performed on a Thermo-Fisher ICAP 6500 Duo instrument. Melting points were obtained on a hot bench. VCD spectra were measured on a Bruker Optics Vertex 70 spectrometer and ECD spectra using a Jasco J815 spectrometer. TLC analyses were performed using precoated Merck TLC silica gel 60 F<sub>254</sub> plates. Purifications by column chromatography on silica gel were performed using Grace Davisil Silica Gel 60 (70–200 mesh and 40–60 mesh) and purifications by preparative thin layer chromatography on silica gel using Merck silica gel 60 PF<sub>254</sub>. Petroleum ether (PE) used for purifications was the low boiling point fraction (40–60 °C).</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> General Procedure for the Synthesis of Chromenes</h4><div class="NLM_p last">The mixture of Michael acceptor derivative (1.0 mmol), salicylaldehyde compound (1.0 mmol, 1.0 equiv), and organocatalyst (0.2 mmol, 0.2 equiv) in 1.5 mL of dry toluene was heated at 80–100 °C for 48–72 h under inert atmosphere (conversion followed by TLC). After cooling to room temperature, the mixture was charged directly on the silica gel column for purification.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> Description of the Title Compounds: 6,8-Dibromo-2-(4-bromophenyl)-3-nitro-2<i>H</i>-chromene (DHM25)</h4><div class="NLM_p last">Mp = 150–152 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 6.67 (s, 1H), 7.24 (d, <i>J</i> = 8.5, 2H), 7.40 (d, <i>J</i> = 2.2, 1H), 7.48 (d, <i>J</i> = 8.5, 2H), 7.67 (d, <i>J</i> = 2.2, 1H), 7.95 (s, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 74.1, 112.6, 115.0, 120.7, 124.3, 127.7, 128.6, 131.7, 132.3, 134.8, 139.3, 142.4, 149.4. HRMS [M + H]<sup>+</sup> calculated for C<sub>15</sub>H<sub>9</sub>NO<sub>3</sub>Br<sub>3</sub> 487.8132, found 487.8133. Anal. Calculated for C<sub>15</sub>H<sub>9</sub>NO<sub>3</sub>Br<sub>3</sub>: C, 36.77; H, 1.65, N, 2.86. found: C, 36.29, H, 1.56, N, 2.73. (<i>S</i>)-DHM25: [α]<sub>D</sub> = +154.6 (<i>c</i> = 1, CHCl<sub>3</sub>); (<i>R</i>)-DHM25: [α]<sub>D</sub> = −157.7 (<i>c</i> = 1, CHCl<sub>3</sub>).</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Cell Lines</h3><div class="NLM_p last">All cells were obtained from ATCC (LGC Standards, Molsheim, France). The leukemic T-cell lines CEM, Jurkat, and H9 were cultured in RPMI1640 supplemented with 8% heat-inactivated FCS and 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine in a 5% CO<sub>2</sub> incubator at 37 °C. All breast tumor cells were cultured in DMEM supplemented with 8% heat-inactivated FCS and 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine in a 5% CO<sub>2</sub> incubator at 37 °C.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Antibodies, Plasmids, and Other Reagents</h3><div class="NLM_p last">LY294002 and Wortmannin were obtained from Calbiochem (Merck Chemicals Ltd., Nottingham, UK). AZD8055 was from Selleckchem (Munich, Germany). The chromene and chromene derivatives are solubilized in DMSO (20 mM). Anti-β-actin was purchased from Sigma (L’Isle-d’Abeau-Chesnes, France). Anti-Akt, anti-Akt-P<sup>S473</sup>, anti-4E-BP1, anti-4E-BP1-P<sup>Thr37/46</sup>, anti-S6, anti-S6K–P<sup>Ser240/244</sup>, anti-PTEN, and anti-mTOR were from Cell Signaling Technology (Boston, MA).</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Molecular Modeling</h3><div class="NLM_p last">mTOR structural model was based on the X-ray experimental structure provided by the Protein Data Bank (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JSN">4JSN</a><a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a>) and completed for the missing residues (1814–1867 and 2436–2492) by homology modeling tools distributed by Yasara.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> DHM compounds were parametrized for the Yamber3 force field following the automated AutoSMILE procedure, consisting of AM1 quantum calculation and RESP charge fitting protocol. Initial positions of DHM compounds have been set by analogy to the quercetin placement in the PI3K catalytic site (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1E8W">1E8W</a><a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a>) because of the similarity in the chemical scaffold of ligands and catalytic site of proteins. Each molecular complex was simulated in a neutralized explicit water solvent box, under periodic boundary conditions and at a constant temperature of 298 K. Molecular dynamics (MD) trajectories of 62 ns were collected at 2 ps intervals for both molecular systems. Production period used for analysis was set after the MD simulation reach an equilibrated state (stable root-mean-square deviation). Clustering analysis upon trajectories were performed using the Jarvis–Patrick method implemented in Gromacs tools.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a></div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Pull Down Assay</h3><div class="NLM_p last">CEM cells (10<sup>7</sup>) were preincubated with indicated concentrations of DHM25, its biotin-conjugated counterpart, or DHM9–biotin for 2 h at 37 °C. Then cells were lysed in a denaturating buffer (50 mM Tris pH 7.4, 2 mM EDTA, 150 mM NaCl, 50 mM NaF, 0.5% Na-deoxycholate monohydrate, 1% Triton X-100, 0.1% SDS) complemented with protease and phosphatase inhibitors (Sigma), and biotin-conjugated DHM9 or DHM25 was immunoprecipitated using streptavidin magnetic beads (Ademtech, Pessac, France) for 1 h at 4 °C. After extensive washing, the immune complex was resuspended in a denaturing and reducing Laemmli Sample Buffer (60 mM Tris-Cl pH 6.8, 2% SDS, 10% glycerol, 5% β-mercaptoethanol, 0.01% bromophenol blue), resolved by SDS/PAGE and revealed by Western blot.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Circular Dichroism</h3><div class="NLM_p last">Both enantiomers were obtained by resolution of racemic DHM25 using chiral HPLC (Chiralpak IA column, MeOH as eluent, 1.0 mL/min: RT<sub>DHM25-E1</sub> = 8.13 min, RT<sub>DHM25-E2</sub> = 10.48 min). The absolute configuration of each DHM25 enantiomer was determined by vibrational and electronic circular dichroism (VCD and ECD) by comparison of experimental to predicted spectra. VCD spectra were recorded on a Bruker Vertex70 spectrometer (with a PMA50 module) and theoretical simulated VCD obtained by the SMD/B3PLYP/6-311+G(d,p)/Lanl2dz method. ECD analyses were performed on a Jasco J815 spectrometer and theoretical simulated ECD obtained by the SMD/TD-CAMB3LYP/6-31++G(d,p)/Lanl2dz method. Thus, DHM25-E1 was identified as the (<i>S</i>) enantiomer and DHM25-E2 as the (<i>R</i>) one.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Reversibility Experiments</h3><div class="NLM_p last">CEM cells (2 × 10<sup>6</sup>) were treated in the presence or absence of DHM25 (5 μM) or AZD8055 (5 μM) for 2 h at 37 °C. Next, cells were extensively washed to eliminate the excess of inhibitor, and cells were resuspended in fresh medium. Restoration of mTOR activity was evaluated by monitoring at different times the phosphorylation level of Akt at serine 473.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Detergent Lysis Experiments and Western Blot Analysis</h3><div class="NLM_p last">Cell lyses and Western blot analyses were performed exactly as previously described.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Measure of Cell Death</h3><div class="NLM_p last">Cell death was assessed using either the viability MTT assay.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a></div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Immunoblot Analysis</h3><div class="NLM_p last">Cells were lysed for 30 min at 4 °C in lysis buffer [25 mM HEPES (pH 7.4), 1% v/v Triton X-100, 150 mM NaCl, and 2 mM EGTA supplemented with a mix of protease inhibitors (Sigma)]. Protein concentration was determined by the bicinchoninic acid method (Pierce, Rockford, IL). Proteins were separated by SDS-PAGE and transferred to a nitrocellulose membrane. The membrane was blocked for 30 min with TBST (50 mM Tris, 160 mM NaCl, 0.05% v/v Tween 20, pH 7.8) containing 5% w/v dried skimmed milk and then incubated overnight with primary antibody at 4 °C in TBSTM. The membrane was washed (TBST), and secondary HRP-labeled antibody (SouthernBiotech, US) was added for 45 min. The proteins were visualized with the enhanced chemiluminescence substrate kit (Pierce).</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Kinase Profiler Screening</h3><div class="NLM_p last">To evaluate the kinases targeted by DHM25 and DHM9, Kinase Profiler Service (Millipore) was used with 243 available kinases. The screening was performed with 1 μM of compound and 10 μM ATP and kinase substrates according to Millipore’s protocol.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Immunofluorescence Imaging</h3><div class="NLM_p last">MDA-MB-231 cells were incubated for 3 h at 37 °C with DHM25-FITC (10 μM) or FITC alone. Cells were then washed twice in PBS and fixed for 15 min in PBS containing 4% w/v paraformaldehyde. The aldehyde groups were quenched for 10 min in PBS supplemented with 5% FCS. mTOR was visualized by using 5 μg/mL of goat anti-mTOR mAb (N19, Santa-Cruz, CA) incubated for 20 min at 4 °C, washed, and incubated for another 20 min at 4 °C with antigoat IgG (H+L) coupled with Alexa Fluor 594-conjugated antibody (Life Technologies, CA). Finally, cells were washed twice with PBS, dried, and mounted with 20 μL of mounting medium (Sigma, St. Louis, MO). Images were acquired using a laser scanning confocal system (TCS SP8 model mounted on a DMI 6000 CS inverted microscope, Leica, Heidelberg, Germany). Images were taken using a 40× oil-immersion objective (1.3, N.A.) and analyzed using ImageJ software (NIH, Bethesda, MD).</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> In Vitro Motility Assays</h3><div class="NLM_p last">After membrane hydration of Boyden chambers (Millipore, Molsheim, France) containing 8 μm pore membranes, 10<sup>5</sup> cells were added to the top chamber. The bottom chamber was filled with low serum (1%)-containing medium in the presence or absence of cl-CD95L (100 ng/mL). Breast cancer cells were incubated for 24 h. To quantify invasion, cells were fixed with methanol and stained with Giemsa. Stained cells were then removed from the top-side of the membrane using a cotton-tipped swab, and five representative pictures for each insert were taken of the invading cells from the reverse side. For each experiment, invading cells were lysed and absorbance at 560 nm was measured.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Mouse Experiments</h3><div class="NLM_p last">NOD/SCID/γc null mice (NSG) were obtained from Dr. C. Rivers (UK). All experiments were performed in agreement with the French Guidelines for animal handling and approved by local ethics committee. Luciferase-expressing MDA-MB-231 cells (5 × 10<sup>5</sup> cells in 50 μL of PBS/Matrigel) were transplanted into mammary fat pads of mice (7 weeks old female). Once tumors were palpable, intraperitoneal injection of DHM25 resuspended in PBS/Tween-80/DMSO (8/1/1) or control medium was performed repeatedly 5 days a week until day 46. Bioluminescence analysis was performed using PhotonIMAGER (Biospace Lab) following addition of endotoxin-free luciferin (30 mg/kg). Tumor volume was calculated using the formula <i>V</i> = 0.52 (L × W2). After completion of the analysis, autopsy of mice was performed, and organ luminescence was assessed.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i35"><a href="/doi/suppl/10.1021/acs.jmedchem.5b00991" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24406" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24406" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.5b00991" class="ext-link">10.1021/acs.jmc.5b00991</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Full experimental details and supporting figures (<a href="/doi/suppl/10.1021/acs.jmedchem.5b00991/suppl_file/jm5b00991_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">SMILES data (<a href="/doi/suppl/10.1021/acs.jmedchem.5b00991/suppl_file/jm5b00991_si_004.csv" class="ext-link">XLS</a></p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b00991/suppl_file/jm5b00991_si_001.pdf">jm5b00991_si_001.pdf (1.07 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b00991/suppl_file/jm5b00991_si_002.pdf">jm5b00991_si_002.pdf (4.12 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b00991/suppl_file/jm5b00991_si_003.pdf">jm5b00991_si_003.pdf (79.65 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b00991/suppl_file/jm5b00991_si_004.csv">jm5b00991_si_004.csv (2.93 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.5b00991" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08123" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08123" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pierre van de Weghe</span> - <span class="hlFld-Affiliation affiliation">Université
de Rennes-1, 2 avenue
du Prof. Leon Bernard, 35043 Rennes, France</span>; 
    <span class="hlFld-Affiliation affiliation">UMR6226, CNRS,
Institut des Sciences Chimiques de Rennes, Equipe Produits Naturels,
Synthèses, Chimie Médicinale, UFR des Sciences Biologiques
et Pharmaceutiques, 2 Av. du Professeur
Léon Bernard, 35043 Rennes, France</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#4b3b222e39392e653d2a25662f2e663c2e2c232e0b3e25223d66392e25252e387a652d39"><span class="__cf_email__" data-cfemail="413128243333246f37202f6c25246c362426292401342f28376c33242f2f2432706f2733">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Patrick Legembre</span> - <span class="hlFld-Affiliation affiliation">Université
de Rennes-1, 2 avenue
du Prof. Leon Bernard, 35043 Rennes, France</span>; 
    <span class="hlFld-Affiliation affiliation">CLCC Eugène
Marquis, INSERM ER440 Oncogenesis, Stress & Signaling, rue bataille
Flandres Dunkerque, 35042 Rennes, France</span>; 
    <span class="hlFld-Affiliation affiliation">Equipe Labellisée
Ligue Contre le Cancer, rue bataille Flandres Dunkerque, Rennes, France</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#512130252338323a7f3d3436343c33233411383f2234233c7f3723"><span class="__cf_email__" data-cfemail="e4948590968d878fca8881838189869681a48d8a97819689ca8296">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Amélie Fouqué</span> - <span class="hlFld-Affiliation affiliation">Université
de Rennes-1, 2 avenue
du Prof. Leon Bernard, 35043 Rennes, France</span>; 
    <span class="hlFld-Affiliation affiliation">CLCC Eugène
Marquis, INSERM ER440 Oncogenesis, Stress & Signaling, rue bataille
Flandres Dunkerque, 35042 Rennes, France</span>; 
    <span class="hlFld-Affiliation affiliation">Equipe Labellisée
Ligue Contre le Cancer, rue bataille Flandres Dunkerque, Rennes, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Olivier Delalande</span> - <span class="hlFld-Affiliation affiliation">Université
de Rennes-1, 2 avenue
du Prof. Leon Bernard, 35043 Rennes, France</span>; 
    <span class="hlFld-Affiliation affiliation">IGDR, CNRS UMR
6290, UFR des Sciences Biologiques et Pharmaceutiques, 2 Av. du Professeur Léon Bernard, 35043 Rennes, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mickael Jean</span> - <span class="hlFld-Affiliation affiliation">Université
de Rennes-1, 2 avenue
du Prof. Leon Bernard, 35043 Rennes, France</span>; 
    <span class="hlFld-Affiliation affiliation">UMR6226, CNRS,
Institut des Sciences Chimiques de Rennes, Equipe Produits Naturels,
Synthèses, Chimie Médicinale, UFR des Sciences Biologiques
et Pharmaceutiques, 2 Av. du Professeur
Léon Bernard, 35043 Rennes, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rémy Castellano</span> - <span class="hlFld-Affiliation affiliation">CRCM, INSERM, U1068;
Institut Paoli-Calmettes; Aix-Marseille Université; CNRS, UMR 7258, Marseille, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Emmanuelle Josselin</span> - <span class="hlFld-Affiliation affiliation">CRCM, INSERM, U1068;
Institut Paoli-Calmettes; Aix-Marseille Université; CNRS, UMR 7258, Marseille, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marine Malleter</span> - <span class="hlFld-Affiliation affiliation">Université
de Rennes-1, 2 avenue
du Prof. Leon Bernard, 35043 Rennes, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kenji
F. Shoji</span> - <span class="hlFld-Affiliation affiliation">Université
de Rennes-1, 2 avenue
du Prof. Leon Bernard, 35043 Rennes, France</span>; 
    <span class="hlFld-Affiliation affiliation">INSERM, U1085, 2 avenue du Prof. Leon Bernard, 35043 Rennes, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mac Dinh Hung</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Chemistry, National Vietnam University, 19 Le Thanh Tong, Hanoi, Vietnam</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hariniaina Rampanarivo</span> - <span class="hlFld-Affiliation affiliation">Université
de Rennes-1, 2 avenue
du Prof. Leon Bernard, 35043 Rennes, France</span>; 
    <span class="hlFld-Affiliation affiliation">CLCC Eugène
Marquis, INSERM ER440 Oncogenesis, Stress & Signaling, rue bataille
Flandres Dunkerque, 35042 Rennes, France</span>; 
    <span class="hlFld-Affiliation affiliation">Equipe Labellisée
Ligue Contre le Cancer, rue bataille Flandres Dunkerque, Rennes, France</span>; 
    <span class="hlFld-Affiliation affiliation">IGDR, CNRS UMR
6290, UFR des Sciences Biologiques et Pharmaceutiques, 2 Av. du Professeur Léon Bernard, 35043 Rennes, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yves Collette</span> - <span class="hlFld-Affiliation affiliation">CRCM, INSERM, U1068;
Institut Paoli-Calmettes; Aix-Marseille Université; CNRS, UMR 7258, Marseille, France</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e1362-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i36">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31072" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31072" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by grants from Ligue Contre le Cancer (Comités d’Ille-et-Vilaine, du Morbihan, des Côtes d’Armor, du Finistère et du Maine et Loire), INCa PLBIO, Ouest Valorisation, and Fondation ARC. A.F. is supported by INCa. The authors also thank members of the TrGET and CRCM animal facilities for their technical assistance. TrGET is supported by Institut Paoli-Calmettes (IPC) and Canceropôle PACA. The authors thank the PRISM platform (Université Rennes-1) for NMR experiments.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">mTOR</td><td class="NLM_def"><p class="first last">mammalian target of rapamycin</p></td></tr><tr><td class="NLM_term">mTORC1 and C2</td><td class="NLM_def"><p class="first last">mammalian target of rapamycin complex 1 and 2</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphatidylinositol-4,5-bisphosphate 3-kinase</p></td></tr><tr><td class="NLM_term">PI3KK</td><td class="NLM_def"><p class="first last">phosphatidylinositol 3-OH-kinase-related kinase</p></td></tr><tr><td class="NLM_term">TNBC</td><td class="NLM_def"><p class="first last">triple-negative breast cancers</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i38">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04744" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04744" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 61 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Myers, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pass, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batty, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Kaay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolarov, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemmings, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wigler, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downes, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonks, N. K.</span></span> <span> </span><span class="NLM_article-title">The lipid phosphatase activity of PTEN is critical for its tumor supressor function</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">13513</span>– <span class="NLM_lpage">13518</span>, <span class="refDoi"> DOI: 10.1073/pnas.95.23.13513</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1073%2Fpnas.95.23.13513" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=13513-13518&author=M.+P.+Myersauthor=I.+Passauthor=I.+H.+Battyauthor=J.+Van+der+Kaayauthor=J.+P.+Stolarovauthor=B.+A.+Hemmingsauthor=M.+H.+Wiglerauthor=C.+P.+Downesauthor=N.+K.+Tonks&title=The+lipid+phosphatase+activity+of+PTEN+is+critical+for+its+tumor+supressor+function&doi=10.1073%2Fpnas.95.23.13513"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1073%2Fpnas.95.23.13513&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.95.23.13513%26sid%3Dliteratum%253Aachs%26aulast%3DMyers%26aufirst%3DM.%2BP.%26aulast%3DPass%26aufirst%3DI.%26aulast%3DBatty%26aufirst%3DI.%2BH.%26aulast%3DVan%2Bder%2BKaay%26aufirst%3DJ.%26aulast%3DStolarov%26aufirst%3DJ.%2BP.%26aulast%3DHemmings%26aufirst%3DB.%2BA.%26aulast%3DWigler%26aufirst%3DM.%2BH.%26aulast%3DDownes%26aufirst%3DC.%2BP.%26aulast%3DTonks%26aufirst%3DN.%2BK.%26atitle%3DThe%2520lipid%2520phosphatase%2520activity%2520of%2520PTEN%2520is%2520critical%2520for%2520its%2520tumor%2520supressor%2520function%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1998%26volume%3D95%26spage%3D13513%26epage%3D13518%26doi%3D10.1073%2Fpnas.95.23.13513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stambolic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Pompa, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brothers, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirtsos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penninger, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siderovski, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, T. W.</span></span> <span> </span><span class="NLM_article-title">Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(00)81780-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1016%2FS0092-8674%2800%2981780-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=9778245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADyaK1cXmslWlsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=29-39&author=V.+Stambolicauthor=A.+Suzukiauthor=J.+L.+de+la+Pompaauthor=G.+M.+Brothersauthor=C.+Mirtsosauthor=T.+Sasakiauthor=J.+Rulandauthor=J.+M.+Penningerauthor=D.+P.+Siderovskiauthor=T.+W.+Mak&title=Negative+regulation+of+PKB%2FAkt-dependent+cell+survival+by+the+tumor+suppressor+PTEN&doi=10.1016%2FS0092-8674%2800%2981780-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Negative regulation of PKB/Akt-Dependent cell survival by the tumor suppressor PTEN</span></div><div class="casAuthors">Stambolic, Vuk; Suzuki, Akira; De La Pompa, Jose Lois; Brothers, Greg M.; Mirtsos, Christine; Sasaki, Takehiko; Ruland, Jurgen; Penninger, Josef M.; Siderovski, David P.; Mak, Tak W.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-39</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">PTEN is a tumor suppressor with sequence homol. to protein tyrosine phosphatases and the cytoskeletal protein tensin.  MPTEN-mutant mouse embryos display regions of increased proliferation.  In contrast, mPTEN-deficient immortalized mouse embryonic fibroblasts exhibit decreased sensitivity to cell death in response to a no. of apoptotic stimuli, accompanied by constitutively elevated activity and phosphorylation of protein kinase B/Akt, a crucial regulator of cell survival.  Expression of exogenous PTEN in mutant cells restores both their sensitivity to agonist-induced apoptosis and normal pattern of PKB/Akt phosphorylation.  Furthermore, PTEN neg. regulates intracellular levels of phosphatidylinositol (3,4,5)-trisphosphate in cells and dephosphorylates it in vitro.  Our results show that PTEN may exert its role as a tumor suppressor by neg. regulating the PI3'K/PKB/Akt signaling pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMeJuD58djBrVg90H21EOLACvtfcHk0ljAGecxD-whng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmslWlsr0%253D&md5=d0ffd63a69325f1296d08bdbc16c5f0f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2981780-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252981780-8%26sid%3Dliteratum%253Aachs%26aulast%3DStambolic%26aufirst%3DV.%26aulast%3DSuzuki%26aufirst%3DA.%26aulast%3Dde%2Bla%2BPompa%26aufirst%3DJ.%2BL.%26aulast%3DBrothers%26aufirst%3DG.%2BM.%26aulast%3DMirtsos%26aufirst%3DC.%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DRuland%26aufirst%3DJ.%26aulast%3DPenninger%26aufirst%3DJ.%2BM.%26aulast%3DSiderovski%26aufirst%3DD.%2BP.%26aulast%3DMak%26aufirst%3DT.%2BW.%26atitle%3DNegative%2520regulation%2520of%2520PKB%252FAkt-dependent%2520cell%2520survival%2520by%2520the%2520tumor%2520suppressor%2520PTEN%26jtitle%3DCell%26date%3D1998%26volume%3D95%26spage%3D29%26epage%3D39%26doi%3D10.1016%2FS0092-8674%2800%2981780-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gewinner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teruya-Feldstein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Etemadmoghadam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowtell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barretina, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rameh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salmena, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandolfi, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span> <span> </span><span class="NLM_article-title">Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">125</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2009.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1016%2Fj.ccr.2009.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=19647222" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVCjsrfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=115-125&author=C.+Gewinnerauthor=Z.+C.+Wangauthor=A.+Richardsonauthor=J.+Teruya-Feldsteinauthor=D.+Etemadmoghadamauthor=D.+Bowtellauthor=J.+Barretinaauthor=W.+M.+Linauthor=L.+Ramehauthor=L.+Salmenaauthor=P.+P.+Pandolfiauthor=L.+C.+Cantley&title=Evidence+that+inositol+polyphosphate+4-phosphatase+type+II+is+a+tumor+suppressor+that+inhibits+PI3K+signaling&doi=10.1016%2Fj.ccr.2009.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling</span></div><div class="casAuthors">Gewinner, Christina; Wang, Zhigang C.; Richardson, Andrea; Teruya-Feldstein, Julie; Etemadmoghadam, Dariush; Bowtell, David; Barretina, Jordi; Lin, William M.; Rameh, Lucia; Salmena, Leonardo; Pandolfi, Pier Paolo; Cantley, Lewis C.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">115-125</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">We report that knocking down the expression of inositol polyphosphate 4-phosphatase type II (INPP4B) in human epithelial cells, like knockdown of PTEN, resulted in enhanced Akt activation and anchorage-independent growth and enhanced overall motility.  In xenograft expts., overexpression of INPP4B resulted in reduced tumor growth.  INPP4B preferentially hydrolyzes phosphatidylinositol-3,4-bisphosphate (PI(3,4)P2) with no effect on phosphatidylinositol-3,4,5-trisphosphate (PI(3,4,5)P3), suggesting that PI(3,4)P2 and PI(3,4,5)P3 may cooperate in Akt activation and cell transformation.  Dual knockdown of INPP4B and PTEN resulted in cellular senescence.  Finally, we found loss of heterozygosity (LOH) at the INPP4B locus in a majority of basal-like breast cancers, as well as in a significant fraction of ovarian cancers, which correlated with lower overall patient survival, suggesting that INPP4B is a tumor suppressor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOv8VFGY_XorVg90H21EOLACvtfcHk0ljAGecxD-whng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVCjsrfL&md5=c7c4d81e03f1f8b515a7a6cb3c6864f9</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2009.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2009.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DGewinner%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DZ.%2BC.%26aulast%3DRichardson%26aufirst%3DA.%26aulast%3DTeruya-Feldstein%26aufirst%3DJ.%26aulast%3DEtemadmoghadam%26aufirst%3DD.%26aulast%3DBowtell%26aufirst%3DD.%26aulast%3DBarretina%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DW.%2BM.%26aulast%3DRameh%26aufirst%3DL.%26aulast%3DSalmena%26aufirst%3DL.%26aulast%3DPandolfi%26aufirst%3DP.%2BP.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DEvidence%2520that%2520inositol%2520polyphosphate%25204-phosphatase%2520type%2520II%2520is%2520a%2520tumor%2520suppressor%2520that%2520inhibits%2520PI3K%2520signaling%26jtitle%3DCancer%2520Cell%26date%3D2009%26volume%3D16%26spage%3D115%26epage%3D125%26doi%3D10.1016%2Fj.ccr.2009.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alessi, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downes, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaffney, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reese, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span> <span> </span><span class="NLM_article-title">Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha</span>. <i>Curr. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">261</span>– <span class="NLM_lpage">269</span>, <span class="refDoi"> DOI: 10.1016/S0960-9822(06)00122-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1016%2FS0960-9822%2806%2900122-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=9094314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADyaK2sXjsFOjtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1997&pages=261-269&author=D.+R.+Alessiauthor=S.+R.+Jamesauthor=C.+P.+Downesauthor=A.+B.+Holmesauthor=P.+R.+Gaffneyauthor=C.+B.+Reeseauthor=P.+Cohen&title=Characterization+of+a+3-phosphoinositide-dependent+protein+kinase+which+phosphorylates+and+activates+protein+kinase+Balpha&doi=10.1016%2FS0960-9822%2806%2900122-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα</span></div><div class="casAuthors">Alessi, Dario R.; James, Stephen R.; Downes, C. Peter; Holmes, Andrew B.; Gaffney, Piers R. J.; Reese, Colin B.; Cohen, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Current Biology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">261-269</span>CODEN:
                <span class="NLM_cas:coden">CUBLE2</span>;
        ISSN:<span class="NLM_cas:issn">0960-9822</span>.
    
            (<span class="NLM_cas:orgname">Current Biology</span>)
        </div><div class="casAbstract">Protein kinase B (PKB), also known as c-Akt, is activated rapidly when mammalian cells are stimulated with insulin and growth factors, and much of the current interest in this enzyme stems from the observation that it lies 'downstream' of phosphoinositide 3-kinase on intracellular signaling pathways.  We recently showed that insulin or insulin-like growth factor 1 induce the phosphorylation of PKB at two residues, Thr308 and Ser473.  The phosphorylation of both residues is required for maximal activation of PKB. The kinases that phosphorylate PKB are, however, unknown.  We have purified 500,000-fold from rabbit skeletal muscle exts. a protein kinase which phosphorylates PKBα at Thr308 and increases its activity over 30-fold.  We tested the kinase in the presence of several inositol phospholipids and found that only low micromolar concns. of the D enantiomers of either phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P3) or PtdIns(3,4)P2 were effective in potently activating the kinase, which has been named PtdIns(3,4,5)P3-dependent protein kinase-1 (PDK1).  None of the inositol phospholipids tested activated or inhibited PKBα or induced its phosphorylation under the conditions used.  PDK1 activity was not affected by wortmannin, indicating that it is not likely to be a member of the phosphoinositide 3-kinase family.  PDK1 is likely to be one of the protein kinases that mediate the activation of PKB by insulin and growth factors.  PDK1 may, therefore, play a key role in mediating many of the actions of the second messenger(s) PtdIns(3,4,5)P3 and/or PtdIns(3,4)P2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2sSM5v7MnWrVg90H21EOLACvtfcHk0ljAGecxD-whng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjsFOjtb8%253D&md5=7f3794216810a4273d091b8d4590aaa9</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS0960-9822%2806%2900122-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-9822%252806%252900122-9%26sid%3Dliteratum%253Aachs%26aulast%3DAlessi%26aufirst%3DD.%2BR.%26aulast%3DJames%26aufirst%3DS.%2BR.%26aulast%3DDownes%26aufirst%3DC.%2BP.%26aulast%3DHolmes%26aufirst%3DA.%2BB.%26aulast%3DGaffney%26aufirst%3DP.%2BR.%26aulast%3DReese%26aufirst%3DC.%2BB.%26aulast%3DCohen%26aufirst%3DP.%26atitle%3DCharacterization%2520of%2520a%25203-phosphoinositide-dependent%2520protein%2520kinase%2520which%2520phosphorylates%2520and%2520activates%2520protein%2520kinase%2520Balpha%26jtitle%3DCurr.%2520Biol.%26date%3D1997%26volume%3D7%26spage%3D261%26epage%3D269%26doi%3D10.1016%2FS0960-9822%2806%2900122-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guertin, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thoreen, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burds, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalaany, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moffat, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span> <span> </span><span class="NLM_article-title">Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1</span>. <i>Dev. Cell</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">859</span>– <span class="NLM_lpage">871</span>, <span class="refDoi"> DOI: 10.1016/j.devcel.2006.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1016%2Fj.devcel.2006.10.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2006&pages=859-871&author=D.+A.+Guertinauthor=D.+M.+Stevensauthor=C.+C.+Thoreenauthor=A.+A.+Burdsauthor=N.+Y.+Kalaanyauthor=J.+Moffatauthor=M.+Brownauthor=K.+J.+Fitzgeraldauthor=D.+M.+Sabatini&title=Ablation+in+mice+of+the+mTORC+components+raptor%2C+rictor%2C+or+mLST8+reveals+that+mTORC2+is+required+for+signaling+to+Akt-FOXO+and+PKCalpha%2C+but+not+S6K1&doi=10.1016%2Fj.devcel.2006.10.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.devcel.2006.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.devcel.2006.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DGuertin%26aufirst%3DD.%2BA.%26aulast%3DStevens%26aufirst%3DD.%2BM.%26aulast%3DThoreen%26aufirst%3DC.%2BC.%26aulast%3DBurds%26aufirst%3DA.%2BA.%26aulast%3DKalaany%26aufirst%3DN.%2BY.%26aulast%3DMoffat%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DFitzgerald%26aufirst%3DK.%2BJ.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DAblation%2520in%2520mice%2520of%2520the%2520mTORC%2520components%2520raptor%252C%2520rictor%252C%2520or%2520mLST8%2520reveals%2520that%2520mTORC2%2520is%2520required%2520for%2520signaling%2520to%2520Akt-FOXO%2520and%2520PKCalpha%252C%2520but%2520not%2520S6K1%26jtitle%3DDev.%2520Cell%26date%3D2006%26volume%3D11%26spage%3D859%26epage%3D871%26doi%3D10.1016%2Fj.devcel.2006.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrazola, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hino, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ru, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, D.</span></span> <span> </span><span class="NLM_article-title">Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">699</span>– <span class="NLM_lpage">704</span>, <span class="refDoi"> DOI: 10.1038/ncb847</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1038%2Fncb847" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=12172555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD38Xms1ahtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2002&pages=699-704&author=X.+Gaoauthor=Y.+Zhangauthor=P.+Arrazolaauthor=O.+Hinoauthor=T.+Kobayashiauthor=R.+S.+Yeungauthor=B.+Ruauthor=D.+Pan&title=Tsc+tumour+suppressor+proteins+antagonize+amino-acid-TOR+signalling&doi=10.1038%2Fncb847"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">TSC tumour suppressor proteins antagonize amino-acid-TOR signalling</span></div><div class="casAuthors">Gao, Xinsheng; Zhang, Yong; Arrazola, Peter; Hino, Okio; Kobayashi, Toshiyuki; Yeung, Raymond S.; Ru, Binggeng; Pan, Duojia</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">699-704</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Target of rapamycin (TOR, protein kinase) mediates a signalling pathway that couples amino acid availability to S6 kinase (S6K) activation, translational initiation, and cell growth.  Tuberous sclerosis 1 (Tsc1) and Tsc2 tumor suppressors responsible for the tuberous sclerosis syndrome can antagonize this amino acid-TOR signalling pathway.  The Tsc1 and Tsc2 can be phys. assoc. with TOR and function upstream of TOR genetically.  In Drosophila melanogaster and mammalian cells, loss of Tsc1 and Tsc2 results in a TOR-dependent increase of the S6K activity.  Although S6K is normally inactivated in animal cells in response to amino acid starvation, the loss of Tsc1-Tsc2 renders cells resistant to amino acid starvation.  The Tsc1-Tsc2 complex may antagonize the TOR-mediated response to amino acid availability.  This study with Drosophila cells identified Tsc1 and Tsc2 as regulators of the amino acid-TOR pathway and provide a new paradigm for how proteins involved in nutrient sensing may function as tumor suppressors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4cE31P84rTLVg90H21EOLACvtfcHk0lgt_0oXgSN7jA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xms1ahtbY%253D&md5=daa9269b4d1f26637dd7b62d8b54d23d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fncb847&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncb847%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DArrazola%26aufirst%3DP.%26aulast%3DHino%26aufirst%3DO.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DYeung%26aufirst%3DR.%2BS.%26aulast%3DRu%26aufirst%3DB.%26aulast%3DPan%26aufirst%3DD.%26atitle%3DTsc%2520tumour%2520suppressor%2520proteins%2520antagonize%2520amino-acid-TOR%2520signalling%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2002%26volume%3D4%26spage%3D699%26epage%3D704%26doi%3D10.1038%2Fncb847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Inoki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, K. L.</span></span> <span> </span><span class="NLM_article-title">TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">648</span>– <span class="NLM_lpage">657</span>, <span class="refDoi"> DOI: 10.1038/ncb839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1038%2Fncb839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=12172553" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD38Xms1ahtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2002&pages=648-657&author=K.+Inokiauthor=Y.+Liauthor=T.+Zhuauthor=J.+Wuauthor=K.+L.+Guan&title=TSC2+is+phosphorylated+and+inhibited+by+Akt+and+suppresses+mTOR+signalling&doi=10.1038%2Fncb839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signaling</span></div><div class="casAuthors">Inoki, Ken; Li, Yong; Zhu, Tianquan; Wu, Jun; Guan, Kun-Liang</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">648-657</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Tuberous sclerosis (TSC) is an autosomal dominant disorder characterized by the formation of hamartomas in a wide range of human tissues.  Mutation in either the TSC1 or TSC2 tumor suppressor gene is responsible for both the familial and sporadic forms of this disease.  TSC1 and TSC2 proteins form a phys. and functional complex in vivo.  Here, we show that TSC1-TSC2 inhibits the p70 ribosomal protein S6 kinase 1 (an activator of translation) and activates the eukaryotic initiation factor 4E binding protein 1 (4E-BP1, an inhibitor of translational initiation).  These functions of TSC1-TSC2 are mediated by inhibition of the mammalian target of rapamycin (mTOR).  Furthermore, TSC2 is directly phosphorylated by Akt, which is involved in stimulating cell growth and is activated by growth stimulating signals, such as insulin.  TSC2 is inactivated by Akt-dependent phosphorylation, which destabilizes TSC2 and disrupts its interaction with TSC1.  Our data indicate a mol. mechanism for TSC2 in insulin signaling, tumor suppressor functions and in the inhibition of cell growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvbCMw4JBsjLVg90H21EOLACvtfcHk0lgt_0oXgSN7jA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xms1ahtL4%253D&md5=bbf55234408a5ac14f49a8c63bfb24e4</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fncb839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncb839%26sid%3Dliteratum%253Aachs%26aulast%3DInoki%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DGuan%26aufirst%3DK.%2BL.%26atitle%3DTSC2%2520is%2520phosphorylated%2520and%2520inhibited%2520by%2520Akt%2520and%2520suppresses%2520mTOR%2520signalling%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2002%26volume%3D4%26spage%3D648%26epage%3D657%26doi%3D10.1038%2Fncb839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tee, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fingar, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blenis, J.</span></span> <span> </span><span class="NLM_article-title">Tuberous sclerosis complex-1 and −2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">13571</span>– <span class="NLM_lpage">13576</span>, <span class="refDoi"> DOI: 10.1073/pnas.202476899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1073%2Fpnas.202476899" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=13571-13576&author=A.+R.+Teeauthor=D.+C.+Fingarauthor=B.+D.+Manningauthor=D.+J.+Kwiatkowskiauthor=L.+C.+Cantleyauthor=J.+Blenis&title=Tuberous+sclerosis+complex-1+and+%E2%88%922+gene+products+function+together+to+inhibit+mammalian+target+of+rapamycin+%28mTOR%29-mediated+downstream+signaling&doi=10.1073%2Fpnas.202476899"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1073%2Fpnas.202476899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.202476899%26sid%3Dliteratum%253Aachs%26aulast%3DTee%26aufirst%3DA.%2BR.%26aulast%3DFingar%26aufirst%3DD.%2BC.%26aulast%3DManning%26aufirst%3DB.%2BD.%26aulast%3DKwiatkowski%26aufirst%3DD.%2BJ.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DBlenis%26aufirst%3DJ.%26atitle%3DTuberous%2520sclerosis%2520complex-1%2520and%2520%25E2%2588%25922%2520gene%2520products%2520function%2520together%2520to%2520inhibit%2520mammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529-mediated%2520downstream%2520signaling%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2002%26volume%3D99%26spage%3D13571%26epage%3D13576%26doi%3D10.1073%2Fpnas.202476899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Inoki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, K. L.</span></span> <span> </span><span class="NLM_article-title">Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling</span>. <i>Genes Dev.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1829</span>– <span class="NLM_lpage">1834</span>, <span class="refDoi"> DOI: 10.1101/gad.1110003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1101%2Fgad.1110003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=12869586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmt1Sjtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2003&pages=1829-1834&author=K.+Inokiauthor=Y.+Liauthor=T.+Xuauthor=K.+L.+Guan&title=Rheb+GTPase+is+a+direct+target+of+TSC2+GAP+activity+and+regulates+mTOR+signaling&doi=10.1101%2Fgad.1110003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling</span></div><div class="casAuthors">Inoki, Ken; Li, Yong; Xu, Tian; Guan, Kun-Liang</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1829-1834</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">Tuberous sclerosis complex (TSC) is a genetic disease caused by mutation in either TSC1 or TSC2.  The TSC1 and TSC2 gene products form a functional complex and inhibit phosphorylation of S6K and 4EBP1.  These functions of TSC1/TSC2 are likely mediated by mTOR.  Here we report that TSC2 is a GTPase-activating protein (GAP) toward Rheb, a Ras family GTPase.  Rheb stimulates phosphorylation of S6K and 4EBP1.  This function of Rheb is blocked by rapamycin and dominant-neg. mTOR.  Rheb stimulates the phosphorylation of mTOR and plays an essential role in regulation of S6K and 4EBP1 in response to nutrients and cellular energy status.  Our data demonstrate that Rheb acts downstream of TSC1/TSC2 and upstream of mTOR to regulate cell growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJUyx1ixLM-LVg90H21EOLACvtfcHk0liiMoK4d9uwfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmt1Sjtrk%253D&md5=40f03531da52ce6f20a13268a7c92e0e</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1101%2Fgad.1110003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.1110003%26sid%3Dliteratum%253Aachs%26aulast%3DInoki%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DGuan%26aufirst%3DK.%2BL.%26atitle%3DRheb%2520GTPase%2520is%2520a%2520direct%2520target%2520of%2520TSC2%2520GAP%2520activity%2520and%2520regulates%2520mTOR%2520signaling%26jtitle%3DGenes%2520Dev.%26date%3D2003%26volume%3D17%26spage%3D1829%26epage%3D1834%26doi%3D10.1101%2Fgad.1110003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarbassov, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guertin, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>307</i></span>,  <span class="NLM_fpage">1098</span>– <span class="NLM_lpage">1101</span>, <span class="refDoi"> DOI: 10.1126/science.1106148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1126%2Fscience.1106148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=15718470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSrtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=2005&pages=1098-1101&author=D.+D.+Sarbassovauthor=D.+A.+Guertinauthor=S.+M.+Aliauthor=D.+M.+Sabatini&title=Phosphorylation+and+regulation+of+Akt%2FPKB+by+the+rictor-mTOR+complex&doi=10.1126%2Fscience.1106148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex</span></div><div class="casAuthors">Sarbassov, Dos D.; Guertin, David A.; Ali, Siraj M.; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">307</span>
        (<span class="NLM_cas:issue">5712</span>),
    <span class="NLM_cas:pages">1098-1101</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Deregulation of Akt/protein kinase B (PKB) is implicated in the pathogenesis of cancer and diabetes.  Akt/PKB activation requires the phosphorylation of Thr308 in the activation loop by the phosphoinositide-dependent kinase 1 (PDK1) and Ser473 within the carboxyl-terminal hydrophobic motif by an unknown kinase.  We show that in Drosophila and human cells the target of rapamycin (TOR) kinase and its assocd. protein rictor are necessary for Ser473 phosphorylation and that a redn. in rictor or mammalian TOR (mTOR) expression inhibited an Akt/PKB effector.  The rictor-mTOR complex directly phosphorylated Akt/PKB on Ser473 in vitro and facilitated Thr308 phosphorylation by PDK1.  Rictor-mTOR may serve as a drug target in tumors that have lost the expression of PTEN, a tumor suppressor that opposes Akt/PKB activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfO1KyVE3glrVg90H21EOLACvtfcHk0liiMoK4d9uwfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSrtbY%253D&md5=de758fd8128561e34301e67a42ae13a6</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1126%2Fscience.1106148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1106148%26sid%3Dliteratum%253Aachs%26aulast%3DSarbassov%26aufirst%3DD.%2BD.%26aulast%3DGuertin%26aufirst%3DD.%2BA.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DPhosphorylation%2520and%2520regulation%2520of%2520Akt%252FPKB%2520by%2520the%2520rictor-mTOR%2520complex%26jtitle%3DScience%26date%3D2005%26volume%3D307%26spage%3D1098%26epage%3D1101%26doi%3D10.1126%2Fscience.1106148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manning, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logsdon, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipovsky, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbott, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span> <span> </span><span class="NLM_article-title">Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2</span>. <i>Genes Dev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1773</span>– <span class="NLM_lpage">1778</span>, <span class="refDoi"> DOI: 10.1101/gad.1314605</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1101%2Fgad.1314605" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=16027169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD2MXotFahtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2005&pages=1773-1778&author=B.+D.+Manningauthor=M.+N.+Logsdonauthor=A.+I.+Lipovskyauthor=D.+Abbottauthor=D.+J.+Kwiatkowskiauthor=L.+C.+Cantley&title=Feedback+inhibition+of+Akt+signaling+limits+the+growth+of+tumors+lacking+Tsc2&doi=10.1101%2Fgad.1314605"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2</span></div><div class="casAuthors">Manning, Brendan D.; Logsdon, M. Nicole; Lipovsky, Alex I.; Abbott, Derek; Kwiatkowski, David J.; Cantley, Lewis C.</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1773-1778</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">The PTEN and TSC2 tumor suppressors inhibit mammalian target of rapamycin (mTOR) signaling and are defective in distinct hamartoma syndromes.  Using mouse genetics, we find that Pten and Tsc2 act synergistically to suppress the severity of a subset of tumors specific to loss of each of these genes.  Interestingly, we find that the slow-growing tumors specific to Tsc2+/- mice exhibit defects in signaling downstream of Akt.  However, Pten haploinsufficiency restores Akt signaling in these tumors and dramatically enhances their severity.  This study demonstrates that attenuation of the PI3K-Akt pathway in tumors lacking TSC2 contributes to their benign nature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwKGLsPscfT7Vg90H21EOLACvtfcHk0liiMoK4d9uwfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXotFahtrk%253D&md5=a6715a7e1831d6c0d63b6d3fefc192b9</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1101%2Fgad.1314605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.1314605%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DB.%2BD.%26aulast%3DLogsdon%26aufirst%3DM.%2BN.%26aulast%3DLipovsky%26aufirst%3DA.%2BI.%26aulast%3DAbbott%26aufirst%3DD.%26aulast%3DKwiatkowski%26aufirst%3DD.%2BJ.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DFeedback%2520inhibition%2520of%2520Akt%2520signaling%2520limits%2520the%2520growth%2520of%2520tumors%2520lacking%2520Tsc2%26jtitle%3DGenes%2520Dev.%26date%3D2005%26volume%3D19%26spage%3D1773%26epage%3D1778%26doi%3D10.1101%2Fgad.1314605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Reilly, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rojo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">She, Q. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicklin, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span> <span> </span><span class="NLM_article-title">mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">1500</span>– <span class="NLM_lpage">1508</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-05-2925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1158%2F0008-5472.CAN-05-2925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=16452206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD28XpsVegtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=1500-1508&author=K.+E.+O%E2%80%99Reillyauthor=F.+Rojoauthor=Q.+B.+Sheauthor=D.+Solitauthor=G.+B.+Millsauthor=D.+Smithauthor=H.+Laneauthor=F.+Hofmannauthor=D.+J.+Hicklinauthor=D.+L.+Ludwigauthor=J.+Baselgaauthor=N.+Rosen&title=mTOR+inhibition+induces+upstream+receptor+tyrosine+kinase+signaling+and+activates+Akt&doi=10.1158%2F0008-5472.CAN-05-2925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt</span></div><div class="casAuthors">O'Reilly, Kathryn E.; Rojo, Fredi; She, Qing-Bai; Solit, David; Mills, Gordon B.; Smith, Debra; Lane, Heidi; Hofmann, Francesco; Hicklin, Daniel J.; Ludwig, Dale L.; Baselga, Jose; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1500-1508</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Stimulation of the insulin and insulin-like growth factor I (IGF-I) receptor activates the phosphoinositide-3-kinase/Akt/mTOR pathway causing pleiotropic cellular effects including an mTOR-dependent loss in insulin receptor substrate-1 expression leading to feedback down-regulation of signaling through the pathway.  In model systems, tumors exhibiting mutational activation of phosphoinositide-3-kinase/Akt kinase, a common event in cancers, are hypersensitive to mTOR inhibitors, including rapamycin.  Despite the activity in model systems, in patients, mTOR inhibitors exhibit more modest antitumor activity.  We now show that mTOR inhibition induces insulin receptor substrate-1 expression and abrogates feedback inhibition of the pathway, resulting in Akt activation both in cancer cell lines and in patient tumors treated with the rapamycin deriv., RAD001.  IGF-I receptor inhibition prevents rapamycin-induced Akt activation and sensitizes tumor cells to inhibition of mTOR.  In contrast, IGF-I reverses the antiproliferative effects of rapamycin in serum-free medium.  The data suggest that feedback down-regulation of receptor tyrosine kinase signaling is a frequent event in tumor cells with constitutive mTOR activation.  Reversal of this feedback loop by rapamycin may attenuate its therapeutic effects, whereas combination therapy that ablates mTOR function and prevents Akt activation may have improved antitumor activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIDQUdQ-jbi7Vg90H21EOLACvtfcHk0ljbLA0eoVhi2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpsVegtg%253D%253D&md5=758cd9999dc156bf498edf32174fc2e7</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-2925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-2925%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DK.%2BE.%26aulast%3DRojo%26aufirst%3DF.%26aulast%3DShe%26aufirst%3DQ.%2BB.%26aulast%3DSolit%26aufirst%3DD.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DLane%26aufirst%3DH.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DHicklin%26aufirst%3DD.%2BJ.%26aulast%3DLudwig%26aufirst%3DD.%2BL.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DmTOR%2520inhibition%2520induces%2520upstream%2520receptor%2520tyrosine%2520kinase%2520signaling%2520and%2520activates%2520Akt%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D1500%26epage%3D1508%26doi%3D10.1158%2F0008-5472.CAN-05-2925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vezina, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudelski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sehgal, S. N.</span></span> <span> </span><span class="NLM_article-title">Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle</span>. <i>J. Antibiot.</i> <span class="NLM_year" style="font-weight: bold;">1975</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">721</span>– <span class="NLM_lpage">726</span>, <span class="refDoi"> DOI: 10.7164/antibiotics.28.721</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.7164%2Fantibiotics.28.721" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1102508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADyaE28Xis1eruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=1975&pages=721-726&author=C.+Vezinaauthor=A.+Kudelskiauthor=S.+N.+Sehgal&title=Rapamycin+%28AY-22%2C989%29%2C+a+new+antifungal+antibiotic.+I.+Taxonomy+of+the+producing+streptomycete+and+isolation+of+the+active+principle&doi=10.7164%2Fantibiotics.28.721"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Rapamycin (AY-22,989), a new antifungal antibiotic.  I.  Taxonomy of the producing streptomycete and isolation of the active principle</span></div><div class="casAuthors">Vezina, Claude; Kudelski, Alicia; Sehgal, S. N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antibiotics</span>
        (<span class="NLM_cas:date">1975</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">721-6</span>CODEN:
                <span class="NLM_cas:coden">JANTAJ</span>;
        ISSN:<span class="NLM_cas:issn">0021-8820</span>.
    </div><div class="casAbstract">Rapamycin (AY-22,989) [53123-88-9] was extd. from the mycelium of Streptomyces hygroscopicus, a streptomyate isolated from an Easter Island soil.  Rapamycin was mainly active against Candida albicans; the min. inhibitory concns. were 0.02-0.2 μg/ml.  It was less active against Microsporum gypseum and Trichophyton granulosum, apparently because of its instability in the culture medium during the prolonged incubation required by these dermatophytes.  Rapamycin was inactive against gram-pos. and gram-neg. bacteria and had low toxicity in mice, the i.p. and oral LD50 values being ∼600 and >2500 mg/kg, resp.  The isolation and purifn. of rapamycin are described, as well as the taxonomic characteristics of the source organism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxg4lqjf3RxrVg90H21EOLACvtfcHk0ljbLA0eoVhi2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE28Xis1eruw%253D%253D&md5=6e4e2119e9b8fdd6d3a47fae665120e9</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.7164%2Fantibiotics.28.721&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7164%252Fantibiotics.28.721%26sid%3Dliteratum%253Aachs%26aulast%3DVezina%26aufirst%3DC.%26aulast%3DKudelski%26aufirst%3DA.%26aulast%3DSehgal%26aufirst%3DS.%2BN.%26atitle%3DRapamycin%2520%2528AY-22%252C989%2529%252C%2520a%2520new%2520antifungal%2520antibiotic.%2520I.%2520Taxonomy%2520of%2520the%2520producing%2520streptomycete%2520and%2520isolation%2520of%2520the%2520active%2520principle%26jtitle%3DJ.%2520Antibiot.%26date%3D1975%26volume%3D28%26spage%3D721%26epage%3D726%26doi%3D10.7164%2Fantibiotics.28.721" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albers, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichikawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keith, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span> <span> </span><span class="NLM_article-title">A mammalian protein targeted by G1-arresting rapamycin-receptor complex</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>369</i></span>,  <span class="NLM_fpage">756</span>– <span class="NLM_lpage">758</span>, <span class="refDoi"> DOI: 10.1038/369756a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1038%2F369756a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=8008069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADyaK2cXlsFSiu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=1994&pages=756-758&author=E.+J.+Brownauthor=M.+W.+Albersauthor=T.+B.+Shinauthor=K.+Ichikawaauthor=C.+T.+Keithauthor=W.+S.+Laneauthor=S.+L.+Schreiber&title=A+mammalian+protein+targeted+by+G1-arresting+rapamycin-receptor+complex&doi=10.1038%2F369756a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">A mammalian protein targeted by G1-arresting rapamycin-receptor complex</span></div><div class="casAuthors">Brown, Eric J.; Albers, Mark W.; Shin, Tae Bum; Ichikawa, Kazuo; Keith, Curtis T.; Lane, William S.; Schreiber, Stuart L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">6483</span>),
    <span class="NLM_cas:pages">756-8</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">The structurally related natural products rapamycin and FK506 bind to the same intracellular receptor, FKBP12, yet the resulting complexes interfere with distinct signaling pathway.  FKBP12-rapamycin inhibits progression through the G1 phase of the cell cycle in osteosarcoma, liver and T cells as well as in yeast, and interferes with mitogenic signaling pathways that are involved in G1 progression, namely with activation of the protein p70S6k and cyclin-dependent kinases.  Here the authors isolate a mammalian FKBP-rapamycin-assocd. protein (FRAP) whose binding to structural variants of rapamycin complexed to FKBP12 correlates with the ability of these ligands to inhibit cell-cycle progression.  Peptide sequences from purified bovine FRAP were used to isolate a human cDNA clone that is highly related to the DRR1/TOR1 and DRR2/TOR2 gene products form Saccharomyces cerevisiae.  Although it has not been previously demonstrated that either of the DRR/TOR gene products can bind the FKBP-rapamycin complex directly, these yeast genes have been genetically linked to a rapamycin-sensitive pathway and are through to encode lipid kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdC-Z1-1ylr7Vg90H21EOLACvtfcHk0ljbLA0eoVhi2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXlsFSiu74%253D&md5=b5c34fc2333e81011d6730cc196eb21a</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2F369756a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F369756a0%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DE.%2BJ.%26aulast%3DAlbers%26aufirst%3DM.%2BW.%26aulast%3DShin%26aufirst%3DT.%2BB.%26aulast%3DIchikawa%26aufirst%3DK.%26aulast%3DKeith%26aufirst%3DC.%2BT.%26aulast%3DLane%26aufirst%3DW.%2BS.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26atitle%3DA%2520mammalian%2520protein%2520targeted%2520by%2520G1-arresting%2520rapamycin-receptor%2520complex%26jtitle%3DNature%26date%3D1994%26volume%3D369%26spage%3D756%26epage%3D758%26doi%3D10.1038%2F369756a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdjument-Bromage, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tempst, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, S. H.</span></span> <span> </span><span class="NLM_article-title">RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">35</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1016/0092-8674(94)90570-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1016%2F0092-8674%2894%2990570-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=7518356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADyaK2cXlvFOhu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=1994&pages=35-43&author=D.+M.+Sabatiniauthor=H.+Erdjument-Bromageauthor=M.+Luiauthor=P.+Tempstauthor=S.+H.+Snyder&title=RAFT1%3A+a+mammalian+protein+that+binds+to+FKBP12+in+a+rapamycin-dependent+fashion+and+is+homologous+to+yeast+TORs&doi=10.1016%2F0092-8674%2894%2990570-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs</span></div><div class="casAuthors">Sabatini, David M.; Erdjument-Bromage, Hediye; Lui, Mary; Tempst, Paul; Snyder, Solomon H.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">35-43</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    </div><div class="casAbstract">The immunosuppressants rapamycin and FK506 bind to the same intracellular protein, the immunophilin FKBP12.  The FKBP12-FK506 complex interacts with the inhibits the Ca2+-activated protein phosphatase calcineurin.  The target of the FKBP12-rapamycin complex has not yet been identified.  The authors report that a protein complex contg. 245 kDa and FKBP12 targets 1 and 2 (RAFT1 and RAFT2), interacts with FKBP12 in a rapamycin-dependent manner.  Sequence (330 amino acids total) of tryptic peptides derived from one 245 kDa RAFT1 reveal striking homologies to the yeast TOR gene products, which were originally identified by mutations that confer rapamycin resistance in yeast.  A RAFT1 cDNA was obtained and found to encode a 289 kDa protein (2549 amino acids) that is 43% and 39% identical to TOR2 and TOR1, resp.  The authors propose that RAFT1 is the direct target of FKBP12-rapamycin and a mammalian homolog of the TOR proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHLQ78s1yfu7Vg90H21EOLACvtfcHk0liyeN11dU0gWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXlvFOhu7Y%253D&md5=062fe79756f6bc632e332d0b1921846d</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2894%2990570-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252894%252990570-3%26sid%3Dliteratum%253Aachs%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26aulast%3DErdjument-Bromage%26aufirst%3DH.%26aulast%3DLui%26aufirst%3DM.%26aulast%3DTempst%26aufirst%3DP.%26aulast%3DSnyder%26aufirst%3DS.%2BH.%26atitle%3DRAFT1%253A%2520a%2520mammalian%2520protein%2520that%2520binds%2520to%2520FKBP12%2520in%2520a%2520rapamycin-dependent%2520fashion%2520and%2520is%2520homologous%2520to%2520yeast%2520TORs%26jtitle%3DCell%26date%3D1994%26volume%3D78%26spage%3D35%26epage%3D43%26doi%3D10.1016%2F0092-8674%2894%2990570-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berlin, V.</span></span> <span> </span><span class="NLM_article-title">RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">12574</span>– <span class="NLM_lpage">12578</span>, <span class="refDoi"> DOI: 10.1073/pnas.91.26.12574</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1073%2Fpnas.91.26.12574" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1994&pages=12574-12578&author=M.+I.+Chiuauthor=H.+Katzauthor=V.+Berlin&title=RAPT1%2C+a+mammalian+homolog+of+yeast+Tor%2C+interacts+with+the+FKBP12%2Frapamycin+complex&doi=10.1073%2Fpnas.91.26.12574"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1073%2Fpnas.91.26.12574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.91.26.12574%26sid%3Dliteratum%253Aachs%26aulast%3DChiu%26aufirst%3DM.%2BI.%26aulast%3DKatz%26aufirst%3DH.%26aulast%3DBerlin%26aufirst%3DV.%26atitle%3DRAPT1%252C%2520a%2520mammalian%2520homolog%2520of%2520yeast%2520Tor%252C%2520interacts%2520with%2520the%2520FKBP12%252Frapamycin%2520complex%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1994%26volume%3D91%26spage%3D12574%26epage%3D12578%26doi%3D10.1073%2Fpnas.91.26.12574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Populo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopes, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soares, P.</span></span> <span> </span><span class="NLM_article-title">The mTOR Signalling Pathway in Human Cancer</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1886</span>– <span class="NLM_lpage">1918</span>, <span class="refDoi"> DOI: 10.3390/ijms13021886</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.3390%2Fijms13021886" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=22408430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BC38XivVKhtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=1886-1918&author=H.+Populoauthor=J.+M.+Lopesauthor=P.+Soares&title=The+mTOR+Signalling+Pathway+in+Human+Cancer&doi=10.3390%2Fijms13021886"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The mTOR signalling pathway in human cancer</span></div><div class="casAuthors">Populo, Helena; Lopes, Jose Manuel; Soares, Paula</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1886-1918</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The conserved serine/threonine kinase mTOR (the mammalian target of rapamycin), a downstream effector of the PI3K/AKT pathway, forms two distinct multiprotein complexes: mTORC1 and mTORC2.  MTORC1 is sensitive to rapamycin, activates S6K1 and 4EBP1, which are involved in mRNA translation.  It is activated by diverse stimuli, such as growth factors, nutrients, energy and stress signals, and essential signalling pathways, such as PI3K, MAPK and AMPK, in order to control cell growth, proliferation and survival.  MTORC2 is considered resistant to rapamycin and is generally insensitive to nutrients and energy signals.  It activates PKC-α and AKT and regulates the actin cytoskeleton.  Deregulation of multiple elements of the mTOR pathway (PI3K amplification/mutation, PTEN loss of function, AKT overexpression, and S6K1, 4EBP1 and eIF4E overexpression) has been reported in many types of cancers, particularly in melanoma, where alterations in major components of the mTOR pathway were reported to have significant effects on tumor progression.  Therefore, mTOR is an appealing therapeutic target and mTOR inhibitors, including the rapamycin analogs deforolimus, everolimus and temsirolimus, are submitted to clin. trials for treating multiple cancers, alone or in combination with inhibitors of other pathways.  Importantly, temsirolimus and everolimus were recently approved by the FDA for the treatment of renal cell carcinoma, PNET and giant cell astrocytoma.  Small mols. that inhibit mTOR kinase activity and dual PI3K-mTOR inhibitors are also being developed.  In this review, we aim to survey relevant research, the mol. mechanisms of signalling, including upstream activation and downstream effectors, and the role of mTOR in cancer, mainly in melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod7yRItoJWpbVg90H21EOLACvtfcHk0liyeN11dU0gWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XivVKhtro%253D&md5=e6c6c9f80fe1a40d4431bd9dfe0d1e45</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.3390%2Fijms13021886&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms13021886%26sid%3Dliteratum%253Aachs%26aulast%3DPopulo%26aufirst%3DH.%26aulast%3DLopes%26aufirst%3DJ.%2BM.%26aulast%3DSoares%26aufirst%3DP.%26atitle%3DThe%2520mTOR%2520Signalling%2520Pathway%2520in%2520Human%2520Cancer%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2012%26volume%3D13%26spage%3D1886%26epage%3D1918%26doi%3D10.3390%2Fijms13021886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crino, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathanson, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henske, E. P.</span></span> <span> </span><span class="NLM_article-title">The tuberous sclerosis complex</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>355</i></span>,  <span class="NLM_fpage">1345</span>– <span class="NLM_lpage">1356</span>, <span class="refDoi"> DOI: 10.1056/NEJMra055323</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1056%2FNEJMra055323" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=17005952" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD2sXisVGit7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2006&pages=1345-1356&author=P.+B.+Crinoauthor=K.+L.+Nathansonauthor=E.+P.+Henske&title=The+tuberous+sclerosis+complex&doi=10.1056%2FNEJMra055323"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The tuberous sclerosis complex</span></div><div class="casAuthors">Crino, Peter B.; Nathanson, Katherine L.; Henske, Elizabeth Petri</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1345-1356</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreefc8lvD2Q7Vg90H21EOLACvtfcHk0liyeN11dU0gWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXisVGit7c%253D&md5=1cbf19b05ac03452756cf07e2d518e95</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1056%2FNEJMra055323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra055323%26sid%3Dliteratum%253Aachs%26aulast%3DCrino%26aufirst%3DP.%2BB.%26aulast%3DNathanson%26aufirst%3DK.%2BL.%26aulast%3DHenske%26aufirst%3DE.%2BP.%26atitle%3DThe%2520tuberous%2520sclerosis%2520complex%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2006%26volume%3D355%26spage%3D1345%26epage%3D1356%26doi%3D10.1056%2FNEJMra055323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wander, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennessy, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slingerland, J. M.</span></span> <span> </span><span class="NLM_article-title">Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">1231</span>– <span class="NLM_lpage">1241</span>, <span class="refDoi"> DOI: 10.1172/JCI44145</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1172%2FJCI44145" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2011&pages=1231-1241&author=S.+A.+Wanderauthor=B.+T.+Hennessyauthor=J.+M.+Slingerland&title=Next-generation+mTOR+inhibitors+in+clinical+oncology%3A+how+pathway+complexity+informs+therapeutic+strategy&doi=10.1172%2FJCI44145"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1172%2FJCI44145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI44145%26sid%3Dliteratum%253Aachs%26aulast%3DWander%26aufirst%3DS.%2BA.%26aulast%3DHennessy%26aufirst%3DB.%2BT.%26aulast%3DSlingerland%26aufirst%3DJ.%2BM.%26atitle%3DNext-generation%2520mTOR%2520inhibitors%2520in%2520clinical%2520oncology%253A%2520how%2520pathway%2520complexity%2520informs%2520therapeutic%2520strategy%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2011%26volume%3D121%26spage%3D1231%26epage%3D1241%26doi%3D10.1172%2FJCI44145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grunt, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mariani, G. L.</span></span> <span> </span><span class="NLM_article-title">Novel approaches for molecular targeted therapy of breast cancer: interfering with PI3K/AKT/mTOR signaling</span>. <i>Curr. Cancer Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">188</span>– <span class="NLM_lpage">204</span>, <span class="refDoi"> DOI: 10.2174/1568009611313020008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.2174%2F1568009611313020008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=23215720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlsFWhs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=188-204&author=T.+W.+Gruntauthor=G.+L.+Mariani&title=Novel+approaches+for+molecular+targeted+therapy+of+breast+cancer%3A+interfering+with+PI3K%2FAKT%2FmTOR+signaling&doi=10.2174%2F1568009611313020008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Novel approaches for molecular targeted therapy of breast cancer: interfering with PI3K/AKT/mTOR signaling</span></div><div class="casAuthors">Grunt, Thomas W.; Mariani, Gabriella L.</div><div class="citationInfo"><span class="NLM_cas:title">Current Cancer Drug Targets</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">188-204</span>CODEN:
                <span class="NLM_cas:coden">CCDTB9</span>;
        ISSN:<span class="NLM_cas:issn">1568-0096</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Breast cancer is one of the most prevalent and devastating malignant diseases in women worldwide.  Fortunately, while breast cancer incidence is still increasing, its death rate is declining.  This is mainly due to early diagnosis and potent therapies such as blockade of estrogen receptor- or of ErbB2 (HER2-neu) membrane receptor-signaling.  In recent years, the PI3K/AKT/mTOR pathway, which transmits signals from the cell membrane into the nucleus and activates multiple oncogenic programs, has been found to play a crucial role in the regulation of breast cancer cell growth.  This pathway is densely interconnected with a multitude of other important regulatory systems for glucose-, lipid- and amino acid-metab., for energy balance, and for autophagy.  It has been found that PI3K/AKT/mTOR signaling modulates estrogen receptor function.  Using transverse and feedback regulatory loops the PI3K/AKT/mTOR cascade can communicate with concurrent and with upstream systems.  Thus, PI3K/AKT/mTOR is a crucial element within a complicated signaling network.  This pathway is hyperactive in more than 70% of breast tumors.  Hence, the protein kinases located along this route represent very attractive and promising drug targets for breast cancer therapy.  Currently, numerous small mol. drugs that inhibit PI3K, AKT and/or mTOR are being developed in preclin. and clin. models of breast cancer.  Some of these compds. are highly selective blocking only one particular kinase complex, whereas others interfere with two (mTORC1 + mTORC2) or even three effectors (PI3K + mTORC1 + mTORC2) of the pathway.  Due to the many interactions with other regulatory systems, silencing of the pathway can cause unexpected results.  Therefore, detailed preclin. and clin. evaluation of these compds. as single drugs and in combination is required to achieve optimal results with maximal clin. benefit and acceptable toxicity.  Also, reliable biomarkers for the identification of patient subsets that will maximally benefit from PI3K/AKT/mTOR inhibition need to be developed.  Thus, selective silencing of PI3K/AKT/mTOR signaling represents a promising approach for breast cancer and might prove useful when combined with other drugs.  Here we review the current preclin. and clin. data and compare the potential benefits of multi- vs. single-targeting PI3K/AKT/mTOR drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlSxKFEBvtSLVg90H21EOLACvtfcHk0ljvuSKq05zOxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlsFWhs7s%253D&md5=9ad30617badbcba72cfaee618d1de3fa</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.2174%2F1568009611313020008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568009611313020008%26sid%3Dliteratum%253Aachs%26aulast%3DGrunt%26aufirst%3DT.%2BW.%26aulast%3DMariani%26aufirst%3DG.%2BL.%26atitle%3DNovel%2520approaches%2520for%2520molecular%2520targeted%2520therapy%2520of%2520breast%2520cancer%253A%2520interfering%2520with%2520PI3K%252FAKT%252FmTOR%2520signaling%26jtitle%3DCurr.%2520Cancer%2520Drug%2520Targets%26date%3D2013%26volume%3D13%26spage%3D188%26epage%3D204%26doi%3D10.2174%2F1568009611313020008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferlay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkin, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steliarova-Foucher, E.</span></span> <span> </span><span class="NLM_article-title">Estimates of cancer incidence and mortality in Europe in 2008</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">765</span>– <span class="NLM_lpage">781</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2009.12.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1016%2Fj.ejca.2009.12.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=20116997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A280%3ADC%252BC3c7js1CktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2010&pages=765-781&author=J.+Ferlayauthor=D.+M.+Parkinauthor=E.+Steliarova-Foucher&title=Estimates+of+cancer+incidence+and+mortality+in+Europe+in+2008&doi=10.1016%2Fj.ejca.2009.12.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Estimates of cancer incidence and mortality in Europe in 2008</span></div><div class="casAuthors">Ferlay J; Parkin D M; Steliarova-Foucher E</div><div class="citationInfo"><span class="NLM_cas:title">European journal of cancer (Oxford, England : 1990)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">765-81</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Up-to-date statistics on cancer occurrence and outcome are essential for the planning and evaluation of programmes for cancer control.  Since the relevant information for 2008 is not generally available as yet, we used statistical models to estimate incidence and mortality data for 25 cancers in 40 European countries (grouped and individually) in 2008.  The calculations are based on published data.  If not collected, national rates were estimated from national mortality data and incidence and mortality data provided by local cancer registries of the same or neighbouring country.  The estimated 2008 rates were applied to the corresponding country population estimates for 2008 to obtain an estimate of the numbers of cancer cases and deaths in Europe in 2008.  There were an estimated 3.2 million new cases of cancer and 1.7 million deaths from cancer in 2008.  The most common cancers were colorectal cancers (436,000 cases, 13.6% of the total), breast cancer (421,000, 13.1%), lung cancer (391,000, 12.2%) and prostate cancer (382,000, 11.9%).  The most common causes of death from cancer were lung cancer (342,000 deaths, 19.9% of the total), colorectal cancer (212,000 deaths, 12.3%), breast cancer (129,000, 7.5%) and stomach cancer (117,000, 6.8%).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQkUT6DwQ4W4ukdrW1FkXG-fW6udTcc2ebMEDonm-XAq7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c7js1CktA%253D%253D&md5=94e72419f8103d9cb1744bd0f3b4c58e</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2009.12.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2009.12.014%26sid%3Dliteratum%253Aachs%26aulast%3DFerlay%26aufirst%3DJ.%26aulast%3DParkin%26aufirst%3DD.%2BM.%26aulast%3DSteliarova-Foucher%26aufirst%3DE.%26atitle%3DEstimates%2520of%2520cancer%2520incidence%2520and%2520mortality%2520in%2520Europe%2520in%25202008%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2010%26volume%3D46%26spage%3D765%26epage%3D781%26doi%3D10.1016%2Fj.ejca.2009.12.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sotiriou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pusztai, L.</span></span> <span> </span><span class="NLM_article-title">Gene-expression signatures in breast cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>360</i></span>,  <span class="NLM_fpage">790</span>– <span class="NLM_lpage">800</span>, <span class="refDoi"> DOI: 10.1056/NEJMra0801289</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1056%2FNEJMra0801289" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=19228622" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD1MXitFWqs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=360&publication_year=2009&pages=790-800&author=C.+Sotiriouauthor=L.+Pusztai&title=Gene-expression+signatures+in+breast+cancer&doi=10.1056%2FNEJMra0801289"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular origins of cancer: gene-expression signatures in breast cancer</span></div><div class="casAuthors">Sotiriou, Christos; Pusztai, Lajos</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">360</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">790-800</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  The altered genetics of breast cancer detected by gene-expression profile is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonfaSW-Hj_RrVg90H21EOLACvtfcHk0ljvuSKq05zOxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXitFWqs70%253D&md5=4fd896e4f33270a59a73f5514057a481</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1056%2FNEJMra0801289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra0801289%26sid%3Dliteratum%253Aachs%26aulast%3DSotiriou%26aufirst%3DC.%26aulast%3DPusztai%26aufirst%3DL.%26atitle%3DGene-expression%2520signatures%2520in%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D360%26spage%3D790%26epage%3D800%26doi%3D10.1056%2FNEJMra0801289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perou, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorlie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisen, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Rijn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffrey, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollack, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnsen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akslen, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fluge, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pergamenschikov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lonning, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borresen-Dale, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, P. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botstein, D.</span></span> <span> </span><span class="NLM_article-title">Molecular portraits of human breast tumours</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>406</i></span>,  <span class="NLM_fpage">747</span>– <span class="NLM_lpage">752</span>, <span class="refDoi"> DOI: 10.1038/35021093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1038%2F35021093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10963602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmt1CnsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=406&publication_year=2000&pages=747-752&author=C.+M.+Perouauthor=T.+Sorlieauthor=M.+B.+Eisenauthor=M.+van+de+Rijnauthor=S.+S.+Jeffreyauthor=C.+A.+Reesauthor=J.+R.+Pollackauthor=D.+T.+Rossauthor=H.+Johnsenauthor=L.+A.+Akslenauthor=O.+Flugeauthor=A.+Pergamenschikovauthor=C.+Williamsauthor=S.+X.+Zhuauthor=P.+E.+Lonningauthor=A.+L.+Borresen-Daleauthor=P.+O.+Brownauthor=D.+Botstein&title=Molecular+portraits+of+human+breast+tumours&doi=10.1038%2F35021093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular portraits of human breast tumors</span></div><div class="casAuthors">Perou, Charles M.; Serlie, Therese; Eisen, Michael B.; Van De Rijn, Matt; Jeffrey, Stefanie S.; Rees, Christian A.; Pollack, Jonathan R.; Rossi, Douglas T.; Johnsen, Hilde; Akslen, Lars A.; Fluge, Oystein; Pergamenschikov, Alexander; Williams, Cheryl; Zhu, Shirley X.; Lenning, Per E.; Berresen-Dale, Anne-Use; Brown, Patrick O.; Botstein, David</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">406</span>
        (<span class="NLM_cas:issue">6797</span>),
    <span class="NLM_cas:pages">747-752</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Human breast tumors are diverse in their natural history and in their responsiveness to treatments.  Variation in transcriptional programs accounts for much of the biol. diversity of human cells and tumors.  In each cell, signal transduction and regulatory systems transduce information from the cell's identity to its environmental status, thereby controlling the level of expression of every gene in the genome.  Here we have characterized variation in gene expression patterns in a set of 65 surgical specimens of human breast tumors from 42 different individuals, using cDNA microarrays representing 8102 human genes.  These patterns provided a distinctive mol. portrait of each tumor.  Twenty of the tumors were sampled twice, before and after a 16-wk course of doxorubicin chemotherapy, and two tumors were paired with a lymph node metastasis from the same patient.  Gene expression patterns in two tumor samples from the same individual were almost always more similar to each other than either was to any other sample.  Sets of co-expressed genes were identified for which variation in mRNA levels could be related to specific features of physiol. variation.  The tumors could be classified into subtypes distinguished by pervasive differences in their gene expression patterns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorYsVvqq_EyLVg90H21EOLACvtfcHk0liplfA33VqnFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmt1CnsLw%253D&md5=f81e9b3e3d5e339ea463428b1c973f8d</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2F35021093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35021093%26sid%3Dliteratum%253Aachs%26aulast%3DPerou%26aufirst%3DC.%2BM.%26aulast%3DSorlie%26aufirst%3DT.%26aulast%3DEisen%26aufirst%3DM.%2BB.%26aulast%3Dvan%2Bde%2BRijn%26aufirst%3DM.%26aulast%3DJeffrey%26aufirst%3DS.%2BS.%26aulast%3DRees%26aufirst%3DC.%2BA.%26aulast%3DPollack%26aufirst%3DJ.%2BR.%26aulast%3DRoss%26aufirst%3DD.%2BT.%26aulast%3DJohnsen%26aufirst%3DH.%26aulast%3DAkslen%26aufirst%3DL.%2BA.%26aulast%3DFluge%26aufirst%3DO.%26aulast%3DPergamenschikov%26aufirst%3DA.%26aulast%3DWilliams%26aufirst%3DC.%26aulast%3DZhu%26aufirst%3DS.%2BX.%26aulast%3DLonning%26aufirst%3DP.%2BE.%26aulast%3DBorresen-Dale%26aufirst%3DA.%2BL.%26aulast%3DBrown%26aufirst%3DP.%2BO.%26aulast%3DBotstein%26aufirst%3DD.%26atitle%3DMolecular%2520portraits%2520of%2520human%2520breast%2520tumours%26jtitle%3DNature%26date%3D2000%26volume%3D406%26spage%3D747%26epage%3D752%26doi%3D10.1038%2F35021093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shak, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baehner, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiller, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickerham, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolmark, N.</span></span> <span> </span><span class="NLM_article-title">A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>351</i></span>,  <span class="NLM_fpage">2817</span>– <span class="NLM_lpage">2826</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa041588</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1056%2FNEJMoa041588" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=15591335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhslymsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2004&pages=2817-2826&author=S.+Paikauthor=S.+Shakauthor=G.+Tangauthor=C.+Kimauthor=J.+Bakerauthor=M.+Croninauthor=F.+L.+Baehnerauthor=M.+G.+Walkerauthor=D.+Watsonauthor=T.+Parkauthor=W.+Hillerauthor=E.+R.+Fisherauthor=D.+L.+Wickerhamauthor=J.+Bryantauthor=N.+Wolmark&title=A+multigene+assay+to+predict+recurrence+of+tamoxifen-treated%2C+node-negative+breast+cancer&doi=10.1056%2FNEJMoa041588"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer</span></div><div class="casAuthors">Paik, Soonmyung; Shak, Steven; Tang, Gong; Kim, Chungyeul; Baker, Joffre; Cronin, Maureen; Baehner, Frederick L.; Walker, Michael G.; Watson, Drew; Park, Taesung; Hiller, William; Fisher, Edwin R.; Wickerham, D. Lawrence; Bryant, John; Wolmark, Norman</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">351</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">2817-2826</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND.  The likelihood of distant recurrence in patients with breast cancer who have no involved lymph nodes and estrogen-receptor-pos. tumors is poorly defined by clin. and histopathol. measures.  METHODS.  The authors tested whether the results of a reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay of 21 prospectively selected genes in paraffin-embedded tumor tissue would correlate with the likelihood of distant recurrence in patients with node-neg., tamoxifen-treated breast cancer who were enrolled in the National Surgical Adjuvant Breast and Bowel Project clin. trial B-14.  The levels of expression of 16 cancer-related genes and 5 ref. genes were used in a prospectively defined algorithm to calc. a recurrence score and to det. a risk group (low, intermediate, or high) for each patient.  RESULTS.  Adequate RT-PCR profiles were obtained in 668 of 675 tumor blocks.  The proportions of patients categorized as having a low, intermediate, or high risk by the RT-PCR assay were 51, 22, and 27%, resp.  The Kaplan-Meier ests. of the rates of distant recurrence at 10 years in the low-risk, intermediate-risk, and high-risk groups were 6.8% (95% confidence interval, 4.0 to 9.6), 14.3% (95% confidence interval, 8.3 to 20.3), and 30.5% (95% confidence interval, 23.6 to 37.4). The rate in the low-risk group was significantly lower than that in the high-risk group.  In a multivariate Cox model, the recurrence score provided significant predictive power that was independent of age and tumor size.  The recurrence score was also predictive of overall survival and could be used as a continuous function to predict distant recurrence in individual patients.  CONCLUSIONS.  The recurrence score has been validated as quantifying the likelihood of distant recurrence in tamoxifen-treated patients with node-neg., estrogen-receptor-pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5GVcEor2yYrVg90H21EOLACvtfcHk0liplfA33VqnFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhslymsw%253D%253D&md5=6dbc153d29b0e35fc253afdb33badf2e</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa041588&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa041588%26sid%3Dliteratum%253Aachs%26aulast%3DPaik%26aufirst%3DS.%26aulast%3DShak%26aufirst%3DS.%26aulast%3DTang%26aufirst%3DG.%26aulast%3DKim%26aufirst%3DC.%26aulast%3DBaker%26aufirst%3DJ.%26aulast%3DCronin%26aufirst%3DM.%26aulast%3DBaehner%26aufirst%3DF.%2BL.%26aulast%3DWalker%26aufirst%3DM.%2BG.%26aulast%3DWatson%26aufirst%3DD.%26aulast%3DPark%26aufirst%3DT.%26aulast%3DHiller%26aufirst%3DW.%26aulast%3DFisher%26aufirst%3DE.%2BR.%26aulast%3DWickerham%26aufirst%3DD.%2BL.%26aulast%3DBryant%26aufirst%3DJ.%26aulast%3DWolmark%26aufirst%3DN.%26atitle%3DA%2520multigene%2520assay%2520to%2520predict%2520recurrence%2520of%2520tamoxifen-treated%252C%2520node-negative%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D351%26spage%3D2817%26epage%3D2826%26doi%3D10.1056%2FNEJMoa041588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVries, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridlyand, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spellman, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roydasgupta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapuk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neve, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryder, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feiler, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokuyasu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kingsley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dairkee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chew, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinkel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ljung, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esserman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albertson, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldman, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J. W.</span></span> <span> </span><span class="NLM_article-title">Genomic and transcriptional aberrations linked to breast cancer pathophysiologies</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">529</span>– <span class="NLM_lpage">541</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2006.10.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1016%2Fj.ccr.2006.10.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=17157792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlCnsrbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2006&pages=529-541&author=K.+Chinauthor=S.+DeVriesauthor=J.+Fridlyandauthor=P.+T.+Spellmanauthor=R.+Roydasguptaauthor=W.+L.+Kuoauthor=A.+Lapukauthor=R.+M.+Neveauthor=Z.+Qianauthor=T.+Ryderauthor=F.+Chenauthor=H.+Feilerauthor=T.+Tokuyasuauthor=C.+Kingsleyauthor=S.+Dairkeeauthor=Z.+Mengauthor=K.+Chewauthor=D.+Pinkelauthor=A.+Jainauthor=B.+M.+Ljungauthor=L.+Essermanauthor=D.+G.+Albertsonauthor=F.+M.+Waldmanauthor=J.+W.+Gray&title=Genomic+and+transcriptional+aberrations+linked+to+breast+cancer+pathophysiologies&doi=10.1016%2Fj.ccr.2006.10.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Genomic and transcriptional aberrations linked to breast cancer pathophysiologies</span></div><div class="casAuthors">Chin, Koei; DeVries, Sandy; Fridlyand, Jane; Spellman, Paul T.; Roydasgupta, Ritu; Kuo, Wen-Lin; Lapuk, Anna; Neve, Richard M.; Qian, Zuwei; Ryder, Tom; Chen, Fanqing; Feiler, Heidi; Tokuyasu, Taku; Kingsley, Chris; Dairkee, Shanaz; Meng, Zhenhang; Chew, Karen; Pinkel, Daniel; Jain, Ajay; Ljung, Britt Marie; Esserman, Laura; Albertson, Donna G.; Waldman, Frederic M.; Gray, Joe W.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">529-541</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">This study explores the roles of genome copy no. abnormalities (CNAs) in breast cancer pathophysiol. by identifying assocns. between recurrent CNAs, gene expression, and clin. outcome in a set of aggressively treated early-stage breast tumors.  It shows that the recurrent CNAs differ between tumor subtypes defined by expression pattern and that stratification of patients according to outcome can be improved by measuring both expression and copy no., esp. high-level amplification.  Sixty-six genes deregulated by the high-level amplifications are potential therapeutic targets.  Nine of these (FGFR1, IKBKB, ERBB2, PROCC, ADAM9, FNTA, ACACA, PNMT, and NR1D1) are considered as therapeutic targets.  Low-level CNAs appear to contribute to cancer progression by altering RNA and cellular metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHiq8I1mqFn7Vg90H21EOLACvtfcHk0liplfA33VqnFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlCnsrbF&md5=8848be946221c3d3236bf9bc3154b77e</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2006.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2006.10.009%26sid%3Dliteratum%253Aachs%26aulast%3DChin%26aufirst%3DK.%26aulast%3DDeVries%26aufirst%3DS.%26aulast%3DFridlyand%26aufirst%3DJ.%26aulast%3DSpellman%26aufirst%3DP.%2BT.%26aulast%3DRoydasgupta%26aufirst%3DR.%26aulast%3DKuo%26aufirst%3DW.%2BL.%26aulast%3DLapuk%26aufirst%3DA.%26aulast%3DNeve%26aufirst%3DR.%2BM.%26aulast%3DQian%26aufirst%3DZ.%26aulast%3DRyder%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DFeiler%26aufirst%3DH.%26aulast%3DTokuyasu%26aufirst%3DT.%26aulast%3DKingsley%26aufirst%3DC.%26aulast%3DDairkee%26aufirst%3DS.%26aulast%3DMeng%26aufirst%3DZ.%26aulast%3DChew%26aufirst%3DK.%26aulast%3DPinkel%26aufirst%3DD.%26aulast%3DJain%26aufirst%3DA.%26aulast%3DLjung%26aufirst%3DB.%2BM.%26aulast%3DEsserman%26aufirst%3DL.%26aulast%3DAlbertson%26aufirst%3DD.%2BG.%26aulast%3DWaldman%26aufirst%3DF.%2BM.%26aulast%3DGray%26aufirst%3DJ.%2BW.%26atitle%3DGenomic%2520and%2520transcriptional%2520aberrations%2520linked%2520to%2520breast%2520cancer%2520pathophysiologies%26jtitle%3DCancer%2520Cell%26date%3D2006%26volume%3D10%26spage%3D529%26epage%3D541%26doi%3D10.1016%2Fj.ccr.2006.10.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foulkes, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefansson, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chappuis, P. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Begin, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goffin, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trudel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akslen, L. A.</span></span> <span> </span><span class="NLM_article-title">Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">1482</span>– <span class="NLM_lpage">1485</span>, <span class="refDoi"> DOI: 10.1093/jnci/djg050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1093%2Fjnci%2Fdjg050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=14519755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnvVCjtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2003&pages=1482-1485&author=W.+D.+Foulkesauthor=I.+M.+Stefanssonauthor=P.+O.+Chappuisauthor=L.+R.+Beginauthor=J.+R.+Goffinauthor=N.+Wongauthor=M.+Trudelauthor=L.+A.+Akslen&title=Germline+BRCA1+mutations+and+a+basal+epithelial+phenotype+in+breast+cancer&doi=10.1093%2Fjnci%2Fdjg050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer</span></div><div class="casAuthors">Foulkes, William D.; Stefansson, Ingunn M.; Chappuis, Pierre O.; Begin, Louis R.; Goffin, John R.; Wong, Nora; Trudel, Michel; Akslen, Lars A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1482-1485</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A basal epithelial phenotype is found in not more than 15% of all invasive breast cancers.  Microarray studies have shown that this phenotype is assocd. with breast cancers that express neither estrogen receptor (ER) nor erbB-2 (HER2/neu) (i.e., ER/erbB-2-neg. tumors).  The ER/erbB-2-neg. phenotype is also found in breast cancers occurring in BRCA1 mutation carriers (i.e., BRCA1-related breast cancers).  The authors tested the hypothesis that BRCA1-related breast cancers are more likely than non-BRCA1/2-related breast cancer to express a basal epithelial phenotype.  Among 292 breast cancer specimens previously analyzed for ER, erbB-2, p53, and germline mutations in BRCA1 and BRCA2, the authors identified 76 that did not overexpress ER or erbB-2.  Of the 72 specimens with sufficient material for testing, 40 expressed stratified epithelial cytokeratin 5 and/or 6 (5/6).  In univariate anal., the expression of cytokeratin 5/6 was statistically significantly assocd. with BRCA1-related breast cancers (odds ratio = 9.0, 95% confidence interval = 1.9 to 43; P = 0.002, two-sided Fisher's exact test).  Thus, germline BRCA1 mutations appear to be assocd. with a distinctive breast cancer phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoncxFMYyWONrVg90H21EOLACvtfcHk0lhRFGXk7BDmsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnvVCjtrk%253D&md5=8cb0919cb53b77c6c50c5c67fbe9c456</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjg050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjg050%26sid%3Dliteratum%253Aachs%26aulast%3DFoulkes%26aufirst%3DW.%2BD.%26aulast%3DStefansson%26aufirst%3DI.%2BM.%26aulast%3DChappuis%26aufirst%3DP.%2BO.%26aulast%3DBegin%26aufirst%3DL.%2BR.%26aulast%3DGoffin%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DN.%26aulast%3DTrudel%26aufirst%3DM.%26aulast%3DAkslen%26aufirst%3DL.%2BA.%26atitle%3DGermline%2520BRCA1%2520mutations%2520and%2520a%2520basal%2520epithelial%2520phenotype%2520in%2520breast%2520cancer%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2003%26volume%3D95%26spage%3D1482%26epage%3D1485%26doi%3D10.1093%2Fjnci%2Fdjg050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">The Cancer Genome Atlas Network.</span> <span> </span><span class="NLM_article-title">Comprehensive
molecular portraits of human breast tumours</span>.  <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume">490</span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">70</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1038%2Fnature11412" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=23000897" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=490&publication_year=2012&pages=61-70&author=The+Cancer+Genome+Atlas+Network.&title=Comprehensive%0Amolecular+portraits+of+human+breast+tumours"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnature11412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11412%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DComprehensive%250Amolecular%2520portraits%2520of%2520human%2520breast%2520tumours%26jtitle%3DNature%26date%3D2012%26volume%3D490%26spage%3D61%26epage%3D70" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rexer, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrett, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arteaga, C. L.</span></span> <span> </span><span class="NLM_article-title">Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">224</span>, <span class="refDoi"> DOI: 10.1186/bcr3039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1186%2Fbcr3039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=22114931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BC38Xms1Cmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=224&author=T.+W.+Millerauthor=B.+N.+Rexerauthor=J.+T.+Garrettauthor=C.+L.+Arteaga&title=Mutations+in+the+phosphatidylinositol+3-kinase+pathway%3A+role+in+tumor+progression+and+therapeutic+implications+in+breast+cancer&doi=10.1186%2Fbcr3039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer</span></div><div class="casAuthors">Miller, Todd W.; Rexer, Brent N.; Garrett, Joan T.; Arteaga, Carlos L.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">224</span>CODEN:
                <span class="NLM_cas:coden">BRCRFS</span>;
        ISSN:<span class="NLM_cas:issn">1465-542X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Mutations in genes that constitute the phosphatidylinositol 3-kinase (PI3K) pathway occur in >70% of breast cancers.  Clin. and exptl. evidence suggest that PI3K pathway activation promotes resistance to some of the current breast cancer therapies.  PI3K is a major signaling hub downstream of human epidermal growth factor receptor (HER)2 and other receptor tyrosine kinases.  PI3K activates AKT, serum/glucocorticoid regulated kinase (SGK), phosphoinositide-dependent kinase 1 (PDK1), mammalian target of rapamycin (mTOR), and several other mols. involved in cell cycle progression and survival.  In estrogen receptor (ER)+ breast cancer cells, PI3K activation promotes estrogen-dependent and -independent ER transcriptional activity, which, in turn, may contribute to anti-estrogen resistance.  Activation of this pathway also confers resistance to HER2-targeted therapies.  In exptl. models of resistance to anti-estrogens and HER2 inhibitors, pharmacol. inhibition of PI3K/AKT/mTOR has been shown to overcome drug resistance.  Early clin. data suggest that combined inhibition of either HER2 or ER plus inhibition of the PI3K pathway might be an effective strategy for treatment of resp. HER2+ and ER+ breast cancers resistant to std. therapies.  Here, we review alterations in the PI3K pathway in breast cancer, their assocn. with therapeutic resistance, and the state of clin. development of PI3K pathway inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1l1_QxsVCwLVg90H21EOLACvtfcHk0lhRFGXk7BDmsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xms1Cmuw%253D%253D&md5=daddd3d8ac7d2e0fc1918f6f5f979dd7</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1186%2Fbcr3039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fbcr3039%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DT.%2BW.%26aulast%3DRexer%26aufirst%3DB.%2BN.%26aulast%3DGarrett%26aufirst%3DJ.%2BT.%26aulast%3DArteaga%26aufirst%3DC.%2BL.%26atitle%3DMutations%2520in%2520the%2520phosphatidylinositol%25203-kinase%2520pathway%253A%2520role%2520in%2520tumor%2520progression%2520and%2520therapeutic%2520implications%2520in%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2011%26volume%3D13%26spage%3D224%26doi%3D10.1186%2Fbcr3039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurren, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spagnuolo, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLean, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Datti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrana, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batey, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schimmer, A. D.</span></span> <span> </span><span class="NLM_article-title">A small-molecule inhibitor of D-cyclin transactivation displays preclinical efficacy in myeloma and leukemia via phosphoinositide 3-kinase pathway</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">1986</span>– <span class="NLM_lpage">1997</span>, <span class="refDoi"> DOI: 10.1182/blood-2010-05-284810</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1182%2Fblood-2010-05-284810" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=21135258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisFKqsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2011&pages=1986-1997&author=X.+Maoauthor=B.+Caoauthor=T.+E.+Woodauthor=R.+Hurrenauthor=J.+Tongauthor=X.+Wangauthor=W.+Wangauthor=J.+Liauthor=Y.+Jinauthor=W.+Sunauthor=P.+A.+Spagnuoloauthor=N.+MacLeanauthor=M.+F.+Moranauthor=A.+Dattiauthor=J.+Wranaauthor=R.+A.+Bateyauthor=A.+D.+Schimmer&title=A+small-molecule+inhibitor+of+D-cyclin+transactivation+displays+preclinical+efficacy+in+myeloma+and+leukemia+via+phosphoinositide+3-kinase+pathway&doi=10.1182%2Fblood-2010-05-284810"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">A small-molecule inhibitor of D-cyclin transactivation displays preclinical efficacy in myeloma and leukemia via phosphoinositide 3-kinase pathway</span></div><div class="casAuthors">Mao, Xinliang; Cao, Biyin; Wood, Tabitha E.; Hurren, Rose; Tong, Jiefei; Wang, Xiaoming; Wang, Wenjie; Li, Jie; Jin, Yueping; Sun, Wenxian; Spagnuolo, Paul A.; MacLean, Neil; Moran, Michael F.; Datti, Alessandro; Wrana, Jeffery; Batey, Robert A.; Schimmer, Aaron D.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1986-1997</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">D-cyclins are universally dysregulated in multiple myeloma and frequently overexpressed in leukemia.  To better understand the role and impact of dysregulated D-cyclins in hematol. malignancies, we conducted a high-throughput screen for inhibitors of cyclin D2 transactivation and identified 8-ethoxy-2-(4-fluorophenyl)-3-nitro-2H-chromene (S14161), which inhibited the expression of cyclins D1, D2, and D3 and arrested cells at the G0/G1 phase.  After D-cyclin suppression, S14161 induced apoptosis in myeloma and leukemia cell lines and primary patient samples preferentially over normal hematopoietic cells.  In mouse models of leukemia, S14161 inhibited tumor growth without evidence of wt. loss or gross organ toxicity.  Mechanistically, S14161 inhibited the activity of phosphoinositide 3-kinase in intact cells and the activity of the phosphoinositide 3-kinases α, β, δ, and γ in a cell-free enzymic assay.  In contrast, it did not inhibit the enzymic activities of other related kinases, including the mammalian target of rapamycin, the DNA-dependent protein kinase catalytic subunit, and phosphoinositide-dependent kinase-1.  Thus, we identified a novel chem. compd. that inhibits D-cyclin transactivation via the phosphoinositide 3-kinase/protein kinase B signaling pathway.  Given its potent antileukemia and antimyeloma activity and minimal toxicity, S14161 could be developed as a novel agent for blood cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsbSkX1io2KLVg90H21EOLACvtfcHk0lhRFGXk7BDmsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisFKqsb8%253D&md5=f20e7396051a7356980ba297101af1d8</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1182%2Fblood-2010-05-284810&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2010-05-284810%26sid%3Dliteratum%253Aachs%26aulast%3DMao%26aufirst%3DX.%26aulast%3DCao%26aufirst%3DB.%26aulast%3DWood%26aufirst%3DT.%2BE.%26aulast%3DHurren%26aufirst%3DR.%26aulast%3DTong%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DW.%26aulast%3DSpagnuolo%26aufirst%3DP.%2BA.%26aulast%3DMacLean%26aufirst%3DN.%26aulast%3DMoran%26aufirst%3DM.%2BF.%26aulast%3DDatti%26aufirst%3DA.%26aulast%3DWrana%26aufirst%3DJ.%26aulast%3DBatey%26aufirst%3DR.%2BA.%26aulast%3DSchimmer%26aufirst%3DA.%2BD.%26atitle%3DA%2520small-molecule%2520inhibitor%2520of%2520D-cyclin%2520transactivation%2520displays%2520preclinical%2520efficacy%2520in%2520myeloma%2520and%2520leukemia%2520via%2520phosphoinositide%25203-kinase%2520pathway%26jtitle%3DBlood%26date%3D2011%26volume%3D117%26spage%3D1986%26epage%3D1997%26doi%3D10.1182%2Fblood-2010-05-284810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dondoni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massi, A.</span></span> <span> </span><span class="NLM_article-title">Asymmetric organocatalysis: from infancy to adolescence</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">4638</span>– <span class="NLM_lpage">4660</span>, <span class="refDoi"> DOI: 10.1002/anie.200704684</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1002%2Fanie.200704684" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnvFKqsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=4638-4660&author=A.+Dondoniauthor=A.+Massi&title=Asymmetric+organocatalysis%3A+from+infancy+to+adolescence&doi=10.1002%2Fanie.200704684"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Asymmetric organocatalysis: from infancy to adolescence</span></div><div class="casAuthors">Dondoni, Alessandro; Massi, Alessandro</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">4638-4660</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">This review deals with selected studies reported in 2006 and the first half of 2007, and is intended to highlight four main aspects that may be taken as testimony of the present status and prospective of organocatalysis: (i) chem. efficiency; (ii) discovery of new substrate combinations to give new asym. syntheses; (iii) development of new catalysts for specific purposes by using mechanistic findings; and (iv) applications of organocatalytic reactions in the asym. total synthesis of target natural products and known compds. of biol. and pharmaceutical relevance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8NC7s6TLVM7Vg90H21EOLACvtfcHk0lhbT1OLqZSI4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnvFKqsLY%253D&md5=174d35a98b1ef4066ca036e0567734e5</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fanie.200704684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200704684%26sid%3Dliteratum%253Aachs%26aulast%3DDondoni%26aufirst%3DA.%26aulast%3DMassi%26aufirst%3DA.%26atitle%3DAsymmetric%2520organocatalysis%253A%2520from%2520infancy%2520to%2520adolescence%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2008%26volume%3D47%26spage%3D4638%26epage%3D4660%26doi%3D10.1002%2Fanie.200704684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seayad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">List, B.</span></span> <span> </span><span class="NLM_article-title">Asymmetric organocatalysis</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">719</span>– <span class="NLM_lpage">724</span>, <span class="refDoi"> DOI: 10.1039/b415217b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1039%2Fb415217b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=15731852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhs1yjsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2005&pages=719-724&author=J.+Seayadauthor=B.+List&title=Asymmetric+organocatalysis&doi=10.1039%2Fb415217b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Asymmetric organocatalysis</span></div><div class="casAuthors">Seayad, Jayasree; List, Benjamin</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">719-724</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review discusses the application of asym. organocatalysts in the org. synthesis based on a mechanistic classification of the catalysts.  The organocatalysts are categorized as either Lewis bases, Lewis acids, Bronsted bases, or Bronsted acids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohanG9zemlv7Vg90H21EOLACvtfcHk0lhbT1OLqZSI4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhs1yjsLY%253D&md5=86d5dc98bb2c4388093f91db06182a3c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1039%2Fb415217b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb415217b%26sid%3Dliteratum%253Aachs%26aulast%3DSeayad%26aufirst%3DJ.%26aulast%3DList%26aufirst%3DB.%26atitle%3DAsymmetric%2520organocatalysis%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2005%26volume%3D3%26spage%3D719%26epage%3D724%26doi%3D10.1039%2Fb415217b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dalko, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moisan, L.</span></span> <span> </span><span class="NLM_article-title">In the golden age of organocatalysis</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">5138</span>– <span class="NLM_lpage">5175</span>, <span class="refDoi"> DOI: 10.1002/anie.200400650</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1002%2Fanie.200400650" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD2cXos1Kmsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2004&pages=5138-5175&author=P.+I.+Dalkoauthor=L.+Moisan&title=In+the+golden+age+of+organocatalysis&doi=10.1002%2Fanie.200400650"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">In the Golden Age of Organocatalysis</span></div><div class="casAuthors">Dalko, Peter I.; Moisan, Lionel</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">5138-5175</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The term organocatalysis describes the acceleration of chem. reactions through the addn. of a substoichiometric quantity of an org. compd.  The interest in this field has increased spectacularly in the last few years as result of both the novelty of the concept and, more importantly, the fact that efficiency and selectivity of many organocatalytic reactions meet the stds. of established org. reactions.  Organocatalytic reactions are becoming powerful tools in the construction of complex mol. skeletons.  The diverse examples show that in recent years organocatalysis has developed within org. chem. into its own subdiscipline, whose Golden Age has already dawned.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0Q1rGp9lQR7Vg90H21EOLACvtfcHk0lhbT1OLqZSI4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXos1Kmsr4%253D&md5=caefd678e8e2e4956e8a06db61bd2a72</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fanie.200400650&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200400650%26sid%3Dliteratum%253Aachs%26aulast%3DDalko%26aufirst%3DP.%2BI.%26aulast%3DMoisan%26aufirst%3DL.%26atitle%3DIn%2520the%2520golden%2520age%2520of%2520organocatalysis%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2004%26volume%3D43%26spage%3D5138%26epage%3D5175%26doi%3D10.1002%2Fanie.200400650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beneteau, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaigne-Delalande, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daburon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Giorgi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichas, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rebillard, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimanche-Boitrel, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taupin, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legembre, P.</span></span> <span> </span><span class="NLM_article-title">Localization of Fas/CD95 into the lipid rafts on down-modulation of the phosphatidylinositol 3-kinase signaling pathway</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">604</span>– <span class="NLM_lpage">613</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-07-0331</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1158%2F1541-7786.MCR-07-0331" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=18403639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD1cXksFKms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2008&pages=604-613&author=M.+Beneteauauthor=M.+Pizonauthor=B.+Chaigne-Delalandeauthor=S.+Daburonauthor=P.+Moreauauthor=F.+De+Giorgiauthor=F.+Ichasauthor=A.+Rebillardauthor=M.+T.+Dimanche-Boitrelauthor=J.+L.+Taupinauthor=J.+F.+Moreauauthor=P.+Legembre&title=Localization+of+Fas%2FCD95+into+the+lipid+rafts+on+down-modulation+of+the+phosphatidylinositol+3-kinase+signaling+pathway&doi=10.1158%2F1541-7786.MCR-07-0331"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Localization of Fas/CD95 into the Lipid Rafts on Down-Modulation of the Phosphatidylinositol 3-Kinase Signaling Pathway</span></div><div class="casAuthors">Beneteau, Marie; Pizon, Mathieu; Chaigne-Delalande, Benjamin; Daburon, Sophie; Moreau, Patrick; De Giorgi, Francesca; Ichas, Francois; Rebillard, Amelie; Dimanche-Boitrel, Marie-Therese; Taupin, Jean-Luc; Moreau, Jean-Francois; Legembre, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">604-613</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Activation of the phosphatidylinositol 3-kinase (PI3K) signaling pathway is known to protect tumor cells from apoptosis and more specifically from the Fas-mediated apoptotic signal.  The antitumoral agent edelfosine sensitizes leukemic cells to death by inducing the redistribution of the apoptotic receptor Fas into plasma membrane subdomains called lipid rafts.  Herein, we show that inhibition of the PI3K signal by edelfosine triggers a Fas-mediated apoptotic signal independently of the Fas/FasL interaction.  Furthermore, similarly to edelfosine, blockade of the PI3K activity, using specific inhibitors LY294002 and wortmannin, leads to the clustering of Fas whose supramol. complex is colocalized within the lipid rafts.  These findings indicate that the antitumoral agent edelfosine down-modulates the PI3K signal to sensitize tumor cells to death through the redistribution of Fas into large platform of membrane rafts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqwlJb9gMSabVg90H21EOLACvtfcHk0ljsyDfvr49pmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXksFKms7Y%253D&md5=7bcc186bc4d5aecb00692960481b4fce</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-07-0331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-07-0331%26sid%3Dliteratum%253Aachs%26aulast%3DBeneteau%26aufirst%3DM.%26aulast%3DPizon%26aufirst%3DM.%26aulast%3DChaigne-Delalande%26aufirst%3DB.%26aulast%3DDaburon%26aufirst%3DS.%26aulast%3DMoreau%26aufirst%3DP.%26aulast%3DDe%2BGiorgi%26aufirst%3DF.%26aulast%3DIchas%26aufirst%3DF.%26aulast%3DRebillard%26aufirst%3DA.%26aulast%3DDimanche-Boitrel%26aufirst%3DM.%2BT.%26aulast%3DTaupin%26aufirst%3DJ.%2BL.%26aulast%3DMoreau%26aufirst%3DJ.%2BF.%26aulast%3DLegembre%26aufirst%3DP.%26atitle%3DLocalization%2520of%2520Fas%252FCD95%2520into%2520the%2520lipid%2520rafts%2520on%2520down-modulation%2520of%2520the%2520phosphatidylinositol%25203-kinase%2520signaling%2520pathway%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2008%26volume%3D6%26spage%3D604%26epage%3D613%26doi%3D10.1158%2F1541-7786.MCR-07-0331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pizon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampanarivo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tauzin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaigne-Delalande, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daburon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castroviejo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legembre, P.</span></span> <span> </span><span class="NLM_article-title">Actin-independent exclusion of CD95 by PI3K/AKT signalling: implications for apoptosis</span>. <i>Eur. J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">2368</span>– <span class="NLM_lpage">2378</span>, <span class="refDoi"> DOI: 10.1002/eji.201041078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1002%2Feji.201041078" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2011&pages=2368-2378&author=M.+Pizonauthor=H.+Rampanarivoauthor=S.+Tauzinauthor=B.+Chaigne-Delalandeauthor=S.+Daburonauthor=M.+Castroviejoauthor=P.+Moreauauthor=J.+F.+Moreauauthor=P.+Legembre&title=Actin-independent+exclusion+of+CD95+by+PI3K%2FAKT+signalling%3A+implications+for+apoptosis&doi=10.1002%2Feji.201041078"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1002%2Feji.201041078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Feji.201041078%26sid%3Dliteratum%253Aachs%26aulast%3DPizon%26aufirst%3DM.%26aulast%3DRampanarivo%26aufirst%3DH.%26aulast%3DTauzin%26aufirst%3DS.%26aulast%3DChaigne-Delalande%26aufirst%3DB.%26aulast%3DDaburon%26aufirst%3DS.%26aulast%3DCastroviejo%26aufirst%3DM.%26aulast%3DMoreau%26aufirst%3DP.%26aulast%3DMoreau%26aufirst%3DJ.%2BF.%26aulast%3DLegembre%26aufirst%3DP.%26atitle%3DActin-independent%2520exclusion%2520of%2520CD95%2520by%2520PI3K%252FAKT%2520signalling%253A%2520implications%2520for%2520apoptosis%26jtitle%3DEur.%2520J.%2520Immunol.%26date%3D2011%26volume%3D41%26spage%3D2368%26epage%3D2378%26doi%3D10.1002%2Feji.201041078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hresko, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueckler, M.</span></span> <span> </span><span class="NLM_article-title">mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>280</i></span>,  <span class="NLM_fpage">40406</span>– <span class="NLM_lpage">40416</span>, <span class="refDoi"> DOI: 10.1074/jbc.M508361200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1074%2Fjbc.M508361200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=40406-40416&author=R.+C.+Hreskoauthor=M.+Mueckler&title=mTOR.RICTOR+is+the+Ser473+kinase+for+Akt%2Fprotein+kinase+B+in+3T3-L1+adipocytes&doi=10.1074%2Fjbc.M508361200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M508361200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M508361200%26sid%3Dliteratum%253Aachs%26aulast%3DHresko%26aufirst%3DR.%2BC.%26aulast%3DMueckler%26aufirst%3DM.%26atitle%3DmTOR.RICTOR%2520is%2520the%2520Ser473%2520kinase%2520for%2520Akt%252Fprotein%2520kinase%2520B%2520in%25203T3-L1%2520adipocytes%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D40406%26epage%3D40416%26doi%3D10.1074%2Fjbc.M508361200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laplante, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span> <span> </span><span class="NLM_article-title">mTOR signaling at a glance</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">3589</span>– <span class="NLM_lpage">3594</span>, <span class="refDoi"> DOI: 10.1242/jcs.051011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1242%2Fjcs.051011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=19812304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVKitrvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2009&pages=3589-3594&author=M.+Laplanteauthor=D.+M.+Sabatini&title=mTOR+signaling+at+a+glance&doi=10.1242%2Fjcs.051011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR signaling at a glance</span></div><div class="casAuthors">Laplante, Mathieu; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3589-3594</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">A review.  The authors highlight and summarize the current understanding of how mTOR nucleates distinct multiprotein complexes, how intra- and extracellular signals are processed by the mTOR complexes, and how such signals affect cell metab., growth, proliferation, and survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5es3QIlHS6bVg90H21EOLACvtfcHk0ljsyDfvr49pmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVKitrvP&md5=7be03ca7a8a3f52e0e974c784a0b9e73</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1242%2Fjcs.051011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.051011%26sid%3Dliteratum%253Aachs%26aulast%3DLaplante%26aufirst%3DM.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DmTOR%2520signaling%2520at%2520a%2520glance%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2009%26volume%3D122%26spage%3D3589%26epage%3D3594%26doi%3D10.1242%2Fjcs.051011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacinto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loewith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruegg, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, M. N.</span></span> <span> </span><span class="NLM_article-title">Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1122</span>– <span class="NLM_lpage">1128</span>, <span class="refDoi"> DOI: 10.1038/ncb1183</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1038%2Fncb1183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=15467718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptFentL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=1122-1128&author=E.+Jacintoauthor=R.+Loewithauthor=A.+Schmidtauthor=S.+Linauthor=M.+A.+Rueggauthor=A.+Hallauthor=M.+N.+Hall&title=Mammalian+TOR+complex+2+controls+the+actin+cytoskeleton+and+is+rapamycin+insensitive&doi=10.1038%2Fncb1183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive</span></div><div class="casAuthors">Jacinto, Estela; Loewith, Robbie; Schmidt, Anja; Lin, Shuo; Rueegg, Markus A.; Hall, Alan; Hall, Michael N.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1122-1128</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The target of rapamycin (TOR) is a highly conserved protein kinase and a central controller of cell growth.  In budding yeast, TOR is found in structurally and functionally distinct protein complexes: TORC1 and TORC2.  A mammalian counterpart of TORC1 (mTORC1) has been described, but it is not known whether TORC2 is conserved in mammals.  Here, the authors report that a mammalian counterpart of TORC2 (mTORC2) also exists.  The mTORC2 contains mTOR, mLST8 and mAVO3, but not raptor.  Like yeast TORC2, mTORC2 is rapamycin insensitive and seems to function upstream of Rho GTPases to regulate the actin cytoskeleton.  The mTORC2 is not upstream of the mTORC1 effector S6K.  Thus, two distinct TOR complexes constitute a primordial signaling network conserved in eukaryotic evolution to control the fundamental process of cell growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcnbO542vXw7Vg90H21EOLACvtfcHk0lg4GK_X1Qf57g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptFentL8%253D&md5=42d53ee5d9dfc24287cf05fd29f41aa8</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fncb1183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncb1183%26sid%3Dliteratum%253Aachs%26aulast%3DJacinto%26aufirst%3DE.%26aulast%3DLoewith%26aufirst%3DR.%26aulast%3DSchmidt%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DRuegg%26aufirst%3DM.%2BA.%26aulast%3DHall%26aufirst%3DA.%26aulast%3DHall%26aufirst%3DM.%2BN.%26atitle%3DMammalian%2520TOR%2520complex%25202%2520controls%2520the%2520actin%2520cytoskeleton%2520and%2520is%2520rapamycin%2520insensitive%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2004%26volume%3D6%26spage%3D1122%26epage%3D1128%26doi%3D10.1038%2Fncb1183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarbassov, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guertin, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latek, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdjument-Bromage, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tempst, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span> <span> </span><span class="NLM_article-title">Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton</span>. <i>Curr. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1296</span>– <span class="NLM_lpage">1302</span>, <span class="refDoi"> DOI: 10.1016/j.cub.2004.06.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1016%2Fj.cub.2004.06.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=15268862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVamsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=1296-1302&author=D.+D.+Sarbassovauthor=S.+M.+Aliauthor=D.+H.+Kimauthor=D.+A.+Guertinauthor=R.+R.+Latekauthor=H.+Erdjument-Bromageauthor=P.+Tempstauthor=D.+M.+Sabatini&title=Rictor%2C+a+novel+binding+partner+of+mTOR%2C+defines+a+rapamycin-insensitive+and+raptor-independent+pathway+that+regulates+the+cytoskeleton&doi=10.1016%2Fj.cub.2004.06.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton</span></div><div class="casAuthors">Sarbassov, Dos D.; Ali, Siraj M.; Kim, Do-Hyung; Guertin, David A.; Latek, Robert R.; Erdjument-Bromage, Hediye; Tempst, Paul; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1296-1302</span>CODEN:
                <span class="NLM_cas:coden">CUBLE2</span>;
        ISSN:<span class="NLM_cas:issn">0960-9822</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The mammalian TOR (mTOR) pathway integrates nutrient- and growth factor-derived signals to regulate growth, the process whereby cells accumulate mass and increase in size.  MTOR is a large protein kinase and the target of rapamycin, an immunosuppressant that also blocks vessel restenosis and has potential anticancer applications.  MTOR interacts with the raptor and GβL proteins to form a complex that is the target of rapamycin.  Here, we demonstrate that mTOR is also part of a distinct complex defined by the novel protein rictor (rapamycin-insensitive companion of mTOR).  Rictor shares homol. with the previously described pianissimo from D. discoidieum, STE20p from S. pombe, and AVO3p from S. cerevisiae.  Interestingly, AVO3p is part of a rapamycin-insensitive TOR complex that does not contain the yeast homolog of raptor and signals to the actin cytoskeleton through PKC1.  Consistent with this finding, the rictor-contg. mTOR complex contains GβL but not raptor and it neither regulates the mTOR effector S6K1 nor is it bound by FKBP12-rapamycin.  We find that the rictor-mTOR complex modulates the phosphorylation of Protein Kinase C α (PKCα) and the actin cytoskeleton, suggesting that this aspect of TOR signaling is conserved between yeast and mammals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXWNgQt5KXB7Vg90H21EOLACvtfcHk0lg4GK_X1Qf57g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVamsLs%253D&md5=78362bf097ed96b9bfc0053e3a54818c</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.cub.2004.06.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cub.2004.06.054%26sid%3Dliteratum%253Aachs%26aulast%3DSarbassov%26aufirst%3DD.%2BD.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DKim%26aufirst%3DD.%2BH.%26aulast%3DGuertin%26aufirst%3DD.%2BA.%26aulast%3DLatek%26aufirst%3DR.%2BR.%26aulast%3DErdjument-Bromage%26aufirst%3DH.%26aulast%3DTempst%26aufirst%3DP.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DRictor%252C%2520a%2520novel%2520binding%2520partner%2520of%2520mTOR%252C%2520defines%2520a%2520rapamycin-insensitive%2520and%2520raptor-independent%2520pathway%2520that%2520regulates%2520the%2520cytoskeleton%26jtitle%3DCurr.%2520Biol.%26date%3D2004%26volume%3D14%26spage%3D1296%26epage%3D1302%26doi%3D10.1016%2Fj.cub.2004.06.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacold, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervantes, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turk, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yaffe, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span> <span> </span><span class="NLM_article-title">mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>341</i></span>,  <span class="NLM_fpage">1236566</span>, <span class="refDoi"> DOI: 10.1126/science.1236566</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1126%2Fscience.1236566" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=23888043" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A280%3ADC%252BC3sfktVWmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=2013&pages=1236566&author=S.+A.+Kangauthor=M.+E.+Pacoldauthor=C.+L.+Cervantesauthor=D.+Limauthor=H.+J.+Louauthor=K.+Ottinaauthor=N.+S.+Grayauthor=B.+E.+Turkauthor=M.+B.+Yaffeauthor=D.+M.+Sabatini&title=mTORC1+phosphorylation+sites+encode+their+sensitivity+to+starvation+and+rapamycin&doi=10.1126%2Fscience.1236566"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin</span></div><div class="casAuthors">Kang Seong A; Pacold Michael E; Cervantes Christopher L; Lim Daniel; Lou Hua Jane; Ottina Kathleen; Gray Nathanael S; Turk Benjamin E; Yaffe Michael B; Sabatini David M</div><div class="citationInfo"><span class="NLM_cas:title">Science (New York, N.Y.)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">6144</span>),
    <span class="NLM_cas:pages">1236566</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The mechanistic target of rapamycin (mTOR) complex 1 (mTORC1) protein kinase promotes growth and is the target of rapamycin, a clinically useful drug that also prolongs life span in model organisms.  A persistent mystery is why the phosphorylation of many bona fide mTORC1 substrates is resistant to rapamycin.  We find that the in vitro kinase activity of mTORC1 toward peptides encompassing established phosphorylation sites varies widely and correlates strongly with the resistance of the sites to rapamycin, as well as to nutrient and growth factor starvation within cells.  Slight modifications of the sites were sufficient to alter mTORC1 activity toward them in vitro and to cause concomitant changes within cells in their sensitivity to rapamycin and starvation.  Thus, the intrinsic capacity of a phosphorylation site to serve as an mTORC1 substrate, a property we call substrate quality, is a major determinant of its sensitivity to modulators of the pathway.  Our results reveal a mechanism through which mTORC1 effectors can respond differentially to the same signals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRVUX1crROrkZPlX7E30qdzfW6udTcc2eZ_kN8OlcY0Zbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sfktVWmsw%253D%253D&md5=904daf44e853714de3fb540a359e2546</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1126%2Fscience.1236566&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1236566%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DS.%2BA.%26aulast%3DPacold%26aufirst%3DM.%2BE.%26aulast%3DCervantes%26aufirst%3DC.%2BL.%26aulast%3DLim%26aufirst%3DD.%26aulast%3DLou%26aufirst%3DH.%2BJ.%26aulast%3DOttina%26aufirst%3DK.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DTurk%26aufirst%3DB.%2BE.%26aulast%3DYaffe%26aufirst%3DM.%2BB.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DmTORC1%2520phosphorylation%2520sites%2520encode%2520their%2520sensitivity%2520to%2520starvation%2520and%2520rapamycin%26jtitle%3DScience%26date%3D2013%26volume%3D341%26spage%3D1236566%26doi%3D10.1126%2Fscience.1236566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ariens, E. J.</span></span> <span> </span><span class="NLM_article-title">Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology</span>. <i>Eur. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">663</span>– <span class="NLM_lpage">668</span>, <span class="refDoi"> DOI: 10.1007/BF00541922</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1007%2FBF00541922" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=6092093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADyaL2cXmtVeksLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1984&pages=663-668&author=E.+J.+Ariens&title=Stereochemistry%2C+a+basis+for+sophisticated+nonsense+in+pharmacokinetics+and+clinical+pharmacology&doi=10.1007%2FBF00541922"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology</span></div><div class="casAuthors">Ariens, E. J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">663-8</span>CODEN:
                <span class="NLM_cas:coden">EJCPAS</span>;
        ISSN:<span class="NLM_cas:issn">0031-6970</span>.
    </div><div class="casAbstract">A review with 47 refs. on the significance of stereochemistry in the pharmacokinetics and pharmacol. of drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLER585gpaQ7Vg90H21EOLACvtfcHk0li45S0n3EB_sQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXmtVeksLc%253D&md5=722a97638b21a2812235912395065a72</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1007%2FBF00541922&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00541922%26sid%3Dliteratum%253Aachs%26aulast%3DAriens%26aufirst%3DE.%2BJ.%26atitle%3DStereochemistry%252C%2520a%2520basis%2520for%2520sophisticated%2520nonsense%2520in%2520pharmacokinetics%2520and%2520clinical%2520pharmacology%26jtitle%3DEur.%2520J.%2520Clin.%2520Pharmacol.%26date%3D1984%26volume%3D26%26spage%3D663%26epage%3D668%26doi%3D10.1007%2FBF00541922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tauzin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debure, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legembre, P.</span></span> <span> </span><span class="NLM_article-title">CD95-mediated cell signaling in cancer: mutations and post-translational modulations</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">1261</span>– <span class="NLM_lpage">1277</span>, <span class="refDoi"> DOI: 10.1007/s00018-011-0866-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1007%2Fs00018-011-0866-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=22042271" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BC38XksFajsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2012&pages=1261-1277&author=S.+Tauzinauthor=L.+Debureauthor=J.+F.+Moreauauthor=P.+Legembre&title=CD95-mediated+cell+signaling+in+cancer%3A+mutations+and+post-translational+modulations&doi=10.1007%2Fs00018-011-0866-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">CD95-mediated cell signaling in cancer: mutations and post-translational modulations</span></div><div class="casAuthors">Tauzin, Sebastien; Debure, Laure; Moreau, Jean-Francois; Legembre, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1261-1277</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">A review.  Apoptosis has emerged as a fundamental process important in tissue homeostasis, immune response, and during development.  CD95 (also known as Fas), a member of the tumor necrosis factor receptor (TNF-R) superfamily, has been initially cloned as a death receptor.  Its cognate ligand, CD95L, is mainly found at the plasma membrane of activated T-lymphocytes and natural killer cells where it contributes to the elimination of transformed and infected cells.  According to its implication in the immune homeostasis and immune surveillance, and since several malignant cells of various histol. origins exhibit loss-of-function mutations, which cause resistance towards the CD95-mediated apoptotic signal, CD95 has been classified as a tumor suppressor gene.  Nevertheless, this assumption has been recently challenged, as in certain pathophysiol. contexts, CD95 engagement transmits non-apoptotic signals that promote inflammation, carcinogenesis or liver/peripheral nerve regeneration.  The focus of this review is to discuss these apparent contradictions of the known function(s) of CD95.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQKJdVcsHgkbVg90H21EOLACvtfcHk0li45S0n3EB_sQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksFajsLc%253D&md5=f65d6f89929446ba7c43a9cad8b0d658</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1007%2Fs00018-011-0866-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-011-0866-4%26sid%3Dliteratum%253Aachs%26aulast%3DTauzin%26aufirst%3DS.%26aulast%3DDebure%26aufirst%3DL.%26aulast%3DMoreau%26aufirst%3DJ.%2BF.%26aulast%3DLegembre%26aufirst%3DP.%26atitle%3DCD95-mediated%2520cell%2520signaling%2520in%2520cancer%253A%2520mutations%2520and%2520post-translational%2520modulations%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2012%26volume%3D69%26spage%3D1261%26epage%3D1277%26doi%3D10.1007%2Fs00018-011-0866-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malleter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tauzin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bessede, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellano, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goubard, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godey, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leveque, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jezequel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campion, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ducret, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macgrogan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debure, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collette, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legembre, P.</span></span> <span> </span><span class="NLM_article-title">CD95L cell surface cleavage triggers a prometastatic signaling pathway in triple-negative breast cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">6711</span>– <span class="NLM_lpage">6721</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-13-1794</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1158%2F0008-5472.CAN-13-1794" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=6711-6721&author=M.+Malleterauthor=S.+Tauzinauthor=A.+Bessedeauthor=R.+Castellanoauthor=A.+Goubardauthor=F.+Godeyauthor=J.+Levequeauthor=P.+Jezequelauthor=L.+Campionauthor=M.+Camponeauthor=T.+Ducretauthor=G.+Macgroganauthor=L.+Debureauthor=Y.+Colletteauthor=P.+Vacherauthor=P.+Legembre&title=CD95L+cell+surface+cleavage+triggers+a+prometastatic+signaling+pathway+in+triple-negative+breast+cancer&doi=10.1158%2F0008-5472.CAN-13-1794"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-13-1794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-13-1794%26sid%3Dliteratum%253Aachs%26aulast%3DMalleter%26aufirst%3DM.%26aulast%3DTauzin%26aufirst%3DS.%26aulast%3DBessede%26aufirst%3DA.%26aulast%3DCastellano%26aufirst%3DR.%26aulast%3DGoubard%26aufirst%3DA.%26aulast%3DGodey%26aufirst%3DF.%26aulast%3DLeveque%26aufirst%3DJ.%26aulast%3DJezequel%26aufirst%3DP.%26aulast%3DCampion%26aufirst%3DL.%26aulast%3DCampone%26aufirst%3DM.%26aulast%3DDucret%26aufirst%3DT.%26aulast%3DMacgrogan%26aufirst%3DG.%26aulast%3DDebure%26aufirst%3DL.%26aulast%3DCollette%26aufirst%3DY.%26aulast%3DVacher%26aufirst%3DP.%26aulast%3DLegembre%26aufirst%3DP.%26atitle%3DCD95L%2520cell%2520surface%2520cleavage%2520triggers%2520a%2520prometastatic%2520signaling%2520pathway%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26spage%3D6711%26epage%3D6721%26doi%3D10.1158%2F0008-5472.CAN-13-1794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tauzin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaigne-Delalande, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selva, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khadra, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daburon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contin-Bordes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanco, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Seyec, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ducret, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Counillon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legembre, P.</span></span> <span> </span><span class="NLM_article-title">The naturally processed CD95L elicits a c-yes/calcium/PI3K-driven cell migration pathway</span>. <i>PLoS Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">e1001090</span>, <span class="refDoi"> DOI: 10.1371/journal.pbio.1001090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1371%2Fjournal.pbio.1001090" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2011&pages=e1001090&author=S.+Tauzinauthor=B.+Chaigne-Delalandeauthor=E.+Selvaauthor=N.+Khadraauthor=S.+Daburonauthor=C.+Contin-Bordesauthor=P.+Blancoauthor=J.+Le+Seyecauthor=T.+Ducretauthor=L.+Counillonauthor=J.+F.+Moreauauthor=P.+Hofmanauthor=P.+Vacherauthor=P.+Legembre&title=The+naturally+processed+CD95L+elicits+a+c-yes%2Fcalcium%2FPI3K-driven+cell+migration+pathway&doi=10.1371%2Fjournal.pbio.1001090"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pbio.1001090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pbio.1001090%26sid%3Dliteratum%253Aachs%26aulast%3DTauzin%26aufirst%3DS.%26aulast%3DChaigne-Delalande%26aufirst%3DB.%26aulast%3DSelva%26aufirst%3DE.%26aulast%3DKhadra%26aufirst%3DN.%26aulast%3DDaburon%26aufirst%3DS.%26aulast%3DContin-Bordes%26aufirst%3DC.%26aulast%3DBlanco%26aufirst%3DP.%26aulast%3DLe%2BSeyec%26aufirst%3DJ.%26aulast%3DDucret%26aufirst%3DT.%26aulast%3DCounillon%26aufirst%3DL.%26aulast%3DMoreau%26aufirst%3DJ.%2BF.%26aulast%3DHofman%26aufirst%3DP.%26aulast%3DVacher%26aufirst%3DP.%26aulast%3DLegembre%26aufirst%3DP.%26atitle%3DThe%2520naturally%2520processed%2520CD95L%2520elicits%2520a%2520c-yes%252Fcalcium%252FPI3K-driven%2520cell%2520migration%2520pathway%26jtitle%3DPLoS%2520Biol.%26date%3D2011%26volume%3D9%26spage%3De1001090%26doi%3D10.1371%2Fjournal.pbio.1001090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kleber, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sancho-Martinez, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiestler, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beisel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gieffers, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiemann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sykora, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreglmann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letellier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuliani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klussmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teodorczyk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grone, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganten, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sultmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuttenberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Deimling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regnier-Vigouroux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herold-Mende, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Villalba, A.</span></span> <span> </span><span class="NLM_article-title">Yes and PI3K bind CD95 to signal invasion of glioblastoma</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">248</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2008.02.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1016%2Fj.ccr.2008.02.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=18328427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjsVKgs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=235-248&author=S.+Kleberauthor=I.+Sancho-Martinezauthor=B.+Wiestlerauthor=A.+Beiselauthor=C.+Gieffersauthor=O.+Hillauthor=M.+Thiemannauthor=W.+Muellerauthor=J.+Sykoraauthor=A.+Kuhnauthor=N.+Schreglmannauthor=E.+Letellierauthor=C.+Zulianiauthor=S.+Klussmannauthor=M.+Teodorczykauthor=H.+J.+Groneauthor=T.+M.+Gantenauthor=H.+Sultmannauthor=J.+Tuttenbergauthor=A.+von+Deimlingauthor=A.+Regnier-Vigourouxauthor=C.+Herold-Mendeauthor=A.+Martin-Villalba&title=Yes+and+PI3K+bind+CD95+to+signal+invasion+of+glioblastoma&doi=10.1016%2Fj.ccr.2008.02.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Yes and PI3K bind CD95 to signal invasion of glioblastoma</span></div><div class="casAuthors">Kleber, Susanne; Sancho-Martinez, Ignacio; Wiestler, Benedict; Beisel, Alexandra; Gieffers, Christian; Hill, Oliver; Thiemann, Meinolf; Mueller, Wolf; Sykora, Jaromir; Kuhn, Andreas; Schreglmann, Nina; Letellier, Elisabeth; Zuliani, Cecilia; Klussmann, Stefan; Teodorczyk, Marcin; Groene, Hermann-Josef; Ganten, Tom M.; Sueltmann, Holger; Tuettenberg, Jochen; von Deimling, Andreas; Regnier-Vigouroux, Anne; Herold-Mende, Christel; Martin-Villalba, Ana</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">235-248</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Invasion of surrounding brain tissue by isolated tumor cells represents one of the main obstacles to a curative therapy of glioblastoma multiforme.  Here we unravel a mechanism regulating glioma infiltration.  Tumor interaction with the surrounding brain tissue induces CD95 Ligand expression.  Binding of CD95 Ligand to CD95 on glioblastoma cells recruits the Src family member Yes and the p85 subunit of phosphatidylinositol 3-kinase to CD95, which signal invasion via the glycogen synthase kinase 3β pathway and subsequent expression of matrix metalloproteinases.  In a murine syngeneic model of intracranial GBM, neutralization of CD95 activity dramatically reduced the no. of invading cells.  Our results uncover CD95 as an activator of PI3K and, most importantly, as a crucial trigger of basal invasion of glioblastoma in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolBSTN2uoJlrVg90H21EOLACvtfcHk0lg8d8RYSRBMGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjsVKgs7w%253D&md5=77909e946e73e5b0236d7b9c336a106c</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2008.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2008.02.003%26sid%3Dliteratum%253Aachs%26aulast%3DKleber%26aufirst%3DS.%26aulast%3DSancho-Martinez%26aufirst%3DI.%26aulast%3DWiestler%26aufirst%3DB.%26aulast%3DBeisel%26aufirst%3DA.%26aulast%3DGieffers%26aufirst%3DC.%26aulast%3DHill%26aufirst%3DO.%26aulast%3DThiemann%26aufirst%3DM.%26aulast%3DMueller%26aufirst%3DW.%26aulast%3DSykora%26aufirst%3DJ.%26aulast%3DKuhn%26aufirst%3DA.%26aulast%3DSchreglmann%26aufirst%3DN.%26aulast%3DLetellier%26aufirst%3DE.%26aulast%3DZuliani%26aufirst%3DC.%26aulast%3DKlussmann%26aufirst%3DS.%26aulast%3DTeodorczyk%26aufirst%3DM.%26aulast%3DGrone%26aufirst%3DH.%2BJ.%26aulast%3DGanten%26aufirst%3DT.%2BM.%26aulast%3DSultmann%26aufirst%3DH.%26aulast%3DTuttenberg%26aufirst%3DJ.%26aulast%3Dvon%2BDeimling%26aufirst%3DA.%26aulast%3DRegnier-Vigouroux%26aufirst%3DA.%26aulast%3DHerold-Mende%26aufirst%3DC.%26aulast%3DMartin-Villalba%26aufirst%3DA.%26atitle%3DYes%2520and%2520PI3K%2520bind%2520CD95%2520to%2520signal%2520invasion%2520of%2520glioblastoma%26jtitle%3DCancer%2520Cell%26date%3D2008%26volume%3D13%26spage%3D235%26epage%3D248%26doi%3D10.1016%2Fj.ccr.2008.02.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takai, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Lange, T.</span></span> <span> </span><span class="NLM_article-title">Tel2 regulates the stability of PI3K-related protein kinases</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">1248</span>– <span class="NLM_lpage">1259</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2007.10.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1016%2Fj.cell.2007.10.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=18160036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmt1Cnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2007&pages=1248-1259&author=H.+Takaiauthor=R.+C.+Wangauthor=K.+K.+Takaiauthor=H.+Yangauthor=T.+de+Lange&title=Tel2+regulates+the+stability+of+PI3K-related+protein+kinases&doi=10.1016%2Fj.cell.2007.10.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Tel2 regulates the stability of PI3K-related protein kinases</span></div><div class="casAuthors">Takai, Hiroyuki; Wang, Richard C.; Takai, Kaori K.; Yang, Haijuan; de Lange, Titia</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1248-1259</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">We report an unexpected role for Tel2 in the expression of all mammalian phosphatidylinositol 3-kinase-related protein kinases (PIKKs).  Although Tel2 was identified as a budding yeast gene required for the telomere length maintenance, we found no obvious telomeric function for mammalian Tel2.  Targeted gene deletion showed that mouse Tel2 is essential in embryonic development, embryonic stem (ES) cells, and embryonic fibroblasts.  Conditional deletion of Tel2 from embryonic fibroblasts compromised their response to IR and UV, diminishing the activation of checkpoint kinases and their downstream effectors.  The effects of Tel2 deletion correlated with significantly reduced protein levels for the PI3K-related kinases ataxia telangiectasia mutated (ATM), ATM and Rad3 related (ATR), and DNA-dependent protein kinase catalytic subunit ataxia (DNA-PKcs).  Tel2 deletion also elicited specific depletion of the mammalian target of rapamycin (mTOR), suppressor with morphol. effect on genitalia 1 (SMG1), and transformation/transcription domain-assocd. protein (TRRAP), and curbed mTOR signaling, indicating that Tel2 affects all six mammalian PIKKs.  While Tel2 deletion did not alter PIKK mRNA levels, in vivo pulse labeling expts. showed that Tel2 controls the stability of ATM and mTOR.  Each of the PIKK family members assocd. with Tel2 in vivo and in vitro expts. indicated that Tel2 binds to part of the HEAT repeat segments of ATM and mTOR.  These data identify Tel2 as a highly conserved regulator of PIKK stability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqr370AHI6hDLVg90H21EOLACvtfcHk0lg8d8RYSRBMGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmt1Cnsg%253D%253D&md5=6015ecddb2b7fc68c1b8d4c05a855ff8</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2007.10.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2007.10.052%26sid%3Dliteratum%253Aachs%26aulast%3DTakai%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DR.%2BC.%26aulast%3DTakai%26aufirst%3DK.%2BK.%26aulast%3DYang%26aufirst%3DH.%26aulast%3Dde%2BLange%26aufirst%3DT.%26atitle%3DTel2%2520regulates%2520the%2520stability%2520of%2520PI3K-related%2520protein%2520kinases%26jtitle%3DCell%26date%3D2007%26volume%3D131%26spage%3D1248%26epage%3D1259%26doi%3D10.1016%2Fj.cell.2007.10.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andrs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korabecny, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodny, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuca, K.</span></span> <span> </span><span class="NLM_article-title">Phosphatidylinositol 3-Kinase (PI3K) and phosphatidylinositol 3-kinase-related kinase (PIKK) inhibitors: Importance of the morpholine ring</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">71</span>, <span class="refDoi"> DOI: 10.1021/jm501026z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501026z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvV2ntLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=41-71&author=M.+Andrsauthor=J.+Korabecnyauthor=D.+Junauthor=Z.+Hodnyauthor=J.+Bartekauthor=K.+Kuca&title=Phosphatidylinositol+3-Kinase+%28PI3K%29+and+phosphatidylinositol+3-kinase-related+kinase+%28PIKK%29+inhibitors%3A+Importance+of+the+morpholine+ring&doi=10.1021%2Fjm501026z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphatidylinositol 3-Kinase (PI3K) and Phosphatidylinositol 3-Kinase-Related Kinase (PIKK) Inhibitors: Importance of the Morpholine Ring</span></div><div class="casAuthors">Andrs, Martin; Korabecny, Jan; Jun, Daniel; Hodny, Zdenek; Bartek, Jiri; Kuca, Kamil</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-71</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Phosphatidylinositol 3-kinases (PI3Ks) and phosphatidylinositol 3-kinase-related protein kinases (PIKKs) are two related families of kinases that play key roles in regulation of cell proliferation, metab., migration, survival, and responses to diverse stresses including DNA damage.  To design novel efficient strategies for treatment of cancer and other diseases, these kinases have been extensively studied.  Despite their different nature, these two kinase families have related origin and share very similar kinase domains.  Therefore, chem. inhibitors of these kinases usually carry analogous structural motifs.  The most common feature of these inhibitors is a crit. hydrogen bond to morpholine oxygen, initially present in the early nonspecific PI3K and PIKK inhibitor 3 (LY294002), which served as a valuable chem. tool for development of many addnl. PI3K and PIKK inhibitors.  While several PI3K pathway inhibitors have recently shown promising clin. responses, inhibitors of the DNA damage-related PIKKs remain thus far largely in preclin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprPlvsq-HTebVg90H21EOLACvtfcHk0lhsKqnEuPf1qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvV2ntLzE&md5=a8c22f580691084554036dec7d0cc95b</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm501026z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501026z%26sid%3Dliteratum%253Aachs%26aulast%3DAndrs%26aufirst%3DM.%26aulast%3DKorabecny%26aufirst%3DJ.%26aulast%3DJun%26aufirst%3DD.%26aulast%3DHodny%26aufirst%3DZ.%26aulast%3DBartek%26aufirst%3DJ.%26aulast%3DKuca%26aufirst%3DK.%26atitle%3DPhosphatidylinositol%25203-Kinase%2520%2528PI3K%2529%2520and%2520phosphatidylinositol%25203-kinase-related%2520kinase%2520%2528PIKK%2529%2520inhibitors%253A%2520Importance%2520of%2520the%2520morpholine%2520ring%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D41%26epage%3D71%26doi%3D10.1021%2Fjm501026z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petter, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitty, A.</span></span> <span> </span><span class="NLM_article-title">The resurgence of covalent drugs</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1038/nrd3410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1038%2Fnrd3410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=21455239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=307-317&author=J.+Singhauthor=R.+C.+Petterauthor=T.+A.+Baillieauthor=A.+Whitty&title=The+resurgence+of+covalent+drugs&doi=10.1038%2Fnrd3410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">The resurgence of covalent drugs</span></div><div class="casAuthors">Singh, Juswinder; Petter, Russell C.; Baillie, Thomas A.; Whitty, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-317</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Covalent drugs haveproved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project.  There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium.  This Review surveys the prevalence and pharmacol. advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreDCEmORV_NbVg90H21EOLACvtfcHk0lhsKqnEuPf1qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D&md5=2190289081e151416c097be4a5b04460</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1038%2Fnrd3410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3410%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DWhitty%26aufirst%3DA.%26atitle%3DThe%2520resurgence%2520of%2520covalent%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D307%26epage%3D317%26doi%3D10.1038%2Fnrd3410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanderson, K.</span></span> <span> </span><span class="NLM_article-title">Irreversible kinase inhibitors gain traction</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">649</span>– <span class="NLM_lpage">651</span>, <span class="refDoi"> DOI: 10.1038/nrd4103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1038%2Fnrd4103" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=649-651&author=K.+Sanderson&title=Irreversible+kinase+inhibitors+gain+traction&doi=10.1038%2Fnrd4103"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fnrd4103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4103%26sid%3Dliteratum%253Aachs%26aulast%3DSanderson%26aufirst%3DK.%26atitle%3DIrreversible%2520kinase%2520inhibitors%2520gain%2520traction%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D649%26epage%3D651%26doi%3D10.1038%2Fnrd4103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peto, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godwin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cutter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darby, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGale, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Leo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albain, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piccart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, K.</span></span> <span> </span><span class="NLM_article-title">Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>379</i></span>,  <span class="NLM_fpage">432</span>– <span class="NLM_lpage">444</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(11)61625-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1016%2FS0140-6736%2811%2961625-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=22152853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A280%3ADC%252BC383gt1CntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2012&pages=432-444&author=R.+Petoauthor=C.+Daviesauthor=J.+Godwinauthor=R.+Grayauthor=H.+C.+Panauthor=M.+Clarkeauthor=D.+Cutterauthor=S.+Darbyauthor=P.+McGaleauthor=C.+Taylorauthor=Y.+C.+Wangauthor=J.+Berghauthor=A.+Di+Leoauthor=K.+Albainauthor=S.+Swainauthor=M.+Piccartauthor=K.+Pritchard&title=Comparisons+between+different+polychemotherapy+regimens+for+early+breast+cancer%3A+meta-analyses+of+long-term+outcome+among+100%2C000+women+in+123+randomised+trials&doi=10.1016%2FS0140-6736%2811%2961625-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials</span></div><div class="casAuthors">Peto R; Davies C; Godwin J; Gray R; Pan H C; Clarke M; Cutter D; Darby S; McGale P; Taylor C; Wang Y C; Bergh J; Di Leo A; Albain K; Swain S; Piccart M; Pritchard K</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">379</span>
        (<span class="NLM_cas:issue">9814</span>),
    <span class="NLM_cas:pages">432-44</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Moderate differences in efficacy between adjuvant chemotherapy regimens for breast cancer are plausible, and could affect treatment choices.  We sought any such differences.  METHODS:  We undertook individual-patient-data meta-analyses of the randomised trials comparing: any taxane-plus-anthracycline-based regimen versus the same, or more, non-taxane chemotherapy (n=44,000); one anthracycline-based regimen versus another (n=7000) or versus cyclophosphamide, methotrexate, and fluorouracil (CMF; n=18,000); and polychemotherapy versus no chemotherapy (n=32,000).  The scheduled dosages of these three drugs and of the anthracyclines doxorubicin (A) and epirubicin (E) were used to define standard CMF, standard 4AC, and CAF and CEF.  Log-rank breast cancer mortality rate ratios (RRs) are reported.  FINDINGS:  In trials adding four separate cycles of a taxane to a fixed anthracycline-based control regimen, extending treatment duration, breast cancer mortality was reduced (RR 0·86, SE 0·04, two-sided significance [2p]=0·0005).  In trials with four such extra cycles of a taxane counterbalanced in controls by extra cycles of other cytotoxic drugs, roughly doubling non-taxane dosage, there was no significant difference (RR 0·94, SE 0·06, 2p=0·33).  Trials with CMF-treated controls showed that standard 4AC and standard CMF were equivalent (RR 0·98, SE 0·05, 2p=0·67), but that anthracycline-based regimens with substantially higher cumulative dosage than standard 4AC (eg, CAF or CEF) were superior to standard CMF (RR 0·78, SE 0·06, 2p=0·0004).  Trials versus no chemotherapy also suggested greater mortality reductions with CAF (RR 0·64, SE 0·09, 2p<0·0001) than with standard 4AC (RR 0·78, SE 0·09, 2p=0·01) or standard CMF (RR 0·76, SE 0·05, 2p<0·0001).  In all meta-analyses involving taxane-based or anthracycline-based regimens, proportional risk reductions were little affected by age, nodal status, tumour diameter or differentiation (moderate or poor; few were well differentiated), oestrogen receptor status, or tamoxifen use.  Hence, largely independently of age (up to at least 70 years) or the tumour characteristics currently available to us for the patients selected to be in these trials, some taxane-plus-anthracycline-based or higher-cumulative-dosage anthracycline-based regimens (not requiring stem cells) reduced breast cancer mortality by, on average, about one-third. 10-year overall mortality differences paralleled breast cancer mortality differences, despite taxane, anthracycline, and other toxicities.  INTERPRETATION:  10-year gains from a one-third breast cancer mortality reduction depend on absolute risks without chemotherapy (which, for oestrogen-receptor-positive disease, are the risks remaining with appropriate endocrine therapy).  Low absolute risk implies low absolute benefit, but information was lacking about tumour gene expression markers or quantitative immunohistochemistry that might help to predict risk, chemosensitivity, or both.  FUNDING:  Cancer Research UK; British Heart Foundation; UK Medical Research Council.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQzc8V8U7-ZGn6oPH0mYWL1fW6udTcc2eZU7Z-nqFp15Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383gt1CntQ%253D%253D&md5=4e5e668864fca9f7649929b7f5445f62</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2811%2961625-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252811%252961625-5%26sid%3Dliteratum%253Aachs%26aulast%3DPeto%26aufirst%3DR.%26aulast%3DDavies%26aufirst%3DC.%26aulast%3DGodwin%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DR.%26aulast%3DPan%26aufirst%3DH.%2BC.%26aulast%3DClarke%26aufirst%3DM.%26aulast%3DCutter%26aufirst%3DD.%26aulast%3DDarby%26aufirst%3DS.%26aulast%3DMcGale%26aufirst%3DP.%26aulast%3DTaylor%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%2BC.%26aulast%3DBergh%26aufirst%3DJ.%26aulast%3DDi%2BLeo%26aufirst%3DA.%26aulast%3DAlbain%26aufirst%3DK.%26aulast%3DSwain%26aufirst%3DS.%26aulast%3DPiccart%26aufirst%3DM.%26aulast%3DPritchard%26aufirst%3DK.%26atitle%3DComparisons%2520between%2520different%2520polychemotherapy%2520regimens%2520for%2520early%2520breast%2520cancer%253A%2520meta-analyses%2520of%2520long-term%2520outcome%2520among%2520100%252C000%2520women%2520in%2520123%2520randomised%2520trials%26jtitle%3DLancet%26date%3D2012%26volume%3D379%26spage%3D432%26epage%3D444%26doi%3D10.1016%2FS0140-6736%2811%2961625-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malleter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tauzin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bessede, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellano, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goubard, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godey, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leveque, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jezequel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campion, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ducret, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macgrogan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debure, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collette, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legembre, P.</span></span> <span> </span><span class="NLM_article-title">CD95L cell surface cleavage triggers a pro-metastatic signaling pathway in triple negative breast cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">6711</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-13-1794</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1158%2F0008-5472.CAN-13-1794" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=6711&author=M.+Malleterauthor=S.+Tauzinauthor=A.+Bessedeauthor=R.+Castellanoauthor=A.+Goubardauthor=F.+Godeyauthor=J.+Levequeauthor=P.+Jezequelauthor=L.+Campionauthor=M.+Camponeauthor=T.+Ducretauthor=G.+Macgroganauthor=L.+Debureauthor=Y.+Colletteauthor=P.+Vacherauthor=P.+Legembre&title=CD95L+cell+surface+cleavage+triggers+a+pro-metastatic+signaling+pathway+in+triple+negative+breast+cancer&doi=10.1158%2F0008-5472.CAN-13-1794"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-13-1794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-13-1794%26sid%3Dliteratum%253Aachs%26aulast%3DMalleter%26aufirst%3DM.%26aulast%3DTauzin%26aufirst%3DS.%26aulast%3DBessede%26aufirst%3DA.%26aulast%3DCastellano%26aufirst%3DR.%26aulast%3DGoubard%26aufirst%3DA.%26aulast%3DGodey%26aufirst%3DF.%26aulast%3DLeveque%26aufirst%3DJ.%26aulast%3DJezequel%26aufirst%3DP.%26aulast%3DCampion%26aufirst%3DL.%26aulast%3DCampone%26aufirst%3DM.%26aulast%3DDucret%26aufirst%3DT.%26aulast%3DMacgrogan%26aufirst%3DG.%26aulast%3DDebure%26aufirst%3DL.%26aulast%3DCollette%26aufirst%3DY.%26aulast%3DVacher%26aufirst%3DP.%26aulast%3DLegembre%26aufirst%3DP.%26atitle%3DCD95L%2520cell%2520surface%2520cleavage%2520triggers%2520a%2520pro-metastatic%2520signaling%2520pathway%2520in%2520triple%2520negative%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26spage%3D6711%26doi%3D10.1158%2F0008-5472.CAN-13-1794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheulen, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mross, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardoso, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dittrich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiermann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morant, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semiglazov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salzberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostapenko, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illiger, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behringer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardy-Bouxin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cincotta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, L.</span></span> <span> </span><span class="NLM_article-title">Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">5314</span>– <span class="NLM_lpage">5322</span>, <span class="refDoi"> DOI: 10.1200/JCO.2005.66.130</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1200%2FJCO.2005.66.130" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=15955899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpslOrtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=5314-5322&author=S.+Chanauthor=M.+E.+Scheulenauthor=S.+Johnstonauthor=K.+Mrossauthor=F.+Cardosoauthor=C.+Dittrichauthor=W.+Eiermannauthor=D.+Hessauthor=R.+Morantauthor=V.+Semiglazovauthor=M.+Bornerauthor=M.+Salzbergauthor=V.+Ostapenkoauthor=H.+J.+Illigerauthor=D.+Behringerauthor=N.+Bardy-Bouxinauthor=J.+Boniauthor=S.+Kongauthor=M.+Cincottaauthor=L.+Moore&title=Phase+II+study+of+temsirolimus+%28CCI-779%29%2C+a+novel+inhibitor+of+mTOR%2C+in+heavily+pretreated+patients+with+locally+advanced+or+metastatic+breast+cancer&doi=10.1200%2FJCO.2005.66.130"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer</span></div><div class="casAuthors">Chan, Stephen; Scheulen, Max E.; Johnston, Stephen; Mross, Klaus; Cardoso, Fatima; Dittrich, Christian; Eiermann, Wolfgang; Hess, Dagmar; Morant, Rudolph; Semiglazov, Vladimir; Borner, Markus; Salzberg, Marc; Ostapenko, Valerijus; Illiger, Hans-Joachim; Behringer, Dirk; Bardy-Bouxin, Nathalie; Boni, Joseph; Kong, Steven; Cincotta, Maria; Moore, Laurence</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5314-5322</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose In this study, two doses of temsirolimus (CCI-779), a novel inhibitor of the mammalian target of rapamycin, were evaluated for efficacy, safety, and pharmacokinetics in patients with locally advanced or metastatic breast cancer who had been heavily pretreated.  Patients and Methods Patients (n = 109) were randomly assigned to receive 75 or 250 mg of temsirolimus weekly as a 30-min i.v. infusion.  Patients were evaluated for tumor response, time to tumor progression, adverse events, and pharmacokinetics of temsirolimus.  Results Temsirolimus produced an objective response rate of 9.2% (10 partial responses) in the intent-to-treat population.  Median time to tumor progression was 12.0 wk.  Efficacy was similar for both dose levels but toxicity was more common with the higher dose level, esp. grade 3 or 4 depression (10% of patients at the 250-mg dose level, 0% at the 75-mg dose level).  The most common temsirolimus-related adverse events of all grades were mucositis (70%), maculopapular rash (51%), and nausea (43%).  The most common, clin. important grade 3 or 4 adverse events were mucositis (9%), leukopenia (7%), hyperglycemia (7%), somnolence (6%), thrombocytopenia (5%), and depression (5%).  Conclusion In heavily pretreated patients with locally advanced or metastatic breast cancer, 75 and 250 mg temsirolimus showed antitumor activity and 75 mg temsirolimus showed a generally tolerable safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-J7CSrX8CmbVg90H21EOLACvtfcHk0lgyC3yOP0rGfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpslOrtLo%253D&md5=32aeaf7db724372273f0f78c7b83c3b7</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.66.130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.66.130%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DS.%26aulast%3DScheulen%26aufirst%3DM.%2BE.%26aulast%3DJohnston%26aufirst%3DS.%26aulast%3DMross%26aufirst%3DK.%26aulast%3DCardoso%26aufirst%3DF.%26aulast%3DDittrich%26aufirst%3DC.%26aulast%3DEiermann%26aufirst%3DW.%26aulast%3DHess%26aufirst%3DD.%26aulast%3DMorant%26aufirst%3DR.%26aulast%3DSemiglazov%26aufirst%3DV.%26aulast%3DBorner%26aufirst%3DM.%26aulast%3DSalzberg%26aufirst%3DM.%26aulast%3DOstapenko%26aufirst%3DV.%26aulast%3DIlliger%26aufirst%3DH.%2BJ.%26aulast%3DBehringer%26aufirst%3DD.%26aulast%3DBardy-Bouxin%26aufirst%3DN.%26aulast%3DBoni%26aufirst%3DJ.%26aulast%3DKong%26aufirst%3DS.%26aulast%3DCincotta%26aufirst%3DM.%26aulast%3DMoore%26aufirst%3DL.%26atitle%3DPhase%2520II%2520study%2520of%2520temsirolimus%2520%2528CCI-779%2529%252C%2520a%2520novel%2520inhibitor%2520of%2520mTOR%252C%2520in%2520heavily%2520pretreated%2520patients%2520with%2520locally%2520advanced%2520or%2520metastatic%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D5314%26epage%3D5322%26doi%3D10.1200%2FJCO.2005.66.130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ellard, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemons, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelmon, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennecke, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandenberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauerbrei, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishaeli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huntsman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntosh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seymour, L.</span></span> <span> </span><span class="NLM_article-title">Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">4536</span>– <span class="NLM_lpage">4541</span>, <span class="refDoi"> DOI: 10.1200/JCO.2008.21.3033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1200%2FJCO.2008.21.3033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=19687332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlCns77K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=4536-4541&author=S.+L.+Ellardauthor=M.+Clemonsauthor=K.+A.+Gelmonauthor=B.+Norrisauthor=H.+Kenneckeauthor=S.+Chiaauthor=K.+Pritchardauthor=A.+Eisenauthor=T.+Vandenbergauthor=M.+Taylorauthor=E.+Sauerbreiauthor=M.+Mishaeliauthor=D.+Huntsmanauthor=W.+Walshauthor=M.+Olivoauthor=L.+McIntoshauthor=L.+Seymour&title=Randomized+phase+II+study+comparing+two+schedules+of+everolimus+in+patients+with+recurrent%2Fmetastatic+breast+cancer%3A+NCIC+Clinical+Trials+Group+IND.163&doi=10.1200%2FJCO.2008.21.3033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC clinical trials group IND.163</span></div><div class="casAuthors">Ellard, Susan L.; Clemons, Mark; Gelmon, Karen A.; Norris, Brian; Kennecke, Hagen; Chia, Stephen; Pritchard, Kathleen; Eisen, Andrea; Vandenberg, Ted; Taylor, Marianne; Sauerbrei, Eric; Mishaeli, Moshe; Huntsman, David; Walsh, Wendy; Olivo, Martin; McIntosh, Lynn; Seymour, Lesley</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">4536-4541</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: To evaluate the safety and efficacy of oral everolimus, a mammalian target of rapamycin (mTOR) inhibitor, in two different schedules in minimally pretreated patients with metastatic breast cancer and to explore for possible biol. correlates of response.  Patients and Methods: Patients who received no or one prior chemotherapy regimen for metastatic breast cancer were entered onto this multicenter, noncomparative, randomized phase II study of everolimus 10 mg daily vs. 70 mg weekly; the multinomial end points of response and progression were evaluated at 8 wk.  A two-stage accrual design was used, with 15 evaluable patients in each schedule in stage 1.  Only daily therapy met criteria for continuing, and another 15 patients were added.  PAKT, PTEN, carbonic anhydrase 9, estrogen receptor (ER), progesterone receptor, and human epidermal growth factor receptor 2 (HER2) were evaluated for possible correlation with response.  Results: The most common drug-related toxicities were fatigue, rash, anorexia, diarrhea, stomatitis, cough, and pneumonitis.  Pneumonitis occurred at higher than expected rates and seemed to be schedule dependent, with the highest incidence on the daily schedule.  Response rate with daily therapy was 12% (95% CI, 3.4% to 28.2%) compared with 0% (95% CI, 0.0% to 20.6%) for weekly therapy.  Twenty-seven percent of patients on daily therapy discontinued treatment compared with 13% on weekly therapy (16% v 6% with pneumonitis, resp.).  No biol. correlates of response could be identified, although there were trends favoring benefit in ER-pos. and HER2-neg. metastatic breast cancer.  Conclusion: Oral everolimus has activity in metastatic breast cancer that is schedule dependent.  Daily therapy with 10 mg is worthy of further study in this patient population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQfymkUESI-7Vg90H21EOLACvtfcHk0lgyC3yOP0rGfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlCns77K&md5=5dd0bfb2c83436e59ae0115c71a9c13e</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1200%2FJCO.2008.21.3033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2008.21.3033%26sid%3Dliteratum%253Aachs%26aulast%3DEllard%26aufirst%3DS.%2BL.%26aulast%3DClemons%26aufirst%3DM.%26aulast%3DGelmon%26aufirst%3DK.%2BA.%26aulast%3DNorris%26aufirst%3DB.%26aulast%3DKennecke%26aufirst%3DH.%26aulast%3DChia%26aufirst%3DS.%26aulast%3DPritchard%26aufirst%3DK.%26aulast%3DEisen%26aufirst%3DA.%26aulast%3DVandenberg%26aufirst%3DT.%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DSauerbrei%26aufirst%3DE.%26aulast%3DMishaeli%26aufirst%3DM.%26aulast%3DHuntsman%26aufirst%3DD.%26aulast%3DWalsh%26aufirst%3DW.%26aulast%3DOlivo%26aufirst%3DM.%26aulast%3DMcIntosh%26aufirst%3DL.%26aulast%3DSeymour%26aufirst%3DL.%26atitle%3DRandomized%2520phase%2520II%2520study%2520comparing%2520two%2520schedules%2520of%2520everolimus%2520in%2520patients%2520with%2520recurrent%252Fmetastatic%2520breast%2520cancer%253A%2520NCIC%2520Clinical%2520Trials%2520Group%2520IND.163%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D4536%26epage%3D4541%26doi%3D10.1200%2FJCO.2008.21.3033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Findlay, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolkacheva, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wigfield, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rebholz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnett, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gout, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downes, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, R. F.</span></span> <span> </span><span class="NLM_article-title">The TSC1–2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>166</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1083/jcb.200403069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1083%2Fjcb.200403069" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2004&pages=213-223&author=L.+S.+Harringtonauthor=G.+M.+Findlayauthor=A.+Grayauthor=T.+Tolkachevaauthor=S.+Wigfieldauthor=H.+Rebholzauthor=J.+Barnettauthor=N.+R.+Leslieauthor=S.+Chengauthor=P.+R.+Shepherdauthor=I.+Goutauthor=C.+P.+Downesauthor=R.+F.+Lamb&title=The+TSC1%E2%80%932+tumor+suppressor+controls+insulin-PI3K+signaling+via+regulation+of+IRS+proteins&doi=10.1083%2Fjcb.200403069"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1083%2Fjcb.200403069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.200403069%26sid%3Dliteratum%253Aachs%26aulast%3DHarrington%26aufirst%3DL.%2BS.%26aulast%3DFindlay%26aufirst%3DG.%2BM.%26aulast%3DGray%26aufirst%3DA.%26aulast%3DTolkacheva%26aufirst%3DT.%26aulast%3DWigfield%26aufirst%3DS.%26aulast%3DRebholz%26aufirst%3DH.%26aulast%3DBarnett%26aufirst%3DJ.%26aulast%3DLeslie%26aufirst%3DN.%2BR.%26aulast%3DCheng%26aufirst%3DS.%26aulast%3DShepherd%26aufirst%3DP.%2BR.%26aulast%3DGout%26aufirst%3DI.%26aulast%3DDownes%26aufirst%3DC.%2BP.%26aulast%3DLamb%26aufirst%3DR.%2BF.%26atitle%3DThe%2520TSC1%25E2%2580%25932%2520tumor%2520suppressor%2520controls%2520insulin-PI3K%2520signaling%2520via%2520regulation%2520of%2520IRS%2520proteins%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2004%26volume%3D166%26spage%3D213%26epage%3D223%26doi%3D10.1083%2Fjcb.200403069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dibble, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asara, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, B. D.</span></span> <span> </span><span class="NLM_article-title">Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">5657</span>– <span class="NLM_lpage">5670</span>, <span class="refDoi"> DOI: 10.1128/MCB.00735-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1128%2FMCB.00735-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=19720745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlKntbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2009&pages=5657-5670&author=C.+C.+Dibbleauthor=J.+M.+Asaraauthor=B.+D.+Manning&title=Characterization+of+Rictor+phosphorylation+sites+reveals+direct+regulation+of+mTOR+complex+2+by+S6K1&doi=10.1128%2FMCB.00735-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1</span></div><div class="casAuthors">Dibble, Christian C.; Asara, John M.; Manning, Brendan D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5657-5670</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The mammalian target of rapamycin (mTOR) functions within two distinct complexes (mTORC1 and mTORC2) to control cell growth, proliferation, survival, and metab.  While there has been great progress in our understanding of mTORC1 regulation, the signaling mechanisms that regulate mTORC2 have not been defined.  In this study, we use liq. chromatog.-tandem mass spectrometry analyses to identify 21 phosphorylation sites on the core mTORC2 component Rictor.  We find that one site, T1135, undergoes growth factor-responsive phosphorylation that is acutely sensitive to rapamycin and is phosphorylated downstream of mTORC1.  We find that Rictor-T1135 is directly phosphorylated by the mTORC1-dependent kinase S6K1.  Although this phosphorylation event does not affect mTORC2 integrity or in vitro kinase activity, expression of a phosphorylation site mutant of Rictor (T1135A) in either wild-type or Rictor null cells causes an increase in the mTORC2-dependent phosphorylation of Akt on S473.  However, Rictor-T1135 phosphorylation does not appear to regulate mTORC2-mediated effects on SGK1 or PKCα.  While the precise mol. mechanism affecting Akt is unknown, phosphorylation of T1135 stimulates binding of Rictor to 14-3-3 proteins.  We provide evidence that Rictor-T1135 phosphorylation acts in parallel with other mTORC1-dependent feedback mechanisms, such as those affecting IRS-1 signaling to PI3K, to regulate the response of Akt to insulin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDFjKOh5u2ArVg90H21EOLACvtfcHk0lgMAdJsSiKN_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlKntbrN&md5=23626dc34532fd8effa77706ac671f49</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1128%2FMCB.00735-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.00735-09%26sid%3Dliteratum%253Aachs%26aulast%3DDibble%26aufirst%3DC.%2BC.%26aulast%3DAsara%26aufirst%3DJ.%2BM.%26aulast%3DManning%26aufirst%3DB.%2BD.%26atitle%3DCharacterization%2520of%2520Rictor%2520phosphorylation%2520sites%2520reveals%2520direct%2520regulation%2520of%2520mTOR%2520complex%25202%2520by%2520S6K1%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2009%26volume%3D29%26spage%3D5657%26epage%3D5670%26doi%3D10.1128%2FMCB.00735-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Julien, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carriere, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roux, P. P.</span></span> <span> </span><span class="NLM_article-title">mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">908</span>– <span class="NLM_lpage">921</span>, <span class="refDoi"> DOI: 10.1128/MCB.00601-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1128%2FMCB.00601-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=19995915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisVequrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2010&pages=908-921&author=L.+A.+Julienauthor=A.+Carriereauthor=J.+Moreauauthor=P.+P.+Roux&title=mTORC1-activated+S6K1+phosphorylates+Rictor+on+threonine+1135+and+regulates+mTORC2+signaling&doi=10.1128%2FMCB.00601-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">mTORC1-activated S6K1 phosphorylates rictor on threonine 1135 and regulates mTORC2 signaling</span></div><div class="casAuthors">Julien, Louis-Andre; Carriere, Audrey; Moreau, Julie; Roux, Philippe P.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">908-921</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The mammalian target of rapamycin (mTOR) is a conserved Ser/Thr kinase that forms two functionally distinct complexes important for nutrient and growth factor signaling.  While mTOR complex 1 (mTORC1) regulates mRNA translation and ribosome biogenesis, mTORC2 plays an important role in the phosphorylation and subsequent activation of Akt.  Interestingly, mTORC1 neg. regulates Akt activation, but whether mTORC1 signaling directly targets mTORC2 remains unknown.  Here we show that growth factors promote the phosphorylation of rictor (rapamycin-insensitive companion of mTOR), an essential subunit of mTORC2.  We found that rictor phosphorylation requires mTORC1 activity and, more specifically, the p70 ribosomal S6 kinase 1 (S6K1).  We identified several phosphorylation sites in rictor and found that Thr1135 is directly phosphorylated by S6K1 in vitro and in vivo, in a rapamycin-sensitive manner.  Phosphorylation of rictor on Thr1135 did not affect mTORC2 assembly, kinase activity, or cellular localization.  However, cells expressing a rictor T1135A mutant were found to have increased mTORC2-dependent phosphorylation of Akt.  In addn., phosphorylation of the Akt substrates FoxO1/3a and glycogen synthase kinase 3α/β (GSK3α/β) was found to be increased in these cells, indicating that S6K1-mediated phosphorylation of rictor inhibits mTORC2 and Akt signaling.  Together, our results uncover a new regulatory link between the two mTOR complexes, whereby rictor integrates mTORC1-dependent signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0-wSn51tBgrVg90H21EOLACvtfcHk0lgMAdJsSiKN_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisVequrg%253D&md5=fb2ba3d2e97aa98c0fd0bf4eb2862c25</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1128%2FMCB.00601-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.00601-09%26sid%3Dliteratum%253Aachs%26aulast%3DJulien%26aufirst%3DL.%2BA.%26aulast%3DCarriere%26aufirst%3DA.%26aulast%3DMoreau%26aufirst%3DJ.%26aulast%3DRoux%26aufirst%3DP.%2BP.%26atitle%3DmTORC1-activated%2520S6K1%2520phosphorylates%2520Rictor%2520on%2520threonine%25201135%2520and%2520regulates%2520mTORC2%2520signaling%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2010%26volume%3D30%26spage%3D908%26epage%3D921%26doi%3D10.1128%2FMCB.00601-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudge, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koos, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidialingam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavletich, N. P.</span></span> <span> </span><span class="NLM_article-title">mTOR kinase structure, mechanism and regulation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>497</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1038/nature12122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1038%2Fnature12122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=23636326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmvFyns7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=497&publication_year=2013&pages=217-223&author=H.+Yangauthor=D.+G.+Rudgeauthor=J.+D.+Koosauthor=B.+Vaidialingamauthor=H.+J.+Yangauthor=N.+P.+Pavletich&title=mTOR+kinase+structure%2C+mechanism+and+regulation&doi=10.1038%2Fnature12122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR kinase structure, mechanism and regulation</span></div><div class="casAuthors">Yang, Haijuan; Rudge, Derek G.; Koos, Joseph D.; Vaidialingam, Bhamini; Yang, Hyo J.; Pavletich, Nikola P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">497</span>
        (<span class="NLM_cas:issue">7448</span>),
    <span class="NLM_cas:pages">217-223</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The mammalian target of rapamycin (mTOR), a phosphoinositide 3-kinase-related protein kinase, controls cell growth in response to nutrients and growth factors and is frequently deregulated in cancer.  Here we report co-crystal structures of a complex of truncated mTOR and mammalian lethal with SEC13 protein 8 (mLST8) with an ATP transition state mimic (MgF3-) and with ATP-site inhibitors (Torin2, PP242, and PI-103).  The structures reveal an intrinsically active kinase conformation, with catalytic residues and a catalytic mechanism remarkably similar to canonical protein kinases.  The active site is highly recessed owing to the FKBP12-rapamycin-binding (FRB) domain and an inhibitory helix protruding from the catalytic cleft.  MTOR-activating mutations map to the structural framework that holds these elements in place, indicating that the kinase is controlled by restricted access.  In vitro biochem. shows that the FRB domain acts as a gatekeeper, with its rapamycin-binding site interacting with substrates to grant them access to the restricted active site.  Rapamycin-FKBP12 inhibits the kinase by directly blocking substrate recruitment and by further restricting active-site access.  The structures also reveal active-site residues and conformational changes that underlie inhibitor potency and specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjvPQtdm6yCbVg90H21EOLACvtfcHk0lgMAdJsSiKN_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmvFyns7k%253D&md5=07809555fbdf2004819a7f2da5727baf</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fnature12122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature12122%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DH.%26aulast%3DRudge%26aufirst%3DD.%2BG.%26aulast%3DKoos%26aufirst%3DJ.%2BD.%26aulast%3DVaidialingam%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DH.%2BJ.%26aulast%3DPavletich%26aufirst%3DN.%2BP.%26atitle%3DmTOR%2520kinase%2520structure%252C%2520mechanism%2520and%2520regulation%26jtitle%3DNature%26date%3D2013%26volume%3D497%26spage%3D217%26epage%3D223%26doi%3D10.1038%2Fnature12122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krieger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darden, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabuurs, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finkelstein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vriend, G.</span></span> <span> </span><span class="NLM_article-title">Making optimal use of empirical energy functions: force-field parameterization in crystal space</span>. <i>Proteins: Struct., Funct., Genet.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">678</span>– <span class="NLM_lpage">683</span>, <span class="refDoi"> DOI: 10.1002/prot.20251</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1002%2Fprot.20251" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=15390263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVaqtLrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2004&pages=678-683&author=E.+Kriegerauthor=T.+Dardenauthor=S.+B.+Nabuursauthor=A.+Finkelsteinauthor=G.+Vriend&title=Making+optimal+use+of+empirical+energy+functions%3A+force-field+parameterization+in+crystal+space&doi=10.1002%2Fprot.20251"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Making optimal use of empirical energy functions: Force-field parameterization in crystal space</span></div><div class="casAuthors">Krieger, Elmar; Darden, Tom; Nabuurs, Sander B.; Finkelstein, Alexei; Vriend, Gert</div><div class="citationInfo"><span class="NLM_cas:title">Proteins: Structure, Function, and Bioinformatics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">678-683</span>CODEN:
                <span class="NLM_cas:coden">PSFBAF</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Today's energy functions are not able yet to distinguish reliably between correct and almost correct protein models.  Improving these near-native models is currently a major bottle-neck in homol. modeling or exptl. structure detn. at low resoln.  Increasingly accurate energy functions are required to complete the "last mile of the protein folding problem," for example during a mol. dynamics simulation.  We present a new approach to reach this goal.  For 50 high resoln. x-ray structures, the complete unit cell was reconstructed, including disordered water mols., counter ions, and hydrogen atoms.  Simulations were then run at the pH at which the crystal was solved, while force-field parameters were iteratively adjusted so that the damage done to the structures was minimal.  Starting with initial parameters from the AMBER force field, the optimization procedure converged at a new force field called YAMBER (Yet Another Model Building and Energy Refinement force field), which is shown to do significantly less damage to x-ray structures, often move homol. models in the right direction, and occasionally make them look like exptl. structures.  Application of YAMBER during the CASP5 structure prediction expt. yielded a model for target 176 that was ranked first among 150 submissions.  Due to its compatibility with the well-established AMBER format, YAMBER can be used by almost any mol. dynamics program.  The parameters are freely available from www.yasara.org/yamber.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZ95LDBJGK6LVg90H21EOLACvtfcHk0lgsT7PcVT4Inw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVaqtLrE&md5=bc51b590b7653f9b413012faee902e4b</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1002%2Fprot.20251&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprot.20251%26sid%3Dliteratum%253Aachs%26aulast%3DKrieger%26aufirst%3DE.%26aulast%3DDarden%26aufirst%3DT.%26aulast%3DNabuurs%26aufirst%3DS.%2BB.%26aulast%3DFinkelstein%26aufirst%3DA.%26aulast%3DVriend%26aufirst%3DG.%26atitle%3DMaking%2520optimal%2520use%2520of%2520empirical%2520energy%2520functions%253A%2520force-field%2520parameterization%2520in%2520crystal%2520space%26jtitle%3DProteins%253A%2520Struct.%252C%2520Funct.%252C%2520Genet.%26date%3D2004%26volume%3D57%26spage%3D678%26epage%3D683%26doi%3D10.1002%2Fprot.20251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walker, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacold, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perisic, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. L.</span></span> <span> </span><span class="NLM_article-title">Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">909</span>– <span class="NLM_lpage">919</span>, <span class="refDoi"> DOI: 10.1016/S1097-2765(05)00089-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1016%2FS1097-2765%2805%2900089-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=11090628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnvVegurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=909-919&author=E.+H.+Walkerauthor=M.+E.+Pacoldauthor=O.+Perisicauthor=L.+Stephensauthor=P.+T.+Hawkinsauthor=M.+P.+Wymannauthor=R.+L.+Williams&title=Structural+determinants+of+phosphoinositide+3-kinase+inhibition+by+wortmannin%2C+LY294002%2C+quercetin%2C+myricetin%2C+and+staurosporine&doi=10.1016%2FS1097-2765%2805%2900089-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine</span></div><div class="casAuthors">Walker, Edward H.; Pacold, Michael E.; Perisic, Olga; Stephens, Len; Hawkins, Philip T.; Wymann, Matthias P.; Williams, Roger L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">909-919</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The specific phosphoinositide 3-kinase (P13K) inhibitors wortmannin and LY294002 have been invaluable tools for elucidating the roles of these enzymes in signal transduction pathways.  The X-ray crystallog. structures of P13K bound to these lipid kinase inhibitors and to the broad-spectrum protein kinase inhibitors quercetin, myricetin, and staurosporine reveal how these compds. fit into the ATP binding pocket.  With a nanomolar IC50, wortmannin most closely fits and fills the active site and induces a conformational change in the catalytic domain.  Surprisingly, LY294002 and the lead compd. on which it was designed, quercetin, as well as the closely related flavonoid myricetin bind P13K in remarkably different orientations that are related to each other by 1800 rotations.  Staurosporine/P13K interactions are reminiscent of low-affinity protein kinase/staurosporine complexes.  These results provide a rich basis for development of isoform-specific P13K inhibitors with therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgIbTky2xQmbVg90H21EOLACvtfcHk0lgsT7PcVT4Inw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnvVegurY%253D&md5=5dd92f9b48c437e43c0023fdff10c1ac</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2805%2900089-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252805%252900089-4%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DE.%2BH.%26aulast%3DPacold%26aufirst%3DM.%2BE.%26aulast%3DPerisic%26aufirst%3DO.%26aulast%3DStephens%26aufirst%3DL.%26aulast%3DHawkins%26aufirst%3DP.%2BT.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26atitle%3DStructural%2520determinants%2520of%2520phosphoinositide%25203-kinase%2520inhibition%2520by%2520wortmannin%252C%2520LY294002%252C%2520quercetin%252C%2520myricetin%252C%2520and%2520staurosporine%26jtitle%3DMol.%2520Cell%26date%3D2000%26volume%3D6%26spage%3D909%26epage%3D919%26doi%3D10.1016%2FS1097-2765%2805%2900089-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
Der Spoel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindahl, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groenhof, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mark, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berendsen, H. J.</span></span> <span> </span><span class="NLM_article-title">GROMACS: fast, flexible, and free</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1701</span>– <span class="NLM_lpage">1718</span>, <span class="refDoi"> DOI: 10.1002/jcc.20291</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1002%2Fjcc.20291" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=16211538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1SlsbbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2005&pages=1701-1718&author=D.+Van%0ADer+Spoelauthor=E.+Lindahlauthor=B.+Hessauthor=G.+Groenhofauthor=A.+E.+Markauthor=H.+J.+Berendsen&title=GROMACS%3A+fast%2C+flexible%2C+and+free&doi=10.1002%2Fjcc.20291"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">GROMACS: Fast, flexible, and free</span></div><div class="casAuthors">Van Der Spoel, David; Lindahl, Erik; Hess, Berk; Groenhof, Gerrit; Mark, Alan E.; Berendsen, Herman J. C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1701-1718</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">This article describes the software suite GROMACS (Groningen MAchine for Chem. Simulation) that was developed at the University of Groningen, The Netherlands, in the early 1990s.  The software, written in ANSI C, originates from a parallel hardware project, and is well suited for parallelization on processor clusters.  By careful optimization of neighbor searching and of inner loop performance, GROMACS is a very fast program for mol. dynamics simulation.  It does not have a force field of its own, but is compatible with GROMOS, OPLS, AMBER, and ENCAD force fields.  In addn., it can handle polarizable shell models and flexible constraints.  The program is versatile, as force routines can be added by the user, tabulated functions can be specified, and analyses can be easily customized.  Nonequil. dynamics and free energy detns. are incorporated.  Interfaces with popular quantum-chem. packages (MOPAC, GAMES-UK, GAUSSIAN) are provided to perform mixed MM/QM simulations.  The package includes about 100 utility and anal. programs.  GROMACS is in the public domain and distributed (with source code and documentation) under the GNU General Public License.  It is maintained by a group of developers from the Universities of Groningen, Uppsala, and Stockholm, and the Max Planck Institute for Polymer Research in Mainz.  Its Web site is http://www.gromacs.org.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxInIDyt9Y8bVg90H21EOLACvtfcHk0lgsT7PcVT4Inw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1SlsbbO&md5=4aa71b1dc0b5b4978a88b0568245a265</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1002%2Fjcc.20291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.20291%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BDer%2BSpoel%26aufirst%3DD.%26aulast%3DLindahl%26aufirst%3DE.%26aulast%3DHess%26aufirst%3DB.%26aulast%3DGroenhof%26aufirst%3DG.%26aulast%3DMark%26aufirst%3DA.%2BE.%26aulast%3DBerendsen%26aufirst%3DH.%2BJ.%26atitle%3DGROMACS%253A%2520fast%252C%2520flexible%252C%2520and%2520free%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2005%26volume%3D26%26spage%3D1701%26epage%3D1718%26doi%3D10.1002%2Fjcc.20291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chaigne-Delalande, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahfouf, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daburon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legembre, P.</span></span> <span> </span><span class="NLM_article-title">CD95 engagement mediates actin-independent and -dependent apoptotic signals</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1654</span>, <span class="refDoi"> DOI: 10.1038/cdd.2009.111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1038%2Fcdd.2009.111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=19680267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVWlsr3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=1654&author=B.+Chaigne-Delalandeauthor=W.+Mahfoufauthor=S.+Daburonauthor=J.+F.+Moreauauthor=P.+Legembre&title=CD95+engagement+mediates+actin-independent+and+-dependent+apoptotic+signals&doi=10.1038%2Fcdd.2009.111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">CD95 engagement mediates actin-independent and -dependent apoptotic signals</span></div><div class="casAuthors">Chaigne-Delalande, B.; Mahfouf, W.; Daburon, S.; Moreau, J.-F.; Legembre, P.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death and Differentiation</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1654-1664</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">CD95 is a death receptor whose stimulation by either the physiol. ligand CD95L or the agonistic antibodies leads to the formation of a multi-mol. complex termed DISC (death-inducing signaling complex) and the subsequent induction of a caspase-driven apoptotic signal.  According to the magnitude of the DISC formation, two types of cells have been identified.  Although type I cells generate an important DISC, the complex is barely found in type II cells.  Analyzing the early stages preceding the DISC formation, we found that unlike CD95L, the commonly used agonistic antibody APO1-3 internalized the death receptor.  Using inhibitors of actin polymn., we showed that the remodeling of the actin cytoskeleton did not alter the capping of the CD95 receptor or its partitioning into the lipid rafts.  In addn., whereas the disruption of F-actin prevented the internalization of CD95, the DISC formation and the apoptotic signal induced by the agonistic antibody APO1-3 in type I cells, it did not affect the signal triggered by the sol. and membrane-bound CD95L, regardless of the type of cells.  In conclusion, the addn. of APO1-3 on type I cells triggers an actin-dependent apoptotic signal, which is absent or marginal in cells (both types I and II) treated with CD95L.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLiWIVfRGh3rVg90H21EOLACvtfcHk0liTy9vofTFlFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVWlsr3O&md5=d2e91ce5d6891969044f44dad0544c18</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1038%2Fcdd.2009.111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcdd.2009.111%26sid%3Dliteratum%253Aachs%26aulast%3DChaigne-Delalande%26aufirst%3DB.%26aulast%3DMahfouf%26aufirst%3DW.%26aulast%3DDaburon%26aufirst%3DS.%26aulast%3DMoreau%26aufirst%3DJ.%2BF.%26aulast%3DLegembre%26aufirst%3DP.%26atitle%3DCD95%2520engagement%2520mediates%2520actin-independent%2520and%2520-dependent%2520apoptotic%2520signals%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2009%26volume%3D16%26spage%3D1654%26doi%3D10.1038%2Fcdd.2009.111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="ref61_1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Armarego, W. L. F.</span>; <span class="NLM_string-name">Chai, C. L. L.</span> </span> <i>Purification of Laboratory Chemicals</i>, <span class="NLM_edition">6</span>th ed.; <span class="NLM_publisher-name">Elsevier</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/ref61_1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1016%2FB978-1-85617-567-8.50011-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=W.+L.+F.+Armarego&author=C.+L.+L.+Chai&title=Purification+of+Laboratory+Chemicals"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=ref61_1&amp;dbid=16384&amp;doi=10.1016%2FB978-1-85617-567-8.50011-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-1-85617-567-8.50011-1%26sid%3Dliteratum%253Aachs%26aulast%3DArmarego%26aufirst%3DW.%2BL.%2BF.%26btitle%3DPurification%2520of%2520Laboratory%2520Chemicals%26pub%3DElsevier%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['ref61_1']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 19 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Chenlu Dai, Naili Luo, Shan Wang, <span class="NLM_string-name hlFld-ContribAuthor">Cunde Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Cesium-Carbonate-Mediated Benzalation of Substituted 2-Aryl-3-nitro-2H-chromenes with Substituted 4-Benzylidene-2-phenyloxazol-5(4H)-ones. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2019,</strong> <em>21 </em>
                                    (8)
                                     , 2828-2832. <a href="https://doi.org/10.1021/acs.orglett.9b00776" title="DOI URL">https://doi.org/10.1021/acs.orglett.9b00776</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.9b00776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.9b00776%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DCesium-Carbonate-Mediated%252BBenzalation%252Bof%252BSubstituted%252B2-Aryl-3-nitro-2H-chromenes%252Bwith%252BSubstituted%252B4-Benzylidene-2-phenyloxazol-5%2525284H%252529-ones%26aulast%3DDai%26aufirst%3DChenlu%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D06032019%26date%3D02042019%26volume%3D21%26issue%3D8%26spage%3D2828%26epage%3D2832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiang  Ruibin</span>, <span class="hlFld-ContribAuthor ">Jin  Bo</span>, <span class="hlFld-ContribAuthor ">Wan  Danying</span>, <span class="hlFld-ContribAuthor ">Feng  Jianguo</span>, <span class="hlFld-ContribAuthor ">Gu  Linhui</span>. </span><span class="cited-content_cbyCitation_article-title">Cardamonin induces G2/M phase arrest and apoptosis through inhibition of NF-κB and mTOR pathways in ovarian cancer. </span><span class="cited-content_cbyCitation_journal-name">Aging</span><span> <strong>2020,</strong> <em>12 </em>
                                    (24)
                                     , 25730-25743. <a href="https://doi.org/10.18632/aging.104184" title="DOI URL">https://doi.org/10.18632/aging.104184</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/aging.104184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Faging.104184%26sid%3Dliteratum%253Aachs%26jtitle%3DAging%26atitle%3DCardamonin%252Binduces%252BG2%25252FM%252Bphase%252Barrest%252Band%252Bapoptosis%252Bthrough%252Binhibition%252Bof%252BNF-%2525CE%2525BAB%252Band%252BmTOR%252Bpathways%252Bin%252Bovarian%252Bcancer%26aulast%3DRuibin%26aufirst%3DJiang%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D24%26spage%3D25730%26epage%3D25743" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rajibul  Islam</span>, <span class="hlFld-ContribAuthor ">Kok Wai  Lam</span>. </span><span class="cited-content_cbyCitation_article-title">Recent progress in small molecule agents for the targeted therapy of triple-negative breast cancer. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>207 </em>, 112812. <a href="https://doi.org/10.1016/j.ejmech.2020.112812" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112812</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112812&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112812%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Bprogress%252Bin%252Bsmall%252Bmolecule%252Bagents%252Bfor%252Bthe%252Btargeted%252Btherapy%252Bof%252Btriple-negative%252Bbreast%252Bcancer%26aulast%3DIslam%26aufirst%3DRajibul%26date%3D2020%26volume%3D207%26spage%3D112812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sofia  Oliveira-Pinto</span>, <span class="hlFld-ContribAuthor ">Olívia  Pontes</span>, <span class="hlFld-ContribAuthor ">Fátima  Baltazar</span>, <span class="hlFld-ContribAuthor ">Marta  Costa</span>. </span><span class="cited-content_cbyCitation_article-title">In vivo efficacy studies of chromene-based compounds in triple-negative breast cancer – A systematic review. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Pharmacology</span><span> <strong>2020,</strong> <em>887 </em>, 173452. <a href="https://doi.org/10.1016/j.ejphar.2020.173452" title="DOI URL">https://doi.org/10.1016/j.ejphar.2020.173452</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejphar.2020.173452&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejphar.2020.173452%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Pharmacology%26atitle%3DIn%252Bvivo%252Befficacy%252Bstudies%252Bof%252Bchromene-based%252Bcompounds%252Bin%252Btriple-negative%252Bbreast%252Bcancer%252B%2525E2%252580%252593%252BA%252Bsystematic%252Breview%26aulast%3DOliveira-Pinto%26aufirst%3DSofia%26date%3D2020%26volume%3D887%26spage%3D173452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ayah  Abdeldayem</span>, <span class="hlFld-ContribAuthor ">Yasir S.  Raouf</span>, <span class="hlFld-ContribAuthor ">Stefan N.  Constantinescu</span>, <span class="hlFld-ContribAuthor ">Richard  Moriggl</span>, <span class="hlFld-ContribAuthor ">Patrick T.  Gunning</span>. </span><span class="cited-content_cbyCitation_article-title">Advances in covalent kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chemical Society Reviews</span><span> <strong>2020,</strong> <em>49 </em>
                                    (9)
                                     , 2617-2687. <a href="https://doi.org/10.1039/C9CS00720B" title="DOI URL">https://doi.org/10.1039/C9CS00720B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9CS00720B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9CS00720B%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Society%2520Reviews%26atitle%3DAdvances%252Bin%252Bcovalent%252Bkinase%252Binhibitors%26aulast%3DAbdeldayem%26aufirst%3DAyah%26date%3D2020%26date%3D2020%26volume%3D49%26issue%3D9%26spage%3D2617%26epage%3D2687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Z.  Wu</span>, <span class="hlFld-ContribAuthor ">J.  Wu</span>, <span class="hlFld-ContribAuthor ">Q.  Zhao</span>, <span class="hlFld-ContribAuthor ">S.  Fu</span>, <span class="hlFld-ContribAuthor ">J.  Jin</span>. </span><span class="cited-content_cbyCitation_article-title">Emerging roles of aerobic glycolysis in breast cancer. </span><span class="cited-content_cbyCitation_journal-name">Clinical and Translational Oncology</span><span> <strong>2020,</strong> <em>22 </em>
                                    (5)
                                     , 631-646. <a href="https://doi.org/10.1007/s12094-019-02187-8" title="DOI URL">https://doi.org/10.1007/s12094-019-02187-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12094-019-02187-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12094-019-02187-8%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520and%2520Translational%2520Oncology%26atitle%3DEmerging%252Broles%252Bof%252Baerobic%252Bglycolysis%252Bin%252Bbreast%252Bcancer%26aulast%3DWu%26aufirst%3DZ.%26date%3D2020%26date%3D2019%26volume%3D22%26issue%3D5%26spage%3D631%26epage%3D646" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chien Thang  Pham</span>, <span class="hlFld-ContribAuthor ">Dinh Hung  Mac</span>, <span class="hlFld-ContribAuthor ">Thai Thanh Thu  Bui</span>. </span><span class="cited-content_cbyCitation_article-title">Crystal structures of 2-(2-bromo-5-fluorophenyl)-8-ethoxy-3-nitro-2
              H
              -thiochromene and 2-(2-bromo-5-fluorophenyl)-7-methoxy-3-nitro-2
              H
              -thiochromene. </span><span class="cited-content_cbyCitation_journal-name">Acta Crystallographica Section E Crystallographic Communications</span><span> <strong>2019,</strong> <em>75 </em>
                                    (11)
                                     , 1783-1786. <a href="https://doi.org/10.1107/S2056989019014178" title="DOI URL">https://doi.org/10.1107/S2056989019014178</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1107/S2056989019014178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1107%2FS2056989019014178%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Crystallographica%2520Section%2520E%2520Crystallographic%2520Communications%26atitle%3DCrystal%252Bstructures%252Bof%252B2-%2525282-bromo-5-fluorophenyl%252529-8-ethoxy-3-nitro-2%252BH%252B-thiochromene%252Band%252B2-%2525282-bromo-5-fluorophenyl%252529-7-methoxy-3-nitro-2%252BH%252B-thiochromene%26aulast%3DPham%26aufirst%3DChien%2BThang%26date%3D2019%26date%3D2019%26volume%3D75%26issue%3D11%26spage%3D1783%26epage%3D1786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aditya  Bhattacharya</span>, <span class="hlFld-ContribAuthor ">Pushpendra  mani Shukla</span>, <span class="hlFld-ContribAuthor ">Lalit  Kumar Kaushik</span>, <span class="hlFld-ContribAuthor ">Biswajit  Maji</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of chromans and kinetic resolution of 2-aryl-3-nitro-2
              H
              -chromenes
              via
              the NHC-bound azolium homoenolate pathway. </span><span class="cited-content_cbyCitation_journal-name">Organic Chemistry Frontiers</span><span> <strong>2019,</strong> <em>6 </em>
                                    (20)
                                     , 3523-3529. <a href="https://doi.org/10.1039/C9QO00868C" title="DOI URL">https://doi.org/10.1039/C9QO00868C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9QO00868C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9QO00868C%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Chemistry%2520Frontiers%26atitle%3DSynthesis%252Bof%252Bchromans%252Band%252Bkinetic%252Bresolution%252Bof%252B2-aryl-3-nitro-2%252BH%252B-chromenes%252Bvia%252Bthe%252BNHC-bound%252Bazolium%252Bhomoenolate%252Bpathway%26aulast%3DBhattacharya%26aufirst%3DAditya%26date%3D2019%26date%3D2019%26volume%3D6%26issue%3D20%26spage%3D3523%26epage%3D3529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thi Thu Huong  Le</span>, <span class="hlFld-ContribAuthor ">Chitose  Youhei</span>, <span class="hlFld-ContribAuthor ">Quy Hien  Le</span>, <span class="hlFld-ContribAuthor ">Thanh Binh  Nguyen</span>, <span class="hlFld-ContribAuthor ">Dinh Hung  Mac</span>. </span><span class="cited-content_cbyCitation_article-title">Convenient one-pot access to 2
              H
              -3-nitrothiochromenes from 2-bromobenzaldehydes, sodium sulfide and β-nitrostyrenes. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2019,</strong> <em>17 </em>
                                    (26)
                                     , 6355-6358. <a href="https://doi.org/10.1039/C9OB01060B" title="DOI URL">https://doi.org/10.1039/C9OB01060B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9OB01060B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9OB01060B%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DConvenient%252Bone-pot%252Baccess%252Bto%252B2%252BH%252B-3-nitrothiochromenes%252Bfrom%252B2-bromobenzaldehydes%25252C%252Bsodium%252Bsulfide%252Band%252B%2525CE%2525B2-nitrostyrenes%26aulast%3DLe%26aufirst%3DThi%2BThu%2BHuong%26date%3D2019%26date%3D2019%26volume%3D17%26issue%3D26%26spage%3D6355%26epage%3D6358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sabita  Nayak</span>, <span class="hlFld-ContribAuthor ">Pravati  Panda</span>, <span class="hlFld-ContribAuthor ">Seetaram  Mohapatra</span>, <span class="hlFld-ContribAuthor ">Bishnuprasad  Raiguru</span>, <span class="hlFld-ContribAuthor ">Nilofar  Baral</span>. </span><span class="cited-content_cbyCitation_article-title">Microwave‐assisted One‐pot, Three‐component Regiospecific and Sterospecific Synthesis of Spiro Indanone Pyrrolidine/Piperidine Fused Nitrochromene Derivatives Through 1,3‐Dipolar Cycloaddition Reactions. </span><span class="cited-content_cbyCitation_journal-name">Journal of Heterocyclic Chemistry</span><span> <strong>2019,</strong> <em>56 </em>
                                    (6)
                                     , 1757-1770. <a href="https://doi.org/10.1002/jhet.3534" title="DOI URL">https://doi.org/10.1002/jhet.3534</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jhet.3534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjhet.3534%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Heterocyclic%2520Chemistry%26atitle%3DMicrowave%2525E2%252580%252590assisted%252BOne%2525E2%252580%252590pot%25252C%252BThree%2525E2%252580%252590component%252BRegiospecific%252Band%252BSterospecific%252BSynthesis%252Bof%252BSpiro%252BIndanone%252BPyrrolidine%25252FPiperidine%252BFused%252BNitrochromene%252BDerivatives%252BThrough%252B1%25252C3%2525E2%252580%252590Dipolar%252BCycloaddition%252BReactions%26aulast%3DNayak%26aufirst%3DSabita%26date%3D2019%26date%3D2019%26volume%3D56%26issue%3D6%26spage%3D1757%26epage%3D1770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Frederik  Cuperjani</span>, <span class="hlFld-ContribAuthor ">Lumturije  Gashi</span>, <span class="hlFld-ContribAuthor ">Fisnik  Kurshumliu</span>, <span class="hlFld-ContribAuthor ">Shemsedin  Dreshaj</span>, <span class="hlFld-ContribAuthor ">Fitim  Selimi</span>. </span><span class="cited-content_cbyCitation_article-title">Relationship between Ribosomal Protein S6-pS240 Expression and other Prognostic Factors in Non-Special Type Invasive Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Breast Care</span><span> <strong>2019,</strong> <em>14 </em>
                                    (3)
                                     , 171-175. <a href="https://doi.org/10.1159/000491427" title="DOI URL">https://doi.org/10.1159/000491427</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1159/000491427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1159%2F000491427%26sid%3Dliteratum%253Aachs%26jtitle%3DBreast%2520Care%26atitle%3DRelationship%252Bbetween%252BRibosomal%252BProtein%252BS6-pS240%252BExpression%252Band%252Bother%252BPrognostic%252BFactors%252Bin%252BNon-Special%252BType%252BInvasive%252BBreast%252BCancer%26aulast%3DCuperjani%26aufirst%3DFrederik%26date%3D2019%26date%3D2018%26volume%3D14%26issue%3D3%26spage%3D171%26epage%3D175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kunnummal Mangott Muhammed  Salim</span>, <span class="hlFld-ContribAuthor ">Aranhikkal  Shamsiya</span>, <span class="hlFld-ContribAuthor ">Bahulayan  Damodaran</span>. </span><span class="cited-content_cbyCitation_article-title">Green Synthesis of Fluorescent Peptidomimetic Triazoles from Biomass-Derived 5-(Chloromethyl)furfural. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2018,</strong> <em>3 </em>
                                    (39)
                                     , 11141-11146. <a href="https://doi.org/10.1002/slct.201802310" title="DOI URL">https://doi.org/10.1002/slct.201802310</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.201802310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.201802310%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DGreen%252BSynthesis%252Bof%252BFluorescent%252BPeptidomimetic%252BTriazoles%252Bfrom%252BBiomass-Derived%252B5-%252528Chloromethyl%252529furfural%26aulast%3DSalim%26aufirst%3DKunnummal%2BMangott%2BMuhammed%26date%3D2018%26date%3D2018%26volume%3D3%26issue%3D39%26spage%3D11141%26epage%3D11146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Muyao  Li</span>, <span class="hlFld-ContribAuthor ">Xiaofei  Zhao</span>, <span class="hlFld-ContribAuthor ">Wen  Yang</span>, <span class="hlFld-ContribAuthor ">Fangrui  Zhong</span>, <span class="hlFld-ContribAuthor ">Lujiang  Yuan</span>, <span class="hlFld-ContribAuthor ">Qiao  Ren</span>. </span><span class="cited-content_cbyCitation_article-title">Asymmetric synthesis and biological evaluation of 3-nitro-2H-chromenes as potential antibacterial agents. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2018,</strong> <em>59 </em>
                                    (39)
                                     , 3511-3515. <a href="https://doi.org/10.1016/j.tetlet.2018.07.046" title="DOI URL">https://doi.org/10.1016/j.tetlet.2018.07.046</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2018.07.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2018.07.046%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DAsymmetric%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B3-nitro-2H-chromenes%252Bas%252Bpotential%252Bantibacterial%252Bagents%26aulast%3DLi%26aufirst%3DMuyao%26date%3D2018%26volume%3D59%26issue%3D39%26spage%3D3511%26epage%3D3515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fabrizio  Marcucci</span>, <span class="hlFld-ContribAuthor ">Cristiano  Rumio</span>. </span><span class="cited-content_cbyCitation_article-title">How Tumor Cells Choose Between Epithelial-Mesenchymal Transition and Autophagy to Resist Stress—Therapeutic Implications. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2018,</strong> <em>9 </em><a href="https://doi.org/10.3389/fphar.2018.00714" title="DOI URL">https://doi.org/10.3389/fphar.2018.00714</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2018.00714&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2018.00714%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DHow%252BTumor%252BCells%252BChoose%252BBetween%252BEpithelial-Mesenchymal%252BTransition%252Band%252BAutophagy%252Bto%252BResist%252BStress%2525E2%252580%252594Therapeutic%252BImplications%26aulast%3DMarcucci%26aufirst%3DFabrizio%26date%3D2018%26date%3D2018%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuqi  Lin</span>, <span class="hlFld-ContribAuthor ">Rong  Liu</span>, <span class="hlFld-ContribAuthor ">Ping  Zhao</span>, <span class="hlFld-ContribAuthor ">Jinxiang  Ye</span>, <span class="hlFld-ContribAuthor ">Zheng  Zheng</span>, <span class="hlFld-ContribAuthor ">Jingan  Huang</span>, <span class="hlFld-ContribAuthor ">Yingying  Zhang</span>, <span class="hlFld-ContribAuthor ">Yu  Gao</span>, <span class="hlFld-ContribAuthor ">Haiying  Chen</span>, <span class="hlFld-ContribAuthor ">Suling  Liu</span>, <span class="hlFld-ContribAuthor ">Jia  Zhou</span>, <span class="hlFld-ContribAuthor ">Ceshi  Chen</span>, <span class="hlFld-ContribAuthor ">Haijun  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel mifepristone derivatives via suppressing KLF5 expression for the treatment of triple-negative breast cancer. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>146 </em>, 354-367. <a href="https://doi.org/10.1016/j.ejmech.2018.01.056" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.01.056</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.01.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.01.056%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252Bmifepristone%252Bderivatives%252Bvia%252Bsuppressing%252BKLF5%252Bexpression%252Bfor%252Bthe%252Btreatment%252Bof%252Btriple-negative%252Bbreast%252Bcancer%26aulast%3DLin%26aufirst%3DYuqi%26date%3D2018%26volume%3D146%26spage%3D354%26epage%3D367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhi  Hong</span>, <span class="hlFld-ContribAuthor ">Yan-Li  Zhan</span>, <span class="hlFld-ContribAuthor ">Dang-Ran  Yu</span>, <span class="hlFld-ContribAuthor ">Ying  Li</span>, <span class="hlFld-ContribAuthor ">Wen-Jia  Yuan</span>, <span class="hlFld-ContribAuthor ">Hong-Yu  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">The pseudosymmetric crystal structure of 2-(2-naphthalenyl)-3-nitro-2H-1-benzopyran, C38H26N2O6. </span><span class="cited-content_cbyCitation_journal-name">Zeitschrift für Kristallographie - New Crystal Structures</span><span> <strong>2017,</strong> <em>232 </em>
                                    (6)
                                     , 893-895. <a href="https://doi.org/10.1515/ncrs-2017-0047" title="DOI URL">https://doi.org/10.1515/ncrs-2017-0047</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1515/ncrs-2017-0047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1515%2Fncrs-2017-0047%26sid%3Dliteratum%253Aachs%26jtitle%3DZeitschrift%2520f%25C3%25BCr%2520Kristallographie%2520-%2520New%2520Crystal%2520Structures%26atitle%3DThe%252Bpseudosymmetric%252Bcrystal%252Bstructure%252Bof%252B2-%2525282-naphthalenyl%252529-3-nitro-2H-1-benzopyran%25252C%252BC38H26N2O6%26aulast%3DHong%26aufirst%3DZhi%26date%3D2017%26volume%3D232%26issue%3D6%26spage%3D893%26epage%3D895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">T. Jency  Mohan</span>, <span class="hlFld-ContribAuthor ">D.  Bahulayan</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and fluorescence property evaluation of blue emitting triazole-linked chromene peptidomimetics. </span><span class="cited-content_cbyCitation_journal-name">Molecular Diversity</span><span> <strong>2017,</strong> <em>21 </em>
                                    (3)
                                     , 585-596. <a href="https://doi.org/10.1007/s11030-017-9744-9" title="DOI URL">https://doi.org/10.1007/s11030-017-9744-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11030-017-9744-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11030-017-9744-9%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Diversity%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bfluorescence%252Bproperty%252Bevaluation%252Bof%252Bblue%252Bemitting%252Btriazole-linked%252Bchromene%252Bpeptidomimetics%26aulast%3DMohan%26aufirst%3DT.%2BJency%26date%3D2017%26date%3D2017%26volume%3D21%26issue%3D3%26spage%3D585%26epage%3D596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Timothy D.  Owens</span>, <span class="hlFld-ContribAuthor ">Yan  Lou</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent Kinase Inhibitors for Cancer. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 76-103. <a href="https://doi.org/10.1016/B978-0-12-409547-2.12399-6" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.12399-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.12399-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.12399-6%26sid%3Dliteratum%253Aachs%26atitle%3DCovalent%252BKinase%252BInhibitors%252Bfor%252BCancer%26aulast%3DOwens%26aufirst%3DTimothy%2BD.%26date%3D2017%26spage%3D76%26epage%3D103%26pub%3DElsevier%26atitle%3DComprehensive%252BMedicinal%252BChemistry%252BIII%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Meng  Li</span>, <span class="hlFld-ContribAuthor ">Lanhai  Lai</span>, <span class="hlFld-ContribAuthor ">Zhennan  Zhao</span>, <span class="hlFld-ContribAuthor ">Tianfeng  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Aquation Is a Crucial Activation Step for Anticancer Action of Ruthenium(II) Polypyridyl Complexes to Trigger Cancer Cell Apoptosis. </span><span class="cited-content_cbyCitation_journal-name">Chemistry - An Asian Journal</span><span> <strong>2016,</strong> <em>11 </em>
                                    (2)
                                     , 310-320. <a href="https://doi.org/10.1002/asia.201501048" title="DOI URL">https://doi.org/10.1002/asia.201501048</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/asia.201501048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fasia.201501048%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520-%2520An%2520Asian%2520Journal%26atitle%3DAquation%252BIs%252Ba%252BCrucial%252BActivation%252BStep%252Bfor%252BAnticancer%252BAction%252Bof%252BRuthenium%252528II%252529%252BPolypyridyl%252BComplexes%252Bto%252BTrigger%252BCancer%252BCell%252BApoptosis%26aulast%3DLi%26aufirst%3DMeng%26date%3D2016%26date%3D2015%26volume%3D11%26issue%3D2%26spage%3D310%26epage%3D320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/medium/jm-2015-00991u_0016.gif" alt="" id="_i2" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00991&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/medium/jm-2015-00991u_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0012.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthesis of Chromene Derivatives</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00991&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/medium/jm-2015-00991u_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0002.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/medium/jm-2015-00991u_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0003.jpeg" id="rightTab-GRAPHIC-d7e602-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Selection of new chromologues according to their ability to kill PI3K-addicted tumor cells and inhibit Akt phosphorylation. A. Representation of the first set of chromologues. B. The indicated compounds were incubated for 24 h with leukemic T cell lines, relying (CEM) or not (H9) on the PI3K signaling pathway for survival, and cell death was measured using an MTT viability assay. C. The 50% effective dose (ED<sub>50</sub>) selectivity determined from data depicted in B. D. Upper panel: The PI3K-addicted T cell leukemia cell line CEM was incubated for 1 or 2 h with 10 μM of the indicated chromologues. Cells were lysed, and the indicated immunoblots were performed. β-Actin was used as a loading control. Lower panel: The immunoblots were assessed by densitometric analysis using ImageJ software, and the percentage of Akt phosphorylation was calculated using the following formula: [(phosphorylated Akt band intensity at time point <i>x</i>/intensity of whole protein band at time point <i>x</i>)/(intensity of P-Akt band at time zero/intensity of whole protein band at time point 0)]. E. Upper panel: The leukemic T cell line CEM was incubated with the indicated compounds for 24 h, and cell death was measured by MTT viability assay. Lower panel: ED<sub>50</sub> was assessed for each molecule using the MTT data depicted in the upper panel. F. CEM cells were incubated with the indicated chromologues (10 μM) for 1 or 2 h. The cells were then lysed, and the indicated immunoblots were performed. Akt was used as a loading control. G. The percentage of Akt phosphorylation (P-Akt) was assessed as indicated in D. H. CEM cells were incubated with the indicated concentrations of chromologues for 2 h. Cells were lysed, and the indicated immunoblots were performed. Akt was used as a loading control. I. The percentage of Akt phosphorylation (P-Akt) was assessed as indicated in D, and the half maximal inhibitory concentration (IC<sub>50</sub>) was determined for each chromologue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0002.jpeg jm-2015-00991u_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00991&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/medium/jm-2015-00991u_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0005.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Cytotoxic activity of different chromologues toward triple-negative, non-triple-negative, or HER2<sup>+</sup> breast cancer cell lines. A. A collection of cancer cell lines covering all types of breast cancers were incubated for 24 h with the indicated chromologues, and cell death was measured by MTT viability assay. B. Table summarizing the ED<sub>50</sub> of DHM25 against the breast cancer cell lines. Data are the means ± SEM of three different experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00991&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/medium/jm-2015-00991u_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0006.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. DHM25 is a selective inhibitor of mTOR. A. DHM9 and DHM25 (1 μM) were tested by KinaseProfile assay to measure their inhibitory effect on 243 kinases. B. Using immunoblotting, the inhibitory effect of DHM25 and rapamycin on mTORC1 and mTORC2 activity was assessed by monitoring S6 and 4EB-P1 phosphorylation (for mTORC1) and Akt (Ser473) phosphorylation (for mTORC2). C. Comparison of the effects of DHM25 on mTOR activity. The amount of phosphorylation of the different substrates was quantified by densitometric analysis using ImageJ software and the following formula: [(phosphorylated band intensity at time point <i>x</i>/intensity of whole protein band at time point <i>x</i>)/(intensity of phosphorylated band at time 0/intensity of whole protein band at time point 0)].</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00991&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/medium/jm-2015-00991u_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0007.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. The (<i>S</i>)-DHM25 enantiomer kills tumor cells and inhibits mTOR more efficiently than (<i>R</i>)-DHM25. A. Representation of the (<i>R</i>)- and (<i>S</i>)-DHM25 enantiomers. B. Leukemic cell lines reliant on PI3K signaling for survival (CEM and Jurkat cells) were incubated with the indicated chemicals for 24 h, and cell death was measured by MTT viability assay. Data represent the means ± SEM of three independent experiments. C. CEM cells were incubated with the Indicated concentrations of (<i>R</i>)- and (<i>S</i>)-DHM25 for 2 h. Cells were lysed, and the indicated immunoblots were performed. Whole Akt and β-actin were used as loading controls. Data are representative of three independent experiments. D. Computer models for (<i>S</i>)-DHM25 and (<i>S</i>)-DHM9 in the catalytic pocket of human mTOR based on experimental structure PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JSN">4JSN</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00991&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/medium/jm-2015-00991u_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0013.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of DHM9 and DHM25 Conjugated to Different Probes</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00991&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/medium/jm-2015-00991u_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0008.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. In cellulo analyses confirm that DHM25 is an mTOR inhibitor. A. DHM25 was conjugated with a biotin moiety. Models present the most representative structure of 60 ns molecular dynamics trajectories into the mTOR catalytic pocket (based on PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JSN">4JSN</a>) computed for DHM25 and its biotin-conjugated counterpart. B. MDA-MB-231 cells were preincubated with FITC alone or DHM25-FITC (10 μM) for 3 h, fixed, and stained with anti-mTOR mAb. Images were analyzed by confocal microscopy (magnification, 40×). Data are representative of three independent experiments. C. CEM cells were incubated for 2 h with the indicated concentrations of DHM25-biotin. Cells were lysed, and phosphorylation of Akt at serine 473 (mTORC2 substrate) was monitored by immunoblot. D. CEM cells were treated with 10 μM DHM25 alone or DHM25 conjugated to biotin for the indicated times, after which cells were lysed and the biotin moiety was pulled down with streptavidin-coated beads. Immunoprecipitates were subjected to an anti-mTOR immunoblot. E. CEM cells were treated for 2 h with the indicated concentration of DHM25 or DHM9 conjugated to biotin. Cells were lysed, and the biotin moiety was pulled down with streptavidin-coated beads. Immunoprecipitates were subjected to an anti-mTOR immunoblot.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00991&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/medium/jm-2015-00991u_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0014.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Reduction of DHM25</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00991&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/medium/jm-2015-00991u_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0015.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Preparation of DHM25 Analogue (variation of the EWG)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00991&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/medium/jm-2015-00991u_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0009.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. DHM25 is a covalent mTOR inhibitor. A. Models present the most representative structure of 60 ns molecular dynamics trajectories computed for DHM25 compounds into the mTOR catalytic pocket (based on PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JSN">4JSN</a>). The lysine at position 2187 (K2187) is very close to the C4 atom of DHM25, suggesting a nucleophilic attack via a Michael addition leading to a covalent bond within the mTOR ATP pocket. B. CEM cells were incubated for 2 h with 10 μM DHM25 or AZD8055. Then cells were extensively washed and incubated for the indicated times in medium devoid of inhibitor. Cells were lysed, and phosphorylation of Akt at serine 473 (mTORC2 substrate) was monitored by immunoblot. C. DHM25 and its derivatives (DHM25-H2) in which the C3–C4 double bond was reduced. D. The indicated cells were treated for 16 h with DHM25 or DHM25-H2, and cell death was evaluated by MTT assay. E. CEM cells were treated for 2 h with the indicated concentration of DHM25 or DHM25-H2, and cells were lysed and the indicated immunoblots were performed. Data are representative of at least three independent experiments. F. The leukemic T cell lines CEM and Jurkat were incubated for 16 h with the indicated concentration of DHM25 or its derivatives. Cell death was assessed by MTT assay. Data represent the mean ± SD of three independent experiments. Data represent the mean ± SD of three independent experiments. G. CEM cells were treated for 2 h with the indicated concentrations of DHM25 or derivatives, and then the cells were lysed and the indicated immunoblots were performed. Data are representative of at least three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00991&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/medium/jm-2015-00991u_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Nontoxic amounts of DHM25 inhibit cell migration in TNBC cells. A. TNBC cell lines (MDA-MB-231 and BT549) were incubated for 16 h with the indicated concentration of DHM25. Cell death was assessed by MTT assay. Data represent the mean ± SD of three independent experiments. B. TNBC cell lines were preincubated for 1 h in the presence or absence of DHM25 (1 μM) and then treated with CD95L (100 ng/mL) for 24 h. Cell migration was analyzed by Boyden chamber assay. Migrating Giemsa-stained cells were lysed, and absorbance was measured at a wavelength of 560 nm. Values represent the means ± SEM of three independent experiments. *<i>p</i> < 0.05, as calculated by two-tailed Mann–Whitney test. C. Upper panel: NSG mice injected with DHM25 (10 mg/kg) or with vehicle (control) were sacrificed 50 days after implantation of MDA-MB-231 xenografts. For each mouse, the primary tumor was harvested and weighed. ***<i>p</i> < 0.0001, as calculated by two-tailed Mann–Whitney test. Lower panel: Metastatic dissemination in the lungs of luminescent MDA-MB-231 tumor cells was evaluated in xenografted mice treated (+) or untreated (−) with DHM25 (10 mg/kg). For each mouse, lungs were harvested and the amount of invasive MDA-MB-231 cells was assessed by bioluminescence imaging (BLI). *<i>p</i> < 0.05, as calculated by two-tailed Mann–Whitney test. Inset: Lungs of xenografted mice analyzed by BLI.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-16/acs.jmedchem.5b00991/20190401/images/large/jm-2015-00991u_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00991&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i38">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05385" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05385" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 61 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Myers, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pass, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batty, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Kaay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolarov, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemmings, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wigler, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downes, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonks, N. K.</span></span> <span> </span><span class="NLM_article-title">The lipid phosphatase activity of PTEN is critical for its tumor supressor function</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">13513</span>– <span class="NLM_lpage">13518</span>, <span class="refDoi"> DOI: 10.1073/pnas.95.23.13513</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1073%2Fpnas.95.23.13513" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=13513-13518&author=M.+P.+Myersauthor=I.+Passauthor=I.+H.+Battyauthor=J.+Van+der+Kaayauthor=J.+P.+Stolarovauthor=B.+A.+Hemmingsauthor=M.+H.+Wiglerauthor=C.+P.+Downesauthor=N.+K.+Tonks&title=The+lipid+phosphatase+activity+of+PTEN+is+critical+for+its+tumor+supressor+function&doi=10.1073%2Fpnas.95.23.13513"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1073%2Fpnas.95.23.13513&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.95.23.13513%26sid%3Dliteratum%253Aachs%26aulast%3DMyers%26aufirst%3DM.%2BP.%26aulast%3DPass%26aufirst%3DI.%26aulast%3DBatty%26aufirst%3DI.%2BH.%26aulast%3DVan%2Bder%2BKaay%26aufirst%3DJ.%26aulast%3DStolarov%26aufirst%3DJ.%2BP.%26aulast%3DHemmings%26aufirst%3DB.%2BA.%26aulast%3DWigler%26aufirst%3DM.%2BH.%26aulast%3DDownes%26aufirst%3DC.%2BP.%26aulast%3DTonks%26aufirst%3DN.%2BK.%26atitle%3DThe%2520lipid%2520phosphatase%2520activity%2520of%2520PTEN%2520is%2520critical%2520for%2520its%2520tumor%2520supressor%2520function%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1998%26volume%3D95%26spage%3D13513%26epage%3D13518%26doi%3D10.1073%2Fpnas.95.23.13513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stambolic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Pompa, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brothers, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirtsos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penninger, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siderovski, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, T. W.</span></span> <span> </span><span class="NLM_article-title">Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(00)81780-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1016%2FS0092-8674%2800%2981780-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=9778245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADyaK1cXmslWlsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=29-39&author=V.+Stambolicauthor=A.+Suzukiauthor=J.+L.+de+la+Pompaauthor=G.+M.+Brothersauthor=C.+Mirtsosauthor=T.+Sasakiauthor=J.+Rulandauthor=J.+M.+Penningerauthor=D.+P.+Siderovskiauthor=T.+W.+Mak&title=Negative+regulation+of+PKB%2FAkt-dependent+cell+survival+by+the+tumor+suppressor+PTEN&doi=10.1016%2FS0092-8674%2800%2981780-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Negative regulation of PKB/Akt-Dependent cell survival by the tumor suppressor PTEN</span></div><div class="casAuthors">Stambolic, Vuk; Suzuki, Akira; De La Pompa, Jose Lois; Brothers, Greg M.; Mirtsos, Christine; Sasaki, Takehiko; Ruland, Jurgen; Penninger, Josef M.; Siderovski, David P.; Mak, Tak W.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-39</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">PTEN is a tumor suppressor with sequence homol. to protein tyrosine phosphatases and the cytoskeletal protein tensin.  MPTEN-mutant mouse embryos display regions of increased proliferation.  In contrast, mPTEN-deficient immortalized mouse embryonic fibroblasts exhibit decreased sensitivity to cell death in response to a no. of apoptotic stimuli, accompanied by constitutively elevated activity and phosphorylation of protein kinase B/Akt, a crucial regulator of cell survival.  Expression of exogenous PTEN in mutant cells restores both their sensitivity to agonist-induced apoptosis and normal pattern of PKB/Akt phosphorylation.  Furthermore, PTEN neg. regulates intracellular levels of phosphatidylinositol (3,4,5)-trisphosphate in cells and dephosphorylates it in vitro.  Our results show that PTEN may exert its role as a tumor suppressor by neg. regulating the PI3'K/PKB/Akt signaling pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMeJuD58djBrVg90H21EOLACvtfcHk0licfpHx83se9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmslWlsr0%253D&md5=d0ffd63a69325f1296d08bdbc16c5f0f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2981780-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252981780-8%26sid%3Dliteratum%253Aachs%26aulast%3DStambolic%26aufirst%3DV.%26aulast%3DSuzuki%26aufirst%3DA.%26aulast%3Dde%2Bla%2BPompa%26aufirst%3DJ.%2BL.%26aulast%3DBrothers%26aufirst%3DG.%2BM.%26aulast%3DMirtsos%26aufirst%3DC.%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DRuland%26aufirst%3DJ.%26aulast%3DPenninger%26aufirst%3DJ.%2BM.%26aulast%3DSiderovski%26aufirst%3DD.%2BP.%26aulast%3DMak%26aufirst%3DT.%2BW.%26atitle%3DNegative%2520regulation%2520of%2520PKB%252FAkt-dependent%2520cell%2520survival%2520by%2520the%2520tumor%2520suppressor%2520PTEN%26jtitle%3DCell%26date%3D1998%26volume%3D95%26spage%3D29%26epage%3D39%26doi%3D10.1016%2FS0092-8674%2800%2981780-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gewinner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teruya-Feldstein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Etemadmoghadam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowtell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barretina, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rameh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salmena, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandolfi, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span> <span> </span><span class="NLM_article-title">Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">125</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2009.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1016%2Fj.ccr.2009.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=19647222" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVCjsrfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=115-125&author=C.+Gewinnerauthor=Z.+C.+Wangauthor=A.+Richardsonauthor=J.+Teruya-Feldsteinauthor=D.+Etemadmoghadamauthor=D.+Bowtellauthor=J.+Barretinaauthor=W.+M.+Linauthor=L.+Ramehauthor=L.+Salmenaauthor=P.+P.+Pandolfiauthor=L.+C.+Cantley&title=Evidence+that+inositol+polyphosphate+4-phosphatase+type+II+is+a+tumor+suppressor+that+inhibits+PI3K+signaling&doi=10.1016%2Fj.ccr.2009.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling</span></div><div class="casAuthors">Gewinner, Christina; Wang, Zhigang C.; Richardson, Andrea; Teruya-Feldstein, Julie; Etemadmoghadam, Dariush; Bowtell, David; Barretina, Jordi; Lin, William M.; Rameh, Lucia; Salmena, Leonardo; Pandolfi, Pier Paolo; Cantley, Lewis C.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">115-125</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">We report that knocking down the expression of inositol polyphosphate 4-phosphatase type II (INPP4B) in human epithelial cells, like knockdown of PTEN, resulted in enhanced Akt activation and anchorage-independent growth and enhanced overall motility.  In xenograft expts., overexpression of INPP4B resulted in reduced tumor growth.  INPP4B preferentially hydrolyzes phosphatidylinositol-3,4-bisphosphate (PI(3,4)P2) with no effect on phosphatidylinositol-3,4,5-trisphosphate (PI(3,4,5)P3), suggesting that PI(3,4)P2 and PI(3,4,5)P3 may cooperate in Akt activation and cell transformation.  Dual knockdown of INPP4B and PTEN resulted in cellular senescence.  Finally, we found loss of heterozygosity (LOH) at the INPP4B locus in a majority of basal-like breast cancers, as well as in a significant fraction of ovarian cancers, which correlated with lower overall patient survival, suggesting that INPP4B is a tumor suppressor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOv8VFGY_XorVg90H21EOLACvtfcHk0ljsVXxS4BlQsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVCjsrfL&md5=c7c4d81e03f1f8b515a7a6cb3c6864f9</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2009.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2009.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DGewinner%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DZ.%2BC.%26aulast%3DRichardson%26aufirst%3DA.%26aulast%3DTeruya-Feldstein%26aufirst%3DJ.%26aulast%3DEtemadmoghadam%26aufirst%3DD.%26aulast%3DBowtell%26aufirst%3DD.%26aulast%3DBarretina%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DW.%2BM.%26aulast%3DRameh%26aufirst%3DL.%26aulast%3DSalmena%26aufirst%3DL.%26aulast%3DPandolfi%26aufirst%3DP.%2BP.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DEvidence%2520that%2520inositol%2520polyphosphate%25204-phosphatase%2520type%2520II%2520is%2520a%2520tumor%2520suppressor%2520that%2520inhibits%2520PI3K%2520signaling%26jtitle%3DCancer%2520Cell%26date%3D2009%26volume%3D16%26spage%3D115%26epage%3D125%26doi%3D10.1016%2Fj.ccr.2009.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alessi, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downes, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaffney, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reese, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span> <span> </span><span class="NLM_article-title">Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha</span>. <i>Curr. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">261</span>– <span class="NLM_lpage">269</span>, <span class="refDoi"> DOI: 10.1016/S0960-9822(06)00122-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1016%2FS0960-9822%2806%2900122-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=9094314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADyaK2sXjsFOjtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1997&pages=261-269&author=D.+R.+Alessiauthor=S.+R.+Jamesauthor=C.+P.+Downesauthor=A.+B.+Holmesauthor=P.+R.+Gaffneyauthor=C.+B.+Reeseauthor=P.+Cohen&title=Characterization+of+a+3-phosphoinositide-dependent+protein+kinase+which+phosphorylates+and+activates+protein+kinase+Balpha&doi=10.1016%2FS0960-9822%2806%2900122-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα</span></div><div class="casAuthors">Alessi, Dario R.; James, Stephen R.; Downes, C. Peter; Holmes, Andrew B.; Gaffney, Piers R. J.; Reese, Colin B.; Cohen, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Current Biology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">261-269</span>CODEN:
                <span class="NLM_cas:coden">CUBLE2</span>;
        ISSN:<span class="NLM_cas:issn">0960-9822</span>.
    
            (<span class="NLM_cas:orgname">Current Biology</span>)
        </div><div class="casAbstract">Protein kinase B (PKB), also known as c-Akt, is activated rapidly when mammalian cells are stimulated with insulin and growth factors, and much of the current interest in this enzyme stems from the observation that it lies 'downstream' of phosphoinositide 3-kinase on intracellular signaling pathways.  We recently showed that insulin or insulin-like growth factor 1 induce the phosphorylation of PKB at two residues, Thr308 and Ser473.  The phosphorylation of both residues is required for maximal activation of PKB. The kinases that phosphorylate PKB are, however, unknown.  We have purified 500,000-fold from rabbit skeletal muscle exts. a protein kinase which phosphorylates PKBα at Thr308 and increases its activity over 30-fold.  We tested the kinase in the presence of several inositol phospholipids and found that only low micromolar concns. of the D enantiomers of either phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P3) or PtdIns(3,4)P2 were effective in potently activating the kinase, which has been named PtdIns(3,4,5)P3-dependent protein kinase-1 (PDK1).  None of the inositol phospholipids tested activated or inhibited PKBα or induced its phosphorylation under the conditions used.  PDK1 activity was not affected by wortmannin, indicating that it is not likely to be a member of the phosphoinositide 3-kinase family.  PDK1 is likely to be one of the protein kinases that mediate the activation of PKB by insulin and growth factors.  PDK1 may, therefore, play a key role in mediating many of the actions of the second messenger(s) PtdIns(3,4,5)P3 and/or PtdIns(3,4)P2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2sSM5v7MnWrVg90H21EOLACvtfcHk0ljsVXxS4BlQsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjsFOjtb8%253D&md5=7f3794216810a4273d091b8d4590aaa9</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS0960-9822%2806%2900122-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-9822%252806%252900122-9%26sid%3Dliteratum%253Aachs%26aulast%3DAlessi%26aufirst%3DD.%2BR.%26aulast%3DJames%26aufirst%3DS.%2BR.%26aulast%3DDownes%26aufirst%3DC.%2BP.%26aulast%3DHolmes%26aufirst%3DA.%2BB.%26aulast%3DGaffney%26aufirst%3DP.%2BR.%26aulast%3DReese%26aufirst%3DC.%2BB.%26aulast%3DCohen%26aufirst%3DP.%26atitle%3DCharacterization%2520of%2520a%25203-phosphoinositide-dependent%2520protein%2520kinase%2520which%2520phosphorylates%2520and%2520activates%2520protein%2520kinase%2520Balpha%26jtitle%3DCurr.%2520Biol.%26date%3D1997%26volume%3D7%26spage%3D261%26epage%3D269%26doi%3D10.1016%2FS0960-9822%2806%2900122-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guertin, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thoreen, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burds, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalaany, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moffat, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span> <span> </span><span class="NLM_article-title">Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1</span>. <i>Dev. Cell</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">859</span>– <span class="NLM_lpage">871</span>, <span class="refDoi"> DOI: 10.1016/j.devcel.2006.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1016%2Fj.devcel.2006.10.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2006&pages=859-871&author=D.+A.+Guertinauthor=D.+M.+Stevensauthor=C.+C.+Thoreenauthor=A.+A.+Burdsauthor=N.+Y.+Kalaanyauthor=J.+Moffatauthor=M.+Brownauthor=K.+J.+Fitzgeraldauthor=D.+M.+Sabatini&title=Ablation+in+mice+of+the+mTORC+components+raptor%2C+rictor%2C+or+mLST8+reveals+that+mTORC2+is+required+for+signaling+to+Akt-FOXO+and+PKCalpha%2C+but+not+S6K1&doi=10.1016%2Fj.devcel.2006.10.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.devcel.2006.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.devcel.2006.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DGuertin%26aufirst%3DD.%2BA.%26aulast%3DStevens%26aufirst%3DD.%2BM.%26aulast%3DThoreen%26aufirst%3DC.%2BC.%26aulast%3DBurds%26aufirst%3DA.%2BA.%26aulast%3DKalaany%26aufirst%3DN.%2BY.%26aulast%3DMoffat%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DFitzgerald%26aufirst%3DK.%2BJ.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DAblation%2520in%2520mice%2520of%2520the%2520mTORC%2520components%2520raptor%252C%2520rictor%252C%2520or%2520mLST8%2520reveals%2520that%2520mTORC2%2520is%2520required%2520for%2520signaling%2520to%2520Akt-FOXO%2520and%2520PKCalpha%252C%2520but%2520not%2520S6K1%26jtitle%3DDev.%2520Cell%26date%3D2006%26volume%3D11%26spage%3D859%26epage%3D871%26doi%3D10.1016%2Fj.devcel.2006.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrazola, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hino, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ru, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, D.</span></span> <span> </span><span class="NLM_article-title">Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">699</span>– <span class="NLM_lpage">704</span>, <span class="refDoi"> DOI: 10.1038/ncb847</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1038%2Fncb847" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=12172555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD38Xms1ahtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2002&pages=699-704&author=X.+Gaoauthor=Y.+Zhangauthor=P.+Arrazolaauthor=O.+Hinoauthor=T.+Kobayashiauthor=R.+S.+Yeungauthor=B.+Ruauthor=D.+Pan&title=Tsc+tumour+suppressor+proteins+antagonize+amino-acid-TOR+signalling&doi=10.1038%2Fncb847"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">TSC tumour suppressor proteins antagonize amino-acid-TOR signalling</span></div><div class="casAuthors">Gao, Xinsheng; Zhang, Yong; Arrazola, Peter; Hino, Okio; Kobayashi, Toshiyuki; Yeung, Raymond S.; Ru, Binggeng; Pan, Duojia</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">699-704</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Target of rapamycin (TOR, protein kinase) mediates a signalling pathway that couples amino acid availability to S6 kinase (S6K) activation, translational initiation, and cell growth.  Tuberous sclerosis 1 (Tsc1) and Tsc2 tumor suppressors responsible for the tuberous sclerosis syndrome can antagonize this amino acid-TOR signalling pathway.  The Tsc1 and Tsc2 can be phys. assoc. with TOR and function upstream of TOR genetically.  In Drosophila melanogaster and mammalian cells, loss of Tsc1 and Tsc2 results in a TOR-dependent increase of the S6K activity.  Although S6K is normally inactivated in animal cells in response to amino acid starvation, the loss of Tsc1-Tsc2 renders cells resistant to amino acid starvation.  The Tsc1-Tsc2 complex may antagonize the TOR-mediated response to amino acid availability.  This study with Drosophila cells identified Tsc1 and Tsc2 as regulators of the amino acid-TOR pathway and provide a new paradigm for how proteins involved in nutrient sensing may function as tumor suppressors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4cE31P84rTLVg90H21EOLACvtfcHk0lgSGrEgGyDUrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xms1ahtbY%253D&md5=daa9269b4d1f26637dd7b62d8b54d23d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fncb847&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncb847%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DArrazola%26aufirst%3DP.%26aulast%3DHino%26aufirst%3DO.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DYeung%26aufirst%3DR.%2BS.%26aulast%3DRu%26aufirst%3DB.%26aulast%3DPan%26aufirst%3DD.%26atitle%3DTsc%2520tumour%2520suppressor%2520proteins%2520antagonize%2520amino-acid-TOR%2520signalling%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2002%26volume%3D4%26spage%3D699%26epage%3D704%26doi%3D10.1038%2Fncb847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Inoki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, K. L.</span></span> <span> </span><span class="NLM_article-title">TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">648</span>– <span class="NLM_lpage">657</span>, <span class="refDoi"> DOI: 10.1038/ncb839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1038%2Fncb839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=12172553" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD38Xms1ahtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2002&pages=648-657&author=K.+Inokiauthor=Y.+Liauthor=T.+Zhuauthor=J.+Wuauthor=K.+L.+Guan&title=TSC2+is+phosphorylated+and+inhibited+by+Akt+and+suppresses+mTOR+signalling&doi=10.1038%2Fncb839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signaling</span></div><div class="casAuthors">Inoki, Ken; Li, Yong; Zhu, Tianquan; Wu, Jun; Guan, Kun-Liang</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">648-657</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Tuberous sclerosis (TSC) is an autosomal dominant disorder characterized by the formation of hamartomas in a wide range of human tissues.  Mutation in either the TSC1 or TSC2 tumor suppressor gene is responsible for both the familial and sporadic forms of this disease.  TSC1 and TSC2 proteins form a phys. and functional complex in vivo.  Here, we show that TSC1-TSC2 inhibits the p70 ribosomal protein S6 kinase 1 (an activator of translation) and activates the eukaryotic initiation factor 4E binding protein 1 (4E-BP1, an inhibitor of translational initiation).  These functions of TSC1-TSC2 are mediated by inhibition of the mammalian target of rapamycin (mTOR).  Furthermore, TSC2 is directly phosphorylated by Akt, which is involved in stimulating cell growth and is activated by growth stimulating signals, such as insulin.  TSC2 is inactivated by Akt-dependent phosphorylation, which destabilizes TSC2 and disrupts its interaction with TSC1.  Our data indicate a mol. mechanism for TSC2 in insulin signaling, tumor suppressor functions and in the inhibition of cell growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvbCMw4JBsjLVg90H21EOLACvtfcHk0li-wxEUrUeRww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xms1ahtL4%253D&md5=bbf55234408a5ac14f49a8c63bfb24e4</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fncb839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncb839%26sid%3Dliteratum%253Aachs%26aulast%3DInoki%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DGuan%26aufirst%3DK.%2BL.%26atitle%3DTSC2%2520is%2520phosphorylated%2520and%2520inhibited%2520by%2520Akt%2520and%2520suppresses%2520mTOR%2520signalling%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2002%26volume%3D4%26spage%3D648%26epage%3D657%26doi%3D10.1038%2Fncb839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tee, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fingar, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blenis, J.</span></span> <span> </span><span class="NLM_article-title">Tuberous sclerosis complex-1 and −2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">13571</span>– <span class="NLM_lpage">13576</span>, <span class="refDoi"> DOI: 10.1073/pnas.202476899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1073%2Fpnas.202476899" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=13571-13576&author=A.+R.+Teeauthor=D.+C.+Fingarauthor=B.+D.+Manningauthor=D.+J.+Kwiatkowskiauthor=L.+C.+Cantleyauthor=J.+Blenis&title=Tuberous+sclerosis+complex-1+and+%E2%88%922+gene+products+function+together+to+inhibit+mammalian+target+of+rapamycin+%28mTOR%29-mediated+downstream+signaling&doi=10.1073%2Fpnas.202476899"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1073%2Fpnas.202476899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.202476899%26sid%3Dliteratum%253Aachs%26aulast%3DTee%26aufirst%3DA.%2BR.%26aulast%3DFingar%26aufirst%3DD.%2BC.%26aulast%3DManning%26aufirst%3DB.%2BD.%26aulast%3DKwiatkowski%26aufirst%3DD.%2BJ.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DBlenis%26aufirst%3DJ.%26atitle%3DTuberous%2520sclerosis%2520complex-1%2520and%2520%25E2%2588%25922%2520gene%2520products%2520function%2520together%2520to%2520inhibit%2520mammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529-mediated%2520downstream%2520signaling%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2002%26volume%3D99%26spage%3D13571%26epage%3D13576%26doi%3D10.1073%2Fpnas.202476899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Inoki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, K. L.</span></span> <span> </span><span class="NLM_article-title">Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling</span>. <i>Genes Dev.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1829</span>– <span class="NLM_lpage">1834</span>, <span class="refDoi"> DOI: 10.1101/gad.1110003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1101%2Fgad.1110003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=12869586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmt1Sjtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2003&pages=1829-1834&author=K.+Inokiauthor=Y.+Liauthor=T.+Xuauthor=K.+L.+Guan&title=Rheb+GTPase+is+a+direct+target+of+TSC2+GAP+activity+and+regulates+mTOR+signaling&doi=10.1101%2Fgad.1110003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling</span></div><div class="casAuthors">Inoki, Ken; Li, Yong; Xu, Tian; Guan, Kun-Liang</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1829-1834</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">Tuberous sclerosis complex (TSC) is a genetic disease caused by mutation in either TSC1 or TSC2.  The TSC1 and TSC2 gene products form a functional complex and inhibit phosphorylation of S6K and 4EBP1.  These functions of TSC1/TSC2 are likely mediated by mTOR.  Here we report that TSC2 is a GTPase-activating protein (GAP) toward Rheb, a Ras family GTPase.  Rheb stimulates phosphorylation of S6K and 4EBP1.  This function of Rheb is blocked by rapamycin and dominant-neg. mTOR.  Rheb stimulates the phosphorylation of mTOR and plays an essential role in regulation of S6K and 4EBP1 in response to nutrients and cellular energy status.  Our data demonstrate that Rheb acts downstream of TSC1/TSC2 and upstream of mTOR to regulate cell growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJUyx1ixLM-LVg90H21EOLACvtfcHk0li-wxEUrUeRww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmt1Sjtrk%253D&md5=40f03531da52ce6f20a13268a7c92e0e</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1101%2Fgad.1110003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.1110003%26sid%3Dliteratum%253Aachs%26aulast%3DInoki%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DGuan%26aufirst%3DK.%2BL.%26atitle%3DRheb%2520GTPase%2520is%2520a%2520direct%2520target%2520of%2520TSC2%2520GAP%2520activity%2520and%2520regulates%2520mTOR%2520signaling%26jtitle%3DGenes%2520Dev.%26date%3D2003%26volume%3D17%26spage%3D1829%26epage%3D1834%26doi%3D10.1101%2Fgad.1110003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarbassov, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guertin, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>307</i></span>,  <span class="NLM_fpage">1098</span>– <span class="NLM_lpage">1101</span>, <span class="refDoi"> DOI: 10.1126/science.1106148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1126%2Fscience.1106148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=15718470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSrtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=2005&pages=1098-1101&author=D.+D.+Sarbassovauthor=D.+A.+Guertinauthor=S.+M.+Aliauthor=D.+M.+Sabatini&title=Phosphorylation+and+regulation+of+Akt%2FPKB+by+the+rictor-mTOR+complex&doi=10.1126%2Fscience.1106148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex</span></div><div class="casAuthors">Sarbassov, Dos D.; Guertin, David A.; Ali, Siraj M.; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">307</span>
        (<span class="NLM_cas:issue">5712</span>),
    <span class="NLM_cas:pages">1098-1101</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Deregulation of Akt/protein kinase B (PKB) is implicated in the pathogenesis of cancer and diabetes.  Akt/PKB activation requires the phosphorylation of Thr308 in the activation loop by the phosphoinositide-dependent kinase 1 (PDK1) and Ser473 within the carboxyl-terminal hydrophobic motif by an unknown kinase.  We show that in Drosophila and human cells the target of rapamycin (TOR) kinase and its assocd. protein rictor are necessary for Ser473 phosphorylation and that a redn. in rictor or mammalian TOR (mTOR) expression inhibited an Akt/PKB effector.  The rictor-mTOR complex directly phosphorylated Akt/PKB on Ser473 in vitro and facilitated Thr308 phosphorylation by PDK1.  Rictor-mTOR may serve as a drug target in tumors that have lost the expression of PTEN, a tumor suppressor that opposes Akt/PKB activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfO1KyVE3glrVg90H21EOLACvtfcHk0lguos0m-LnJ_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSrtbY%253D&md5=de758fd8128561e34301e67a42ae13a6</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1126%2Fscience.1106148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1106148%26sid%3Dliteratum%253Aachs%26aulast%3DSarbassov%26aufirst%3DD.%2BD.%26aulast%3DGuertin%26aufirst%3DD.%2BA.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DPhosphorylation%2520and%2520regulation%2520of%2520Akt%252FPKB%2520by%2520the%2520rictor-mTOR%2520complex%26jtitle%3DScience%26date%3D2005%26volume%3D307%26spage%3D1098%26epage%3D1101%26doi%3D10.1126%2Fscience.1106148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manning, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logsdon, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipovsky, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbott, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span> <span> </span><span class="NLM_article-title">Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2</span>. <i>Genes Dev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1773</span>– <span class="NLM_lpage">1778</span>, <span class="refDoi"> DOI: 10.1101/gad.1314605</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1101%2Fgad.1314605" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=16027169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD2MXotFahtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2005&pages=1773-1778&author=B.+D.+Manningauthor=M.+N.+Logsdonauthor=A.+I.+Lipovskyauthor=D.+Abbottauthor=D.+J.+Kwiatkowskiauthor=L.+C.+Cantley&title=Feedback+inhibition+of+Akt+signaling+limits+the+growth+of+tumors+lacking+Tsc2&doi=10.1101%2Fgad.1314605"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2</span></div><div class="casAuthors">Manning, Brendan D.; Logsdon, M. Nicole; Lipovsky, Alex I.; Abbott, Derek; Kwiatkowski, David J.; Cantley, Lewis C.</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1773-1778</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">The PTEN and TSC2 tumor suppressors inhibit mammalian target of rapamycin (mTOR) signaling and are defective in distinct hamartoma syndromes.  Using mouse genetics, we find that Pten and Tsc2 act synergistically to suppress the severity of a subset of tumors specific to loss of each of these genes.  Interestingly, we find that the slow-growing tumors specific to Tsc2+/- mice exhibit defects in signaling downstream of Akt.  However, Pten haploinsufficiency restores Akt signaling in these tumors and dramatically enhances their severity.  This study demonstrates that attenuation of the PI3K-Akt pathway in tumors lacking TSC2 contributes to their benign nature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwKGLsPscfT7Vg90H21EOLACvtfcHk0lguos0m-LnJ_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXotFahtrk%253D&md5=a6715a7e1831d6c0d63b6d3fefc192b9</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1101%2Fgad.1314605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.1314605%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DB.%2BD.%26aulast%3DLogsdon%26aufirst%3DM.%2BN.%26aulast%3DLipovsky%26aufirst%3DA.%2BI.%26aulast%3DAbbott%26aufirst%3DD.%26aulast%3DKwiatkowski%26aufirst%3DD.%2BJ.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DFeedback%2520inhibition%2520of%2520Akt%2520signaling%2520limits%2520the%2520growth%2520of%2520tumors%2520lacking%2520Tsc2%26jtitle%3DGenes%2520Dev.%26date%3D2005%26volume%3D19%26spage%3D1773%26epage%3D1778%26doi%3D10.1101%2Fgad.1314605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Reilly, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rojo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">She, Q. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicklin, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span> <span> </span><span class="NLM_article-title">mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">1500</span>– <span class="NLM_lpage">1508</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-05-2925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1158%2F0008-5472.CAN-05-2925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=16452206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD28XpsVegtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=1500-1508&author=K.+E.+O%E2%80%99Reillyauthor=F.+Rojoauthor=Q.+B.+Sheauthor=D.+Solitauthor=G.+B.+Millsauthor=D.+Smithauthor=H.+Laneauthor=F.+Hofmannauthor=D.+J.+Hicklinauthor=D.+L.+Ludwigauthor=J.+Baselgaauthor=N.+Rosen&title=mTOR+inhibition+induces+upstream+receptor+tyrosine+kinase+signaling+and+activates+Akt&doi=10.1158%2F0008-5472.CAN-05-2925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt</span></div><div class="casAuthors">O'Reilly, Kathryn E.; Rojo, Fredi; She, Qing-Bai; Solit, David; Mills, Gordon B.; Smith, Debra; Lane, Heidi; Hofmann, Francesco; Hicklin, Daniel J.; Ludwig, Dale L.; Baselga, Jose; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1500-1508</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Stimulation of the insulin and insulin-like growth factor I (IGF-I) receptor activates the phosphoinositide-3-kinase/Akt/mTOR pathway causing pleiotropic cellular effects including an mTOR-dependent loss in insulin receptor substrate-1 expression leading to feedback down-regulation of signaling through the pathway.  In model systems, tumors exhibiting mutational activation of phosphoinositide-3-kinase/Akt kinase, a common event in cancers, are hypersensitive to mTOR inhibitors, including rapamycin.  Despite the activity in model systems, in patients, mTOR inhibitors exhibit more modest antitumor activity.  We now show that mTOR inhibition induces insulin receptor substrate-1 expression and abrogates feedback inhibition of the pathway, resulting in Akt activation both in cancer cell lines and in patient tumors treated with the rapamycin deriv., RAD001.  IGF-I receptor inhibition prevents rapamycin-induced Akt activation and sensitizes tumor cells to inhibition of mTOR.  In contrast, IGF-I reverses the antiproliferative effects of rapamycin in serum-free medium.  The data suggest that feedback down-regulation of receptor tyrosine kinase signaling is a frequent event in tumor cells with constitutive mTOR activation.  Reversal of this feedback loop by rapamycin may attenuate its therapeutic effects, whereas combination therapy that ablates mTOR function and prevents Akt activation may have improved antitumor activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIDQUdQ-jbi7Vg90H21EOLACvtfcHk0lijOIJ5vLGe-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpsVegtg%253D%253D&md5=758cd9999dc156bf498edf32174fc2e7</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-2925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-2925%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DK.%2BE.%26aulast%3DRojo%26aufirst%3DF.%26aulast%3DShe%26aufirst%3DQ.%2BB.%26aulast%3DSolit%26aufirst%3DD.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DLane%26aufirst%3DH.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DHicklin%26aufirst%3DD.%2BJ.%26aulast%3DLudwig%26aufirst%3DD.%2BL.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DmTOR%2520inhibition%2520induces%2520upstream%2520receptor%2520tyrosine%2520kinase%2520signaling%2520and%2520activates%2520Akt%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D1500%26epage%3D1508%26doi%3D10.1158%2F0008-5472.CAN-05-2925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vezina, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudelski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sehgal, S. N.</span></span> <span> </span><span class="NLM_article-title">Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle</span>. <i>J. Antibiot.</i> <span class="NLM_year" style="font-weight: bold;">1975</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">721</span>– <span class="NLM_lpage">726</span>, <span class="refDoi"> DOI: 10.7164/antibiotics.28.721</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.7164%2Fantibiotics.28.721" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1102508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADyaE28Xis1eruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=1975&pages=721-726&author=C.+Vezinaauthor=A.+Kudelskiauthor=S.+N.+Sehgal&title=Rapamycin+%28AY-22%2C989%29%2C+a+new+antifungal+antibiotic.+I.+Taxonomy+of+the+producing+streptomycete+and+isolation+of+the+active+principle&doi=10.7164%2Fantibiotics.28.721"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Rapamycin (AY-22,989), a new antifungal antibiotic.  I.  Taxonomy of the producing streptomycete and isolation of the active principle</span></div><div class="casAuthors">Vezina, Claude; Kudelski, Alicia; Sehgal, S. N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antibiotics</span>
        (<span class="NLM_cas:date">1975</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">721-6</span>CODEN:
                <span class="NLM_cas:coden">JANTAJ</span>;
        ISSN:<span class="NLM_cas:issn">0021-8820</span>.
    </div><div class="casAbstract">Rapamycin (AY-22,989) [53123-88-9] was extd. from the mycelium of Streptomyces hygroscopicus, a streptomyate isolated from an Easter Island soil.  Rapamycin was mainly active against Candida albicans; the min. inhibitory concns. were 0.02-0.2 μg/ml.  It was less active against Microsporum gypseum and Trichophyton granulosum, apparently because of its instability in the culture medium during the prolonged incubation required by these dermatophytes.  Rapamycin was inactive against gram-pos. and gram-neg. bacteria and had low toxicity in mice, the i.p. and oral LD50 values being ∼600 and >2500 mg/kg, resp.  The isolation and purifn. of rapamycin are described, as well as the taxonomic characteristics of the source organism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxg4lqjf3RxrVg90H21EOLACvtfcHk0ljlvFAaVqWoyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE28Xis1eruw%253D%253D&md5=6e4e2119e9b8fdd6d3a47fae665120e9</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.7164%2Fantibiotics.28.721&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7164%252Fantibiotics.28.721%26sid%3Dliteratum%253Aachs%26aulast%3DVezina%26aufirst%3DC.%26aulast%3DKudelski%26aufirst%3DA.%26aulast%3DSehgal%26aufirst%3DS.%2BN.%26atitle%3DRapamycin%2520%2528AY-22%252C989%2529%252C%2520a%2520new%2520antifungal%2520antibiotic.%2520I.%2520Taxonomy%2520of%2520the%2520producing%2520streptomycete%2520and%2520isolation%2520of%2520the%2520active%2520principle%26jtitle%3DJ.%2520Antibiot.%26date%3D1975%26volume%3D28%26spage%3D721%26epage%3D726%26doi%3D10.7164%2Fantibiotics.28.721" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albers, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichikawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keith, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span> <span> </span><span class="NLM_article-title">A mammalian protein targeted by G1-arresting rapamycin-receptor complex</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>369</i></span>,  <span class="NLM_fpage">756</span>– <span class="NLM_lpage">758</span>, <span class="refDoi"> DOI: 10.1038/369756a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1038%2F369756a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=8008069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADyaK2cXlsFSiu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=1994&pages=756-758&author=E.+J.+Brownauthor=M.+W.+Albersauthor=T.+B.+Shinauthor=K.+Ichikawaauthor=C.+T.+Keithauthor=W.+S.+Laneauthor=S.+L.+Schreiber&title=A+mammalian+protein+targeted+by+G1-arresting+rapamycin-receptor+complex&doi=10.1038%2F369756a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">A mammalian protein targeted by G1-arresting rapamycin-receptor complex</span></div><div class="casAuthors">Brown, Eric J.; Albers, Mark W.; Shin, Tae Bum; Ichikawa, Kazuo; Keith, Curtis T.; Lane, William S.; Schreiber, Stuart L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">6483</span>),
    <span class="NLM_cas:pages">756-8</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">The structurally related natural products rapamycin and FK506 bind to the same intracellular receptor, FKBP12, yet the resulting complexes interfere with distinct signaling pathway.  FKBP12-rapamycin inhibits progression through the G1 phase of the cell cycle in osteosarcoma, liver and T cells as well as in yeast, and interferes with mitogenic signaling pathways that are involved in G1 progression, namely with activation of the protein p70S6k and cyclin-dependent kinases.  Here the authors isolate a mammalian FKBP-rapamycin-assocd. protein (FRAP) whose binding to structural variants of rapamycin complexed to FKBP12 correlates with the ability of these ligands to inhibit cell-cycle progression.  Peptide sequences from purified bovine FRAP were used to isolate a human cDNA clone that is highly related to the DRR1/TOR1 and DRR2/TOR2 gene products form Saccharomyces cerevisiae.  Although it has not been previously demonstrated that either of the DRR/TOR gene products can bind the FKBP-rapamycin complex directly, these yeast genes have been genetically linked to a rapamycin-sensitive pathway and are through to encode lipid kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdC-Z1-1ylr7Vg90H21EOLACvtfcHk0ljlvFAaVqWoyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXlsFSiu74%253D&md5=b5c34fc2333e81011d6730cc196eb21a</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2F369756a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F369756a0%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DE.%2BJ.%26aulast%3DAlbers%26aufirst%3DM.%2BW.%26aulast%3DShin%26aufirst%3DT.%2BB.%26aulast%3DIchikawa%26aufirst%3DK.%26aulast%3DKeith%26aufirst%3DC.%2BT.%26aulast%3DLane%26aufirst%3DW.%2BS.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26atitle%3DA%2520mammalian%2520protein%2520targeted%2520by%2520G1-arresting%2520rapamycin-receptor%2520complex%26jtitle%3DNature%26date%3D1994%26volume%3D369%26spage%3D756%26epage%3D758%26doi%3D10.1038%2F369756a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdjument-Bromage, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tempst, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, S. H.</span></span> <span> </span><span class="NLM_article-title">RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">35</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1016/0092-8674(94)90570-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1016%2F0092-8674%2894%2990570-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=7518356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADyaK2cXlvFOhu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=1994&pages=35-43&author=D.+M.+Sabatiniauthor=H.+Erdjument-Bromageauthor=M.+Luiauthor=P.+Tempstauthor=S.+H.+Snyder&title=RAFT1%3A+a+mammalian+protein+that+binds+to+FKBP12+in+a+rapamycin-dependent+fashion+and+is+homologous+to+yeast+TORs&doi=10.1016%2F0092-8674%2894%2990570-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs</span></div><div class="casAuthors">Sabatini, David M.; Erdjument-Bromage, Hediye; Lui, Mary; Tempst, Paul; Snyder, Solomon H.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">35-43</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    </div><div class="casAbstract">The immunosuppressants rapamycin and FK506 bind to the same intracellular protein, the immunophilin FKBP12.  The FKBP12-FK506 complex interacts with the inhibits the Ca2+-activated protein phosphatase calcineurin.  The target of the FKBP12-rapamycin complex has not yet been identified.  The authors report that a protein complex contg. 245 kDa and FKBP12 targets 1 and 2 (RAFT1 and RAFT2), interacts with FKBP12 in a rapamycin-dependent manner.  Sequence (330 amino acids total) of tryptic peptides derived from one 245 kDa RAFT1 reveal striking homologies to the yeast TOR gene products, which were originally identified by mutations that confer rapamycin resistance in yeast.  A RAFT1 cDNA was obtained and found to encode a 289 kDa protein (2549 amino acids) that is 43% and 39% identical to TOR2 and TOR1, resp.  The authors propose that RAFT1 is the direct target of FKBP12-rapamycin and a mammalian homolog of the TOR proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHLQ78s1yfu7Vg90H21EOLACvtfcHk0lj0Yjr7H0E0dA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXlvFOhu7Y%253D&md5=062fe79756f6bc632e332d0b1921846d</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2894%2990570-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252894%252990570-3%26sid%3Dliteratum%253Aachs%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26aulast%3DErdjument-Bromage%26aufirst%3DH.%26aulast%3DLui%26aufirst%3DM.%26aulast%3DTempst%26aufirst%3DP.%26aulast%3DSnyder%26aufirst%3DS.%2BH.%26atitle%3DRAFT1%253A%2520a%2520mammalian%2520protein%2520that%2520binds%2520to%2520FKBP12%2520in%2520a%2520rapamycin-dependent%2520fashion%2520and%2520is%2520homologous%2520to%2520yeast%2520TORs%26jtitle%3DCell%26date%3D1994%26volume%3D78%26spage%3D35%26epage%3D43%26doi%3D10.1016%2F0092-8674%2894%2990570-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berlin, V.</span></span> <span> </span><span class="NLM_article-title">RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">12574</span>– <span class="NLM_lpage">12578</span>, <span class="refDoi"> DOI: 10.1073/pnas.91.26.12574</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1073%2Fpnas.91.26.12574" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1994&pages=12574-12578&author=M.+I.+Chiuauthor=H.+Katzauthor=V.+Berlin&title=RAPT1%2C+a+mammalian+homolog+of+yeast+Tor%2C+interacts+with+the+FKBP12%2Frapamycin+complex&doi=10.1073%2Fpnas.91.26.12574"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1073%2Fpnas.91.26.12574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.91.26.12574%26sid%3Dliteratum%253Aachs%26aulast%3DChiu%26aufirst%3DM.%2BI.%26aulast%3DKatz%26aufirst%3DH.%26aulast%3DBerlin%26aufirst%3DV.%26atitle%3DRAPT1%252C%2520a%2520mammalian%2520homolog%2520of%2520yeast%2520Tor%252C%2520interacts%2520with%2520the%2520FKBP12%252Frapamycin%2520complex%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1994%26volume%3D91%26spage%3D12574%26epage%3D12578%26doi%3D10.1073%2Fpnas.91.26.12574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Populo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopes, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soares, P.</span></span> <span> </span><span class="NLM_article-title">The mTOR Signalling Pathway in Human Cancer</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1886</span>– <span class="NLM_lpage">1918</span>, <span class="refDoi"> DOI: 10.3390/ijms13021886</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.3390%2Fijms13021886" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=22408430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BC38XivVKhtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=1886-1918&author=H.+Populoauthor=J.+M.+Lopesauthor=P.+Soares&title=The+mTOR+Signalling+Pathway+in+Human+Cancer&doi=10.3390%2Fijms13021886"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The mTOR signalling pathway in human cancer</span></div><div class="casAuthors">Populo, Helena; Lopes, Jose Manuel; Soares, Paula</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1886-1918</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The conserved serine/threonine kinase mTOR (the mammalian target of rapamycin), a downstream effector of the PI3K/AKT pathway, forms two distinct multiprotein complexes: mTORC1 and mTORC2.  MTORC1 is sensitive to rapamycin, activates S6K1 and 4EBP1, which are involved in mRNA translation.  It is activated by diverse stimuli, such as growth factors, nutrients, energy and stress signals, and essential signalling pathways, such as PI3K, MAPK and AMPK, in order to control cell growth, proliferation and survival.  MTORC2 is considered resistant to rapamycin and is generally insensitive to nutrients and energy signals.  It activates PKC-α and AKT and regulates the actin cytoskeleton.  Deregulation of multiple elements of the mTOR pathway (PI3K amplification/mutation, PTEN loss of function, AKT overexpression, and S6K1, 4EBP1 and eIF4E overexpression) has been reported in many types of cancers, particularly in melanoma, where alterations in major components of the mTOR pathway were reported to have significant effects on tumor progression.  Therefore, mTOR is an appealing therapeutic target and mTOR inhibitors, including the rapamycin analogs deforolimus, everolimus and temsirolimus, are submitted to clin. trials for treating multiple cancers, alone or in combination with inhibitors of other pathways.  Importantly, temsirolimus and everolimus were recently approved by the FDA for the treatment of renal cell carcinoma, PNET and giant cell astrocytoma.  Small mols. that inhibit mTOR kinase activity and dual PI3K-mTOR inhibitors are also being developed.  In this review, we aim to survey relevant research, the mol. mechanisms of signalling, including upstream activation and downstream effectors, and the role of mTOR in cancer, mainly in melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod7yRItoJWpbVg90H21EOLACvtfcHk0lj0Yjr7H0E0dA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XivVKhtro%253D&md5=e6c6c9f80fe1a40d4431bd9dfe0d1e45</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.3390%2Fijms13021886&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms13021886%26sid%3Dliteratum%253Aachs%26aulast%3DPopulo%26aufirst%3DH.%26aulast%3DLopes%26aufirst%3DJ.%2BM.%26aulast%3DSoares%26aufirst%3DP.%26atitle%3DThe%2520mTOR%2520Signalling%2520Pathway%2520in%2520Human%2520Cancer%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2012%26volume%3D13%26spage%3D1886%26epage%3D1918%26doi%3D10.3390%2Fijms13021886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crino, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathanson, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henske, E. P.</span></span> <span> </span><span class="NLM_article-title">The tuberous sclerosis complex</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>355</i></span>,  <span class="NLM_fpage">1345</span>– <span class="NLM_lpage">1356</span>, <span class="refDoi"> DOI: 10.1056/NEJMra055323</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1056%2FNEJMra055323" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=17005952" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD2sXisVGit7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2006&pages=1345-1356&author=P.+B.+Crinoauthor=K.+L.+Nathansonauthor=E.+P.+Henske&title=The+tuberous+sclerosis+complex&doi=10.1056%2FNEJMra055323"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The tuberous sclerosis complex</span></div><div class="casAuthors">Crino, Peter B.; Nathanson, Katherine L.; Henske, Elizabeth Petri</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1345-1356</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreefc8lvD2Q7Vg90H21EOLACvtfcHk0lgPk_xl627EJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXisVGit7c%253D&md5=1cbf19b05ac03452756cf07e2d518e95</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1056%2FNEJMra055323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra055323%26sid%3Dliteratum%253Aachs%26aulast%3DCrino%26aufirst%3DP.%2BB.%26aulast%3DNathanson%26aufirst%3DK.%2BL.%26aulast%3DHenske%26aufirst%3DE.%2BP.%26atitle%3DThe%2520tuberous%2520sclerosis%2520complex%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2006%26volume%3D355%26spage%3D1345%26epage%3D1356%26doi%3D10.1056%2FNEJMra055323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wander, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennessy, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slingerland, J. M.</span></span> <span> </span><span class="NLM_article-title">Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">1231</span>– <span class="NLM_lpage">1241</span>, <span class="refDoi"> DOI: 10.1172/JCI44145</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1172%2FJCI44145" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2011&pages=1231-1241&author=S.+A.+Wanderauthor=B.+T.+Hennessyauthor=J.+M.+Slingerland&title=Next-generation+mTOR+inhibitors+in+clinical+oncology%3A+how+pathway+complexity+informs+therapeutic+strategy&doi=10.1172%2FJCI44145"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1172%2FJCI44145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI44145%26sid%3Dliteratum%253Aachs%26aulast%3DWander%26aufirst%3DS.%2BA.%26aulast%3DHennessy%26aufirst%3DB.%2BT.%26aulast%3DSlingerland%26aufirst%3DJ.%2BM.%26atitle%3DNext-generation%2520mTOR%2520inhibitors%2520in%2520clinical%2520oncology%253A%2520how%2520pathway%2520complexity%2520informs%2520therapeutic%2520strategy%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2011%26volume%3D121%26spage%3D1231%26epage%3D1241%26doi%3D10.1172%2FJCI44145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grunt, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mariani, G. L.</span></span> <span> </span><span class="NLM_article-title">Novel approaches for molecular targeted therapy of breast cancer: interfering with PI3K/AKT/mTOR signaling</span>. <i>Curr. Cancer Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">188</span>– <span class="NLM_lpage">204</span>, <span class="refDoi"> DOI: 10.2174/1568009611313020008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.2174%2F1568009611313020008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=23215720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlsFWhs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=188-204&author=T.+W.+Gruntauthor=G.+L.+Mariani&title=Novel+approaches+for+molecular+targeted+therapy+of+breast+cancer%3A+interfering+with+PI3K%2FAKT%2FmTOR+signaling&doi=10.2174%2F1568009611313020008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Novel approaches for molecular targeted therapy of breast cancer: interfering with PI3K/AKT/mTOR signaling</span></div><div class="casAuthors">Grunt, Thomas W.; Mariani, Gabriella L.</div><div class="citationInfo"><span class="NLM_cas:title">Current Cancer Drug Targets</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">188-204</span>CODEN:
                <span class="NLM_cas:coden">CCDTB9</span>;
        ISSN:<span class="NLM_cas:issn">1568-0096</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Breast cancer is one of the most prevalent and devastating malignant diseases in women worldwide.  Fortunately, while breast cancer incidence is still increasing, its death rate is declining.  This is mainly due to early diagnosis and potent therapies such as blockade of estrogen receptor- or of ErbB2 (HER2-neu) membrane receptor-signaling.  In recent years, the PI3K/AKT/mTOR pathway, which transmits signals from the cell membrane into the nucleus and activates multiple oncogenic programs, has been found to play a crucial role in the regulation of breast cancer cell growth.  This pathway is densely interconnected with a multitude of other important regulatory systems for glucose-, lipid- and amino acid-metab., for energy balance, and for autophagy.  It has been found that PI3K/AKT/mTOR signaling modulates estrogen receptor function.  Using transverse and feedback regulatory loops the PI3K/AKT/mTOR cascade can communicate with concurrent and with upstream systems.  Thus, PI3K/AKT/mTOR is a crucial element within a complicated signaling network.  This pathway is hyperactive in more than 70% of breast tumors.  Hence, the protein kinases located along this route represent very attractive and promising drug targets for breast cancer therapy.  Currently, numerous small mol. drugs that inhibit PI3K, AKT and/or mTOR are being developed in preclin. and clin. models of breast cancer.  Some of these compds. are highly selective blocking only one particular kinase complex, whereas others interfere with two (mTORC1 + mTORC2) or even three effectors (PI3K + mTORC1 + mTORC2) of the pathway.  Due to the many interactions with other regulatory systems, silencing of the pathway can cause unexpected results.  Therefore, detailed preclin. and clin. evaluation of these compds. as single drugs and in combination is required to achieve optimal results with maximal clin. benefit and acceptable toxicity.  Also, reliable biomarkers for the identification of patient subsets that will maximally benefit from PI3K/AKT/mTOR inhibition need to be developed.  Thus, selective silencing of PI3K/AKT/mTOR signaling represents a promising approach for breast cancer and might prove useful when combined with other drugs.  Here we review the current preclin. and clin. data and compare the potential benefits of multi- vs. single-targeting PI3K/AKT/mTOR drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlSxKFEBvtSLVg90H21EOLACvtfcHk0lgPk_xl627EJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlsFWhs7s%253D&md5=9ad30617badbcba72cfaee618d1de3fa</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.2174%2F1568009611313020008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568009611313020008%26sid%3Dliteratum%253Aachs%26aulast%3DGrunt%26aufirst%3DT.%2BW.%26aulast%3DMariani%26aufirst%3DG.%2BL.%26atitle%3DNovel%2520approaches%2520for%2520molecular%2520targeted%2520therapy%2520of%2520breast%2520cancer%253A%2520interfering%2520with%2520PI3K%252FAKT%252FmTOR%2520signaling%26jtitle%3DCurr.%2520Cancer%2520Drug%2520Targets%26date%3D2013%26volume%3D13%26spage%3D188%26epage%3D204%26doi%3D10.2174%2F1568009611313020008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferlay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkin, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steliarova-Foucher, E.</span></span> <span> </span><span class="NLM_article-title">Estimates of cancer incidence and mortality in Europe in 2008</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">765</span>– <span class="NLM_lpage">781</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2009.12.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1016%2Fj.ejca.2009.12.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=20116997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A280%3ADC%252BC3c7js1CktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2010&pages=765-781&author=J.+Ferlayauthor=D.+M.+Parkinauthor=E.+Steliarova-Foucher&title=Estimates+of+cancer+incidence+and+mortality+in+Europe+in+2008&doi=10.1016%2Fj.ejca.2009.12.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Estimates of cancer incidence and mortality in Europe in 2008</span></div><div class="casAuthors">Ferlay J; Parkin D M; Steliarova-Foucher E</div><div class="citationInfo"><span class="NLM_cas:title">European journal of cancer (Oxford, England : 1990)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">765-81</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Up-to-date statistics on cancer occurrence and outcome are essential for the planning and evaluation of programmes for cancer control.  Since the relevant information for 2008 is not generally available as yet, we used statistical models to estimate incidence and mortality data for 25 cancers in 40 European countries (grouped and individually) in 2008.  The calculations are based on published data.  If not collected, national rates were estimated from national mortality data and incidence and mortality data provided by local cancer registries of the same or neighbouring country.  The estimated 2008 rates were applied to the corresponding country population estimates for 2008 to obtain an estimate of the numbers of cancer cases and deaths in Europe in 2008.  There were an estimated 3.2 million new cases of cancer and 1.7 million deaths from cancer in 2008.  The most common cancers were colorectal cancers (436,000 cases, 13.6% of the total), breast cancer (421,000, 13.1%), lung cancer (391,000, 12.2%) and prostate cancer (382,000, 11.9%).  The most common causes of death from cancer were lung cancer (342,000 deaths, 19.9% of the total), colorectal cancer (212,000 deaths, 12.3%), breast cancer (129,000, 7.5%) and stomach cancer (117,000, 6.8%).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQkUT6DwQ4W4ukdrW1FkXG-fW6udTcc2ebxI7a2oUBlnrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c7js1CktA%253D%253D&md5=94e72419f8103d9cb1744bd0f3b4c58e</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2009.12.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2009.12.014%26sid%3Dliteratum%253Aachs%26aulast%3DFerlay%26aufirst%3DJ.%26aulast%3DParkin%26aufirst%3DD.%2BM.%26aulast%3DSteliarova-Foucher%26aufirst%3DE.%26atitle%3DEstimates%2520of%2520cancer%2520incidence%2520and%2520mortality%2520in%2520Europe%2520in%25202008%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2010%26volume%3D46%26spage%3D765%26epage%3D781%26doi%3D10.1016%2Fj.ejca.2009.12.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sotiriou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pusztai, L.</span></span> <span> </span><span class="NLM_article-title">Gene-expression signatures in breast cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>360</i></span>,  <span class="NLM_fpage">790</span>– <span class="NLM_lpage">800</span>, <span class="refDoi"> DOI: 10.1056/NEJMra0801289</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1056%2FNEJMra0801289" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=19228622" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD1MXitFWqs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=360&publication_year=2009&pages=790-800&author=C.+Sotiriouauthor=L.+Pusztai&title=Gene-expression+signatures+in+breast+cancer&doi=10.1056%2FNEJMra0801289"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular origins of cancer: gene-expression signatures in breast cancer</span></div><div class="casAuthors">Sotiriou, Christos; Pusztai, Lajos</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">360</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">790-800</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  The altered genetics of breast cancer detected by gene-expression profile is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonfaSW-Hj_RrVg90H21EOLACvtfcHk0ljzPeARkclSXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXitFWqs70%253D&md5=4fd896e4f33270a59a73f5514057a481</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1056%2FNEJMra0801289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra0801289%26sid%3Dliteratum%253Aachs%26aulast%3DSotiriou%26aufirst%3DC.%26aulast%3DPusztai%26aufirst%3DL.%26atitle%3DGene-expression%2520signatures%2520in%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D360%26spage%3D790%26epage%3D800%26doi%3D10.1056%2FNEJMra0801289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perou, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorlie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisen, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Rijn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffrey, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollack, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnsen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akslen, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fluge, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pergamenschikov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lonning, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borresen-Dale, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, P. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botstein, D.</span></span> <span> </span><span class="NLM_article-title">Molecular portraits of human breast tumours</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>406</i></span>,  <span class="NLM_fpage">747</span>– <span class="NLM_lpage">752</span>, <span class="refDoi"> DOI: 10.1038/35021093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1038%2F35021093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10963602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmt1CnsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=406&publication_year=2000&pages=747-752&author=C.+M.+Perouauthor=T.+Sorlieauthor=M.+B.+Eisenauthor=M.+van+de+Rijnauthor=S.+S.+Jeffreyauthor=C.+A.+Reesauthor=J.+R.+Pollackauthor=D.+T.+Rossauthor=H.+Johnsenauthor=L.+A.+Akslenauthor=O.+Flugeauthor=A.+Pergamenschikovauthor=C.+Williamsauthor=S.+X.+Zhuauthor=P.+E.+Lonningauthor=A.+L.+Borresen-Daleauthor=P.+O.+Brownauthor=D.+Botstein&title=Molecular+portraits+of+human+breast+tumours&doi=10.1038%2F35021093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular portraits of human breast tumors</span></div><div class="casAuthors">Perou, Charles M.; Serlie, Therese; Eisen, Michael B.; Van De Rijn, Matt; Jeffrey, Stefanie S.; Rees, Christian A.; Pollack, Jonathan R.; Rossi, Douglas T.; Johnsen, Hilde; Akslen, Lars A.; Fluge, Oystein; Pergamenschikov, Alexander; Williams, Cheryl; Zhu, Shirley X.; Lenning, Per E.; Berresen-Dale, Anne-Use; Brown, Patrick O.; Botstein, David</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">406</span>
        (<span class="NLM_cas:issue">6797</span>),
    <span class="NLM_cas:pages">747-752</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Human breast tumors are diverse in their natural history and in their responsiveness to treatments.  Variation in transcriptional programs accounts for much of the biol. diversity of human cells and tumors.  In each cell, signal transduction and regulatory systems transduce information from the cell's identity to its environmental status, thereby controlling the level of expression of every gene in the genome.  Here we have characterized variation in gene expression patterns in a set of 65 surgical specimens of human breast tumors from 42 different individuals, using cDNA microarrays representing 8102 human genes.  These patterns provided a distinctive mol. portrait of each tumor.  Twenty of the tumors were sampled twice, before and after a 16-wk course of doxorubicin chemotherapy, and two tumors were paired with a lymph node metastasis from the same patient.  Gene expression patterns in two tumor samples from the same individual were almost always more similar to each other than either was to any other sample.  Sets of co-expressed genes were identified for which variation in mRNA levels could be related to specific features of physiol. variation.  The tumors could be classified into subtypes distinguished by pervasive differences in their gene expression patterns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorYsVvqq_EyLVg90H21EOLACvtfcHk0ljzPeARkclSXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmt1CnsLw%253D&md5=f81e9b3e3d5e339ea463428b1c973f8d</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2F35021093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35021093%26sid%3Dliteratum%253Aachs%26aulast%3DPerou%26aufirst%3DC.%2BM.%26aulast%3DSorlie%26aufirst%3DT.%26aulast%3DEisen%26aufirst%3DM.%2BB.%26aulast%3Dvan%2Bde%2BRijn%26aufirst%3DM.%26aulast%3DJeffrey%26aufirst%3DS.%2BS.%26aulast%3DRees%26aufirst%3DC.%2BA.%26aulast%3DPollack%26aufirst%3DJ.%2BR.%26aulast%3DRoss%26aufirst%3DD.%2BT.%26aulast%3DJohnsen%26aufirst%3DH.%26aulast%3DAkslen%26aufirst%3DL.%2BA.%26aulast%3DFluge%26aufirst%3DO.%26aulast%3DPergamenschikov%26aufirst%3DA.%26aulast%3DWilliams%26aufirst%3DC.%26aulast%3DZhu%26aufirst%3DS.%2BX.%26aulast%3DLonning%26aufirst%3DP.%2BE.%26aulast%3DBorresen-Dale%26aufirst%3DA.%2BL.%26aulast%3DBrown%26aufirst%3DP.%2BO.%26aulast%3DBotstein%26aufirst%3DD.%26atitle%3DMolecular%2520portraits%2520of%2520human%2520breast%2520tumours%26jtitle%3DNature%26date%3D2000%26volume%3D406%26spage%3D747%26epage%3D752%26doi%3D10.1038%2F35021093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shak, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baehner, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiller, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickerham, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolmark, N.</span></span> <span> </span><span class="NLM_article-title">A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>351</i></span>,  <span class="NLM_fpage">2817</span>– <span class="NLM_lpage">2826</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa041588</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1056%2FNEJMoa041588" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=15591335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhslymsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2004&pages=2817-2826&author=S.+Paikauthor=S.+Shakauthor=G.+Tangauthor=C.+Kimauthor=J.+Bakerauthor=M.+Croninauthor=F.+L.+Baehnerauthor=M.+G.+Walkerauthor=D.+Watsonauthor=T.+Parkauthor=W.+Hillerauthor=E.+R.+Fisherauthor=D.+L.+Wickerhamauthor=J.+Bryantauthor=N.+Wolmark&title=A+multigene+assay+to+predict+recurrence+of+tamoxifen-treated%2C+node-negative+breast+cancer&doi=10.1056%2FNEJMoa041588"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer</span></div><div class="casAuthors">Paik, Soonmyung; Shak, Steven; Tang, Gong; Kim, Chungyeul; Baker, Joffre; Cronin, Maureen; Baehner, Frederick L.; Walker, Michael G.; Watson, Drew; Park, Taesung; Hiller, William; Fisher, Edwin R.; Wickerham, D. Lawrence; Bryant, John; Wolmark, Norman</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">351</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">2817-2826</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND.  The likelihood of distant recurrence in patients with breast cancer who have no involved lymph nodes and estrogen-receptor-pos. tumors is poorly defined by clin. and histopathol. measures.  METHODS.  The authors tested whether the results of a reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay of 21 prospectively selected genes in paraffin-embedded tumor tissue would correlate with the likelihood of distant recurrence in patients with node-neg., tamoxifen-treated breast cancer who were enrolled in the National Surgical Adjuvant Breast and Bowel Project clin. trial B-14.  The levels of expression of 16 cancer-related genes and 5 ref. genes were used in a prospectively defined algorithm to calc. a recurrence score and to det. a risk group (low, intermediate, or high) for each patient.  RESULTS.  Adequate RT-PCR profiles were obtained in 668 of 675 tumor blocks.  The proportions of patients categorized as having a low, intermediate, or high risk by the RT-PCR assay were 51, 22, and 27%, resp.  The Kaplan-Meier ests. of the rates of distant recurrence at 10 years in the low-risk, intermediate-risk, and high-risk groups were 6.8% (95% confidence interval, 4.0 to 9.6), 14.3% (95% confidence interval, 8.3 to 20.3), and 30.5% (95% confidence interval, 23.6 to 37.4). The rate in the low-risk group was significantly lower than that in the high-risk group.  In a multivariate Cox model, the recurrence score provided significant predictive power that was independent of age and tumor size.  The recurrence score was also predictive of overall survival and could be used as a continuous function to predict distant recurrence in individual patients.  CONCLUSIONS.  The recurrence score has been validated as quantifying the likelihood of distant recurrence in tamoxifen-treated patients with node-neg., estrogen-receptor-pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5GVcEor2yYrVg90H21EOLACvtfcHk0ljhpGVY0BcySg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhslymsw%253D%253D&md5=6dbc153d29b0e35fc253afdb33badf2e</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa041588&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa041588%26sid%3Dliteratum%253Aachs%26aulast%3DPaik%26aufirst%3DS.%26aulast%3DShak%26aufirst%3DS.%26aulast%3DTang%26aufirst%3DG.%26aulast%3DKim%26aufirst%3DC.%26aulast%3DBaker%26aufirst%3DJ.%26aulast%3DCronin%26aufirst%3DM.%26aulast%3DBaehner%26aufirst%3DF.%2BL.%26aulast%3DWalker%26aufirst%3DM.%2BG.%26aulast%3DWatson%26aufirst%3DD.%26aulast%3DPark%26aufirst%3DT.%26aulast%3DHiller%26aufirst%3DW.%26aulast%3DFisher%26aufirst%3DE.%2BR.%26aulast%3DWickerham%26aufirst%3DD.%2BL.%26aulast%3DBryant%26aufirst%3DJ.%26aulast%3DWolmark%26aufirst%3DN.%26atitle%3DA%2520multigene%2520assay%2520to%2520predict%2520recurrence%2520of%2520tamoxifen-treated%252C%2520node-negative%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D351%26spage%3D2817%26epage%3D2826%26doi%3D10.1056%2FNEJMoa041588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVries, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridlyand, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spellman, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roydasgupta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapuk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neve, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryder, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feiler, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokuyasu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kingsley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dairkee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chew, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinkel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ljung, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esserman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albertson, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldman, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J. W.</span></span> <span> </span><span class="NLM_article-title">Genomic and transcriptional aberrations linked to breast cancer pathophysiologies</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">529</span>– <span class="NLM_lpage">541</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2006.10.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1016%2Fj.ccr.2006.10.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=17157792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlCnsrbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2006&pages=529-541&author=K.+Chinauthor=S.+DeVriesauthor=J.+Fridlyandauthor=P.+T.+Spellmanauthor=R.+Roydasguptaauthor=W.+L.+Kuoauthor=A.+Lapukauthor=R.+M.+Neveauthor=Z.+Qianauthor=T.+Ryderauthor=F.+Chenauthor=H.+Feilerauthor=T.+Tokuyasuauthor=C.+Kingsleyauthor=S.+Dairkeeauthor=Z.+Mengauthor=K.+Chewauthor=D.+Pinkelauthor=A.+Jainauthor=B.+M.+Ljungauthor=L.+Essermanauthor=D.+G.+Albertsonauthor=F.+M.+Waldmanauthor=J.+W.+Gray&title=Genomic+and+transcriptional+aberrations+linked+to+breast+cancer+pathophysiologies&doi=10.1016%2Fj.ccr.2006.10.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Genomic and transcriptional aberrations linked to breast cancer pathophysiologies</span></div><div class="casAuthors">Chin, Koei; DeVries, Sandy; Fridlyand, Jane; Spellman, Paul T.; Roydasgupta, Ritu; Kuo, Wen-Lin; Lapuk, Anna; Neve, Richard M.; Qian, Zuwei; Ryder, Tom; Chen, Fanqing; Feiler, Heidi; Tokuyasu, Taku; Kingsley, Chris; Dairkee, Shanaz; Meng, Zhenhang; Chew, Karen; Pinkel, Daniel; Jain, Ajay; Ljung, Britt Marie; Esserman, Laura; Albertson, Donna G.; Waldman, Frederic M.; Gray, Joe W.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">529-541</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">This study explores the roles of genome copy no. abnormalities (CNAs) in breast cancer pathophysiol. by identifying assocns. between recurrent CNAs, gene expression, and clin. outcome in a set of aggressively treated early-stage breast tumors.  It shows that the recurrent CNAs differ between tumor subtypes defined by expression pattern and that stratification of patients according to outcome can be improved by measuring both expression and copy no., esp. high-level amplification.  Sixty-six genes deregulated by the high-level amplifications are potential therapeutic targets.  Nine of these (FGFR1, IKBKB, ERBB2, PROCC, ADAM9, FNTA, ACACA, PNMT, and NR1D1) are considered as therapeutic targets.  Low-level CNAs appear to contribute to cancer progression by altering RNA and cellular metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHiq8I1mqFn7Vg90H21EOLACvtfcHk0ljhpGVY0BcySg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlCnsrbF&md5=8848be946221c3d3236bf9bc3154b77e</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2006.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2006.10.009%26sid%3Dliteratum%253Aachs%26aulast%3DChin%26aufirst%3DK.%26aulast%3DDeVries%26aufirst%3DS.%26aulast%3DFridlyand%26aufirst%3DJ.%26aulast%3DSpellman%26aufirst%3DP.%2BT.%26aulast%3DRoydasgupta%26aufirst%3DR.%26aulast%3DKuo%26aufirst%3DW.%2BL.%26aulast%3DLapuk%26aufirst%3DA.%26aulast%3DNeve%26aufirst%3DR.%2BM.%26aulast%3DQian%26aufirst%3DZ.%26aulast%3DRyder%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DFeiler%26aufirst%3DH.%26aulast%3DTokuyasu%26aufirst%3DT.%26aulast%3DKingsley%26aufirst%3DC.%26aulast%3DDairkee%26aufirst%3DS.%26aulast%3DMeng%26aufirst%3DZ.%26aulast%3DChew%26aufirst%3DK.%26aulast%3DPinkel%26aufirst%3DD.%26aulast%3DJain%26aufirst%3DA.%26aulast%3DLjung%26aufirst%3DB.%2BM.%26aulast%3DEsserman%26aufirst%3DL.%26aulast%3DAlbertson%26aufirst%3DD.%2BG.%26aulast%3DWaldman%26aufirst%3DF.%2BM.%26aulast%3DGray%26aufirst%3DJ.%2BW.%26atitle%3DGenomic%2520and%2520transcriptional%2520aberrations%2520linked%2520to%2520breast%2520cancer%2520pathophysiologies%26jtitle%3DCancer%2520Cell%26date%3D2006%26volume%3D10%26spage%3D529%26epage%3D541%26doi%3D10.1016%2Fj.ccr.2006.10.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foulkes, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefansson, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chappuis, P. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Begin, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goffin, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trudel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akslen, L. A.</span></span> <span> </span><span class="NLM_article-title">Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">1482</span>– <span class="NLM_lpage">1485</span>, <span class="refDoi"> DOI: 10.1093/jnci/djg050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1093%2Fjnci%2Fdjg050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=14519755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnvVCjtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2003&pages=1482-1485&author=W.+D.+Foulkesauthor=I.+M.+Stefanssonauthor=P.+O.+Chappuisauthor=L.+R.+Beginauthor=J.+R.+Goffinauthor=N.+Wongauthor=M.+Trudelauthor=L.+A.+Akslen&title=Germline+BRCA1+mutations+and+a+basal+epithelial+phenotype+in+breast+cancer&doi=10.1093%2Fjnci%2Fdjg050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer</span></div><div class="casAuthors">Foulkes, William D.; Stefansson, Ingunn M.; Chappuis, Pierre O.; Begin, Louis R.; Goffin, John R.; Wong, Nora; Trudel, Michel; Akslen, Lars A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1482-1485</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A basal epithelial phenotype is found in not more than 15% of all invasive breast cancers.  Microarray studies have shown that this phenotype is assocd. with breast cancers that express neither estrogen receptor (ER) nor erbB-2 (HER2/neu) (i.e., ER/erbB-2-neg. tumors).  The ER/erbB-2-neg. phenotype is also found in breast cancers occurring in BRCA1 mutation carriers (i.e., BRCA1-related breast cancers).  The authors tested the hypothesis that BRCA1-related breast cancers are more likely than non-BRCA1/2-related breast cancer to express a basal epithelial phenotype.  Among 292 breast cancer specimens previously analyzed for ER, erbB-2, p53, and germline mutations in BRCA1 and BRCA2, the authors identified 76 that did not overexpress ER or erbB-2.  Of the 72 specimens with sufficient material for testing, 40 expressed stratified epithelial cytokeratin 5 and/or 6 (5/6).  In univariate anal., the expression of cytokeratin 5/6 was statistically significantly assocd. with BRCA1-related breast cancers (odds ratio = 9.0, 95% confidence interval = 1.9 to 43; P = 0.002, two-sided Fisher's exact test).  Thus, germline BRCA1 mutations appear to be assocd. with a distinctive breast cancer phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoncxFMYyWONrVg90H21EOLACvtfcHk0ljhpGVY0BcySg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnvVCjtrk%253D&md5=8cb0919cb53b77c6c50c5c67fbe9c456</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjg050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjg050%26sid%3Dliteratum%253Aachs%26aulast%3DFoulkes%26aufirst%3DW.%2BD.%26aulast%3DStefansson%26aufirst%3DI.%2BM.%26aulast%3DChappuis%26aufirst%3DP.%2BO.%26aulast%3DBegin%26aufirst%3DL.%2BR.%26aulast%3DGoffin%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DN.%26aulast%3DTrudel%26aufirst%3DM.%26aulast%3DAkslen%26aufirst%3DL.%2BA.%26atitle%3DGermline%2520BRCA1%2520mutations%2520and%2520a%2520basal%2520epithelial%2520phenotype%2520in%2520breast%2520cancer%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2003%26volume%3D95%26spage%3D1482%26epage%3D1485%26doi%3D10.1093%2Fjnci%2Fdjg050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">The Cancer Genome Atlas Network.</span> <span> </span><span class="NLM_article-title">Comprehensive
molecular portraits of human breast tumours</span>.  <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume">490</span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">70</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1038%2Fnature11412" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=23000897" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=490&publication_year=2012&pages=61-70&author=The+Cancer+Genome+Atlas+Network.&title=Comprehensive%0Amolecular+portraits+of+human+breast+tumours"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnature11412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11412%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DComprehensive%250Amolecular%2520portraits%2520of%2520human%2520breast%2520tumours%26jtitle%3DNature%26date%3D2012%26volume%3D490%26spage%3D61%26epage%3D70" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rexer, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrett, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arteaga, C. L.</span></span> <span> </span><span class="NLM_article-title">Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">224</span>, <span class="refDoi"> DOI: 10.1186/bcr3039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1186%2Fbcr3039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=22114931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BC38Xms1Cmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=224&author=T.+W.+Millerauthor=B.+N.+Rexerauthor=J.+T.+Garrettauthor=C.+L.+Arteaga&title=Mutations+in+the+phosphatidylinositol+3-kinase+pathway%3A+role+in+tumor+progression+and+therapeutic+implications+in+breast+cancer&doi=10.1186%2Fbcr3039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer</span></div><div class="casAuthors">Miller, Todd W.; Rexer, Brent N.; Garrett, Joan T.; Arteaga, Carlos L.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">224</span>CODEN:
                <span class="NLM_cas:coden">BRCRFS</span>;
        ISSN:<span class="NLM_cas:issn">1465-542X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Mutations in genes that constitute the phosphatidylinositol 3-kinase (PI3K) pathway occur in >70% of breast cancers.  Clin. and exptl. evidence suggest that PI3K pathway activation promotes resistance to some of the current breast cancer therapies.  PI3K is a major signaling hub downstream of human epidermal growth factor receptor (HER)2 and other receptor tyrosine kinases.  PI3K activates AKT, serum/glucocorticoid regulated kinase (SGK), phosphoinositide-dependent kinase 1 (PDK1), mammalian target of rapamycin (mTOR), and several other mols. involved in cell cycle progression and survival.  In estrogen receptor (ER)+ breast cancer cells, PI3K activation promotes estrogen-dependent and -independent ER transcriptional activity, which, in turn, may contribute to anti-estrogen resistance.  Activation of this pathway also confers resistance to HER2-targeted therapies.  In exptl. models of resistance to anti-estrogens and HER2 inhibitors, pharmacol. inhibition of PI3K/AKT/mTOR has been shown to overcome drug resistance.  Early clin. data suggest that combined inhibition of either HER2 or ER plus inhibition of the PI3K pathway might be an effective strategy for treatment of resp. HER2+ and ER+ breast cancers resistant to std. therapies.  Here, we review alterations in the PI3K pathway in breast cancer, their assocn. with therapeutic resistance, and the state of clin. development of PI3K pathway inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1l1_QxsVCwLVg90H21EOLACvtfcHk0lgFVJTPykm1lA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xms1Cmuw%253D%253D&md5=daddd3d8ac7d2e0fc1918f6f5f979dd7</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1186%2Fbcr3039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fbcr3039%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DT.%2BW.%26aulast%3DRexer%26aufirst%3DB.%2BN.%26aulast%3DGarrett%26aufirst%3DJ.%2BT.%26aulast%3DArteaga%26aufirst%3DC.%2BL.%26atitle%3DMutations%2520in%2520the%2520phosphatidylinositol%25203-kinase%2520pathway%253A%2520role%2520in%2520tumor%2520progression%2520and%2520therapeutic%2520implications%2520in%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2011%26volume%3D13%26spage%3D224%26doi%3D10.1186%2Fbcr3039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurren, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spagnuolo, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLean, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Datti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrana, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batey, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schimmer, A. D.</span></span> <span> </span><span class="NLM_article-title">A small-molecule inhibitor of D-cyclin transactivation displays preclinical efficacy in myeloma and leukemia via phosphoinositide 3-kinase pathway</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">1986</span>– <span class="NLM_lpage">1997</span>, <span class="refDoi"> DOI: 10.1182/blood-2010-05-284810</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1182%2Fblood-2010-05-284810" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=21135258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisFKqsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2011&pages=1986-1997&author=X.+Maoauthor=B.+Caoauthor=T.+E.+Woodauthor=R.+Hurrenauthor=J.+Tongauthor=X.+Wangauthor=W.+Wangauthor=J.+Liauthor=Y.+Jinauthor=W.+Sunauthor=P.+A.+Spagnuoloauthor=N.+MacLeanauthor=M.+F.+Moranauthor=A.+Dattiauthor=J.+Wranaauthor=R.+A.+Bateyauthor=A.+D.+Schimmer&title=A+small-molecule+inhibitor+of+D-cyclin+transactivation+displays+preclinical+efficacy+in+myeloma+and+leukemia+via+phosphoinositide+3-kinase+pathway&doi=10.1182%2Fblood-2010-05-284810"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">A small-molecule inhibitor of D-cyclin transactivation displays preclinical efficacy in myeloma and leukemia via phosphoinositide 3-kinase pathway</span></div><div class="casAuthors">Mao, Xinliang; Cao, Biyin; Wood, Tabitha E.; Hurren, Rose; Tong, Jiefei; Wang, Xiaoming; Wang, Wenjie; Li, Jie; Jin, Yueping; Sun, Wenxian; Spagnuolo, Paul A.; MacLean, Neil; Moran, Michael F.; Datti, Alessandro; Wrana, Jeffery; Batey, Robert A.; Schimmer, Aaron D.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1986-1997</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">D-cyclins are universally dysregulated in multiple myeloma and frequently overexpressed in leukemia.  To better understand the role and impact of dysregulated D-cyclins in hematol. malignancies, we conducted a high-throughput screen for inhibitors of cyclin D2 transactivation and identified 8-ethoxy-2-(4-fluorophenyl)-3-nitro-2H-chromene (S14161), which inhibited the expression of cyclins D1, D2, and D3 and arrested cells at the G0/G1 phase.  After D-cyclin suppression, S14161 induced apoptosis in myeloma and leukemia cell lines and primary patient samples preferentially over normal hematopoietic cells.  In mouse models of leukemia, S14161 inhibited tumor growth without evidence of wt. loss or gross organ toxicity.  Mechanistically, S14161 inhibited the activity of phosphoinositide 3-kinase in intact cells and the activity of the phosphoinositide 3-kinases α, β, δ, and γ in a cell-free enzymic assay.  In contrast, it did not inhibit the enzymic activities of other related kinases, including the mammalian target of rapamycin, the DNA-dependent protein kinase catalytic subunit, and phosphoinositide-dependent kinase-1.  Thus, we identified a novel chem. compd. that inhibits D-cyclin transactivation via the phosphoinositide 3-kinase/protein kinase B signaling pathway.  Given its potent antileukemia and antimyeloma activity and minimal toxicity, S14161 could be developed as a novel agent for blood cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsbSkX1io2KLVg90H21EOLACvtfcHk0lgFVJTPykm1lA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisFKqsb8%253D&md5=f20e7396051a7356980ba297101af1d8</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1182%2Fblood-2010-05-284810&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2010-05-284810%26sid%3Dliteratum%253Aachs%26aulast%3DMao%26aufirst%3DX.%26aulast%3DCao%26aufirst%3DB.%26aulast%3DWood%26aufirst%3DT.%2BE.%26aulast%3DHurren%26aufirst%3DR.%26aulast%3DTong%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DW.%26aulast%3DSpagnuolo%26aufirst%3DP.%2BA.%26aulast%3DMacLean%26aufirst%3DN.%26aulast%3DMoran%26aufirst%3DM.%2BF.%26aulast%3DDatti%26aufirst%3DA.%26aulast%3DWrana%26aufirst%3DJ.%26aulast%3DBatey%26aufirst%3DR.%2BA.%26aulast%3DSchimmer%26aufirst%3DA.%2BD.%26atitle%3DA%2520small-molecule%2520inhibitor%2520of%2520D-cyclin%2520transactivation%2520displays%2520preclinical%2520efficacy%2520in%2520myeloma%2520and%2520leukemia%2520via%2520phosphoinositide%25203-kinase%2520pathway%26jtitle%3DBlood%26date%3D2011%26volume%3D117%26spage%3D1986%26epage%3D1997%26doi%3D10.1182%2Fblood-2010-05-284810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dondoni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massi, A.</span></span> <span> </span><span class="NLM_article-title">Asymmetric organocatalysis: from infancy to adolescence</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">4638</span>– <span class="NLM_lpage">4660</span>, <span class="refDoi"> DOI: 10.1002/anie.200704684</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1002%2Fanie.200704684" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnvFKqsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=4638-4660&author=A.+Dondoniauthor=A.+Massi&title=Asymmetric+organocatalysis%3A+from+infancy+to+adolescence&doi=10.1002%2Fanie.200704684"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Asymmetric organocatalysis: from infancy to adolescence</span></div><div class="casAuthors">Dondoni, Alessandro; Massi, Alessandro</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">4638-4660</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">This review deals with selected studies reported in 2006 and the first half of 2007, and is intended to highlight four main aspects that may be taken as testimony of the present status and prospective of organocatalysis: (i) chem. efficiency; (ii) discovery of new substrate combinations to give new asym. syntheses; (iii) development of new catalysts for specific purposes by using mechanistic findings; and (iv) applications of organocatalytic reactions in the asym. total synthesis of target natural products and known compds. of biol. and pharmaceutical relevance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8NC7s6TLVM7Vg90H21EOLACvtfcHk0lgFVJTPykm1lA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnvFKqsLY%253D&md5=174d35a98b1ef4066ca036e0567734e5</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fanie.200704684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200704684%26sid%3Dliteratum%253Aachs%26aulast%3DDondoni%26aufirst%3DA.%26aulast%3DMassi%26aufirst%3DA.%26atitle%3DAsymmetric%2520organocatalysis%253A%2520from%2520infancy%2520to%2520adolescence%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2008%26volume%3D47%26spage%3D4638%26epage%3D4660%26doi%3D10.1002%2Fanie.200704684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seayad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">List, B.</span></span> <span> </span><span class="NLM_article-title">Asymmetric organocatalysis</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">719</span>– <span class="NLM_lpage">724</span>, <span class="refDoi"> DOI: 10.1039/b415217b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1039%2Fb415217b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=15731852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhs1yjsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2005&pages=719-724&author=J.+Seayadauthor=B.+List&title=Asymmetric+organocatalysis&doi=10.1039%2Fb415217b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Asymmetric organocatalysis</span></div><div class="casAuthors">Seayad, Jayasree; List, Benjamin</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">719-724</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review discusses the application of asym. organocatalysts in the org. synthesis based on a mechanistic classification of the catalysts.  The organocatalysts are categorized as either Lewis bases, Lewis acids, Bronsted bases, or Bronsted acids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohanG9zemlv7Vg90H21EOLACvtfcHk0lj2K_jgEpOzzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhs1yjsLY%253D&md5=86d5dc98bb2c4388093f91db06182a3c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1039%2Fb415217b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb415217b%26sid%3Dliteratum%253Aachs%26aulast%3DSeayad%26aufirst%3DJ.%26aulast%3DList%26aufirst%3DB.%26atitle%3DAsymmetric%2520organocatalysis%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2005%26volume%3D3%26spage%3D719%26epage%3D724%26doi%3D10.1039%2Fb415217b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dalko, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moisan, L.</span></span> <span> </span><span class="NLM_article-title">In the golden age of organocatalysis</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">5138</span>– <span class="NLM_lpage">5175</span>, <span class="refDoi"> DOI: 10.1002/anie.200400650</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1002%2Fanie.200400650" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD2cXos1Kmsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2004&pages=5138-5175&author=P.+I.+Dalkoauthor=L.+Moisan&title=In+the+golden+age+of+organocatalysis&doi=10.1002%2Fanie.200400650"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">In the Golden Age of Organocatalysis</span></div><div class="casAuthors">Dalko, Peter I.; Moisan, Lionel</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">5138-5175</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The term organocatalysis describes the acceleration of chem. reactions through the addn. of a substoichiometric quantity of an org. compd.  The interest in this field has increased spectacularly in the last few years as result of both the novelty of the concept and, more importantly, the fact that efficiency and selectivity of many organocatalytic reactions meet the stds. of established org. reactions.  Organocatalytic reactions are becoming powerful tools in the construction of complex mol. skeletons.  The diverse examples show that in recent years organocatalysis has developed within org. chem. into its own subdiscipline, whose Golden Age has already dawned.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0Q1rGp9lQR7Vg90H21EOLACvtfcHk0lj2K_jgEpOzzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXos1Kmsr4%253D&md5=caefd678e8e2e4956e8a06db61bd2a72</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fanie.200400650&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200400650%26sid%3Dliteratum%253Aachs%26aulast%3DDalko%26aufirst%3DP.%2BI.%26aulast%3DMoisan%26aufirst%3DL.%26atitle%3DIn%2520the%2520golden%2520age%2520of%2520organocatalysis%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2004%26volume%3D43%26spage%3D5138%26epage%3D5175%26doi%3D10.1002%2Fanie.200400650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beneteau, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaigne-Delalande, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daburon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Giorgi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichas, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rebillard, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimanche-Boitrel, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taupin, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legembre, P.</span></span> <span> </span><span class="NLM_article-title">Localization of Fas/CD95 into the lipid rafts on down-modulation of the phosphatidylinositol 3-kinase signaling pathway</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">604</span>– <span class="NLM_lpage">613</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-07-0331</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1158%2F1541-7786.MCR-07-0331" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=18403639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD1cXksFKms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2008&pages=604-613&author=M.+Beneteauauthor=M.+Pizonauthor=B.+Chaigne-Delalandeauthor=S.+Daburonauthor=P.+Moreauauthor=F.+De+Giorgiauthor=F.+Ichasauthor=A.+Rebillardauthor=M.+T.+Dimanche-Boitrelauthor=J.+L.+Taupinauthor=J.+F.+Moreauauthor=P.+Legembre&title=Localization+of+Fas%2FCD95+into+the+lipid+rafts+on+down-modulation+of+the+phosphatidylinositol+3-kinase+signaling+pathway&doi=10.1158%2F1541-7786.MCR-07-0331"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Localization of Fas/CD95 into the Lipid Rafts on Down-Modulation of the Phosphatidylinositol 3-Kinase Signaling Pathway</span></div><div class="casAuthors">Beneteau, Marie; Pizon, Mathieu; Chaigne-Delalande, Benjamin; Daburon, Sophie; Moreau, Patrick; De Giorgi, Francesca; Ichas, Francois; Rebillard, Amelie; Dimanche-Boitrel, Marie-Therese; Taupin, Jean-Luc; Moreau, Jean-Francois; Legembre, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">604-613</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Activation of the phosphatidylinositol 3-kinase (PI3K) signaling pathway is known to protect tumor cells from apoptosis and more specifically from the Fas-mediated apoptotic signal.  The antitumoral agent edelfosine sensitizes leukemic cells to death by inducing the redistribution of the apoptotic receptor Fas into plasma membrane subdomains called lipid rafts.  Herein, we show that inhibition of the PI3K signal by edelfosine triggers a Fas-mediated apoptotic signal independently of the Fas/FasL interaction.  Furthermore, similarly to edelfosine, blockade of the PI3K activity, using specific inhibitors LY294002 and wortmannin, leads to the clustering of Fas whose supramol. complex is colocalized within the lipid rafts.  These findings indicate that the antitumoral agent edelfosine down-modulates the PI3K signal to sensitize tumor cells to death through the redistribution of Fas into large platform of membrane rafts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqwlJb9gMSabVg90H21EOLACvtfcHk0lj2K_jgEpOzzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXksFKms7Y%253D&md5=7bcc186bc4d5aecb00692960481b4fce</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-07-0331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-07-0331%26sid%3Dliteratum%253Aachs%26aulast%3DBeneteau%26aufirst%3DM.%26aulast%3DPizon%26aufirst%3DM.%26aulast%3DChaigne-Delalande%26aufirst%3DB.%26aulast%3DDaburon%26aufirst%3DS.%26aulast%3DMoreau%26aufirst%3DP.%26aulast%3DDe%2BGiorgi%26aufirst%3DF.%26aulast%3DIchas%26aufirst%3DF.%26aulast%3DRebillard%26aufirst%3DA.%26aulast%3DDimanche-Boitrel%26aufirst%3DM.%2BT.%26aulast%3DTaupin%26aufirst%3DJ.%2BL.%26aulast%3DMoreau%26aufirst%3DJ.%2BF.%26aulast%3DLegembre%26aufirst%3DP.%26atitle%3DLocalization%2520of%2520Fas%252FCD95%2520into%2520the%2520lipid%2520rafts%2520on%2520down-modulation%2520of%2520the%2520phosphatidylinositol%25203-kinase%2520signaling%2520pathway%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2008%26volume%3D6%26spage%3D604%26epage%3D613%26doi%3D10.1158%2F1541-7786.MCR-07-0331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pizon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampanarivo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tauzin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaigne-Delalande, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daburon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castroviejo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legembre, P.</span></span> <span> </span><span class="NLM_article-title">Actin-independent exclusion of CD95 by PI3K/AKT signalling: implications for apoptosis</span>. <i>Eur. J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">2368</span>– <span class="NLM_lpage">2378</span>, <span class="refDoi"> DOI: 10.1002/eji.201041078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1002%2Feji.201041078" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2011&pages=2368-2378&author=M.+Pizonauthor=H.+Rampanarivoauthor=S.+Tauzinauthor=B.+Chaigne-Delalandeauthor=S.+Daburonauthor=M.+Castroviejoauthor=P.+Moreauauthor=J.+F.+Moreauauthor=P.+Legembre&title=Actin-independent+exclusion+of+CD95+by+PI3K%2FAKT+signalling%3A+implications+for+apoptosis&doi=10.1002%2Feji.201041078"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1002%2Feji.201041078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Feji.201041078%26sid%3Dliteratum%253Aachs%26aulast%3DPizon%26aufirst%3DM.%26aulast%3DRampanarivo%26aufirst%3DH.%26aulast%3DTauzin%26aufirst%3DS.%26aulast%3DChaigne-Delalande%26aufirst%3DB.%26aulast%3DDaburon%26aufirst%3DS.%26aulast%3DCastroviejo%26aufirst%3DM.%26aulast%3DMoreau%26aufirst%3DP.%26aulast%3DMoreau%26aufirst%3DJ.%2BF.%26aulast%3DLegembre%26aufirst%3DP.%26atitle%3DActin-independent%2520exclusion%2520of%2520CD95%2520by%2520PI3K%252FAKT%2520signalling%253A%2520implications%2520for%2520apoptosis%26jtitle%3DEur.%2520J.%2520Immunol.%26date%3D2011%26volume%3D41%26spage%3D2368%26epage%3D2378%26doi%3D10.1002%2Feji.201041078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hresko, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueckler, M.</span></span> <span> </span><span class="NLM_article-title">mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>280</i></span>,  <span class="NLM_fpage">40406</span>– <span class="NLM_lpage">40416</span>, <span class="refDoi"> DOI: 10.1074/jbc.M508361200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1074%2Fjbc.M508361200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=40406-40416&author=R.+C.+Hreskoauthor=M.+Mueckler&title=mTOR.RICTOR+is+the+Ser473+kinase+for+Akt%2Fprotein+kinase+B+in+3T3-L1+adipocytes&doi=10.1074%2Fjbc.M508361200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M508361200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M508361200%26sid%3Dliteratum%253Aachs%26aulast%3DHresko%26aufirst%3DR.%2BC.%26aulast%3DMueckler%26aufirst%3DM.%26atitle%3DmTOR.RICTOR%2520is%2520the%2520Ser473%2520kinase%2520for%2520Akt%252Fprotein%2520kinase%2520B%2520in%25203T3-L1%2520adipocytes%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D40406%26epage%3D40416%26doi%3D10.1074%2Fjbc.M508361200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laplante, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span> <span> </span><span class="NLM_article-title">mTOR signaling at a glance</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">3589</span>– <span class="NLM_lpage">3594</span>, <span class="refDoi"> DOI: 10.1242/jcs.051011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1242%2Fjcs.051011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=19812304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVKitrvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2009&pages=3589-3594&author=M.+Laplanteauthor=D.+M.+Sabatini&title=mTOR+signaling+at+a+glance&doi=10.1242%2Fjcs.051011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR signaling at a glance</span></div><div class="casAuthors">Laplante, Mathieu; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3589-3594</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">A review.  The authors highlight and summarize the current understanding of how mTOR nucleates distinct multiprotein complexes, how intra- and extracellular signals are processed by the mTOR complexes, and how such signals affect cell metab., growth, proliferation, and survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5es3QIlHS6bVg90H21EOLACvtfcHk0lgqN8KjjbZ2Qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVKitrvP&md5=7be03ca7a8a3f52e0e974c784a0b9e73</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1242%2Fjcs.051011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.051011%26sid%3Dliteratum%253Aachs%26aulast%3DLaplante%26aufirst%3DM.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DmTOR%2520signaling%2520at%2520a%2520glance%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2009%26volume%3D122%26spage%3D3589%26epage%3D3594%26doi%3D10.1242%2Fjcs.051011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacinto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loewith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruegg, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, M. N.</span></span> <span> </span><span class="NLM_article-title">Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1122</span>– <span class="NLM_lpage">1128</span>, <span class="refDoi"> DOI: 10.1038/ncb1183</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1038%2Fncb1183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=15467718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptFentL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=1122-1128&author=E.+Jacintoauthor=R.+Loewithauthor=A.+Schmidtauthor=S.+Linauthor=M.+A.+Rueggauthor=A.+Hallauthor=M.+N.+Hall&title=Mammalian+TOR+complex+2+controls+the+actin+cytoskeleton+and+is+rapamycin+insensitive&doi=10.1038%2Fncb1183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive</span></div><div class="casAuthors">Jacinto, Estela; Loewith, Robbie; Schmidt, Anja; Lin, Shuo; Rueegg, Markus A.; Hall, Alan; Hall, Michael N.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1122-1128</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The target of rapamycin (TOR) is a highly conserved protein kinase and a central controller of cell growth.  In budding yeast, TOR is found in structurally and functionally distinct protein complexes: TORC1 and TORC2.  A mammalian counterpart of TORC1 (mTORC1) has been described, but it is not known whether TORC2 is conserved in mammals.  Here, the authors report that a mammalian counterpart of TORC2 (mTORC2) also exists.  The mTORC2 contains mTOR, mLST8 and mAVO3, but not raptor.  Like yeast TORC2, mTORC2 is rapamycin insensitive and seems to function upstream of Rho GTPases to regulate the actin cytoskeleton.  The mTORC2 is not upstream of the mTORC1 effector S6K.  Thus, two distinct TOR complexes constitute a primordial signaling network conserved in eukaryotic evolution to control the fundamental process of cell growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcnbO542vXw7Vg90H21EOLACvtfcHk0lgqN8KjjbZ2Qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptFentL8%253D&md5=42d53ee5d9dfc24287cf05fd29f41aa8</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fncb1183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncb1183%26sid%3Dliteratum%253Aachs%26aulast%3DJacinto%26aufirst%3DE.%26aulast%3DLoewith%26aufirst%3DR.%26aulast%3DSchmidt%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DRuegg%26aufirst%3DM.%2BA.%26aulast%3DHall%26aufirst%3DA.%26aulast%3DHall%26aufirst%3DM.%2BN.%26atitle%3DMammalian%2520TOR%2520complex%25202%2520controls%2520the%2520actin%2520cytoskeleton%2520and%2520is%2520rapamycin%2520insensitive%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2004%26volume%3D6%26spage%3D1122%26epage%3D1128%26doi%3D10.1038%2Fncb1183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarbassov, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guertin, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latek, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdjument-Bromage, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tempst, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span> <span> </span><span class="NLM_article-title">Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton</span>. <i>Curr. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1296</span>– <span class="NLM_lpage">1302</span>, <span class="refDoi"> DOI: 10.1016/j.cub.2004.06.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1016%2Fj.cub.2004.06.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=15268862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVamsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=1296-1302&author=D.+D.+Sarbassovauthor=S.+M.+Aliauthor=D.+H.+Kimauthor=D.+A.+Guertinauthor=R.+R.+Latekauthor=H.+Erdjument-Bromageauthor=P.+Tempstauthor=D.+M.+Sabatini&title=Rictor%2C+a+novel+binding+partner+of+mTOR%2C+defines+a+rapamycin-insensitive+and+raptor-independent+pathway+that+regulates+the+cytoskeleton&doi=10.1016%2Fj.cub.2004.06.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton</span></div><div class="casAuthors">Sarbassov, Dos D.; Ali, Siraj M.; Kim, Do-Hyung; Guertin, David A.; Latek, Robert R.; Erdjument-Bromage, Hediye; Tempst, Paul; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1296-1302</span>CODEN:
                <span class="NLM_cas:coden">CUBLE2</span>;
        ISSN:<span class="NLM_cas:issn">0960-9822</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The mammalian TOR (mTOR) pathway integrates nutrient- and growth factor-derived signals to regulate growth, the process whereby cells accumulate mass and increase in size.  MTOR is a large protein kinase and the target of rapamycin, an immunosuppressant that also blocks vessel restenosis and has potential anticancer applications.  MTOR interacts with the raptor and GβL proteins to form a complex that is the target of rapamycin.  Here, we demonstrate that mTOR is also part of a distinct complex defined by the novel protein rictor (rapamycin-insensitive companion of mTOR).  Rictor shares homol. with the previously described pianissimo from D. discoidieum, STE20p from S. pombe, and AVO3p from S. cerevisiae.  Interestingly, AVO3p is part of a rapamycin-insensitive TOR complex that does not contain the yeast homolog of raptor and signals to the actin cytoskeleton through PKC1.  Consistent with this finding, the rictor-contg. mTOR complex contains GβL but not raptor and it neither regulates the mTOR effector S6K1 nor is it bound by FKBP12-rapamycin.  We find that the rictor-mTOR complex modulates the phosphorylation of Protein Kinase C α (PKCα) and the actin cytoskeleton, suggesting that this aspect of TOR signaling is conserved between yeast and mammals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXWNgQt5KXB7Vg90H21EOLACvtfcHk0lilV-h51m_tNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVamsLs%253D&md5=78362bf097ed96b9bfc0053e3a54818c</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.cub.2004.06.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cub.2004.06.054%26sid%3Dliteratum%253Aachs%26aulast%3DSarbassov%26aufirst%3DD.%2BD.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DKim%26aufirst%3DD.%2BH.%26aulast%3DGuertin%26aufirst%3DD.%2BA.%26aulast%3DLatek%26aufirst%3DR.%2BR.%26aulast%3DErdjument-Bromage%26aufirst%3DH.%26aulast%3DTempst%26aufirst%3DP.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DRictor%252C%2520a%2520novel%2520binding%2520partner%2520of%2520mTOR%252C%2520defines%2520a%2520rapamycin-insensitive%2520and%2520raptor-independent%2520pathway%2520that%2520regulates%2520the%2520cytoskeleton%26jtitle%3DCurr.%2520Biol.%26date%3D2004%26volume%3D14%26spage%3D1296%26epage%3D1302%26doi%3D10.1016%2Fj.cub.2004.06.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacold, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervantes, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turk, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yaffe, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span> <span> </span><span class="NLM_article-title">mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>341</i></span>,  <span class="NLM_fpage">1236566</span>, <span class="refDoi"> DOI: 10.1126/science.1236566</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1126%2Fscience.1236566" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=23888043" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A280%3ADC%252BC3sfktVWmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=2013&pages=1236566&author=S.+A.+Kangauthor=M.+E.+Pacoldauthor=C.+L.+Cervantesauthor=D.+Limauthor=H.+J.+Louauthor=K.+Ottinaauthor=N.+S.+Grayauthor=B.+E.+Turkauthor=M.+B.+Yaffeauthor=D.+M.+Sabatini&title=mTORC1+phosphorylation+sites+encode+their+sensitivity+to+starvation+and+rapamycin&doi=10.1126%2Fscience.1236566"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin</span></div><div class="casAuthors">Kang Seong A; Pacold Michael E; Cervantes Christopher L; Lim Daniel; Lou Hua Jane; Ottina Kathleen; Gray Nathanael S; Turk Benjamin E; Yaffe Michael B; Sabatini David M</div><div class="citationInfo"><span class="NLM_cas:title">Science (New York, N.Y.)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">6144</span>),
    <span class="NLM_cas:pages">1236566</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The mechanistic target of rapamycin (mTOR) complex 1 (mTORC1) protein kinase promotes growth and is the target of rapamycin, a clinically useful drug that also prolongs life span in model organisms.  A persistent mystery is why the phosphorylation of many bona fide mTORC1 substrates is resistant to rapamycin.  We find that the in vitro kinase activity of mTORC1 toward peptides encompassing established phosphorylation sites varies widely and correlates strongly with the resistance of the sites to rapamycin, as well as to nutrient and growth factor starvation within cells.  Slight modifications of the sites were sufficient to alter mTORC1 activity toward them in vitro and to cause concomitant changes within cells in their sensitivity to rapamycin and starvation.  Thus, the intrinsic capacity of a phosphorylation site to serve as an mTORC1 substrate, a property we call substrate quality, is a major determinant of its sensitivity to modulators of the pathway.  Our results reveal a mechanism through which mTORC1 effectors can respond differentially to the same signals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRVUX1crROrkZPlX7E30qdzfW6udTcc2eb9QVUstn_QiLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sfktVWmsw%253D%253D&md5=904daf44e853714de3fb540a359e2546</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1126%2Fscience.1236566&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1236566%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DS.%2BA.%26aulast%3DPacold%26aufirst%3DM.%2BE.%26aulast%3DCervantes%26aufirst%3DC.%2BL.%26aulast%3DLim%26aufirst%3DD.%26aulast%3DLou%26aufirst%3DH.%2BJ.%26aulast%3DOttina%26aufirst%3DK.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DTurk%26aufirst%3DB.%2BE.%26aulast%3DYaffe%26aufirst%3DM.%2BB.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DmTORC1%2520phosphorylation%2520sites%2520encode%2520their%2520sensitivity%2520to%2520starvation%2520and%2520rapamycin%26jtitle%3DScience%26date%3D2013%26volume%3D341%26spage%3D1236566%26doi%3D10.1126%2Fscience.1236566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ariens, E. J.</span></span> <span> </span><span class="NLM_article-title">Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology</span>. <i>Eur. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">663</span>– <span class="NLM_lpage">668</span>, <span class="refDoi"> DOI: 10.1007/BF00541922</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1007%2FBF00541922" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=6092093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADyaL2cXmtVeksLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1984&pages=663-668&author=E.+J.+Ariens&title=Stereochemistry%2C+a+basis+for+sophisticated+nonsense+in+pharmacokinetics+and+clinical+pharmacology&doi=10.1007%2FBF00541922"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology</span></div><div class="casAuthors">Ariens, E. J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">663-8</span>CODEN:
                <span class="NLM_cas:coden">EJCPAS</span>;
        ISSN:<span class="NLM_cas:issn">0031-6970</span>.
    </div><div class="casAbstract">A review with 47 refs. on the significance of stereochemistry in the pharmacokinetics and pharmacol. of drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLER585gpaQ7Vg90H21EOLACvtfcHk0lilV-h51m_tNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXmtVeksLc%253D&md5=722a97638b21a2812235912395065a72</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1007%2FBF00541922&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00541922%26sid%3Dliteratum%253Aachs%26aulast%3DAriens%26aufirst%3DE.%2BJ.%26atitle%3DStereochemistry%252C%2520a%2520basis%2520for%2520sophisticated%2520nonsense%2520in%2520pharmacokinetics%2520and%2520clinical%2520pharmacology%26jtitle%3DEur.%2520J.%2520Clin.%2520Pharmacol.%26date%3D1984%26volume%3D26%26spage%3D663%26epage%3D668%26doi%3D10.1007%2FBF00541922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tauzin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debure, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legembre, P.</span></span> <span> </span><span class="NLM_article-title">CD95-mediated cell signaling in cancer: mutations and post-translational modulations</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">1261</span>– <span class="NLM_lpage">1277</span>, <span class="refDoi"> DOI: 10.1007/s00018-011-0866-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1007%2Fs00018-011-0866-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=22042271" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BC38XksFajsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2012&pages=1261-1277&author=S.+Tauzinauthor=L.+Debureauthor=J.+F.+Moreauauthor=P.+Legembre&title=CD95-mediated+cell+signaling+in+cancer%3A+mutations+and+post-translational+modulations&doi=10.1007%2Fs00018-011-0866-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">CD95-mediated cell signaling in cancer: mutations and post-translational modulations</span></div><div class="casAuthors">Tauzin, Sebastien; Debure, Laure; Moreau, Jean-Francois; Legembre, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1261-1277</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">A review.  Apoptosis has emerged as a fundamental process important in tissue homeostasis, immune response, and during development.  CD95 (also known as Fas), a member of the tumor necrosis factor receptor (TNF-R) superfamily, has been initially cloned as a death receptor.  Its cognate ligand, CD95L, is mainly found at the plasma membrane of activated T-lymphocytes and natural killer cells where it contributes to the elimination of transformed and infected cells.  According to its implication in the immune homeostasis and immune surveillance, and since several malignant cells of various histol. origins exhibit loss-of-function mutations, which cause resistance towards the CD95-mediated apoptotic signal, CD95 has been classified as a tumor suppressor gene.  Nevertheless, this assumption has been recently challenged, as in certain pathophysiol. contexts, CD95 engagement transmits non-apoptotic signals that promote inflammation, carcinogenesis or liver/peripheral nerve regeneration.  The focus of this review is to discuss these apparent contradictions of the known function(s) of CD95.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQKJdVcsHgkbVg90H21EOLACvtfcHk0lilV-h51m_tNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksFajsLc%253D&md5=f65d6f89929446ba7c43a9cad8b0d658</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1007%2Fs00018-011-0866-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-011-0866-4%26sid%3Dliteratum%253Aachs%26aulast%3DTauzin%26aufirst%3DS.%26aulast%3DDebure%26aufirst%3DL.%26aulast%3DMoreau%26aufirst%3DJ.%2BF.%26aulast%3DLegembre%26aufirst%3DP.%26atitle%3DCD95-mediated%2520cell%2520signaling%2520in%2520cancer%253A%2520mutations%2520and%2520post-translational%2520modulations%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2012%26volume%3D69%26spage%3D1261%26epage%3D1277%26doi%3D10.1007%2Fs00018-011-0866-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malleter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tauzin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bessede, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellano, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goubard, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godey, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leveque, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jezequel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campion, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ducret, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macgrogan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debure, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collette, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legembre, P.</span></span> <span> </span><span class="NLM_article-title">CD95L cell surface cleavage triggers a prometastatic signaling pathway in triple-negative breast cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">6711</span>– <span class="NLM_lpage">6721</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-13-1794</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1158%2F0008-5472.CAN-13-1794" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=6711-6721&author=M.+Malleterauthor=S.+Tauzinauthor=A.+Bessedeauthor=R.+Castellanoauthor=A.+Goubardauthor=F.+Godeyauthor=J.+Levequeauthor=P.+Jezequelauthor=L.+Campionauthor=M.+Camponeauthor=T.+Ducretauthor=G.+Macgroganauthor=L.+Debureauthor=Y.+Colletteauthor=P.+Vacherauthor=P.+Legembre&title=CD95L+cell+surface+cleavage+triggers+a+prometastatic+signaling+pathway+in+triple-negative+breast+cancer&doi=10.1158%2F0008-5472.CAN-13-1794"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-13-1794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-13-1794%26sid%3Dliteratum%253Aachs%26aulast%3DMalleter%26aufirst%3DM.%26aulast%3DTauzin%26aufirst%3DS.%26aulast%3DBessede%26aufirst%3DA.%26aulast%3DCastellano%26aufirst%3DR.%26aulast%3DGoubard%26aufirst%3DA.%26aulast%3DGodey%26aufirst%3DF.%26aulast%3DLeveque%26aufirst%3DJ.%26aulast%3DJezequel%26aufirst%3DP.%26aulast%3DCampion%26aufirst%3DL.%26aulast%3DCampone%26aufirst%3DM.%26aulast%3DDucret%26aufirst%3DT.%26aulast%3DMacgrogan%26aufirst%3DG.%26aulast%3DDebure%26aufirst%3DL.%26aulast%3DCollette%26aufirst%3DY.%26aulast%3DVacher%26aufirst%3DP.%26aulast%3DLegembre%26aufirst%3DP.%26atitle%3DCD95L%2520cell%2520surface%2520cleavage%2520triggers%2520a%2520prometastatic%2520signaling%2520pathway%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26spage%3D6711%26epage%3D6721%26doi%3D10.1158%2F0008-5472.CAN-13-1794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tauzin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaigne-Delalande, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selva, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khadra, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daburon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contin-Bordes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanco, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Seyec, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ducret, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Counillon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legembre, P.</span></span> <span> </span><span class="NLM_article-title">The naturally processed CD95L elicits a c-yes/calcium/PI3K-driven cell migration pathway</span>. <i>PLoS Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">e1001090</span>, <span class="refDoi"> DOI: 10.1371/journal.pbio.1001090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1371%2Fjournal.pbio.1001090" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2011&pages=e1001090&author=S.+Tauzinauthor=B.+Chaigne-Delalandeauthor=E.+Selvaauthor=N.+Khadraauthor=S.+Daburonauthor=C.+Contin-Bordesauthor=P.+Blancoauthor=J.+Le+Seyecauthor=T.+Ducretauthor=L.+Counillonauthor=J.+F.+Moreauauthor=P.+Hofmanauthor=P.+Vacherauthor=P.+Legembre&title=The+naturally+processed+CD95L+elicits+a+c-yes%2Fcalcium%2FPI3K-driven+cell+migration+pathway&doi=10.1371%2Fjournal.pbio.1001090"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pbio.1001090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pbio.1001090%26sid%3Dliteratum%253Aachs%26aulast%3DTauzin%26aufirst%3DS.%26aulast%3DChaigne-Delalande%26aufirst%3DB.%26aulast%3DSelva%26aufirst%3DE.%26aulast%3DKhadra%26aufirst%3DN.%26aulast%3DDaburon%26aufirst%3DS.%26aulast%3DContin-Bordes%26aufirst%3DC.%26aulast%3DBlanco%26aufirst%3DP.%26aulast%3DLe%2BSeyec%26aufirst%3DJ.%26aulast%3DDucret%26aufirst%3DT.%26aulast%3DCounillon%26aufirst%3DL.%26aulast%3DMoreau%26aufirst%3DJ.%2BF.%26aulast%3DHofman%26aufirst%3DP.%26aulast%3DVacher%26aufirst%3DP.%26aulast%3DLegembre%26aufirst%3DP.%26atitle%3DThe%2520naturally%2520processed%2520CD95L%2520elicits%2520a%2520c-yes%252Fcalcium%252FPI3K-driven%2520cell%2520migration%2520pathway%26jtitle%3DPLoS%2520Biol.%26date%3D2011%26volume%3D9%26spage%3De1001090%26doi%3D10.1371%2Fjournal.pbio.1001090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kleber, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sancho-Martinez, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiestler, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beisel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gieffers, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiemann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sykora, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreglmann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letellier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuliani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klussmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teodorczyk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grone, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganten, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sultmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuttenberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Deimling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regnier-Vigouroux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herold-Mende, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Villalba, A.</span></span> <span> </span><span class="NLM_article-title">Yes and PI3K bind CD95 to signal invasion of glioblastoma</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">248</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2008.02.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1016%2Fj.ccr.2008.02.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=18328427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjsVKgs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=235-248&author=S.+Kleberauthor=I.+Sancho-Martinezauthor=B.+Wiestlerauthor=A.+Beiselauthor=C.+Gieffersauthor=O.+Hillauthor=M.+Thiemannauthor=W.+Muellerauthor=J.+Sykoraauthor=A.+Kuhnauthor=N.+Schreglmannauthor=E.+Letellierauthor=C.+Zulianiauthor=S.+Klussmannauthor=M.+Teodorczykauthor=H.+J.+Groneauthor=T.+M.+Gantenauthor=H.+Sultmannauthor=J.+Tuttenbergauthor=A.+von+Deimlingauthor=A.+Regnier-Vigourouxauthor=C.+Herold-Mendeauthor=A.+Martin-Villalba&title=Yes+and+PI3K+bind+CD95+to+signal+invasion+of+glioblastoma&doi=10.1016%2Fj.ccr.2008.02.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Yes and PI3K bind CD95 to signal invasion of glioblastoma</span></div><div class="casAuthors">Kleber, Susanne; Sancho-Martinez, Ignacio; Wiestler, Benedict; Beisel, Alexandra; Gieffers, Christian; Hill, Oliver; Thiemann, Meinolf; Mueller, Wolf; Sykora, Jaromir; Kuhn, Andreas; Schreglmann, Nina; Letellier, Elisabeth; Zuliani, Cecilia; Klussmann, Stefan; Teodorczyk, Marcin; Groene, Hermann-Josef; Ganten, Tom M.; Sueltmann, Holger; Tuettenberg, Jochen; von Deimling, Andreas; Regnier-Vigouroux, Anne; Herold-Mende, Christel; Martin-Villalba, Ana</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">235-248</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Invasion of surrounding brain tissue by isolated tumor cells represents one of the main obstacles to a curative therapy of glioblastoma multiforme.  Here we unravel a mechanism regulating glioma infiltration.  Tumor interaction with the surrounding brain tissue induces CD95 Ligand expression.  Binding of CD95 Ligand to CD95 on glioblastoma cells recruits the Src family member Yes and the p85 subunit of phosphatidylinositol 3-kinase to CD95, which signal invasion via the glycogen synthase kinase 3β pathway and subsequent expression of matrix metalloproteinases.  In a murine syngeneic model of intracranial GBM, neutralization of CD95 activity dramatically reduced the no. of invading cells.  Our results uncover CD95 as an activator of PI3K and, most importantly, as a crucial trigger of basal invasion of glioblastoma in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolBSTN2uoJlrVg90H21EOLACvtfcHk0liVSS2uNSAIsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjsVKgs7w%253D&md5=77909e946e73e5b0236d7b9c336a106c</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2008.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2008.02.003%26sid%3Dliteratum%253Aachs%26aulast%3DKleber%26aufirst%3DS.%26aulast%3DSancho-Martinez%26aufirst%3DI.%26aulast%3DWiestler%26aufirst%3DB.%26aulast%3DBeisel%26aufirst%3DA.%26aulast%3DGieffers%26aufirst%3DC.%26aulast%3DHill%26aufirst%3DO.%26aulast%3DThiemann%26aufirst%3DM.%26aulast%3DMueller%26aufirst%3DW.%26aulast%3DSykora%26aufirst%3DJ.%26aulast%3DKuhn%26aufirst%3DA.%26aulast%3DSchreglmann%26aufirst%3DN.%26aulast%3DLetellier%26aufirst%3DE.%26aulast%3DZuliani%26aufirst%3DC.%26aulast%3DKlussmann%26aufirst%3DS.%26aulast%3DTeodorczyk%26aufirst%3DM.%26aulast%3DGrone%26aufirst%3DH.%2BJ.%26aulast%3DGanten%26aufirst%3DT.%2BM.%26aulast%3DSultmann%26aufirst%3DH.%26aulast%3DTuttenberg%26aufirst%3DJ.%26aulast%3Dvon%2BDeimling%26aufirst%3DA.%26aulast%3DRegnier-Vigouroux%26aufirst%3DA.%26aulast%3DHerold-Mende%26aufirst%3DC.%26aulast%3DMartin-Villalba%26aufirst%3DA.%26atitle%3DYes%2520and%2520PI3K%2520bind%2520CD95%2520to%2520signal%2520invasion%2520of%2520glioblastoma%26jtitle%3DCancer%2520Cell%26date%3D2008%26volume%3D13%26spage%3D235%26epage%3D248%26doi%3D10.1016%2Fj.ccr.2008.02.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takai, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Lange, T.</span></span> <span> </span><span class="NLM_article-title">Tel2 regulates the stability of PI3K-related protein kinases</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">1248</span>– <span class="NLM_lpage">1259</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2007.10.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1016%2Fj.cell.2007.10.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=18160036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmt1Cnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2007&pages=1248-1259&author=H.+Takaiauthor=R.+C.+Wangauthor=K.+K.+Takaiauthor=H.+Yangauthor=T.+de+Lange&title=Tel2+regulates+the+stability+of+PI3K-related+protein+kinases&doi=10.1016%2Fj.cell.2007.10.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Tel2 regulates the stability of PI3K-related protein kinases</span></div><div class="casAuthors">Takai, Hiroyuki; Wang, Richard C.; Takai, Kaori K.; Yang, Haijuan; de Lange, Titia</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1248-1259</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">We report an unexpected role for Tel2 in the expression of all mammalian phosphatidylinositol 3-kinase-related protein kinases (PIKKs).  Although Tel2 was identified as a budding yeast gene required for the telomere length maintenance, we found no obvious telomeric function for mammalian Tel2.  Targeted gene deletion showed that mouse Tel2 is essential in embryonic development, embryonic stem (ES) cells, and embryonic fibroblasts.  Conditional deletion of Tel2 from embryonic fibroblasts compromised their response to IR and UV, diminishing the activation of checkpoint kinases and their downstream effectors.  The effects of Tel2 deletion correlated with significantly reduced protein levels for the PI3K-related kinases ataxia telangiectasia mutated (ATM), ATM and Rad3 related (ATR), and DNA-dependent protein kinase catalytic subunit ataxia (DNA-PKcs).  Tel2 deletion also elicited specific depletion of the mammalian target of rapamycin (mTOR), suppressor with morphol. effect on genitalia 1 (SMG1), and transformation/transcription domain-assocd. protein (TRRAP), and curbed mTOR signaling, indicating that Tel2 affects all six mammalian PIKKs.  While Tel2 deletion did not alter PIKK mRNA levels, in vivo pulse labeling expts. showed that Tel2 controls the stability of ATM and mTOR.  Each of the PIKK family members assocd. with Tel2 in vivo and in vitro expts. indicated that Tel2 binds to part of the HEAT repeat segments of ATM and mTOR.  These data identify Tel2 as a highly conserved regulator of PIKK stability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqr370AHI6hDLVg90H21EOLACvtfcHk0lh5cSODJPUWfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmt1Cnsg%253D%253D&md5=6015ecddb2b7fc68c1b8d4c05a855ff8</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2007.10.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2007.10.052%26sid%3Dliteratum%253Aachs%26aulast%3DTakai%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DR.%2BC.%26aulast%3DTakai%26aufirst%3DK.%2BK.%26aulast%3DYang%26aufirst%3DH.%26aulast%3Dde%2BLange%26aufirst%3DT.%26atitle%3DTel2%2520regulates%2520the%2520stability%2520of%2520PI3K-related%2520protein%2520kinases%26jtitle%3DCell%26date%3D2007%26volume%3D131%26spage%3D1248%26epage%3D1259%26doi%3D10.1016%2Fj.cell.2007.10.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andrs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korabecny, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodny, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuca, K.</span></span> <span> </span><span class="NLM_article-title">Phosphatidylinositol 3-Kinase (PI3K) and phosphatidylinositol 3-kinase-related kinase (PIKK) inhibitors: Importance of the morpholine ring</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">71</span>, <span class="refDoi"> DOI: 10.1021/jm501026z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501026z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvV2ntLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=41-71&author=M.+Andrsauthor=J.+Korabecnyauthor=D.+Junauthor=Z.+Hodnyauthor=J.+Bartekauthor=K.+Kuca&title=Phosphatidylinositol+3-Kinase+%28PI3K%29+and+phosphatidylinositol+3-kinase-related+kinase+%28PIKK%29+inhibitors%3A+Importance+of+the+morpholine+ring&doi=10.1021%2Fjm501026z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphatidylinositol 3-Kinase (PI3K) and Phosphatidylinositol 3-Kinase-Related Kinase (PIKK) Inhibitors: Importance of the Morpholine Ring</span></div><div class="casAuthors">Andrs, Martin; Korabecny, Jan; Jun, Daniel; Hodny, Zdenek; Bartek, Jiri; Kuca, Kamil</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-71</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Phosphatidylinositol 3-kinases (PI3Ks) and phosphatidylinositol 3-kinase-related protein kinases (PIKKs) are two related families of kinases that play key roles in regulation of cell proliferation, metab., migration, survival, and responses to diverse stresses including DNA damage.  To design novel efficient strategies for treatment of cancer and other diseases, these kinases have been extensively studied.  Despite their different nature, these two kinase families have related origin and share very similar kinase domains.  Therefore, chem. inhibitors of these kinases usually carry analogous structural motifs.  The most common feature of these inhibitors is a crit. hydrogen bond to morpholine oxygen, initially present in the early nonspecific PI3K and PIKK inhibitor 3 (LY294002), which served as a valuable chem. tool for development of many addnl. PI3K and PIKK inhibitors.  While several PI3K pathway inhibitors have recently shown promising clin. responses, inhibitors of the DNA damage-related PIKKs remain thus far largely in preclin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprPlvsq-HTebVg90H21EOLACvtfcHk0lh5cSODJPUWfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvV2ntLzE&md5=a8c22f580691084554036dec7d0cc95b</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm501026z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501026z%26sid%3Dliteratum%253Aachs%26aulast%3DAndrs%26aufirst%3DM.%26aulast%3DKorabecny%26aufirst%3DJ.%26aulast%3DJun%26aufirst%3DD.%26aulast%3DHodny%26aufirst%3DZ.%26aulast%3DBartek%26aufirst%3DJ.%26aulast%3DKuca%26aufirst%3DK.%26atitle%3DPhosphatidylinositol%25203-Kinase%2520%2528PI3K%2529%2520and%2520phosphatidylinositol%25203-kinase-related%2520kinase%2520%2528PIKK%2529%2520inhibitors%253A%2520Importance%2520of%2520the%2520morpholine%2520ring%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D41%26epage%3D71%26doi%3D10.1021%2Fjm501026z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petter, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitty, A.</span></span> <span> </span><span class="NLM_article-title">The resurgence of covalent drugs</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1038/nrd3410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1038%2Fnrd3410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=21455239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=307-317&author=J.+Singhauthor=R.+C.+Petterauthor=T.+A.+Baillieauthor=A.+Whitty&title=The+resurgence+of+covalent+drugs&doi=10.1038%2Fnrd3410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">The resurgence of covalent drugs</span></div><div class="casAuthors">Singh, Juswinder; Petter, Russell C.; Baillie, Thomas A.; Whitty, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-317</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Covalent drugs haveproved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project.  There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium.  This Review surveys the prevalence and pharmacol. advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreDCEmORV_NbVg90H21EOLACvtfcHk0lh5cSODJPUWfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D&md5=2190289081e151416c097be4a5b04460</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1038%2Fnrd3410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3410%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DWhitty%26aufirst%3DA.%26atitle%3DThe%2520resurgence%2520of%2520covalent%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D307%26epage%3D317%26doi%3D10.1038%2Fnrd3410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanderson, K.</span></span> <span> </span><span class="NLM_article-title">Irreversible kinase inhibitors gain traction</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">649</span>– <span class="NLM_lpage">651</span>, <span class="refDoi"> DOI: 10.1038/nrd4103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1038%2Fnrd4103" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=649-651&author=K.+Sanderson&title=Irreversible+kinase+inhibitors+gain+traction&doi=10.1038%2Fnrd4103"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fnrd4103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4103%26sid%3Dliteratum%253Aachs%26aulast%3DSanderson%26aufirst%3DK.%26atitle%3DIrreversible%2520kinase%2520inhibitors%2520gain%2520traction%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D649%26epage%3D651%26doi%3D10.1038%2Fnrd4103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peto, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godwin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cutter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darby, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGale, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Leo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albain, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piccart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, K.</span></span> <span> </span><span class="NLM_article-title">Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>379</i></span>,  <span class="NLM_fpage">432</span>– <span class="NLM_lpage">444</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(11)61625-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1016%2FS0140-6736%2811%2961625-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=22152853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A280%3ADC%252BC383gt1CntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2012&pages=432-444&author=R.+Petoauthor=C.+Daviesauthor=J.+Godwinauthor=R.+Grayauthor=H.+C.+Panauthor=M.+Clarkeauthor=D.+Cutterauthor=S.+Darbyauthor=P.+McGaleauthor=C.+Taylorauthor=Y.+C.+Wangauthor=J.+Berghauthor=A.+Di+Leoauthor=K.+Albainauthor=S.+Swainauthor=M.+Piccartauthor=K.+Pritchard&title=Comparisons+between+different+polychemotherapy+regimens+for+early+breast+cancer%3A+meta-analyses+of+long-term+outcome+among+100%2C000+women+in+123+randomised+trials&doi=10.1016%2FS0140-6736%2811%2961625-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials</span></div><div class="casAuthors">Peto R; Davies C; Godwin J; Gray R; Pan H C; Clarke M; Cutter D; Darby S; McGale P; Taylor C; Wang Y C; Bergh J; Di Leo A; Albain K; Swain S; Piccart M; Pritchard K</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">379</span>
        (<span class="NLM_cas:issue">9814</span>),
    <span class="NLM_cas:pages">432-44</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Moderate differences in efficacy between adjuvant chemotherapy regimens for breast cancer are plausible, and could affect treatment choices.  We sought any such differences.  METHODS:  We undertook individual-patient-data meta-analyses of the randomised trials comparing: any taxane-plus-anthracycline-based regimen versus the same, or more, non-taxane chemotherapy (n=44,000); one anthracycline-based regimen versus another (n=7000) or versus cyclophosphamide, methotrexate, and fluorouracil (CMF; n=18,000); and polychemotherapy versus no chemotherapy (n=32,000).  The scheduled dosages of these three drugs and of the anthracyclines doxorubicin (A) and epirubicin (E) were used to define standard CMF, standard 4AC, and CAF and CEF.  Log-rank breast cancer mortality rate ratios (RRs) are reported.  FINDINGS:  In trials adding four separate cycles of a taxane to a fixed anthracycline-based control regimen, extending treatment duration, breast cancer mortality was reduced (RR 0·86, SE 0·04, two-sided significance [2p]=0·0005).  In trials with four such extra cycles of a taxane counterbalanced in controls by extra cycles of other cytotoxic drugs, roughly doubling non-taxane dosage, there was no significant difference (RR 0·94, SE 0·06, 2p=0·33).  Trials with CMF-treated controls showed that standard 4AC and standard CMF were equivalent (RR 0·98, SE 0·05, 2p=0·67), but that anthracycline-based regimens with substantially higher cumulative dosage than standard 4AC (eg, CAF or CEF) were superior to standard CMF (RR 0·78, SE 0·06, 2p=0·0004).  Trials versus no chemotherapy also suggested greater mortality reductions with CAF (RR 0·64, SE 0·09, 2p<0·0001) than with standard 4AC (RR 0·78, SE 0·09, 2p=0·01) or standard CMF (RR 0·76, SE 0·05, 2p<0·0001).  In all meta-analyses involving taxane-based or anthracycline-based regimens, proportional risk reductions were little affected by age, nodal status, tumour diameter or differentiation (moderate or poor; few were well differentiated), oestrogen receptor status, or tamoxifen use.  Hence, largely independently of age (up to at least 70 years) or the tumour characteristics currently available to us for the patients selected to be in these trials, some taxane-plus-anthracycline-based or higher-cumulative-dosage anthracycline-based regimens (not requiring stem cells) reduced breast cancer mortality by, on average, about one-third. 10-year overall mortality differences paralleled breast cancer mortality differences, despite taxane, anthracycline, and other toxicities.  INTERPRETATION:  10-year gains from a one-third breast cancer mortality reduction depend on absolute risks without chemotherapy (which, for oestrogen-receptor-positive disease, are the risks remaining with appropriate endocrine therapy).  Low absolute risk implies low absolute benefit, but information was lacking about tumour gene expression markers or quantitative immunohistochemistry that might help to predict risk, chemosensitivity, or both.  FUNDING:  Cancer Research UK; British Heart Foundation; UK Medical Research Council.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQzc8V8U7-ZGn6oPH0mYWL1fW6udTcc2eayf3yAYafSabntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383gt1CntQ%253D%253D&md5=4e5e668864fca9f7649929b7f5445f62</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2811%2961625-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252811%252961625-5%26sid%3Dliteratum%253Aachs%26aulast%3DPeto%26aufirst%3DR.%26aulast%3DDavies%26aufirst%3DC.%26aulast%3DGodwin%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DR.%26aulast%3DPan%26aufirst%3DH.%2BC.%26aulast%3DClarke%26aufirst%3DM.%26aulast%3DCutter%26aufirst%3DD.%26aulast%3DDarby%26aufirst%3DS.%26aulast%3DMcGale%26aufirst%3DP.%26aulast%3DTaylor%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%2BC.%26aulast%3DBergh%26aufirst%3DJ.%26aulast%3DDi%2BLeo%26aufirst%3DA.%26aulast%3DAlbain%26aufirst%3DK.%26aulast%3DSwain%26aufirst%3DS.%26aulast%3DPiccart%26aufirst%3DM.%26aulast%3DPritchard%26aufirst%3DK.%26atitle%3DComparisons%2520between%2520different%2520polychemotherapy%2520regimens%2520for%2520early%2520breast%2520cancer%253A%2520meta-analyses%2520of%2520long-term%2520outcome%2520among%2520100%252C000%2520women%2520in%2520123%2520randomised%2520trials%26jtitle%3DLancet%26date%3D2012%26volume%3D379%26spage%3D432%26epage%3D444%26doi%3D10.1016%2FS0140-6736%2811%2961625-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malleter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tauzin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bessede, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellano, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goubard, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godey, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leveque, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jezequel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campion, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ducret, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macgrogan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debure, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collette, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legembre, P.</span></span> <span> </span><span class="NLM_article-title">CD95L cell surface cleavage triggers a pro-metastatic signaling pathway in triple negative breast cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">6711</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-13-1794</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1158%2F0008-5472.CAN-13-1794" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=6711&author=M.+Malleterauthor=S.+Tauzinauthor=A.+Bessedeauthor=R.+Castellanoauthor=A.+Goubardauthor=F.+Godeyauthor=J.+Levequeauthor=P.+Jezequelauthor=L.+Campionauthor=M.+Camponeauthor=T.+Ducretauthor=G.+Macgroganauthor=L.+Debureauthor=Y.+Colletteauthor=P.+Vacherauthor=P.+Legembre&title=CD95L+cell+surface+cleavage+triggers+a+pro-metastatic+signaling+pathway+in+triple+negative+breast+cancer&doi=10.1158%2F0008-5472.CAN-13-1794"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-13-1794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-13-1794%26sid%3Dliteratum%253Aachs%26aulast%3DMalleter%26aufirst%3DM.%26aulast%3DTauzin%26aufirst%3DS.%26aulast%3DBessede%26aufirst%3DA.%26aulast%3DCastellano%26aufirst%3DR.%26aulast%3DGoubard%26aufirst%3DA.%26aulast%3DGodey%26aufirst%3DF.%26aulast%3DLeveque%26aufirst%3DJ.%26aulast%3DJezequel%26aufirst%3DP.%26aulast%3DCampion%26aufirst%3DL.%26aulast%3DCampone%26aufirst%3DM.%26aulast%3DDucret%26aufirst%3DT.%26aulast%3DMacgrogan%26aufirst%3DG.%26aulast%3DDebure%26aufirst%3DL.%26aulast%3DCollette%26aufirst%3DY.%26aulast%3DVacher%26aufirst%3DP.%26aulast%3DLegembre%26aufirst%3DP.%26atitle%3DCD95L%2520cell%2520surface%2520cleavage%2520triggers%2520a%2520pro-metastatic%2520signaling%2520pathway%2520in%2520triple%2520negative%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26spage%3D6711%26doi%3D10.1158%2F0008-5472.CAN-13-1794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheulen, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mross, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardoso, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dittrich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiermann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morant, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semiglazov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salzberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostapenko, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illiger, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behringer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardy-Bouxin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cincotta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, L.</span></span> <span> </span><span class="NLM_article-title">Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">5314</span>– <span class="NLM_lpage">5322</span>, <span class="refDoi"> DOI: 10.1200/JCO.2005.66.130</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1200%2FJCO.2005.66.130" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=15955899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpslOrtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=5314-5322&author=S.+Chanauthor=M.+E.+Scheulenauthor=S.+Johnstonauthor=K.+Mrossauthor=F.+Cardosoauthor=C.+Dittrichauthor=W.+Eiermannauthor=D.+Hessauthor=R.+Morantauthor=V.+Semiglazovauthor=M.+Bornerauthor=M.+Salzbergauthor=V.+Ostapenkoauthor=H.+J.+Illigerauthor=D.+Behringerauthor=N.+Bardy-Bouxinauthor=J.+Boniauthor=S.+Kongauthor=M.+Cincottaauthor=L.+Moore&title=Phase+II+study+of+temsirolimus+%28CCI-779%29%2C+a+novel+inhibitor+of+mTOR%2C+in+heavily+pretreated+patients+with+locally+advanced+or+metastatic+breast+cancer&doi=10.1200%2FJCO.2005.66.130"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer</span></div><div class="casAuthors">Chan, Stephen; Scheulen, Max E.; Johnston, Stephen; Mross, Klaus; Cardoso, Fatima; Dittrich, Christian; Eiermann, Wolfgang; Hess, Dagmar; Morant, Rudolph; Semiglazov, Vladimir; Borner, Markus; Salzberg, Marc; Ostapenko, Valerijus; Illiger, Hans-Joachim; Behringer, Dirk; Bardy-Bouxin, Nathalie; Boni, Joseph; Kong, Steven; Cincotta, Maria; Moore, Laurence</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5314-5322</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose In this study, two doses of temsirolimus (CCI-779), a novel inhibitor of the mammalian target of rapamycin, were evaluated for efficacy, safety, and pharmacokinetics in patients with locally advanced or metastatic breast cancer who had been heavily pretreated.  Patients and Methods Patients (n = 109) were randomly assigned to receive 75 or 250 mg of temsirolimus weekly as a 30-min i.v. infusion.  Patients were evaluated for tumor response, time to tumor progression, adverse events, and pharmacokinetics of temsirolimus.  Results Temsirolimus produced an objective response rate of 9.2% (10 partial responses) in the intent-to-treat population.  Median time to tumor progression was 12.0 wk.  Efficacy was similar for both dose levels but toxicity was more common with the higher dose level, esp. grade 3 or 4 depression (10% of patients at the 250-mg dose level, 0% at the 75-mg dose level).  The most common temsirolimus-related adverse events of all grades were mucositis (70%), maculopapular rash (51%), and nausea (43%).  The most common, clin. important grade 3 or 4 adverse events were mucositis (9%), leukopenia (7%), hyperglycemia (7%), somnolence (6%), thrombocytopenia (5%), and depression (5%).  Conclusion In heavily pretreated patients with locally advanced or metastatic breast cancer, 75 and 250 mg temsirolimus showed antitumor activity and 75 mg temsirolimus showed a generally tolerable safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-J7CSrX8CmbVg90H21EOLACvtfcHk0lhnEmgA2R7YqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpslOrtLo%253D&md5=32aeaf7db724372273f0f78c7b83c3b7</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.66.130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.66.130%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DS.%26aulast%3DScheulen%26aufirst%3DM.%2BE.%26aulast%3DJohnston%26aufirst%3DS.%26aulast%3DMross%26aufirst%3DK.%26aulast%3DCardoso%26aufirst%3DF.%26aulast%3DDittrich%26aufirst%3DC.%26aulast%3DEiermann%26aufirst%3DW.%26aulast%3DHess%26aufirst%3DD.%26aulast%3DMorant%26aufirst%3DR.%26aulast%3DSemiglazov%26aufirst%3DV.%26aulast%3DBorner%26aufirst%3DM.%26aulast%3DSalzberg%26aufirst%3DM.%26aulast%3DOstapenko%26aufirst%3DV.%26aulast%3DIlliger%26aufirst%3DH.%2BJ.%26aulast%3DBehringer%26aufirst%3DD.%26aulast%3DBardy-Bouxin%26aufirst%3DN.%26aulast%3DBoni%26aufirst%3DJ.%26aulast%3DKong%26aufirst%3DS.%26aulast%3DCincotta%26aufirst%3DM.%26aulast%3DMoore%26aufirst%3DL.%26atitle%3DPhase%2520II%2520study%2520of%2520temsirolimus%2520%2528CCI-779%2529%252C%2520a%2520novel%2520inhibitor%2520of%2520mTOR%252C%2520in%2520heavily%2520pretreated%2520patients%2520with%2520locally%2520advanced%2520or%2520metastatic%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D5314%26epage%3D5322%26doi%3D10.1200%2FJCO.2005.66.130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ellard, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemons, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelmon, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennecke, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandenberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauerbrei, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishaeli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huntsman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntosh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seymour, L.</span></span> <span> </span><span class="NLM_article-title">Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">4536</span>– <span class="NLM_lpage">4541</span>, <span class="refDoi"> DOI: 10.1200/JCO.2008.21.3033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1200%2FJCO.2008.21.3033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=19687332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlCns77K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=4536-4541&author=S.+L.+Ellardauthor=M.+Clemonsauthor=K.+A.+Gelmonauthor=B.+Norrisauthor=H.+Kenneckeauthor=S.+Chiaauthor=K.+Pritchardauthor=A.+Eisenauthor=T.+Vandenbergauthor=M.+Taylorauthor=E.+Sauerbreiauthor=M.+Mishaeliauthor=D.+Huntsmanauthor=W.+Walshauthor=M.+Olivoauthor=L.+McIntoshauthor=L.+Seymour&title=Randomized+phase+II+study+comparing+two+schedules+of+everolimus+in+patients+with+recurrent%2Fmetastatic+breast+cancer%3A+NCIC+Clinical+Trials+Group+IND.163&doi=10.1200%2FJCO.2008.21.3033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC clinical trials group IND.163</span></div><div class="casAuthors">Ellard, Susan L.; Clemons, Mark; Gelmon, Karen A.; Norris, Brian; Kennecke, Hagen; Chia, Stephen; Pritchard, Kathleen; Eisen, Andrea; Vandenberg, Ted; Taylor, Marianne; Sauerbrei, Eric; Mishaeli, Moshe; Huntsman, David; Walsh, Wendy; Olivo, Martin; McIntosh, Lynn; Seymour, Lesley</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">4536-4541</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: To evaluate the safety and efficacy of oral everolimus, a mammalian target of rapamycin (mTOR) inhibitor, in two different schedules in minimally pretreated patients with metastatic breast cancer and to explore for possible biol. correlates of response.  Patients and Methods: Patients who received no or one prior chemotherapy regimen for metastatic breast cancer were entered onto this multicenter, noncomparative, randomized phase II study of everolimus 10 mg daily vs. 70 mg weekly; the multinomial end points of response and progression were evaluated at 8 wk.  A two-stage accrual design was used, with 15 evaluable patients in each schedule in stage 1.  Only daily therapy met criteria for continuing, and another 15 patients were added.  PAKT, PTEN, carbonic anhydrase 9, estrogen receptor (ER), progesterone receptor, and human epidermal growth factor receptor 2 (HER2) were evaluated for possible correlation with response.  Results: The most common drug-related toxicities were fatigue, rash, anorexia, diarrhea, stomatitis, cough, and pneumonitis.  Pneumonitis occurred at higher than expected rates and seemed to be schedule dependent, with the highest incidence on the daily schedule.  Response rate with daily therapy was 12% (95% CI, 3.4% to 28.2%) compared with 0% (95% CI, 0.0% to 20.6%) for weekly therapy.  Twenty-seven percent of patients on daily therapy discontinued treatment compared with 13% on weekly therapy (16% v 6% with pneumonitis, resp.).  No biol. correlates of response could be identified, although there were trends favoring benefit in ER-pos. and HER2-neg. metastatic breast cancer.  Conclusion: Oral everolimus has activity in metastatic breast cancer that is schedule dependent.  Daily therapy with 10 mg is worthy of further study in this patient population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQfymkUESI-7Vg90H21EOLACvtfcHk0lhQwvPzg6L2lA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlCns77K&md5=5dd0bfb2c83436e59ae0115c71a9c13e</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1200%2FJCO.2008.21.3033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2008.21.3033%26sid%3Dliteratum%253Aachs%26aulast%3DEllard%26aufirst%3DS.%2BL.%26aulast%3DClemons%26aufirst%3DM.%26aulast%3DGelmon%26aufirst%3DK.%2BA.%26aulast%3DNorris%26aufirst%3DB.%26aulast%3DKennecke%26aufirst%3DH.%26aulast%3DChia%26aufirst%3DS.%26aulast%3DPritchard%26aufirst%3DK.%26aulast%3DEisen%26aufirst%3DA.%26aulast%3DVandenberg%26aufirst%3DT.%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DSauerbrei%26aufirst%3DE.%26aulast%3DMishaeli%26aufirst%3DM.%26aulast%3DHuntsman%26aufirst%3DD.%26aulast%3DWalsh%26aufirst%3DW.%26aulast%3DOlivo%26aufirst%3DM.%26aulast%3DMcIntosh%26aufirst%3DL.%26aulast%3DSeymour%26aufirst%3DL.%26atitle%3DRandomized%2520phase%2520II%2520study%2520comparing%2520two%2520schedules%2520of%2520everolimus%2520in%2520patients%2520with%2520recurrent%252Fmetastatic%2520breast%2520cancer%253A%2520NCIC%2520Clinical%2520Trials%2520Group%2520IND.163%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D4536%26epage%3D4541%26doi%3D10.1200%2FJCO.2008.21.3033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Findlay, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolkacheva, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wigfield, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rebholz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnett, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gout, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downes, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, R. F.</span></span> <span> </span><span class="NLM_article-title">The TSC1–2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>166</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1083/jcb.200403069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1083%2Fjcb.200403069" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2004&pages=213-223&author=L.+S.+Harringtonauthor=G.+M.+Findlayauthor=A.+Grayauthor=T.+Tolkachevaauthor=S.+Wigfieldauthor=H.+Rebholzauthor=J.+Barnettauthor=N.+R.+Leslieauthor=S.+Chengauthor=P.+R.+Shepherdauthor=I.+Goutauthor=C.+P.+Downesauthor=R.+F.+Lamb&title=The+TSC1%E2%80%932+tumor+suppressor+controls+insulin-PI3K+signaling+via+regulation+of+IRS+proteins&doi=10.1083%2Fjcb.200403069"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1083%2Fjcb.200403069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.200403069%26sid%3Dliteratum%253Aachs%26aulast%3DHarrington%26aufirst%3DL.%2BS.%26aulast%3DFindlay%26aufirst%3DG.%2BM.%26aulast%3DGray%26aufirst%3DA.%26aulast%3DTolkacheva%26aufirst%3DT.%26aulast%3DWigfield%26aufirst%3DS.%26aulast%3DRebholz%26aufirst%3DH.%26aulast%3DBarnett%26aufirst%3DJ.%26aulast%3DLeslie%26aufirst%3DN.%2BR.%26aulast%3DCheng%26aufirst%3DS.%26aulast%3DShepherd%26aufirst%3DP.%2BR.%26aulast%3DGout%26aufirst%3DI.%26aulast%3DDownes%26aufirst%3DC.%2BP.%26aulast%3DLamb%26aufirst%3DR.%2BF.%26atitle%3DThe%2520TSC1%25E2%2580%25932%2520tumor%2520suppressor%2520controls%2520insulin-PI3K%2520signaling%2520via%2520regulation%2520of%2520IRS%2520proteins%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2004%26volume%3D166%26spage%3D213%26epage%3D223%26doi%3D10.1083%2Fjcb.200403069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dibble, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asara, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, B. D.</span></span> <span> </span><span class="NLM_article-title">Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">5657</span>– <span class="NLM_lpage">5670</span>, <span class="refDoi"> DOI: 10.1128/MCB.00735-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1128%2FMCB.00735-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=19720745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlKntbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2009&pages=5657-5670&author=C.+C.+Dibbleauthor=J.+M.+Asaraauthor=B.+D.+Manning&title=Characterization+of+Rictor+phosphorylation+sites+reveals+direct+regulation+of+mTOR+complex+2+by+S6K1&doi=10.1128%2FMCB.00735-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1</span></div><div class="casAuthors">Dibble, Christian C.; Asara, John M.; Manning, Brendan D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5657-5670</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The mammalian target of rapamycin (mTOR) functions within two distinct complexes (mTORC1 and mTORC2) to control cell growth, proliferation, survival, and metab.  While there has been great progress in our understanding of mTORC1 regulation, the signaling mechanisms that regulate mTORC2 have not been defined.  In this study, we use liq. chromatog.-tandem mass spectrometry analyses to identify 21 phosphorylation sites on the core mTORC2 component Rictor.  We find that one site, T1135, undergoes growth factor-responsive phosphorylation that is acutely sensitive to rapamycin and is phosphorylated downstream of mTORC1.  We find that Rictor-T1135 is directly phosphorylated by the mTORC1-dependent kinase S6K1.  Although this phosphorylation event does not affect mTORC2 integrity or in vitro kinase activity, expression of a phosphorylation site mutant of Rictor (T1135A) in either wild-type or Rictor null cells causes an increase in the mTORC2-dependent phosphorylation of Akt on S473.  However, Rictor-T1135 phosphorylation does not appear to regulate mTORC2-mediated effects on SGK1 or PKCα.  While the precise mol. mechanism affecting Akt is unknown, phosphorylation of T1135 stimulates binding of Rictor to 14-3-3 proteins.  We provide evidence that Rictor-T1135 phosphorylation acts in parallel with other mTORC1-dependent feedback mechanisms, such as those affecting IRS-1 signaling to PI3K, to regulate the response of Akt to insulin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDFjKOh5u2ArVg90H21EOLACvtfcHk0lhQwvPzg6L2lA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlKntbrN&md5=23626dc34532fd8effa77706ac671f49</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1128%2FMCB.00735-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.00735-09%26sid%3Dliteratum%253Aachs%26aulast%3DDibble%26aufirst%3DC.%2BC.%26aulast%3DAsara%26aufirst%3DJ.%2BM.%26aulast%3DManning%26aufirst%3DB.%2BD.%26atitle%3DCharacterization%2520of%2520Rictor%2520phosphorylation%2520sites%2520reveals%2520direct%2520regulation%2520of%2520mTOR%2520complex%25202%2520by%2520S6K1%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2009%26volume%3D29%26spage%3D5657%26epage%3D5670%26doi%3D10.1128%2FMCB.00735-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Julien, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carriere, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roux, P. P.</span></span> <span> </span><span class="NLM_article-title">mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">908</span>– <span class="NLM_lpage">921</span>, <span class="refDoi"> DOI: 10.1128/MCB.00601-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1128%2FMCB.00601-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=19995915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisVequrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2010&pages=908-921&author=L.+A.+Julienauthor=A.+Carriereauthor=J.+Moreauauthor=P.+P.+Roux&title=mTORC1-activated+S6K1+phosphorylates+Rictor+on+threonine+1135+and+regulates+mTORC2+signaling&doi=10.1128%2FMCB.00601-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">mTORC1-activated S6K1 phosphorylates rictor on threonine 1135 and regulates mTORC2 signaling</span></div><div class="casAuthors">Julien, Louis-Andre; Carriere, Audrey; Moreau, Julie; Roux, Philippe P.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">908-921</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The mammalian target of rapamycin (mTOR) is a conserved Ser/Thr kinase that forms two functionally distinct complexes important for nutrient and growth factor signaling.  While mTOR complex 1 (mTORC1) regulates mRNA translation and ribosome biogenesis, mTORC2 plays an important role in the phosphorylation and subsequent activation of Akt.  Interestingly, mTORC1 neg. regulates Akt activation, but whether mTORC1 signaling directly targets mTORC2 remains unknown.  Here we show that growth factors promote the phosphorylation of rictor (rapamycin-insensitive companion of mTOR), an essential subunit of mTORC2.  We found that rictor phosphorylation requires mTORC1 activity and, more specifically, the p70 ribosomal S6 kinase 1 (S6K1).  We identified several phosphorylation sites in rictor and found that Thr1135 is directly phosphorylated by S6K1 in vitro and in vivo, in a rapamycin-sensitive manner.  Phosphorylation of rictor on Thr1135 did not affect mTORC2 assembly, kinase activity, or cellular localization.  However, cells expressing a rictor T1135A mutant were found to have increased mTORC2-dependent phosphorylation of Akt.  In addn., phosphorylation of the Akt substrates FoxO1/3a and glycogen synthase kinase 3α/β (GSK3α/β) was found to be increased in these cells, indicating that S6K1-mediated phosphorylation of rictor inhibits mTORC2 and Akt signaling.  Together, our results uncover a new regulatory link between the two mTOR complexes, whereby rictor integrates mTORC1-dependent signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0-wSn51tBgrVg90H21EOLACvtfcHk0lhQwvPzg6L2lA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisVequrg%253D&md5=fb2ba3d2e97aa98c0fd0bf4eb2862c25</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1128%2FMCB.00601-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.00601-09%26sid%3Dliteratum%253Aachs%26aulast%3DJulien%26aufirst%3DL.%2BA.%26aulast%3DCarriere%26aufirst%3DA.%26aulast%3DMoreau%26aufirst%3DJ.%26aulast%3DRoux%26aufirst%3DP.%2BP.%26atitle%3DmTORC1-activated%2520S6K1%2520phosphorylates%2520Rictor%2520on%2520threonine%25201135%2520and%2520regulates%2520mTORC2%2520signaling%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2010%26volume%3D30%26spage%3D908%26epage%3D921%26doi%3D10.1128%2FMCB.00601-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudge, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koos, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidialingam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavletich, N. P.</span></span> <span> </span><span class="NLM_article-title">mTOR kinase structure, mechanism and regulation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>497</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1038/nature12122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1038%2Fnature12122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=23636326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmvFyns7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=497&publication_year=2013&pages=217-223&author=H.+Yangauthor=D.+G.+Rudgeauthor=J.+D.+Koosauthor=B.+Vaidialingamauthor=H.+J.+Yangauthor=N.+P.+Pavletich&title=mTOR+kinase+structure%2C+mechanism+and+regulation&doi=10.1038%2Fnature12122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR kinase structure, mechanism and regulation</span></div><div class="casAuthors">Yang, Haijuan; Rudge, Derek G.; Koos, Joseph D.; Vaidialingam, Bhamini; Yang, Hyo J.; Pavletich, Nikola P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">497</span>
        (<span class="NLM_cas:issue">7448</span>),
    <span class="NLM_cas:pages">217-223</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The mammalian target of rapamycin (mTOR), a phosphoinositide 3-kinase-related protein kinase, controls cell growth in response to nutrients and growth factors and is frequently deregulated in cancer.  Here we report co-crystal structures of a complex of truncated mTOR and mammalian lethal with SEC13 protein 8 (mLST8) with an ATP transition state mimic (MgF3-) and with ATP-site inhibitors (Torin2, PP242, and PI-103).  The structures reveal an intrinsically active kinase conformation, with catalytic residues and a catalytic mechanism remarkably similar to canonical protein kinases.  The active site is highly recessed owing to the FKBP12-rapamycin-binding (FRB) domain and an inhibitory helix protruding from the catalytic cleft.  MTOR-activating mutations map to the structural framework that holds these elements in place, indicating that the kinase is controlled by restricted access.  In vitro biochem. shows that the FRB domain acts as a gatekeeper, with its rapamycin-binding site interacting with substrates to grant them access to the restricted active site.  Rapamycin-FKBP12 inhibits the kinase by directly blocking substrate recruitment and by further restricting active-site access.  The structures also reveal active-site residues and conformational changes that underlie inhibitor potency and specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjvPQtdm6yCbVg90H21EOLACvtfcHk0lgXbl4Szd1lzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmvFyns7k%253D&md5=07809555fbdf2004819a7f2da5727baf</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fnature12122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature12122%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DH.%26aulast%3DRudge%26aufirst%3DD.%2BG.%26aulast%3DKoos%26aufirst%3DJ.%2BD.%26aulast%3DVaidialingam%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DH.%2BJ.%26aulast%3DPavletich%26aufirst%3DN.%2BP.%26atitle%3DmTOR%2520kinase%2520structure%252C%2520mechanism%2520and%2520regulation%26jtitle%3DNature%26date%3D2013%26volume%3D497%26spage%3D217%26epage%3D223%26doi%3D10.1038%2Fnature12122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krieger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darden, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabuurs, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finkelstein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vriend, G.</span></span> <span> </span><span class="NLM_article-title">Making optimal use of empirical energy functions: force-field parameterization in crystal space</span>. <i>Proteins: Struct., Funct., Genet.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">678</span>– <span class="NLM_lpage">683</span>, <span class="refDoi"> DOI: 10.1002/prot.20251</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1002%2Fprot.20251" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=15390263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVaqtLrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2004&pages=678-683&author=E.+Kriegerauthor=T.+Dardenauthor=S.+B.+Nabuursauthor=A.+Finkelsteinauthor=G.+Vriend&title=Making+optimal+use+of+empirical+energy+functions%3A+force-field+parameterization+in+crystal+space&doi=10.1002%2Fprot.20251"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Making optimal use of empirical energy functions: Force-field parameterization in crystal space</span></div><div class="casAuthors">Krieger, Elmar; Darden, Tom; Nabuurs, Sander B.; Finkelstein, Alexei; Vriend, Gert</div><div class="citationInfo"><span class="NLM_cas:title">Proteins: Structure, Function, and Bioinformatics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">678-683</span>CODEN:
                <span class="NLM_cas:coden">PSFBAF</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Today's energy functions are not able yet to distinguish reliably between correct and almost correct protein models.  Improving these near-native models is currently a major bottle-neck in homol. modeling or exptl. structure detn. at low resoln.  Increasingly accurate energy functions are required to complete the "last mile of the protein folding problem," for example during a mol. dynamics simulation.  We present a new approach to reach this goal.  For 50 high resoln. x-ray structures, the complete unit cell was reconstructed, including disordered water mols., counter ions, and hydrogen atoms.  Simulations were then run at the pH at which the crystal was solved, while force-field parameters were iteratively adjusted so that the damage done to the structures was minimal.  Starting with initial parameters from the AMBER force field, the optimization procedure converged at a new force field called YAMBER (Yet Another Model Building and Energy Refinement force field), which is shown to do significantly less damage to x-ray structures, often move homol. models in the right direction, and occasionally make them look like exptl. structures.  Application of YAMBER during the CASP5 structure prediction expt. yielded a model for target 176 that was ranked first among 150 submissions.  Due to its compatibility with the well-established AMBER format, YAMBER can be used by almost any mol. dynamics program.  The parameters are freely available from www.yasara.org/yamber.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZ95LDBJGK6LVg90H21EOLACvtfcHk0lgXbl4Szd1lzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVaqtLrE&md5=bc51b590b7653f9b413012faee902e4b</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1002%2Fprot.20251&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprot.20251%26sid%3Dliteratum%253Aachs%26aulast%3DKrieger%26aufirst%3DE.%26aulast%3DDarden%26aufirst%3DT.%26aulast%3DNabuurs%26aufirst%3DS.%2BB.%26aulast%3DFinkelstein%26aufirst%3DA.%26aulast%3DVriend%26aufirst%3DG.%26atitle%3DMaking%2520optimal%2520use%2520of%2520empirical%2520energy%2520functions%253A%2520force-field%2520parameterization%2520in%2520crystal%2520space%26jtitle%3DProteins%253A%2520Struct.%252C%2520Funct.%252C%2520Genet.%26date%3D2004%26volume%3D57%26spage%3D678%26epage%3D683%26doi%3D10.1002%2Fprot.20251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walker, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacold, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perisic, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. L.</span></span> <span> </span><span class="NLM_article-title">Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">909</span>– <span class="NLM_lpage">919</span>, <span class="refDoi"> DOI: 10.1016/S1097-2765(05)00089-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1016%2FS1097-2765%2805%2900089-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=11090628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnvVegurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=909-919&author=E.+H.+Walkerauthor=M.+E.+Pacoldauthor=O.+Perisicauthor=L.+Stephensauthor=P.+T.+Hawkinsauthor=M.+P.+Wymannauthor=R.+L.+Williams&title=Structural+determinants+of+phosphoinositide+3-kinase+inhibition+by+wortmannin%2C+LY294002%2C+quercetin%2C+myricetin%2C+and+staurosporine&doi=10.1016%2FS1097-2765%2805%2900089-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine</span></div><div class="casAuthors">Walker, Edward H.; Pacold, Michael E.; Perisic, Olga; Stephens, Len; Hawkins, Philip T.; Wymann, Matthias P.; Williams, Roger L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">909-919</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The specific phosphoinositide 3-kinase (P13K) inhibitors wortmannin and LY294002 have been invaluable tools for elucidating the roles of these enzymes in signal transduction pathways.  The X-ray crystallog. structures of P13K bound to these lipid kinase inhibitors and to the broad-spectrum protein kinase inhibitors quercetin, myricetin, and staurosporine reveal how these compds. fit into the ATP binding pocket.  With a nanomolar IC50, wortmannin most closely fits and fills the active site and induces a conformational change in the catalytic domain.  Surprisingly, LY294002 and the lead compd. on which it was designed, quercetin, as well as the closely related flavonoid myricetin bind P13K in remarkably different orientations that are related to each other by 1800 rotations.  Staurosporine/P13K interactions are reminiscent of low-affinity protein kinase/staurosporine complexes.  These results provide a rich basis for development of isoform-specific P13K inhibitors with therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgIbTky2xQmbVg90H21EOLACvtfcHk0lgXbl4Szd1lzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnvVegurY%253D&md5=5dd92f9b48c437e43c0023fdff10c1ac</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2805%2900089-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252805%252900089-4%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DE.%2BH.%26aulast%3DPacold%26aufirst%3DM.%2BE.%26aulast%3DPerisic%26aufirst%3DO.%26aulast%3DStephens%26aufirst%3DL.%26aulast%3DHawkins%26aufirst%3DP.%2BT.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26atitle%3DStructural%2520determinants%2520of%2520phosphoinositide%25203-kinase%2520inhibition%2520by%2520wortmannin%252C%2520LY294002%252C%2520quercetin%252C%2520myricetin%252C%2520and%2520staurosporine%26jtitle%3DMol.%2520Cell%26date%3D2000%26volume%3D6%26spage%3D909%26epage%3D919%26doi%3D10.1016%2FS1097-2765%2805%2900089-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
Der Spoel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindahl, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groenhof, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mark, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berendsen, H. J.</span></span> <span> </span><span class="NLM_article-title">GROMACS: fast, flexible, and free</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1701</span>– <span class="NLM_lpage">1718</span>, <span class="refDoi"> DOI: 10.1002/jcc.20291</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1002%2Fjcc.20291" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=16211538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1SlsbbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2005&pages=1701-1718&author=D.+Van%0ADer+Spoelauthor=E.+Lindahlauthor=B.+Hessauthor=G.+Groenhofauthor=A.+E.+Markauthor=H.+J.+Berendsen&title=GROMACS%3A+fast%2C+flexible%2C+and+free&doi=10.1002%2Fjcc.20291"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">GROMACS: Fast, flexible, and free</span></div><div class="casAuthors">Van Der Spoel, David; Lindahl, Erik; Hess, Berk; Groenhof, Gerrit; Mark, Alan E.; Berendsen, Herman J. C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1701-1718</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">This article describes the software suite GROMACS (Groningen MAchine for Chem. Simulation) that was developed at the University of Groningen, The Netherlands, in the early 1990s.  The software, written in ANSI C, originates from a parallel hardware project, and is well suited for parallelization on processor clusters.  By careful optimization of neighbor searching and of inner loop performance, GROMACS is a very fast program for mol. dynamics simulation.  It does not have a force field of its own, but is compatible with GROMOS, OPLS, AMBER, and ENCAD force fields.  In addn., it can handle polarizable shell models and flexible constraints.  The program is versatile, as force routines can be added by the user, tabulated functions can be specified, and analyses can be easily customized.  Nonequil. dynamics and free energy detns. are incorporated.  Interfaces with popular quantum-chem. packages (MOPAC, GAMES-UK, GAUSSIAN) are provided to perform mixed MM/QM simulations.  The package includes about 100 utility and anal. programs.  GROMACS is in the public domain and distributed (with source code and documentation) under the GNU General Public License.  It is maintained by a group of developers from the Universities of Groningen, Uppsala, and Stockholm, and the Max Planck Institute for Polymer Research in Mainz.  Its Web site is http://www.gromacs.org.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxInIDyt9Y8bVg90H21EOLACvtfcHk0ljp5evLNImORw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1SlsbbO&md5=4aa71b1dc0b5b4978a88b0568245a265</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1002%2Fjcc.20291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.20291%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BDer%2BSpoel%26aufirst%3DD.%26aulast%3DLindahl%26aufirst%3DE.%26aulast%3DHess%26aufirst%3DB.%26aulast%3DGroenhof%26aufirst%3DG.%26aulast%3DMark%26aufirst%3DA.%2BE.%26aulast%3DBerendsen%26aufirst%3DH.%2BJ.%26atitle%3DGROMACS%253A%2520fast%252C%2520flexible%252C%2520and%2520free%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2005%26volume%3D26%26spage%3D1701%26epage%3D1718%26doi%3D10.1002%2Fjcc.20291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chaigne-Delalande, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahfouf, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daburon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legembre, P.</span></span> <span> </span><span class="NLM_article-title">CD95 engagement mediates actin-independent and -dependent apoptotic signals</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1654</span>, <span class="refDoi"> DOI: 10.1038/cdd.2009.111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1038%2Fcdd.2009.111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=19680267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVWlsr3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=1654&author=B.+Chaigne-Delalandeauthor=W.+Mahfoufauthor=S.+Daburonauthor=J.+F.+Moreauauthor=P.+Legembre&title=CD95+engagement+mediates+actin-independent+and+-dependent+apoptotic+signals&doi=10.1038%2Fcdd.2009.111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">CD95 engagement mediates actin-independent and -dependent apoptotic signals</span></div><div class="casAuthors">Chaigne-Delalande, B.; Mahfouf, W.; Daburon, S.; Moreau, J.-F.; Legembre, P.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death and Differentiation</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1654-1664</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">CD95 is a death receptor whose stimulation by either the physiol. ligand CD95L or the agonistic antibodies leads to the formation of a multi-mol. complex termed DISC (death-inducing signaling complex) and the subsequent induction of a caspase-driven apoptotic signal.  According to the magnitude of the DISC formation, two types of cells have been identified.  Although type I cells generate an important DISC, the complex is barely found in type II cells.  Analyzing the early stages preceding the DISC formation, we found that unlike CD95L, the commonly used agonistic antibody APO1-3 internalized the death receptor.  Using inhibitors of actin polymn., we showed that the remodeling of the actin cytoskeleton did not alter the capping of the CD95 receptor or its partitioning into the lipid rafts.  In addn., whereas the disruption of F-actin prevented the internalization of CD95, the DISC formation and the apoptotic signal induced by the agonistic antibody APO1-3 in type I cells, it did not affect the signal triggered by the sol. and membrane-bound CD95L, regardless of the type of cells.  In conclusion, the addn. of APO1-3 on type I cells triggers an actin-dependent apoptotic signal, which is absent or marginal in cells (both types I and II) treated with CD95L.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLiWIVfRGh3rVg90H21EOLACvtfcHk0ljp5evLNImORw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVWlsr3O&md5=d2e91ce5d6891969044f44dad0544c18</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1038%2Fcdd.2009.111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcdd.2009.111%26sid%3Dliteratum%253Aachs%26aulast%3DChaigne-Delalande%26aufirst%3DB.%26aulast%3DMahfouf%26aufirst%3DW.%26aulast%3DDaburon%26aufirst%3DS.%26aulast%3DMoreau%26aufirst%3DJ.%2BF.%26aulast%3DLegembre%26aufirst%3DP.%26atitle%3DCD95%2520engagement%2520mediates%2520actin-independent%2520and%2520-dependent%2520apoptotic%2520signals%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2009%26volume%3D16%26spage%3D1654%26doi%3D10.1038%2Fcdd.2009.111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-ref61_1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Armarego, W. L. F.</span>; <span class="NLM_string-name">Chai, C. L. L.</span> </span> <i>Purification of Laboratory Chemicals</i>, <span class="NLM_edition">6</span>th ed.; <span class="NLM_publisher-name">Elsevier</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/ref61_1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;key=10.1016%2FB978-1-85617-567-8.50011-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=W.+L.+F.+Armarego&author=C.+L.+L.+Chai&title=Purification+of+Laboratory+Chemicals"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=ref61_1&amp;dbid=16384&amp;doi=10.1016%2FB978-1-85617-567-8.50011-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-1-85617-567-8.50011-1%26sid%3Dliteratum%253Aachs%26aulast%3DArmarego%26aufirst%3DW.%2BL.%2BF.%26btitle%3DPurification%2520of%2520Laboratory%2520Chemicals%26pub%3DElsevier%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JSN" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JSN','PDB','4JSN'); return false;">PDB: 4JSN</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1E8W" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1E8W','PDB','1E8W'); return false;">PDB: 1E8W</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i35"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b00991">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_45662"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.5b00991">10.1021/acs.jmc.5b00991</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Full experimental details and supporting figures (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b00991/suppl_file/jm5b00991_si_001.pdf">PDF</a>)</p></li><li><p class="inline">SMILES data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b00991/suppl_file/jm5b00991_si_004.csv">XLS</a></p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b00991/suppl_file/jm5b00991_si_001.pdf">jm5b00991_si_001.pdf (1.07 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b00991/suppl_file/jm5b00991_si_002.pdf">jm5b00991_si_002.pdf (4.12 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b00991/suppl_file/jm5b00991_si_003.pdf">jm5b00991_si_003.pdf (79.65 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b00991/suppl_file/jm5b00991_si_004.csv">jm5b00991_si_004.csv (2.93 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.5b00991&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.5b00991%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2015.58.issue-16%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.5b00991" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                11MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679ac3b0a9a93291","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
